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1. Introduction
The evolution of multicellular metazoan organisms was marked by the inclusion of an extracellular
matrix (ECM), a multicomponent, proteinaceous network between cells that contributes to the spatial
arrangement of cells and the resulting tissue organization. The development of an ECM that provides
support in larger organisms may have represented an advantage in the face of selection pressure for
the evolution of the ECM.
The study of the ECM, or material outside the cells of tissues, began with the cell theory of life in
the 1850s [1]. Advances in our understanding of the composition of the ECM occurred prior to 1975
with the application of new techniques in chemical, physical, and biological research [2]. These new
techniques provided information about the molecular structure of collagen and the chemical nature of
the crosslinks that stabilize the collagen higher-ordered structure. Analysis of biosynthetic pathways
has revealed that ECM components are synthesized and secreted by conserved mechanisms throughout
metazoan organisms. Additionally, a comparison between organisms has revealed that ECM proteins
are oligomeric, commonly forming trimers and pentamers of protein monomers that often possess
repeated motifs that predate the evolutionary origin of animals. With the advance of molecular
biology and cell biology fields, new collagens and noncollagenous constituents were discovered and
characterized to give our current view of the ECM as a complex and dynamic biomaterial. Today, we
recognize that the ECM plays an essential role in development and disease, supporting cell survival,
differentiation, and tissue organization.
The ECM has been the focus of research for over a century. Scientists strive to understand the
processes involved in biosynthesis and turnover, and many important discoveries have helped to pave
the way to the application of extracellular matrices in ways that translate to patient care. Despite these
efforts, there are still many unanswered questions that remain. This book deals with molecular and
cellular aspects of the role of ECM in development and disease. Cells exist in three-dimensional
scaffolding that holds together the millions of cells that make up our blood vessels, organs, skin, and
all tissues of the body. The matrix serves as a reservoir of signaling molecules as well. In bacterial
cultures, biofilms form as an ECM and play essential roles in disease and drug resistance. Topics such
as matrix structure and function, cell attachment, and cell surface proteins mediating cell–matrix
interactions, synthesis, regulation, composition, structure, assembly, remodeling, and function of the
matrix are covered. A common thread uniting the topics is the essential nature that the matrix plays
in normal development and pathophysiology. Providing new knowledge will lead us to improved
Int. J. Mol. Sci. 2019, 20, 205; doi:10.3390/ijms20010205 www.mdpi.com/journal/ijms1
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diagnostics, preventions to disease progression, and therapeutic strategies for repair and regeneration
of tissues.
2. Extracellular Matrix and Hereditary Diseases
The link between ECM molecules and phenotypic characteristics of specific hereditary diseases
is reviewed by Arseni and colleagues [3], with an emphasis on the most prevalent of all ECM
proteins, collagens, and mutations that result in bone fragility, muscle weakness, and skin defects.
The authors review the dynamic state of collagen molecules (chains), domains, and molecular
interaction, highlighting the dynamic nature of the ECM and the complexity of understanding how
mutations contribute to hereditary diseases.
Extending the focus on collagens and point mutations that lead to inherited diseases,
primarily affecting the cartilage and skeletal systems such as Stickler syndrome and congenital
spondyloepiphyseal dysplasia, Chakkalakal and colleagues [4] reported new findings on mutations
of collagen type II that impact protein secretion, the unfolded protein response, and ultimately, cell
survival. This research reinforces the findings that collagen mutations near the C-terminus contribute
to disease by causing retention in the ER and inducing the ER-stress response.
Another prevalent ECM molecule is hyaluronan. Stridh and colleagues [5] provided novel
findings on the role of hyaluronan produced by renomedullary interstitial cells in kidney function.
Hyaluronan is vital to the balance of fluid electrolytes. Through this knowledge, they discovered a
rapid hyaluronan turnover mechanism alternative to regulating synthesis. They build on previous
work showing that hyaluronan levels change corresponding to body hydration levels. This new work
adds that hormone-regulated hyaluronidase activity decreases hyaluronan.
3. Extracellular Matrix and Reproduction
Hyaluronan plays an essential role during embryonic development. Eva Nagyova [6] reviews
the biological role of hyaluronan-rich oocyte-cumulus ECM in female reproduction. In her review,
she focuses on key molecules that play an important role in the formation of the cumulus ECM,
generated by the oocyte-cumulus complex. One of these key molecules, inter-alpha-trypsin inhibitor
protein forms covalent interactions with hyaluronan to create the major structural component of the
cumulus ECM.
During implantation and placentation, plasminogen activator inhibitor type 1 (PAI-1) is
responsible for inhibiting ECM degradation, thereby causing inhibition of trophoblast invasion. An
increase of PAI-1 in the blood is associated with an increased risk for infertility and pregnancy
complications. PAI-1 levels are increased in patients with recurrent pregnancy losses, preeclampsia,
intrauterine growth restriction, gestational diabetes mellitus in the previous pregnancy, endometriosis
and polycystic ovary syndrome. Ye and colleagues [7] provide an overview of the current knowledge
of the role of PAI-1 in reproductive diseases. Based on this review, PAI-1 may represent a promising
biomarker for reproductive diseases.
4. Extracellular Matrix and Cancer
Cancer is defined as a disease of uncontrolled cell proliferation and dysregulation of the
microenvironment, which included the ECM. Walker et al. [8] reviewed the role of the ECM in
cancer development and progression from a biochemical as well as biophysical perspective while
Wang et al. [9] reviewed the link between increased risk of thrombosis in cancer patients. Also related
to cancer is the recent article by Del Ben et al. [10], which focuses on the role of the ECM molecule
vitronectin in nonalcoholic steatohepatitis (NASH), a leading cause of liver cirrhosis and hepatocellular
carcinoma. The results of their studies indicate that a fragment of vitronectin may serve as an effective
biomarker for noninvasive diagnosis of NASH. Rijal et al. [11] and Song et al. [12] address novel
three-dimensional ECM scaffolds with application to cancer research. Rijal et al. [11] reported the
generation of breast-specific ECM that can be used to form a hydrogel porous scaffold for studying
2
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human breast cancer. Song et al. [12] further reviewed the three-dimensional scaffolds that may
accurately reflect the complexity of native tissues and cancer microenvironments for future studies.
5. Extracellular Matrix and Muscle
Mast cells have been implicated in the development of cardiac fibrosis. The controversial role
that mast cells may play in promoting a profibrotic environment in cardiac muscle is reviewed by
Levick and Widiapradja [13]. The role of the members of the thrombospondin family is reviewed
by Chistiakov et al. [14], highlighting the potential for the therapeutic treatment of cardiovascular
disease by targeting cardiac thrombospondin-mediated signaling in cardiovascular disease. Rohm and
colleagues [15] present their current findings that will impact patients with pulmonary hypertension,
right ventricular dysfunction and vascular remodeling. In their studies, they investigated the potential
of elevated levels of a novel isoform of tenascin-C as a diagnostic serum biomarker.
McRae et al. [16] provide novel information about the dysregulated ECM in Duchenne muscular
dystrophy and the effect of glucocorticoids on the versican-rich transitional matrix in both hindlimb
and diaphragm muscle of a mouse model system. Versican may serve as a therapeutic target to
promote myoblast fusion during muscle development and regeneration in patients with Duchenne
muscular dystrophy.
Using a zebrafish model for muscle development, Dancevic et al. [17] demonstrated that
ADAMTS5 plays an essential role in somite differentiation due to a new and novel role associated
with the sonic hedgehog (shh) signaling pathway, in addition to its role in ECM remodeling. Their
results suggest that a loss of ADAMTS5 causes changes in shh signaling which has been associated
with musculoskeletal diseases.
6. Extracellular Matrix and Tissue Engineering Applications
Alvarèz Fallas et al. [18] and Uricuiolo and De Coppi [19] addressed the challenge of muscle
regeneration. Alvarèz Fallas et al. [18] addressed the application of decellularized skeletal muscle tissue
that preserves the tissue-specific ECM to support tissue engineering and regenerative medicine using
both ex vivo and in vivo models. Their work shows that decellularized diaphragm is a suitable scaffold
for skeletal muscle tissue engineering and regeneration. Uricuiolo and De Coppi [19] review the
literature on the repair of volumetric muscle loss and the promising aspects of applying decellularized
tissues as natural scaffolds for therapeutic outcomes.
7. Integrins
Finally, LaFoya and colleagues [20] review the many diverse roles for members of the integrin
family. Integrins are traditionally thought of as receptors for the molecules of the ECM, however,
in addition to this important role, they also play roles in cell–cell interactions, as growth factors
and hormone receptors, and as interaction sites for viruses and bacteria. The many non-ECM
integrin ligands are actively being characterized and may find many interesting uses in biotechnology.
For example, it has been shown that RGD peptides attached to liposomes or viral particles increase
tissue specificity.
8. Concluding Remarks
We thank all the authors who have generously contributed their articles to this book.
By disseminating and sharing our research, we ensure that advances in the field can be made. It is by
dissemination of our work that the next innovation will arise.
Funding: This project was funded by the National Institutes of Health National Institute for General Medical
Sciences IDeA Program grant number P20GM109095.
Conflicts of Interest: The authors declare no conflicts of interest.
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Abstract: The extracellular matrix (ECM) is a highly dynamic and heterogeneous structure that
plays multiple roles in living organisms. Its integrity and homeostasis are crucial for normal tissue
development and organ physiology. Loss or alteration of ECM components turns towards a disease
outcome. In this review, we provide a general overview of ECM components with a special focus
on collagens, the most abundant and diverse ECM molecules. We discuss the different functions of
the ECM including its impact on cell proliferation, migration and differentiation by highlighting the
relevance of the bidirectional cross-talk between the matrix and surrounding cells. By systematically
reviewing all the hereditary disorders associated to altered collagen structure or resulting in excessive
collagen degradation, we point to the functional relevance of the collagen and therefore of the
ECM elements for human health. Moreover, the large overlapping spectrum of clinical features
of the collagen-related disorders makes in some cases the patient clinical diagnosis very difficult.
A better understanding of ECM complexity and molecular mechanisms regulating the expression
and functions of the various ECM elements will be fundamental to fully recognize the different
clinical entities.
Keywords: collagen; extracellular matrix; skin defects; bone fragility; muscle weakness
1. Introduction
The extracellular matrix (ECM) is a non-cellular complex network that provides a structural
scaffold to the surrounding cells and, at the same time, a deposit of cytokines and growth factors
capable of influencing cell behaviour.
The main ECM components include collagens, proteoglycans and glycoproteins [1]. In addition,
many proteins such as growth factors, cytokines and proteolytic enzymes are associated to the ECM.
Through all these components the ECM provides environmental information to the cells, which in
turn respond by adapting their behaviour and adjusting proliferation, migration and differentiation.
The ECM is highly dynamic and its remodelling has to be tightly regulated in order to maintain tissue
homeostasis. Deregulation of the ECM structure or composition contributes to the onset of a variety of
pathological conditions characterized by a wide range of tissue alterations, further straightening the
functional relevance of the ECM. After a general overview of the ECM main features and functions
we will focus on the most abundant elements of the ECM, the collagens. We will discuss the different
collagen types, their synthesis and structural organization as well as the relevance of properly
assembled collagen fibres by discussing their impact on human health.
Int. J. Mol. Sci. 2018, 19, 1407; doi:10.3390/ijms19051407 www.mdpi.com/journal/ijms6
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2. The ECM: Molecular and Structural Diversity
The ECM is a highly dynamic and heterogeneous structure. Each tissue has an ECM with a unique
composition generated in early embryonic stages and then maintained and remodelled throughout
the entire life. The great complexity of ECM structure and functions makes the research in this field
very challenging. A significant input derives from the definition of the “matrisome,” a list of proteins
contributing to the ECM in different organisms and tissues, which has been predicted by integrating the
information derived from experimental knowledge, genome comparative studies and bioinformatics
tools [2]. This plastic and evolving list of ECM proteins, comprising between 1% and 1.5% of the
mammalian proteome, requires further investigations and biochemical characterization [3].
2.1. Chemical Composition and Mechanical Properties
Hundreds of ECM components are known, many of which are capable of binding to other ECM
components on specific sites, thus making the matrix a highly intricate structure (Figure 1).
Figure 1. Schematic representation of the complex meshwork of proteins forming the extracellular
matrix (ECM). The main ECM components, namely collagens, proteoglycans, hyaluronan, fibronectin,
laminin and elastin, as well as the integrin ECM receptors, are depicted. The ECM provides mechanical
support and anchoring for cells and tissues but it also acts as a reservoir of growth factors and cytokines
and regulator of normal tissue development and homeostasis. Alterations in any of these functions
result in a pathological status characterized by various tissue abnormalities.
Although the molecular composition can vary widely, the ECM main components are:
proteoglycans, hyaluronan, adhesive glycoproteins (fibronectins and laminins) and fibrous proteins
(collagens and elastin). Proteoglycans are constituted by large carbohydrates (generically referred as
glycosaminoglycans, GAGs) attached to a protein core. The anionic polysaccharides GAGs allow the
sequestration of water and other cations such as calcium [3]. Several types of protein core exist and
various types of GAGs can bind to each other in a wide variety of combinations. Proteoglycans promote
cell-ECM adhesion but also bind to secreted proteins and growth factors in the ECM. Many components
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of this category have space-filling and lubrication functions. A special type of GAG is hyaluronan
(HA), the only GAG element of the ECM that lacks a protein core. It is a linear polysaccharide
composed of the repeating disaccharide units N-acetyl-D-glucosamine and D-glucuronate [4]. It is
particularly abundant in human tissues, including joints, eyes, umbilical cord, synovial fluids, skeletal
tissues, hurt and lung. In spite of its simple structure, HA plays a role in several biological processes,
including cell signalling, inflammation, wound healing and cell development [5] and contributes to
maintain tissue homeostasis by interacting with other ECM proteins or proteoglycans [6]. Thanks to
its hygroscopic features, it acts as space filler among cells and contributes to the maintenance of tissue
hydration. Its biocompatibility makes HA suitable for tissue engineering and clinical applications,
where it can be used as a diagnostic marker [7].
In mammals, around 200 glycoproteins provide interactions with other ECM components thus
allowing ECM formation and assembly. They share multiple repeating domains and motifs typical
of the ECM constituents and promote cell adhesion, cell signalling and binding to growth factors [8].
The best-studied ECM glycoproteins are fibronectins and laminins. Fibronectins are proteins encoded
by a single gene through multiple alternative splicing. The dimerization of two fibronectin monomers
results in the final molecule, which contains repeating units named type I, II and III. Type I and
II are tight together by disulphide bonds, the third one has seven-stranded β-barrel composition.
All these modules are organized in order to contain binding sites for a variety of other molecules,
such as heparin sulphate proteoglycans (HSPGs), integrins and collagens [9]. Fibronectins can be
soluble or associated to fibrils thus acting as bridging factors among different ECM components and
anchoring cells to matrix fibres. Laminins are large cross-shaped ECM proteins composed of α, β and
γ chains. In particular, twelve genes encode 5α, 4β and 3γ chains, which can differentially combine to
generate many types of laminins. Among these, laminin G domain-like (LG) of the laminin α2 chain
is composed by a β sandwich structure and contains a calcium-binding site, surrounded by a large
number of epitopes involved in the interaction with cellular receptors and extracellular ligands ([10,11]
and references therein).
Fibrous proteins include collagens and elastin. Collagens are the most abundant proteins of
the ECM and a detailed description of their structure and functions is found below (Section 4).
Elastin is a key element of the ECM that provides elasticity and flexibility to different tissues
including large arteries, ligaments, tendon, lung, skin and cartilage. It is synthesized and secreted as
tropoelastin, a soluble precursor implicated in the formation of elastic fibres through the interaction
with the N-terminal domains of fibrillins 1 and 2. Tropoelastin contains several hydrophobic domains
(consisting in proline, glycine, valine and alanine) that are responsible for the extensibility properties
of the protein. The tensile strength provided by collagen fibrils is therefore counterbalanced by the
extensibility of elastic fibres, which, conversely to collagen, can undergo progressive stretching and
relaxation cycles. Dynamic tissues are thus able to sustain mechanical stress without being permanently
affected but reverting the tissues back to their original shape, a property known as viscoelasticity [12].
The ECM tensile strength is determined by the dynamic activities of lysil oxidase (LOX) and lysil
hydroxylase, two enzymes involved in regulating the cross-linking between collagens and elastin [13].
2.2. ECM-Bound Growth and Secreted Factors
Although not structural components of the matrix, many growth factors can bind to elements
of the ECM and therefore are categorized as ECM constituents. Indeed, it was shown that vascular
endothelial growth factor (VEGF) binds to the type III modules of fibronectin and this interaction
depends on the heparin-binding residues of fibronectin [14]. VEGF and fibroblast growth factor
(FGF) can bind to HSPGs from where they are cleaved off as soluble ligands by the heparanase
enzyme. Hepatocyte growth factor (HGF) binds to the 70 kDa N-terminal and the 40 kDa C-terminal
fragments of fibronectin [15], whereas platelet-derived growth factor (PDGF) binds the type III and
the variable domains of fibronectin [16]. Differently, transforming growth factor-beta (TGFβ) binds to
the latent transforming growth factor beta binding protein (LTBPs), which in turn binds to fibrillins
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and fibronectin-rich matrices [14,15,17,18]. Also, fibrillin-containing microfibrils of the ECM regulate
the availability and activity of bone morphogenetic proteins (BMPs) and growth and differentiation
factor-5 (GDF-5), cytokines of the TGFβ family [19]. Overall, the different growth factors associated
to the ECM could be released locally and become available for the interaction with their canonical
receptors. Thus, the ECM serves as a storage for growth factors and chemokines, whose interactions
with the matrix control their half-life, local concentration and biological activity.
3. ECM Functions
For many years, the ECM has been defined as a static structure whose unique function was to
provide support and shape to cells and tissues. Although this passive role is definitively fundamental
for organism organization and maintenance, it is now clear that the ECM is much more than simple
scaffolding. Synthesized and organized by the cells, the matrix itself can actively regulate cell
behaviour [20]. Indeed, the ECM provides a substrate over which cells can adhere and migrate by
sensing the ECM constituents. In turn, cells will secrete new elements that result in ECM remodelling.
Therefore, through the coordinated action of its main molecular constituents, the ECM can influence
cell proliferation, adhesion and migration as well as differentiation and cell death [21].
3.1. Structural Roles of ECM
The ECM plays important structural roles during development and in particular during the
formation of the skeleton. In tissues with mechanical functions such as cartilage, bone and tendons,
the ECM is the major component that confers structural properties.
Thanks to its biologically diverse array of macromolecules, the ECM provides a robust and
dynamic scaffold capable to evolve during the normal physiological development but also to face
insults that could disrupt tissue homeostasis. ECM reactions to these conditions are mediated by
its physical, biochemical and biomechanical properties. Depending on its chemical composition,
its topography and dimensionality, the ECM exerts different stimuli on the cells, which sense these
forces and in turn respond to them. Cell migration, which is critical for proper normal embryonic
development, is one of the best examples. Both motile (like the immune cells) and non-motile cells
(such as adult epithelial cells) sense the composition and density of the surroundings and respond by
migrating towards or moving away from the source.
Tissue elasticity also depends on the ECM chemical composition, which defines soft or stiff
matrices. Human tumours for example are surrounded by a stiff matrix with high collagen
concentrations and the ECM rigidity might represent an optimal growing milieu for some surrounding
cells that are therefore attracted towards this source [22]. This phenomenon, known as desmoplasia, is
usually associated with malignant tumours and it is present in many solid tumours. Tissue stiffness
can drive malignant transformation via integrin-mediated mechanisms [23] and such fibrotic “stiff”
lesions are associated with a poor prognosis [24].
ECM protein receptors, including integrin, syndecan, discoidin domain receptors (DDRs) and
proteoglycans, can act synergistically to anchor the cells to the matrix and favour the reciprocal matrix
organization. These adhesion dynamics are particularly important to maintain the right balance
between self-renewal and differentiation of stem cells [25]. In this respect, it has been shown that the
genomic loss of integrin β1 encoding gene in the basal cells of mouse mammary epithelium affects
stem cell regeneration and results in irregular branching ducts due to developmental defects of the
mammary gland [26].
3.2. Signalling Modulation
As previously mentioned, the ECM can sequester several growth factors that are not structural
components of the matrix per se but become active elements of the ECM. Chemokines, cytokines and
growth factors, such as VEGFs, Wnts and FGFs, can be retained by the ECM and therefore create a
“reservoir” of signalling molecules. By retaining these factors, the ECM may preserve the ligand source
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in proximity of the receiving cells and prevent their diffusion to the extracellular space. In addition,
through the adhesion with ECM components, the ECM can modulate the ligand-receptors interaction and
control the formation of morphogen gradients, whose concentration regulates developmental processes [21].
One example of ECM molecule directly implicated in the regulation of morphogens gradients is represented
by the HSPGs, which binds morphogens but also many cell surface co-receptors, thus acting as a linking
platform that mediates the interactions of morphogens with the other ECM components [27].
The ECM also contributes to ligand maturation. One representative example is the TGFβ proteins,
which indirectly connect to fibrillins and fibronectins [18] and are stored in the ECM in their inactive
form until proteolitically activated by matrix metalloproteinases (MMP) or by mechanical forces.
Furthermore, the ECM can trigger signalling events, as shown by the biologically active fragments
derived from the proteolytic cleavage of collagens, proteoglycans, elastin and laminins ([28] and
references therein). Matrikines were first described by Maquart and colleagues in 1999 [29] and then
named matricryptins one year later by Davis and colleagues with the following definition “biologically
active sites that are not exposed in the mature, secreted form of ECM molecules but which become
exposed after structural or conformational alterations” [30]. Among them, endostatin derived from
collagen XVIII [31,32] is the most extensively studied matricryptin. The ectodomains of membrane
collagens XIII, XVII, XXIII and XXV [33] are matricryptins involved in cell adhesion, migration
or proliferation [34]. Matrikines from collagens IV are involved in angiogenesis [35] and synapse
formation [36]. The ectodomains of syndecans 1–4 are also matricryptins, whereas fragments derived
from hyaluronan degradation regulate inflammation and wound healing ([28] and references therein).
Therefore, these ECM-fragments may act by regulating cell proliferation, cell death, cell differentiation
and angiogenesis [35]. Also, ECM receptors play a role in signal transduction, in particular the collagen
receptors DDRs with their intracellular tyrosine kinase activity and the integrin proteins capable of
transmitting chemical signals into the cells [37]. Upon ligand binding, receptors get activated and
trigger intracellular signalling events that through the involvement of Rho, Rock and the pathway of
MAP kinases modulate cellular survival, proliferation and differentiation [21].
3.3. ECM in Development
The ECM provides several different contributions to the developmental events where it plays
a dual role, both as functional as well as structural supporting element. A well-known example is
provided by the morphogens, soluble factors contributing to define the patterning of surrounding cells
during embryonic development. Morphogens are produced in restricted areas of the embryo from
which they diffuse and, thanks to the presence of the ECM, generate gradients of signalling molecules
that influence cell migration, adhesion and contractility by the activation of intracellular signalling
pathways. Meanwhile, the ECM behaves as a structural element by defining the roads for cell migration,
delimiting differentiating tissues and maintaining the shape of developing organs. In this context,
the ECM assumes architectural roles, such as insulation of tissue to avoid nonspecific adhesion between
tissues or, conversely, mediating adhesion between different tissue layers. The opposite functions
of insulating or gluing embryonic tissues together show the flexibility of the ECM, which can select
one or the other or even synchronize both events according to environmental stimuli. An example
of coexistence is observed during muscle differentiation, where a sticky ECM is required to bind the
extremities of the cells, whereas a slippery matrix coats the lateral sides [38]. A slippery ECM is defined
as an intact basement membrane (composed by laminin, integrin and glycoproteins) that allows tissues
to freely slide on each other. GAGs with their negative charges and the resulting chain-chain repulsions,
are the main cause of tissue slippery. Conversely, the removal of laminin induces a fragmentation of
the basement membrane that, together with the presence of cell adhesion molecules (CAM), results in
tissue sticking.
ECM plasticity is also fundamental during branching morphogenesis of several vertebrate organs
such as lung, kidney and mammary gland but also in skeletal development. During osteogenesis,
skeletal progenitor cells undergo several morphological changes to ultimately give rise to the adult
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bone [39]. In mature bone, the ECM is the result of active and opposing remodelling events exerted by
the osteoclasts and osteoblasts, which degrade and deposit the bone matrix, respectively. An imbalance
between degradation and deposition leads to alteration of bone density and disease.
3.4. Cell Migration
The ability of cells to move is central for embryo development as well as maintenance of
multicellular organisms. Cell movement strictly depends on the balance between adherence to and
release from the ECM in a dynamic fashion. The adhesive properties of the cells are mainly regulated
by integrins, which play both structural and signalling roles. Integrins can sense the physical state of
the matrix, by interacting with specific ECM molecules, such as collagens and laminins and activate
downstream intracellular signalling cascades involving the focal adhesion kinase (FAK) signalling
pathway, the mitogen-activated protein (MAP) kinases and the Rho family GTPases [40,41]. Cells tend to
migrate along oriented fibrils in a non-random movement. The removal of specific ECM components
at a specific time, such as MMP-dependent proteolysis, can instead reorganize the ECM structure and
therefore alter or promote the migration process. Thus, the ECM is not only a substrate but it plays
dynamic and opposing roles in regulating cell migration. On one side, the basement membrane with
its dense fibrillar protein network acts as a barrier to migrating cells, on the other, the ECM promotes
cell movement by exposing chemotactic factors that can attract or repulse cells. The ECM remodelling
contributes to the formation of organized pathways along which the cells can migrate in an oriented way.
Collective cell migration along oriented patterns is an essential aspect of wound healing, a multi-steps
process in which the skin repairs itself after injury. During this process, the ECM regulates the interactions
between epidermal, dermal and bone marrow cells, it influences cell proliferation and orchestrates the
deposition of new connective tissue and the migration of keratinocytes to the wound site.
3.5. ECM Remodelling
To fulfil its activities, the ECM requires a constant and regulated remodelling whose precise
orchestration is crucial for tissue homeostasis and developmental processes characterized by transient
and dynamic signalling events. ECM remodelling implies changes in ECM composition (novel
synthesis or degradation of specific ECM components) or ECM architecture (modification of the
macromolecule organization). Several enzymes are involved in ECM remodelling, below is provided a
short description of the most known and characterized enzymes.
Matrix metalloproteinases (MMPs) are a large family of enzymes that participate in the
degradation of all major ECM components, including those of the basement membrane. They are
zinc-dependent endopeptidases initially secreted in the extracellular environment as inactive zymogens
with a pro-peptide domain that needs to be removed to allow enzyme activation. The MMPs can be
either soluble or membrane-bound and present a substrate-specificity. At least 24 MMPs proteins
have been so far identified and, based on their structural organization and substrate specificity, MMPs
can be classified into: collagenases, gelatinases, stromelysins, matrilysins and membrane-type I [42].
Under physiological conditions MMP activities are tightly regulated but they may increase during
pathological events.
Adamlysins, also called ADAMs (a disintegrin and metalloproteinases) and ADAMTS (ADAMs
with a thrombospondin motif), are ECM proteinases involved in cell phenotype regulation, adhesion and
migration. The ADAMs include both transmembrane and secreted proteins, whereas the ADAMTSs only
contain secreted proteins. 21 ADAMs and 19 ADAMTS are known. They share several structural domains
including the metalloproteinase as well as the disintegrin domain, the latest being involved in the binding
to integrins. ADAMs are involved in cytokines processing and growth factor receptor shedding [43] while
ADAMTS play a role in degradation of ECM components, particularly collagens and proteoglycans [44].
Meprins are membrane-bound or secreted metalloproteinases capable to cleave ECM molecules
including the collagen type IV and fibronectins. In addition, they are involved in the synthesis of mature
collagen molecules and in the activation of other metalloproteinases including MMPs and ADAMs [45].
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The right balance between ECM degradation and deposition has to be guaranteed for the correct
tissue integrity. It is therefore evident the relevance of ECM proteinase inhibitors. The tissue inhibitors
of metalloproteinases (TIMPs) represent a small family composed of only four members with the
function of reversibly inhibiting the activity of MMPs and ADAMs. TIMPs present two distinct
domains, one at the N- and one at the C-terminal region of the protein, which are responsible for the
binding and inhibition of MMP activity, respectively. Although each TIMP molecule is active against
various MMPs, they all show some substrate preferences [46].
Other enzymes may be involved in ECM remodelling. Various proteolytic enzymes, including
serine proteinases, cathepsins, heparanases, sulphatases and hyaluronidases, were shown to target ECM
proteins. Plasmin and elastase are serine proteinases, the first degrades fibrin, fibronectin and laminin [47],
whereas the latter degrades fibronectin and elastin [48]. Cathepsins are lysosomal proteases, which are
appointed to the degradation of intracellular or endocytosed proteins. Under specific circumstances
cathepsins can be secreted in the extracellular environment where they contribute to the ECM protein
degradation. Heparanases and sulphatases cleave heparin sulphate [49] and remove its 6-O-sulphate
residues, respectively. They affect the ability of heparin sulphate to bind several growth factors such as
VEGF, PDGF and FGF, thus altering the downstream signalling events [50]. Hyaluronidases are a family
of enzymes capable of degrading HA [51].
4. Collagens
Collagens are the major insoluble fibrous proteins in humans and other vertebrates, accounting
for about a quarter of their total protein mass. So far 28 different types of collagens have been identified
in vertebrates. They assemble to adopt a triple-helix conformation that gives rise to long thin fibrils
or two-dimensional reticulum or even associate with other ECM elements. The different types of
collagens and their structure are crucial to provide mechanical stability, elasticity and strength to
tissues and organs.
4.1. Collagen Synthesis and Organization
Fibrillar collagens are the most abundant collagens in humans and they are synthetized as long
precursors, known as procollagens, which contain a large polypeptide extension at both the N- and
C-terminal ends. The C-propeptide has an essential role inside the rough endoplasmic (ER) reticulum
where it initiates the assembly of three coiled subunits (α chains) one around the other and along a
central axis in order to generate right-handed triple-helix. In vertebrates, over 40 genes encode collagen
α chains, which are differentially combined to form 28 different collagen types. Despite the different
structural organization, all collagen types share the triple-helix structure. An essential element for the
assembly of the three α chains is the proline-rich tripeptide Gly-X-Y repetition, which characterizes
all collagens. In the triple helix, glycine residues are localised in the central part, thus allowing a close
packing of the molecule [52,53]. Proline and hydroxyproline residues usually occupy the X and Y positions
of the tripeptide. Moreover, hydroxylation of prolines and lysines in the middle region of the chains
allows the formation of intra-molecular hydrogen bonds that stabilize the entire complex. The extent
of lysine hydroxylation varies between tissues and collagen types. Some of the hydroxylysines are
further modified by glycosylation with galactose and glucose [54]. Notably, the short N- and C-terminal
portion of the chains, which do not assemble in the triple-helix, are required for the extracellular secretion
of the polypeptide and the formation of collagen fibrils. The N- and C-propeptides (telopeptides) are
subsequently removed by procollagen aminoproteinases and procollagen carboxyproteinases, respectively,
giving rise to tropocollagen units [55,56]. Finally, adjacent tropocollagens are bound together through the
formation of intermolecular interactions that involve lysine and hydroxylysine residues, thus providing
the tensile strength of collagen fibrils. Finally, fibrils assemble into fibres of larger diameter [52]. Details
on the synthesis of the other collagen types are included (Section 4.2) and shown in Figure 2.
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Figure 2. Schematic representation of collagen biosynthesis steps. The main biosynthesis steps of various
collagen types are indicated. Green arrows highlight the contiguous processing steps whereas red arrows
indicate the final step of collagen assembly into the different structural conformations. Coloured boxes on
the right indicate potential alterations occurring during collagen processing at different steps, thus causing
abnormalities in the structure and/or assembly. Abbreviations: NC, non-collagenous domain.
4.2. Nomenclature and Classification
Collagens can be grouped based on their structure, function and tissue distribution. They are
designated by Roman numerals according to the order of their discovery (I-XXVIII) [53]. They are
formed by three identical chains (homotrimers) or by two/three different chains (heterotrimers).
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The most abundant collagen of the human body, the interstitial type I collagen, is made by two
identical α1 and one α2 chain, which shows high sequence homology with α1 [57]. In most other cases,
including the collagen type II, they are homotrimers made by three identical α1 chains. The length
of the triple helical region differs among the various collagens. The tripeptide repetition is the
predominant motif in fibril collagens whereas it is much shorter and frequently interrupted by
non-triple helical domains in other collagen types (such as the non-fibrillar collagens). Non-collagenous
(NC) regions may also have structural function as shown by the transmembrane collagens [58].
Following a classification based on collagen function and composition, we can distinguish:
Fiber-forming collagens: they are characterized by a fibrillar shape and a rope structure.
Under electron microscopy they show characteristic banding pattern. Fibril collagens assemble to form
fibres whose diameter ranges from 12 to >500 nm and the length varies depending on the tissue and
developmental stage. They are stabilized by non-reducible covalent crosslinks among specific triple-helix
domains and telopeptides [59]. They include the most abundant collagens of the organisms, such as the
interstitial collagens (types I, II and III) and the collagen types V and XI, whose main functions consist in
providing structural support, balance of pulling forces and enabling cell movement.
FACITs (fibril-associated collagens with interrupted triple helices): they contain short collagenous
regions with interruptions in the triple helix intercalated by four NC regions. These molecules are
mostly heterotrimers and carry a glycosaminoglycan side chain. They include collagen types IX,
XII and XIV, which associate with various collagen fibrils.
Network-forming collagens: they are non-fibrillar collagens that aggregate linearly or laterally to
form open networks. They are longer than classical collagens and can give rise to different kinds of
networks depending on the collagen type. In particular, collagen type IV, the main component of epithelial
basement membranes as well as vascular basal lamina, is irregularly assembled. Differently, collagen types
VIII and X form regular hexagonal networks. The function of these network-forming collagens varies and
likely depends on their structural organization [53,60].
Transmembrane collagens: they are expressed in many different tissues and cells. This group of
collagens plays an important role in epithelial and neural cell adhesion as well as in epithelial–mesenchymal
interaction during morphogenesis. They are characterized by the presence of several triple helical regions
in the extracellular C-terminal domain interspersed by NC stretches. Next to the extracellular portion
of the protein, there is a conserved coiled-coil domain essential for the trimerization of transmembrane
collagens. Collagen types XIII and XVII are included in this group [61].
MULTIPLEXINs (multiple triple-helix domains and interruptions): collagen types XV and
XVIII consist of several collagen domains with NC interruptions in the triple helixes, which are
able to form oligomeric assemblies. They are found in some basement membranes covalently
linked to glycosaminoglycan chains. The NC1 domain of collagen types XV and XVIII includes
a peptide (endostatin) that following proteolytic cleavage is released in the extracellular environment.
Several studies show the anti-angiogenic properties of endostatin as inhibitor of endothelial cell
migration and tumour growth [62,63].
Anchoring fibrils: collagen type VII is the major component of the anchoring fibrils, whose function is
to secure the adhesion of the epidermal and dermal layers. It consists of a central collagenous triple-helical
domain flanked by NC1 and NC2 domains. The NC2 domain is proteolytically cleaved while NC1 is
preserved to anchor other ECM elements, including collagens and laminins. The anchoring filaments are
assembled in an antiparallel manner, tail to tail with some C-terminal overlap [62,64].
Beaded-filament-forming collagen: collagen type VI is the archetypal beaded filament-forming
collagen. It is widely expressed and holds up tissue integrity. Collagen VI monomers are made up of
short triple helical domains, which aggregate linearly to form beaded filaments or laterally through
their globular domains, thus creating 3D networks. For this reason collagen type VI can also be
included among the network-forming collagens [60]. The N and C non-collagenous regions of the
monomers are preserved and antiparallel dimers and tetramers are assembled intracellularly [53,62].
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Notably, collagen-like triple helical domains are found in several other proteins that do not have
structural function and therefore are not considered as real collagens [65].
4.3. Collagen Degradation
Collagens have a great structural stability, resulting in high resistance against degradation by
bacterial collagenases and other peptidases. Nevertheless, under physiological conditions most
connective tissues undergo to a persistent turnover and continuous remodelling. Collagen degradation
is a multi-step process that relies first on the activity of extracellular proteases to break down the ECM
collagen fibrils and subsequently on the cellular uptake and intracellular lysosomal degradation of
fragmented fibrils [66]. The extracellular fragmentation of collagens is mainly mediated by proteinases
such as the MMPs (collagenases and stromelysin), cysteine cathepsins and serine proteinases (plasmin).
MMPs can target a wide range of ECM proteins, not only collagens. They act at neutral pH and
recognize specific cleavage sites on the target molecules [67]. Cathepsins are lysosomal proteases
active at acidic pH, which can be active both intracellularly and upon secretion. Cathepsin S was
shown to target and degrade collagens [68]. An indirect collagen digestion can be achieved in
response to plasminogen activation to plasmin. The pro-MMP-2 enzyme is activated by plasmin into
MMP-2, also known as gelatinase A. Upon activation, MMP-2 can degrade several collagen types,
fibronectin, elastin as well as gelatin, the denatured form of collagen [69]. The extracellular collagen
fragments are then recruited through phagocytosis from the neighbouring cells, mainly fibroblasts
and macrophages, which send them to degradation via the lysosomal pathway [70]. The relationship
between the extracellular and intracellular pathways is complex and not fully understood. It has
been shown that in macrophages uPARAP/Endo180 acts as collagen internalization receptor after the
interaction with pro-uPA (pro-urokinase plasminogen activator) and uPAR (urokinase plasminogen
activator receptor [71]) proteins. Moreover, collagen internalization requires the expression of specific
integrins and cytokines, including TGFβ and interleukin 1α. Finally, lysosomes fuse together to
generate large structures containing collagen and ECM fragments that undergo enzymatic digestion
by cysteine cathepsins [72,73].
5. Collagen Alterations in Pathological Events
The tight regulation of ECM synthesis and remodelling is fundamental for human health,
as attested by the high number of hereditary disorders caused by mutations in genes encoding
structural elements of the ECM or proteases implicated in the remodelling process. Alterations of ECM
remodelling can also influence the course and progression of several other pathological conditions,
including fibrosis, skin disorders and cancer [74]. The excessive ECM production and the concomitant
loss of degradation leading to fibrosis will not be discussed in this review, which is focused on the
human genetic disorders associated to an altered collagen structure (Table 1) or resulting in excessive
degradation of specific collagen elements (Table 2). A general overview of the clinical features
associated to these collagen-related disorders is also provided (Tables 1 and 2).
Since collagens are present throughout the entire body, alterations impairing the quality or
quantity of collagen structures can affect any tissue or organ. Since each collagen is generally expressed
in several different tissues and it is tightly associated with other ECM elements, alterations result in
widely overlapping features that make the diagnosis difficult. Nevertheless, we thereafter propose a
tentative classification of the collagen-related disorders according to the major clinical features and
affected organs listed in Tables 1 and 2.
Skeletal and cartilage abnormalities: collagen type I is the major ECM component secreted by
osteoblasts during bone development. Therefore, alterations in this molecule can give rise to the
osteogenesis imperfecta (OI) characterized by bone fragility, as well as the Caffey disease with its infantile
episodes of excessive new bone formation (hyperostosis). Also, mutations in COL2A1 gene result in
skeletal abnormalities including the incomplete bone ossification in patients with achondrogenesis type
II before birth or the short stature (dwarfism) of patients with Kniest dysplasia. Dwarfism can also
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be caused by alterations of collagen type IX or X (multiple epiphyseal dysplasia or the Schmid-type
metaphyseal chondrodysplasia, respectively) or by mutations in COL11A1, COL11A2 or COL27A1 genes.
Moreover, collagen types II, IX and XI are implicated in the formation and maintenance of the cartilage,
thus they are relevant for the joint health and long bone development. Mutations in COL2A1 gene
may result in cartilage alterations characterized by progressive degeneration at the joints (patients with
osteoarthritis with mild chondrodysplasia), by hypercellular cartilage with large chondrocytes (Torrance
type of platyspondylic lethal skeletal dysplasia) or by a translucent and abnormal gelatinous texture
(achondrogenesis type II). Additionally, the presence of fibrous cartilage can be found associated with
skeleton defects in patients with fibrochondrogenesis-1 or multiple epiphyseal dysplasia, due to mutations
in COL11A or COL9A gene, respectively.
Skin alterations: some of the collagen-related disorders present severe skin alterations.
The dystrophic forms of epidermolysis bullosa (EB) with mutations in COL7A1 or COL17A1 gene is
one of the major forms of EB where patients present a fragile skin, which can shed at the slightest touch.
In milder cases blistering may affect the hands, feet, knees and elbows but in severe cases blistering may
lead to vision loss, disfigurement and strictures of the gastrointestinal tract. Skin defects are also the
main features of patients with the Ehlers-Danlos syndrome (EDS), a genetically heterogeneous disorder
with more than nineteen causative genes. Mutations in COL5A1 or COL5A2 are responsible for the
classical form of EDS. Patients present a soft, velvety skin that is highly stretchy (skin hyperextensibility)
and fragile. Affected individuals tend to bruise easily and in some cases, they show atrophic scars.
Skin alterations are also found in patients with Bethlem myopathy-1 caused by mutations in COL6A
genes. Even though muscle dystrophy is the main clinical feature in this group of patients, they present
follicular hyperkeratosis on the arms and legs, soft, velvety skin on the hand palms and feet soles,
abnormal wound healing that leads to shallow scars.
Finally, alterations of MMP1 gene expression have been associated to disorders with skin defects:
overexpression of MMP1 in primary dermal fibroblasts of patients with trichothiodystrophy is
responsible for collagen type I degradation and altered wound healing features whereas a functional
single nucleotide polymorphism in MMP1 promoter is associated with increased collagen type VII
degradation and high severity of recessive dystrophic EB.
Hearing loss and visual defects: many of the collagen-related disorders are characterized by
sensorineural hearing loss. In particular, all the disorders due to alterations of collagen type XI (see Table 1),
the Alport syndrome and the X-linked deafness-6 due to alterations of collagen type IV and the OI and
EDS disorders by collagen type I defects may reveal sensorineural hearing loss. Notably, some of these
disorders are also associated to visual problems that may include myopia, cataract and in some cases
(Stickler syndrome) retinal detachment. More severe vision defects can be observed in patients with the
Knobloch syndrome-1 due to alterations of the type XVIII collagen. These patients are affected by high
myopia, cataract, dislocated lens, vitreoretinal degeneration and retinal detachment. Finally, alterations of
type IV collagen can also result in visual defects as observed in patients with retinal arterial tortuosity,
Axenfeld-Rieger anomaly and Small vessel disease of the brain.
Muscle weakness: collagen types VI certainly plays a relevant role in skeletal muscle maintenance
and regeneration. Alterations of its major elements, the α1 and α2 chains, result in Bethlem myopathy-1,
Ullrich congenital muscular dystrophy-1 or the autosomal recessive myosclerosis, all characterized by
progressive muscle weakness (hypotonia) and joint stiffness (contractures) with different degree of severity.
In the most severe cases weakness of respiratory muscles are reported. Differently, alterations affecting
the α3 chain of collagen type VI are found in rare cases with dystonia 27. These patients reveal dystonic
action and postural tremor mainly involving the face, neck, bulbar muscles and upper limbs. A severe
generalized hypotonia leading to exercise intolerance, feeding difficulties and respiratory insufficiency
are present in patients with congenital myasthenic syndrome type 19 due to mutations in COL13A1
gene. Also, patients with EDS reveal weak muscle tone and hypermobile joints, which can delay the
development of motor skills such as sitting, standing and walking. Two cases with OI due to mutations
in SPARC gene present underdeveloped muscles of the lower extremities, muscle hypotonia and gross
16
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motor developmental delay, whereas a single family with congenital fibrosis of extraocular muscles-5
caused by mutations in COL25A1 gene showed ophthalmoplegia of the extraocular muscles.
Small vessel anomalies and kidney disease: the type IV collagen is the major constituent
of the basement membranes. It is a non-fibrillar collagen made of three distinct heterotrimers
generated by the products (α chains) of 6 distinct genes. Mutations in COL4A1 and COL4A2 result
in thickness and damaged vascular basement membranes that affect the straightness of the vessels
in patients with susceptibility to intracerebral haemorrhage, hereditary angiopathy or small vessel
disease of the brain. Also, the retinal arterial tortuosity derives from mutations in the COL4A1 gene.
Differently, alterations impairing the α3, α4 or α5 chains of collagen type IV result in defects of the
glomerular basement membrane that affect kidney functionality. This is observed in patients with
Alport syndrome who experience high levels of haematuria and proteinuria due to the progressive
loss of kidney activity. Persistent and recurrent haematuria is also observed in the benign form of
familial haematuria due to mutations in COL4A3 or COL4A4 genes.
Most of the collagen-related disorders affect early childhood health but mild situations can
also occur during adulthood. Indeed, the severity of clinical features in patients affected by
Stickler syndrome varies among individuals and mild cases with late onset have also been reported.
Conversely, when collagen alterations result in severe deformations, the survival of the entire organism
is compromised as shown by PPIB mutations in type IX osteogenesis imperfecta. Patients affected by
such severe form of OI die during gestation or shortly after birth. It is worthwhile considering that
the severity of the disorder relies on several different factors where tissue distribution and function
of the affected collagen play leading roles. The OI with its various degree of severity is the result
of structural alterations of collagen type I, the most abundant collagen in humans. In particular,
mutations inactivating one of COL1A1 alleles and resulting in reduced levels of an otherwise normal
type I collagen are usually responsible for the mild forms of OI whereas dominant negative mutations
in COL1A1 or COL1A2 genes account for the most severe forms. Notably, among the most common
mutations responsible for the severe form of OI are those involving the substitutions of the glycine
amino acid in the G-X-Y repeats, essential for the formation of the triple helix. This strongly points to the
notion that structural alterations are more detrimental to human health than collagen impoverishment.
Similarly, mutations in COL2A1 gene result in several rare autosomal dominant clinical entities that
share skeletal dysplasia, short stature and sensorial defects. The wide range of clinical manifestations
were not fully understood but a recent study on over 700 cases (harbouring 415 different mutations)
revealed that one-third of the mutations affect the glycine amino acid in the G-X-Y repeats and give
rise to the severe achondrogenesis type II disease, which is typically identified in utero and may result
in embryo death. In contrast, mutations resulting in a premature stop codon or the p.Arg275Cys
substitution are responsible for the less severe cases affected by Stickler syndrome or Czech dysplasia [75].
In summary, the type of mutation, the tissue distribution and the function of the affected collagens all
impact on the clinical spectrum of collagen-related disorders.
17
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6. Conclusions
The large number of genetic disorders associated to collagen alterations clearly strengthens the
relevance of this wide group of proteins, which have been for long time considered inert elements with
no other function than maintenance of tissue shape and architecture. The observation that mutations in
collagen coding genes result in alterations of relevant developmental processes (skeletal and cartilage
development) or defects of tissue homeostasis (skin, sensorineural, visual and muscle alterations)
clearly demonstrate a regulatory role for this type of molecules. Therefore, not only the collagens
but also the ECM with its broad number of elements and its wide complexity plays a role of primary
importance among the mechanisms implicated in embryonic development, normal organ physiology
and human health. Moreover, the wide and largely overlapping spectrum of clinical features of
collagen, or even ECM-related disorders, makes in some instances the clinical diagnosis and patient
management very difficult. A better understanding of the signalling events regulating the expression,
functions and dynamic interplay of the various ECM elements will improve our knowledge on the
pathogenesis of ECM-related disorders and, in parallel, will provide the tools for the identification of
potential therapeutic targets.
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Abstract: Inherited point mutations in collagen II in humans affecting mainly cartilage are broadly
classified as chondrodysplasias. Most mutations occur in the glycine (Gly) of the Gly-X-Y repeats
leading to destabilization of the triple helix. Arginine to cysteine substitutions that occur at either the
X or Y position within the Gly-X-Y cause different phenotypes like Stickler syndrome and congenital
spondyloepiphyseal dysplasia (SEDC). We investigated the consequences of arginine to cysteine
substitutions (X or Y position within the Gly-X-Y) towards the N and C terminus of the triple helix.
Protein expression and its secretion trafficking were analyzed. Substitutions R75C, R134C and R704C
did not alter the thermal stability with respect to wild type; R740C and R789C proteins displayed
significantly reduced melting temperatures (Tm) affecting thermal stability. Additionally, R740C and
R789C were susceptible to proteases; in cell culture, R789C protein was further cleaved by matrix
metalloproteinases (MMPs) resulting in expression of only a truncated fragment affecting its secretion
and intracellular retention. Retention of misfolded R740C and R789C proteins triggered an ER stress
response leading to apoptosis of the expressing cells. Arginine to cysteine mutations towards the
C-terminus of the triple helix had a deleterious effect, whereas mutations towards the N-terminus of
the triple helix (R75C and R134C) and R704C had less impact.
Keywords: collagen II; chondrodysplasia; mutation; unfolded protein response; triple helix
1. Introduction
Collagens are the major proteins in the connective tissues, and collagen II is the major collagen
type in cartilage. However, it is also expressed in the vitreous of the eye and is detected during early
embryogenesis [1]. It is also expressed in nonchondrogenic tissues including notochord and several
parts of the developing eye [2]. Structurally, collagen II consists of three α chains, which are wound
around each other into a right-handed triple helix, which consists of repeats of three amino acids
(Gly-X-Y repeats). In various heritable connective tissue disorders, glycine substitutions in the collagen
chains cause structural changes that result in reduced thermal stability [3–5].
Int. J. Mol. Sci. 2018, 19, 541; doi:10.3390/ijms19020541 www.mdpi.com/journal/ijms42
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Cells synthesize collagen II α chains as longer precursors called procollagens. Simultaneously,
the growing polypeptide chains are co-translationally transported into the rough endoplasmic
reticulum (ER) where they undergo a series of post-translational modifications [6]. In addition to
post-translational modifications, the ER performs a stringent quality control for unfolded molecules,
and these are either retained or degraded. The correct folding and assembly of proteins within the
endoplasmic reticulum (ER) are prerequisites for subsequent transport from this organelle to the
Golgi apparatus [7]. Only recently, the pathway of collagen secretion from the Golgi complex to the
plasma membrane in large cargo vesicles has been elucidated [8]. The recognition and retention of
unassembled or misfolded proteins requires an interaction with molecular chaperones within the
ER [9]. One classic example of this process occurs during the biosynthesis of procollagen. Incompletely
folded intermediates or misfolded products are recognized by chaperones that prevent their secretion
and eventually lead to intracellular accumulation [10]. Procollagens are secreted into the extracellular
matrix (ECM) through the Golgi apparatus. The collagen II structure is susceptible to mutations
as it involves this complex process of collagen synthesis, folding and assembly, leading to disease
states that are collectively termed chondrodysplasias and comprise a wide range of well-characterized
clinical phenotypes [11–13]. Most chondrodysplasias are due to point mutations in the gene encoding
collagen II. Glycin replacement within the Gly-X-Y repeats accounts for 34% of all mutations [14].
These changes result in abnormal conformation and destabilization of the triple helix [15]. Only a
few non-glycine missense mutations have been reported, and among these, the arginine to cysteine
substitutions predominate [16].
Point mutations leading to a change from arginine to cysteine are interesting since they produce
a broader spectrum of unusual phenotypes with either normal or short stature, but never lethal
conditions, i.e., congenital spondyloepiphyseal dysplasia (SEDC), Stickler syndrome, Czech dysplasia
metatarsal type and osteoarthritis-associated SED. Different amino acid substitutions in the X position
of Gly-X-Y repeats have been shown to cause variable phenotypes in Stickler syndrome [17], while it
was speculated that substitutions in the Y position might lead to SEDC.
In the present study, we analyzed the impact of arginine to cysteine mutations at the protein level
and their effect on intracellular trafficking and secretion. A panel of mutations towards the N- (R75C,
R134C) and C- (R704C, R740C and R789C) terminus of the triple helix was selected. These mutations
cause a spectrum of different clinical phenotypes in humans including Czech dysplasia metatarsal
type (R75C) [18]), Stickler syndrome (R704C) [19,20] and spondyloepiphyseal dysplasia congenita
(R789C) [21]. All of these mutations are located in the triple helical region and in the X or Y position
of the Gly-X-Y repeats. In addition to these mutants, two artificial mutations R134C and R740C,
which are not naturally identified, but lying in the X position of a Gly-X-Y repeat in the triple helix,
were also studied.
2. Results
2.1. Collagen II Mutations towards the C Terminus Affect Secretion and Increase Susceptibility to Proteases
Collagen II variants were detected in supernatants and cells lysates of transiently-transfected
293 Epstein–Barr nuclear antigen (EBNA) and HT1080 cells (Figure 1A). All variants were expressed
in both cell lines, but R740C and R789C were not as efficiently secreted as the other proteins and
found in higher amounts in the cell lysate, indicating an intracellular retention. In addition, the R789C
protein migrated much faster on SDS PAGE gels, suggesting a proteolytic processing already in the
cells (Figure 1A). All secreted proteins were purified using affinity chromatography on a nickel column
and detectable with specific antibodies directed against collagen II and the myc epitope, respectively
(Figure 1B). Purified collagen II variants were digested with trypsin to evaluate the formation of a
correctly-aligned and stable triple helix. WT, R75C, R134C and R704C collagens were trypsin resistant,
while R740C and R789C collagens were completely degraded (Figure 1C). This implies that the secreted
R740C and R789C proteins are not forming stable triple helical structures.
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Figure 1. Recombinant expression of collagen II variants. (A) 293 Epstein–Barr nuclear antigen (EBNA)
(upper panel) and HT1080 cells (lower panel) were transfected with collagen II constructs (WT, R75C,
R134C, R704C, R740C and R789C) and the expression and secretion was analyzed using immunoblots.
Supernatants (S) and cell lysates (L) were harvested three days post-transfection and separated by
SDS PAGE (8% gel) under reducing conditions. Collagen II was detected with an antibody directed
against the myc epitope. (B) Coomassie blue stained SDS-PAGE gel and immunoblot of purified
collagen II variants using an antibody directed against collagen II (upper panel) and the myc epitope
(lower panel). (C) Collagen II variants were treated with trypsin at 25 ◦C for 2 min followed by
SDS-PAGE. The collagens were visualized by silver staining. WT, as well as R75C, R134C and R704C
collagens were resistant to trypsin and displayed a single band of the size of the triple helical domain
without the N- and C-propeptides (indicated by an arrow), whereas R740C and R789C collagens were
completely degraded.
2.2. C-Terminal Mutations (R740C and R789C) Lead to Thermal Instability of the Triple Helix
Circular dichroism (CD) spectroscopy of WT, R75C, R134C and R704C proteins displayed typical
collagen CD spectra with a positive ellipticity at 222 nm, indicating a correctly folded triple helical
structure (Figure 2A). In contrast, the collagen II mutants R740C and R789C (yellow and orange line)
showed a negative ellipticity at 222 nm, indicating a decreased triple helical content in these proteins
and confirming the trypsin sensitivity.
Melting temperatures (Tm) of purified collagens were determined by incremental heating with
simultaneous measurement of the molar ellipticity at 222 nm. Melting curves of all purified collagen
II proteins are depicted in Figure 2B using a curve fit model assuming that 100% of the molecules
were folded initially. The curves for WT, R75C, R134C and R704C collagens show similar profiles,
while R740C and R789C proteins showed a decreased Tm value indicating a decreased thermal
instability as compared to other collagens. The calculated melting temperatures are summarized
in Table 1.
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Figure 2. CD spectra and melting curves of purified collagen II variants. (A) Spectra were recorded
using collagens at a concentration of 60 μg/mL after dialysis against 100 mM acetic acid. The structure
of the mutant collagen II proteins R740C and R789C was altered as compared to other collagen II
variants, and the shape of the spectra already indicated a decrease in triple helical structure. (B) Melting
curves of collagen II proteins (60 μg/mL) were recorded after dialysis into 100 mM acetic acid at 222 nm
with a 1 ◦C/min temperature gradient from 10–55 ◦C. To calculate the percentage of folding, a curve fit
model was used assuming that initially 100% of the collagen molecules were folded. The R740C and
R789C proteins displayed a decreased thermal stability when compared to all other collagen II variants.
Table 1. Melting temperatures (Tm) of the purified collagen II variants.
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2.3. Inhibition of MMP Activity Prevents Cleavage of R789C
To investigate if the shift in R789C protein mobility is due to MMP cleavage, cells expressing
wild type and R789C collagen were incubated for two days with the MMP inhibitor GM6001. In the
presence of GM6001, significant amounts of R789C proteins remained uncleaved, in contrast to what
was seen in the absence of the inhibitor (Figure 3). This suggests that the mutation R789C increases the
susceptibility and/or accessibility for MMPs to cleave collagen II. Interestingly, the resulting uncleaved
R789C protein was now detected in the supernatant in large amounts indicating that inhibition of
cleavage results in increased secretion. Even though some uncleaved protein was secreted, a large
proportion of both uncleaved and cleaved collagen was still retained intracellularly.
 
Figure 3. Analysis of proteolytic processing using the MMP inhibitor GM6001. Cells expressing
wildtype (WT) and R789C collagens were cultured for two days in the absence (A) or presence (B) of
the MMP inhibitor GM6001 (25 μM). Supernatants (S) and cell lysates (L) were harvested and analyzed
by immunoblot with an antibody direct against the myc epitope. After treatment with GM6001,
the R789C collagen was partially protected from degradation, indicating that the reduced mass and
shift in mobility are caused by a proteolytic cleavage by MMPs.
2.4. Effect of Mutations on Intracellular Collagen Trafficking in Transfected HT1080 Cells
Collagen II trafficking was visualized by co-staining with antibodies directed against PDI and the
58K protein as marker for the ER and the Golgi apparatus, respectively, in transfected HT1080 cells.
WT, R75C, R134C and R704C collagen II proteins co-localized mainly with the perinuclear Golgi
apparatus, demonstrating that the intracellular trafficking of these proteins from ER to Golgi apparatus
is not affected by the mutation (Figure 4). In contrast, the mutant R740C and R789C were mainly
detected in the ER, which is typically spread throughout the whole cell. Overlapping staining for
collagen II and PDI in cells expressing R740C and R789C proteins suggests that the protein is retained
in the ER compartment due to the mutation (Figure 4).
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Figure 4. Immunofluorescence microscopy of transfected HT1080 cells showing the intracellular
localization of wildtype and mutant collagen II variants. HT1080 cells transfected with collagen II
constructs were analyzed three days post-transfection with antibodies directed against the myc epitope
of collagen II (green) and either against PDI as a marker for ER or 58K as a marker for the Golgi
apparatus (both in red). Colocalization of collagen with 58K in the Golgi compartment is seen in cells
expressing WT, R75C, R134C and R704C collagen (arrows). In cells expressing R740C and R789C
collagens, significant amounts of protein colocalize with PDI in the ER detected outside the Golgi
apparatus (arrowheads). Scale bar, 25 μm.
2.5. C-Terminal Mutations Induce Activation of the Unfolded Protein Response Due to Accumulation of
Misfolded Collagen II Proteins
Intracellular retention of misfolded proteins in the ER leads to activation of a complex signal
transduction pathway called the unfolded protein response (UPR) [22,23]. UPR results in the induction
of ER stress response genes by two potent transcription factors, activating transcription factor-6 and
XBP-1 (X-box DNA binding protein-1). Active XBP-1 is generated by excision of a 26-nucleotide
sequence from the XBP-1 transcript by IRE1 endonuclease in response to accumulation of misfolded
proteins in the ER [22,23]. XBP-1 splicing was investigated by RT-PCR from RNA isolated from
HT1080 cells using specific primers giving rise to a 248-bp band in the case of unspliced XBP-1 and to
a 222-bp band where XBP-1 is spliced. Figure 5A shows the PCR products resolved on a 2.5% agarose
gel. In cells expressing WT, R75C, R134C and R704C collagen, only the unspliced form of XBP-1 was
detected, while in cells expressing R740C and R789C collagen, the spliced variant (XBP-S) could also
be detected. This suggests that the intracellular retention of misfolded proteins has triggered an ER
stress response.
Expression and Association of Chaperones with Mutant Collagen II Proteins
Activation of XBP-1 results in upregulation of ER-resident molecular chaperones. To investigate
whether the splicing of XBP-1 associated with accumulation of R740C and R789C mutant collagen II
proteins results in increased expression and association of BiP in transfected HT1080 cells, cells were
stained for collagen II and BiP. BiP expression was observed in cells expressing WT collagen,
and collagen II staining was observed around the Golgi compartment in the transfected cells (Figure 5B)
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with only little co-staining detected between BiP and collagen II. In cells expressing R740C and R789C
collagens, significant co-staining of BiP and collagen II proteins was observed, and the intensity of BiP
staining was also increased in these cells, compared to the cells transfected with wildtype collagen II.
Figure 5. Detection of stress-induced XBP-1 splicing and BiP expression in transfected HT1080 cells.
(A) mRNA isolated from HT1080 cells was used for RT-PCR with primers specific for XBP-1. The PCR
products were separated on 2.5% agarose gels. XBP-1 mRNA (248 bp) could be detected in all cells.
Splicing of XBP-1 due to ER stress gives rise to a 222-bp fragment that was seen only in cells transfected
with R740C and R789C constructs. (B) HT1080 cells transfected with collagen II constructs were
analyzed three days post-transfection by staining with antibodies directed against collagen (red) and
BiP (green). BiP expression was observed in all the cells. However, increased BiP expression and
colocalization with collagen II resulting in strong yellow signals were seen only in cells expressing
R740C and R789C collagens. Scale bar, 25 μm.
2.6. Intracellular Accumulation of Misfolded Proteins Induces Apoptosis in Cells Expressing Mutant Collagens
Retention of large amounts of misfolded proteins affects cell viability. We therefore analyzed
if HT1080 cells expressing mutant collagens undergo apoptosis as a consequence of ER stress.
The executioner caspase caspase-3 has to be activated by other proteases like caspase-8 and -9.
Caspase-3 then cleaves a large number of cellular proteins, and their degradation finally disrupts
cellular homeostasis and causes cell death.
Three days after transfection, R740C- and R789C-expressing HT1080 cells were positive for
activated caspase-3 detected by immunostaining using a FITC-conjugated anti-active caspase-3
antibody. In non-transfected cells or cells expressing WT, R75C, R134C and R704C collagens, no active
caspase-3 staining could be detected (Figure 6 and Supplemental Figure S1).
Thus, cells expressing R740C and R789C collagens become apoptotic, most likely due to an ER
stress response triggered by irreversible accumulation of misfolded proteins. Apoptosis is accompanied
by cleavage and fragmentation of nuclear DNA. We therefore analyzed if DNA fragmentation could
be detected in HT1080 cells expressing R740C and R789C collagens. Nick-labeled DNA was not
observed in non-transfected cells and cells transfected with wild type and R704C constructs, whereas
nick-labeled DNA was observed in cells expressing R740C and R789C (Figure 6).
Apoptosis was quantified in HT1080 cells four days post-transfection by comet assays (single
cell gel electrophoresis) (Figure 7). Nuclear DNA fragmentation leads to DNA tailing that can be
visualized by a comet-shaped appearance. Such comets tails were observed in cells transfected with
R740C and R789C constructs (Figure 7A). From each genotype (20 cells per genotype), the mean tail
length was determined using the CometScore software (Figure 7B). Apoptosis in cells expressing
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R740C and R789C collagens was indicated by a significant increase in tail length corresponding to
DNA fragmentation.
Figure 6. Detection of apoptosis in HT1080 cells transfected with collagen II constructs. HT1080 cells
transfected with collagen II constructs were analyzed three days post-transfection for the presence of
active caspase-3 (green) as a marker for apoptosis. Active caspase-3 was only found in cells expressing
R740C and R789C collagens (left panel, indicated by arrow heads). Four days after transfection,
HT1080 cells transfected with R740C and R789C constructs were positive for TUNEL staining (green,
right panel, indicated by arrow heads). Nick labeling was neither seen in non-transfected cells, nor in
cells transfected with other collagen constructs (Supplemental Figure S1). Scale bar, 25 μm.
Figure 7. Single cell gel electrophoresis (comet assay) of HT1080 cells transfected with collagen II
variants. (A) Nuclei of non-transfected (NT) and WT collagen-expressing cells were round when
visualized after electrophoresis. In contrast, a comet-shaped appearance of fragmented nuclei was
seen in cells transfected with R740C and R789C, indicating ongoing DNA fragmentation. Scale bar,
25 μm. (B) The mean tail length was evaluated for these comets (20 cells for each genotype) using the
CometScore software. A significant increase in tail length was observed in cells transfected with
R740C and R789C collagen constructs, while cells transfected with all other constructs behaved
similar to non-transfected controls. Asterisks indicate significant difference compared to and WT
collagen-expressing cells with p < 0.05.
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3. Discussion
Point mutations in fibrillar collagens cause a number of abnormalities in connective tissues,
leading for example to brittle bone disease, osteoarthritis and osteochondrodysplasias [24,25]. In the
present study, a set of COL2A1 mutations leading to substitution of an arginine to cysteine residue
in the triple helix were studied. The mutations were selected based on their localization within the
triple helix and position with the Gly-X-Y repeats. Interestingly, the selected mutations cause a rather
heterogeneous disease spectrum in humans including Czech dysplasia metatarsal type (R75C), Stickler
syndrome (R704C) and spondyloepiphyseal dysplasia congenital (R789C). We included two artificial
mutations (R134C and R740C) and analyzed their effects on intracellular protein trafficking, secretion
and cell survival.
We were able to express all variants in both 293 EBNA and HT1080 cells. WT, R75C, R134C and
R704C proteins were mainly detected in the cell culture supernatant indicating a normal secretion.
The variant R740C showed a retarded secretion with similar protein amounts in the supernatant and
cell lysate, respectively. R789C collagen was not only retained intracellularly, but also processed,
resulting in a prominent band at around 90–100 kDa. This cleavage took place already in the
intracellular compartment. Altered secretion and moderate intracellular retention of R789C collagen
was reported earlier when this construct was expressed in SW-1353 and HT1080 cells [26,27]. However,
the processing was observed for the first time and is in contrast to earlier reports [27,28]. This apparent
difference might be explained by expression levels depending on the vectors used and it is likely that
a cell starts to degrade the protein when a certain amount has been accumulated. Even though two
variants were not properly secreted, we were able to purify sufficient amounts of all constructs to
perform biochemical analysis. CD spectroscopy with collagen-specific spectra indicated correct folding
of the variants WT, R75C, R134C and R704C. The melting temperature of wild type collagen II with
38.6 ◦C was 2.4 ◦C lower than for collagen extracted from bovine nasal cartilage [29]. This difference
in the absolute melting temperature might be caused by inefficient hydroxylation by 293 EBNA
cells [30,31]. The R75C, R134C and R704C proteins had a 2.5 ◦C lower melting temperature than
the wild type protein, suggesting slight structural differences even though these changes were not
pronounced enough to loose trypsin resistance. In contrast and in agreement with earlier studies [26,27],
R740C and R789C collagens had a significantly reduced melting temperature, and incubation with
trypsin led to complete degradation, confirming an unstable triple helix in these variants. Such an
instability could well contribute to the disease mechanism in human patients and has been reported to
be involved for mutations in COL2A1 causing Kniest dysplasia [32], in COL3A1 causing Ehlers-Danlos
syndrome type IV [33] and in COL17A1 causing junctional epidermolysis bullosa [34].
The cleavage of partially-misfolded R789C collagen might be due to an increased accessibility
for proteases at regions around the site of mutation. MMP-1, MMP-8 and MMP-13 [35,36] are able
to initiate the intrahelical cleavage of triple helical collagen at neutral pH. These collagenases cleave
the collagens types I, II and III specifically at a single site (Gly775–Leu/Ile776) within each α chain of
the triple helical collagen molecule [37]. The exact cleavage position in the R789C protein is yet to be
identified, but it is attractive to speculate that the mutation in close proximity of the well-known MMP
cleavage site facilitates cleavage due to local unfolding [38–40]. The fact that pretreatment of the cells
with the MMP inhibitor GM6001 abrogated the processing further supports the notion that MMPs are
responsible for the cleavage. Interestingly, the inhibition of cleavage leads to an increased secretion of
the now fully-intact protein into the supernatant. This is in good agreement with earlier studies in
which mutating the MMP cleavage site resulted in an increased secretion of R789C collagen [27,28,41].
Increased collagen cleavage by MMPs at this position has indeed been shown in patients with specific
forms of osteoarthritis, as well as in transgenic mice with osteoarthritis [42–44]. This might explain
why specific collagen mutations predispose for cartilage degeneration.
The fibroblastic cell line HT1080 is commonly used to study protein expression, trafficking and
secretion of collagen II [45,46]. Immunoblotting already suggested that a considerable amount of
R740C and R789C protein was present in cell lysates owing to intracellular retention. Co-staining
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with compartment-specific antibodies revealed that WT, R75C, R134C and R704C proteins were found
mainly in the Golgi compartment, indicating that these proteins are being transported efficiently to the
extracellular space. In contrast, R740C and R789C proteins showed only weak co-localization with
the 58k Golgi marker and were instead detected in other cellular compartments. Co-staining with
PDI, an ER-resident chaperone, suggests that mutant and misfolded R740C and R789C proteins are
retained in the ER [47,48]. A similar intracellular retention of the misfolded proteins in the ER due to
point mutations was reported for other cartilage proteins such as COMP, collagen IX and matrilin-3 in
patients and animal models [49,50].
The retention of misfolded protein in the ER leads to the activation of a complex signal
transduction pathway called the unfolded protein response (UPR) [22,23]. The fact that a targeted
induction of ER stress alone is able to induce cartilage pathology [51] underlines the crucial role of
this process in disease initiation. The splicing of XBP-1 mRNA is a hallmark of the mammalian UPR,
and we indeed detected this unconventional splicing event in cells expressing R740C and R789C
collagen. A similar observation was made in response to misfolded protein accumulation due to a
mutation in the NC1 domain of collagen X [52]. XBP-1 splicing in turn leads to an upregulation of
ER-resident molecular chaperones like BiP [53]. We also detected an upregulation and colocalization of
BiP with R740C and R789C procollagen chains, and similar findings were reported for collagen chains
harboring mutations in type I collagen from patients with osteogenesis imperfecta [54].
Prolonged accumulation of misfolded proteins in the ER without degradation can lead to
programmed cell death [55,56]. Indeed, the large amount of rounded and dead cells observed in
cultures expressing R740C and R789C collagens may indicate that the cells are undergoing apoptosis.
We were able to detect an increase of active caspase-3 and TUNEL staining in cells transfected with
R740C and R789C constructs, confirming earlier observations [57]. An increased apoptosis may also
explain the reduced number of chondrocytes observed in both patients and animal models [37,58,59].
In addition to intracellular disturbances described above, changes in the ECM might also contribute to
the phenotype. It has been shown earlier for mutations in COMP that both intra- and extra-cellular
pathways are involved in the pathogenesis of pseudoachondroplasia [60] and that disruption of the
ECM structure may cause phenotypes even in the absence of impaired secretion [61]. The structure
of the ECM could be affected by reduced amounts, the complete absence or the presence of mutated
collagen II. The amount and quality of extracellular collagen II depends on the specific mutation,
and this might explain why different mutations cause such a spectrum of disease phenotypes.
In our study, mutations at the N-terminus (R75C, R134C) of the triple helix resulted in less
pronounced effects on all parameters investigated compared to mutations at the C-terminus. Similar
findings were reported for mutations in collagen I in which glycine substitutions towards the
C-terminus of the collagen I chains are clinically more severe than those towards the N-terminus [62].
This might be due to the fact that triple helix formation and propagation initiates at the C-terminus,
and mutations at this structurally-important site will interfere with protein stability [63–65].
Our findings suggest that the phenotype of patients harboring the C-terminal mutation R789C in
the collagen II chain might be caused by accumulation of the mutated collagen II protein in the ER,
leading to ER-stress and apoptosis of chondrocytes. However, this seems not to be a universal disease
mechanism common for all collagen mutations. According to our study, even the rather C-terminal
R704C and also the N-terminal R75C mutation neither induce ER stress nor apoptosis and might cause
a disease predominantly via extracellular interference. In addition, it is tempting to speculate that
other factors such as genetic modifiers or the presence of additional mutations in other gene loci yet to
be identified contribute to a chondrodysplasia phenotype. Similar observations were made in patients
with multiple epiphyseal dysplasia (MED) [66].
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4. Materials and Methods
4.1. Collagen II cDNA, Site-Directed Mutagenesis and Removal of Endogenous Signal Peptide
Human collagen II cDNA of 4.5 kb including the poly-adenylation signal was kindly provided
by Fibrogen Europe. The eukaryotic expression vector pCEP-Pu containing a BM-40 signal peptide,
puromycin resistance [67] and an N-terminal sequence coding for the his6-myc tag [68] was used
for expression of collagen II variants in the mammalian cells. Site-directed mutagenesis was carried
out using the XL Quick Change mutagenesis kit (Stratagene, La Jolla, CA, USA). Mutations were
introduced into collagen II cDNA resulting in exchange of R75C, R134C, R704C, R740C and R789C.
The primer pairs that were used for sited-directed mutagenesis are represented in Table 2. Nucleotide
change leading to mutation is indicated in bold. The mutated constructs were inserted into the
episomal expression vector pCEP-Pu- his6-myc tag (N-terminal) in-frame with the sequence of the
signal peptide of BM-40 as described earlier [66].












Numbers 75, 134, 704, 740 and 789 stand for the amino acid residue numbered from the start of the triple helix
where the mutation of interest is located. Nucleotides marked in bold indicate the nucleotide change to introduce
the desired mutation.
4.2. Cell Culture and Transfection
Human embryonic kidney-derived 293 EBNA cells (Invitrogen) and human fibrosarcoma-derived
HT1080 (CCL-121 from ATTC) cells were cultured in DMEM-F12 medium containing 200 U/mL
penicillin, 200 μg/mL streptomycin, 20 mM L-glutamine and 10% FBS (Biochrom, Berlin, Germany),
from now on referred to as standard medium, at 37 ◦C in a humified incubator with a 5% CO2
atmosphere. One hundred micrograms per milliliter of ascorbate were added to the cell culture
medium during expression of recombinant collagens. Cells were transfected using FuGene6 reagent
(Roche, Munich, Germany) following manufacturers instruction.
4.3. Purification of Collagen II Proteins
After 24 h post-transfection of 293 EBNA cells with collagen II constructs, cells were selected
using puromycin, and the supernatants were harvested from stably-transfected cells and the secreted
proteins purified on a nickel column by ion exchange chromatography, as previously described in [68].
4.4. CD Spectroscopy and Melting Curves
CD spectroscopy was performed with purified collagen II proteins, which were dialyzed in
100 mM acetic acid, and the concentration was adjusted to 60 μg/mL. Two hundred microliters of
collagen solution were used, and a spectrum between 190 nm and 280 nm was recorded using a Jasco
J-715 Polarimeter at 4 ◦C. Melting curves were determined at 222 nm in the temperature range of
10–55 ◦C at increments of 1 ◦C/min.
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4.5. SDS-PAGE and Immunoblotting
SDS polyacrylamide gel electrophoresis was performed using the buffer system of Laemmli.
Protein samples were mixed with an equal volume of 2× SDS sample buffer (50 mM Tris-HCl,
pH 6.8, 2% (w/v) SDS, 20% glycerol and 0.025% (w/v) bromophenol blue), whereas cells were lysed
and resuspended in 1× SDS sample buffer. Before loading, samples were reduced and denatured
by adding 5% β-mercaptoethanol and boiled at 95 ◦C for 5 min. Equal amounts of supernatants
and cell lysates obtained 72 h after transfection were resolved on 8% (w/v) SDS-PAGE gels and
were analyzed by immunoblotting. After SDS-PAGE, proteins were transferred to nitrocellulose and
incubated for 1 h in TBS in the presence of 5% (w/v) milk protein. Rabbit anti-myc antibodies or
goat anti-collagen II antibodies were used at a dilution of 1:1500, and the bound primary antibodies
were detected using a 1:2000 dilution of horseradish peroxidase-conjugated rabbit anti-goat or swine
anti-rabbit IgG (Dako Corp., Glostrup, Denmark). Blots were developed with a self-made enhanced
chemiluminescence (ECL) reaction.
4.6. Trypsin Digestion
Protease treatment of purified collagen II variant proteins (3 micrograms) was carried out in
a 50-μL reaction volume containing digestion buffer (50 mM Tris-HCl, pH 7.4, containing 150 mM
NaCl and 10 mM EDTA). Trypsin was added to the samples at a concentration of 100 μg/mL and
was incubated for 2 min at 25 ◦C. The digestion was stopped by addition of soybean trypsin inhibitor
(Sigma, Munich, Germany) at a final concentration of 5 μg/mL. SDS-PAGE sample buffer containing
5% β-mercaptoethanol was added, and the samples were resolved on 8% SDS-PAGE. The resolved
proteins were visualized by silver staining.
4.7. Inhibition of Matrix Metalloproteinase Cleavage
HT1080 cells were transfected with collagen II constructs, and three days after transfection,
the supernatants were collected. Fresh culture medium was supplemented with 25 μM GM6001
(1 mM stock in DMSO) and 100 μg/mL of ascorbate. Supernatants and cell lysates were harvested
48 h after addition of the inhibitor. Proteins were resolved by SDS-PAGE on 8% gels and collagen II,
and after blotting, collagen II and fragments thereof were detected using the anti-myc antibody.
4.8. Reverse Transcription-PCR for Analysis of Spliced XBP1 Transcripts
RNA was extracted using the TRIZOL reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instruction from cells 72 h post-transfection. To avoid ER stress induced
by glucose starvation, fresh medium with serum was added 2 h prior to RNA extraction.
One hundred nanograms of total RNA/reaction were used for cDNA synthesis using reverse
transcriptase and random hexamers (Roche Diagnostics, Basel, Switzerland). XBP1 transcripts
were analyzed by PCR of the cDNA using primers corresponding to the spliced and unspliced
forms of the XBP1 transcripts (5′-GGAGTTAAGACAGCGCTTGG-3′, bp 401–420) and antisense
(5′-ACTGGGTCCAAGTTGTCCAG-3′, bp 648–629) primers spanning the XBP1 RNA processing
sequence (GenBank Accession Number AB076383) [37], The PCR products corresponding to unspliced
and spliced XBP1 (248 and 222 bp, respectively) were obtained after 35 cycles using a primer annealing
temperature of 60 ◦C. The products were resolved on 2.5% (w/v) agarose gels and visualized under
ultraviolet light.
4.9. Immunofluorescence Staining of HT1080 Cells
Transfected and non-transfected cells were grown on glass cover slips in 24-well dishes.
After 3 days of transfection, the cells were fixed with 2% paraformaldehyde and permeabilized
using 0.2% Triton X-100 in PBS. Cells were blocked with 10% normal goat serum in PBS after
three washes with PBS. Primary antibodies were added at a dilution of 1:1000 and incubated for
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60 min, followed by washings to remove unbound antibodies. Bound primary antibodies were
detected with a secondary fluorescent-labelled antibody for a further 60 min. Antibodies directed
against protein disulfide isomerase (PDI) (Biomol, Hamburg, Germany) and the 58K protein Sigma
(Munich, Germany) were used as markers for the ER and the Golgi apparatus, respectively. Mouse
anti-myc antibodies were used to detect the myc epitope of recombinantly-expressed collagen II.
Rabbit anti-BiP was used for the detection of BiP. Secondary anti-rabbit and secondary anti-mouse
Cy3- and Alexa488-conjugated antibodies were from Molecular Probes (Leiden, The Netherlands).
Nuclei were stained with bisbenzimide (Sigma, 0.1 μg/mL). The slides were finally mounted in DAKO
fluorescent mounting medium and examined under an Axiophot fluorescence microscope (Zeiss,
Oberkochen, Germany).
4.10. Nick Labelling
TUNEL staining was performed to detect apoptosis using the DeadEnd™ Fluorometric TUNEL
System (Promega, Madison, WI, USA) following a slightly modified manufacturer’s protocol.
Cells were fixed by 25-min immersion in 4% paraformaldehyde solution four days post-transfection.
After two washes in PBS for 5 min cells were permeabilized with 0.2% Triton X-100 solution in PBS
for 5 min. After rinsing cells in PBS, 100 μL of equilibration buffer were added for 5–10 min at room
temperature. Cells were then incubated with 50 μL of reaction buffer (rTdT incubation buffer) for
60 min inside a dark humidified chamber at 37 ◦C. The tailing reaction was terminated by adding
2× saline sodium citrate solution (SSC) for 15 min. Nuclei were stained with bisbenzimide (0.1 μg/mL
in PBS) for 5 min. After washing with deionized water for 5 min at room temperature, cover slips were
mounted on histo-slides with DAKO mounting medium.
4.11. Comet Assay or Single Cell Gel Electrophoresis
Four days after transfection, cells were trypsinized, counted and diluted to give approximately
5 × 104 cells/mL. Eighty microliters of the cell suspension were added to 400 μL of 0.5% low melting
agarose maintained at 37 ◦C, and 90 μL of this suspension were pipetted onto a slide, which was
precoated with 1.0% agarose. An additional 1% low melting agarose layer without cells was added
after solidification of the layer. Alkaline lysis solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris-HCl,
1% Triton X-100, 10% DMSO, pH to 10.0) was added to the slides at 4 ◦C for 1 h in the dark to lyse
cells. After lysis, the slides were placed in neutralizing solution (400 mM Tris-HCl, pH 7.5) and
rinsed three times for 30 min to remove salts and detergents. Slides were then placed in a horizontal
electrophoresis chamber with alkaline buffer (300 mM NaOH, 1 mM EDTA, pH > 13) and incubated for
20–60 min to allow unwinding of the DNA. Electrophoresis of the slides was run for 30 min at 0.6 V/cm.
After electrophoresis, the slides were rinsed with neutralization buffer twice and stained with 100 μL
ethidium bromide solution (10 mg/mL). Slides were scored immediately or alternatively dried in cold
100% ethanol before storage. DNA tailing due to fragmentation was visualized as comets using an
inverted fluorescence microscope and evaluated using TriTek CometScore™ software (TriTek Corp,
Sumerduck, VA, USA).
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/19/2/541/s1.
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Abstract: The content of hyaluronan (HA) in the interstitium of the renal medulla changes in relation to
body hydration status. We investigated if hormones of central importance for body fluid homeostasis
affect HA production by renomedullary interstitial cells in culture (RMICs). Simultaneous treatment
with vasopressin and angiotensin II (Ang II) reduced HA by 69%. No change occurred in the mRNA
expressions of hyaluronan synthase 2 (HAS2) or hyaluronidases (Hyals), while Hyal activity in the
supernatant increased by 67% and CD44 expression reduced by 42%. The autocoid endothelin (ET-1) at
low concentrations (10−10 and 10−8 M) increased HA 3-fold. On the contrary, at a high concentration
(10−6 M) ET-1 reduced HA by 47%. The ET-A receptor antagonist BQ123 not only reversed the reducing
effect of high ET-1 on HA, but elevated it to the same level as low concentration ET-1, suggesting separate
regulating roles for ET-A and ET-B receptors. This was corroborated by the addition of ET-B receptor
antagonist BQ788 to low concentration ET-1, which abolished the HA increase. HAS2 and Hyal2 mRNA
did not alter, while Hyal1 mRNA was increased at all ET-1 concentrations tested. Hyal activity was
elevated the most by high ET-1 concentration, and blockade of ET-A receptors by BQ123 prevented about
30% of this response. The present study demonstrates an important regulatory influence of hormones
involved in body fluid balance on HA handling by RMICs, thereby supporting the concept of a dynamic
involvement of interstitial HA in renal fluid handling.
Keywords: hyaluronan; kidney; interstitium; medulla; endothelin; vasopressin; angiotensin II
1. Introduction
Hyaluronan (HA) is a negatively charged interstitial glycosaminoglycan with large water
attracting ability [1]. In the kidney, HA is predominantly found in the inner medulla during normal
physiological conditions [2–5]. This site is responsible for the fine tuning of fluid electrolyte balance
primarily under the influence of hormones such as angiotensin II (Ang II), aldosterone and vasopressin.
The differential intrarenal distribution of HA is important for urine concentration and dilution [6].
We have previously demonstrated that during acute hydration medullary HA increases and, in contrast,
HA content decreases during water deprivation [2,3]. It has been suggested that apart from the changes
occurring in vasopressin-regulated aquaporins, the physicochemical properties of the interstitial
matrix changes in relation to hydration status, which influences primarily water permeability [6].
Ginetzinsky [7] demonstrated that the HA-degrading enzyme hyaluronidase (Hyal) is excreted in
the urine in larger amounts during dehydration and drops to virtually zero during hydration. It was
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suggested that the interstitial matrix was altered by Hyal activity, thereby changing the level of
diuresis. Under pathological conditions of altered kidney function, HA is inappropriately regulated [6].
During renal ischemia-reperfusion injury or tubulointerstitial inflammation, renal cortical levels of HA
increase, while medullary levels are largely unaltered, which may contribute to the pathophysiology of
the disease process [4,8,9]. Indeed, suppression of HA accumulation during renal ischemia-reperfusion
improves renal function, suggesting a protecting effect against ischemic insults [10]. During diabetes,
both cortical and medullary levels are elevated [6], which may contribute to the phenotype due to the
pro-inflammatory and water-attracting properties of HA.
We have previously demonstrated that a major contributor of interstitial HA in renal medulla
is the renomedullary interstitial cell (RMIC) [11,12]. These cells express receptors for hormones and
autocoids known to be involved in the regulation of fluid and electrolyte balance [13]. These receptors
include Ang II AT1, vasopressin V1a, endothelin (ET)-A and -B, and bradykinin B2. RMICs in culture
produce less HA during hyperosmotic conditions than during iso- and hypo-osmotic conditions [11,12],
supporting the in vivo observations that HA content decreases during dehydration, while it increases
during hydration [2,3].
Despite the observations from our and other laboratories that renal HA content changes during
physiological and pathophysiological conditions, the mechanisms regulating HA content under these
conditions are unclear. Thus, the aim of the present study was to determine the effects of hormones
and an autocoid involved in normal regulation of body fluid balance on HA turnover by RMICs
in culture. Furthermore, the importance of Hyal activity and of the HA scavenging receptor CD44
expression [14,15] for HA turnover were also investigated.
2. Results
2.1. Hyaluronan (HA) in Supernatant
The HA content in the supernatant of RMICs grown under iso-osmotic conditions was 0.29 ± 0.11 ng
HA/ng cell protein (Figure 1). Changing growth media to hypo-osmotic conditions resulted in a more
than 4-fold elevation of the HA content (p < 0.05). A similar increase occurred after treatment with the
Hyal inhibitor L-ascorbic acid 6-hexadecanoate (Asc-P) (more than 3-fold elevation, p < 0.05), while the HA
synthesis inhibitor 4-methylumbelliferone (4-MU) reduced the HA content by 52% (p < 0.05).
Figure 1. Hyaluronan (HA) content in supernatants of cultured renomedullary interstitial cells
(RMICs) during control conditions (normal osmolality) and after 24 h exposure to hypo-osmotic
media conditions (200 mOsm/kg H2O), a hyaluronidase inhibitor (Asc-P) or the HA synthesis inhibitor
4-MU.* p < 0.05 vs. corresponding value of control cells (normal osmolality).
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Neither Ang II nor vasopressin alone reduced HA in the supernatant significantly (−16% and
−58%, respectively, ns). However, when the combination of Ang II and vasopressin was used, HA was
reduced by 69% (p < 0.05) (Figure 2).
Figure 2. Hyaluronan (HA) content in the supernatant of cultured RMICs during control conditions
(normal osmolality) and after 24 h exposure to angiotensin II (Ang II, 10−6 M), vasopressin (10−6 M),
and a combination of Ang II and vasopressin. * p < 0.05 vs. corresponding value of control cells
(normal osmolality).
Endothelin-1 (ET-1) at 10−10 M and 10−8 M increased supernatant HA more than 3-fold (p < 0.05),
while, on the contrary, a high concentration of ET-1 (10−6 M) reduced HA by 47% (p < 0.05, Figure 3)
as compared with untreated control cells. The ET-A receptor antagonist BQ123 not only reversed
the reducing effect of the high concentration of ET-1 on HA, but elevated it to the same level as low
concentration ET-1 (10−10 M), suggesting an important mechanism involving the still active ET-B
receptor. This was corroborated by the addition of ET-B receptor antagonist BQ788 to low concentration
ET-1, which abolished the increase in HA.
Figure 3. Hyaluronan (HA) content in the supernatant of cultured RMICs during control conditions
and after 24 h exposure to endothelin (ET-1), with or without the ET-A receptor antagonist BQ123 or the
ET-B receptor antagonist BQ788. * p < 0.05 vs. corresponding value of control cells (normal osmolality).
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2.2. Hyaluronidase (Hyal) Activity in Supernatant
The Hyal activity in the supernatant of cells grown in low-osmolality media was 44% lower
(p < 0.05) compared to during iso-osmotic conditions (Figure 4). Neither Ang II nor vasopressin alone
altered the activity. However, the combination of Ang II and vasopressin increased the Hyal activity by
67% (p < 0.05). ET-1 increased the supernatant activity at 10−8 M and 10−6 M. At 10−8 M the activity
increased by 54%, while the high concentration (10−6 M) elevated the Hyal activity by 137%. When the
ET-A receptor antagonist BQ123 was added, the elevation in activity after the high concentration of
ET-1 (10−6 M) was reduced and thus similar to that of the lower concentrations used (55%).
Figure 4. Hyaluronidase (Hyal) activity in supernatants of cultured RMICs during different treatments.
Values are related to the amount of total cell protein in each culture dish. RI, relative intensity.
* p < 0.05 vs. control cells (normal osmolality).
2.3. Hyaluronan Synthase (HAS) and Hyaluronidase mRNA in Renomedullary Interstitial Cells in
Culture (RMICS)
HAS2 and Hyal2 mRNA expression did not change in most of the treatment groups
(Figures 5 and 6), however, HAS2 was increased in ET-1 groups of low and medium concentration,
and BQ788 together with low concentration ET-1 increased expression of both HAS2 and Hyal2.
Figure 5. mRNA expressions of hyaluronan synthase 2 (HAS2) in RMICs during different treatments.
All values are in relation to cells grown at normal osmolality = 100%. * p < 0.05 vs. control cells
(normal osmolality).
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In RMICs grown in hypo-osmolar conditions the Hyal1 mRNA was reduced by 35% as compared
to iso-osmolar conditions (p < 0.05, Figure 7), while Ang II and vasopressin, alone or in combination,
did not change the expression. All concentrations of ET-1 elevated the Hyal1 mRNA expression
similarly. This elevation was not affected by the ET-A receptor blocker BQ123, but was abolished by
the ET-B receptor blocker BQ788.
Figure 6. mRNA expressions of hyaluronidase 2 (Hyal 2) in RMICs during different treatments.
All values are in relation to cells grown at normal osmolality = 100%. * p < 0.05 vs. control cells
(normal osmolality).
Figure 7. mRNA expressions of hyaluronidase 1 (Hyal 1) in RMICs during different treatments.
All values are in relation to cells grown at normal osmolality = 100%. * p < 0.05 vs. control cells
(normal osmolality).
2.4. CD44 on RMIC Surface
The CD44 surface expression on RMICs grown in hypo-osmolar conditions was 68% lower
than that on cells grown at iso-osmolar conditions (p < 0.05, Figure 8). No change in expression
occurred by Ang II or vasopressin separately, but when combined the CD44 expression was reduced
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by 42% (p < 0.05). The lowest concentration of ET-1 (10−10 M) increased CD44 expression more than
4-fold (p < 0.05). The intermediate concentration of ET-1 (10−8 M) also increased the CD44 expression,
but to a lesser extent. Low concentration of ET-1 in combination with ET-B receptor blocker BQ788
normalized CD44 expression. The higher concentration of ET-1 together with the ET-A receptor blocker
BQ123 tended to increase CD44 expression, suggesting an effect over ET-B receptors.
Figure 8. Expression of the scavenging receptor CD44 on the cell surface of RMICs during different
treatments. All values are in relation to cells grown at normal osmolality = 100%. * p < 0.05 vs. control
cells (normal osmolality).
3. Discussion
The present study demonstrates an important regulatory role of hormones involved in body
fluid balance on HA turnover by cultured RMICs. Furthermore, the results demonstrate an important
mechanism over altered Hyal activity to regulate HA turnover, which provides a rapid way to change
HA as opposed to primarily regulating synthesis. Our previous studies have suggested an important
role for HA in renomedullary water handling. During acute hydration the rat medullary interstitial HA
content increases, while the opposite occurs during water deprivation [2,3]. The elevation in medullary
interstitial HA content during excess water intake will antagonize medullary water reabsorption by
changing the interstitial matrix properties, thereby resulting in reduced fluid conductance. The opposite
occurs during water deprivation in conjunction with increased vasopressin-regulated aquaporins.
Our present findings widen our understanding on how the composition of the renomedullary
interstitial matrix changes in response to hydration status and also sets focus on hyaluronidases
in order to achieve rapid responses.
Changes in overall HA content are due to changes in HA synthesis and/or HA degradation.
The present study suggests that regulation of the degradation pathway is of major importance for
the changes seen in supernatant HA both after a hypo-osmolar challenge as well as after hormonal
action. The mRNA expression of HAS2 and Hyal2 in RMICs did not change after hypo-osmotic
challenge, Ang II, or vasopressin, suggesting a change in Hyal activity. Our previous in vivo data in
rats show no changes in the mRNA levels of HAS or Hyals after 2 h hydration when medullary HA is
elevated [16], again suggesting a change in the activity. In the case of ET-1, mRNA levels of Hyal1 were
elevated, while hypo-osmolality reduced the Hyal1 expression, which strengthens the proposition that
the degradation pathway is an important way to change HA. It is of interest in this context that lack
of hyaluronidases exacerbates renal post-ischemic injury, inflammation, and fibrosis, pointing to an
ongoing defense mechanism [17].
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The mechanism(s) underlying Hyal activation in the present study are not known but it is generally
accepted that mRNA levels may not reflect activity or protein levels. Changing activity would be a
more rapid way to increase catabolic function as opposed to primarily producing more of the enzyme
per se. In a study by Albeiroti and colleagues [18] on platelets, it was demonstrated that Hyal2 is
activated by being transported from intracellular sites to the surface of the cell, thereby achieving
catabolic activity. This activation in an embryonic kidney cell line (as opposed to that in platelets)
requires coexistence with CD44 expression on the plasma membrane [19]. In the present study on
RMICs, we demonstrate that CD44 surface expression decreases during hypo-osmolar conditions of the
media and lowers Hyal activity, which results in elevated amounts of HA in the media, thus suggesting
reduced catabolic and internalization processes. The same line of reasoning regarding effects of Hyal
activity and CD44 expression cannot be performed after treatment with Ang II, vasopressin, or ET-1,
thus suggesting another pathway of Hyal activation which may include intracellular calcium and IP3
signaling [13].
In a previous in vitro study [11] in cultured rat RMICs, we found that the HA binding receptor
CD44 is downregulated under hypo-osmotic conditions (mimicking in vivo hydration), while it is
upregulated under hyperosmotic conditions (mimicking water deprivation). This was corroborated by
the present study, which showed reduced CD44 expression when reducing growth media osmolality.
Once HA binds to CD44 it can be internalized and degraded [14,20,21]. Furthermore, in an in vitro
study [22] it was demonstrated that low ionic strength inhibits HA hydrolysis catalyzed by Hyal.
This would imply that during hypo-osmotic conditions when low ionic strength applies both
the cellular uptake of HA over CD44 and the breakdown of HA by Hyal, is reduced. The acute
hydration-induced elevation in HA in vivo (within 2 h) [3] suggests an important role over inhibition
of Hyals and not primarily increased HAS expression or activity.
ET-1 resulted in a biphasic response on supernatant HA levels which was related to agonist
concentration. Such a concentration dependent biphasic response has previously been described for
ET-1 on the effect on vascular smooth muscle (i.e., low concentration results in dilation and high
concentration results in contraction) [23,24]. In the present study, low concentration ET-1 increased
HA in the supernatant, while the high concentration reduced HA. When the high concentration was
combined with the ET-A receptor antagonist BQ123, HA was returned to a level comparable with low
concentration ET-1. It can be hypothesized that low concentration ET-1 primarily affects ET-B receptors,
which increase HA by increasing nitric oxide (NO) production [25–27]. This was corroborated by the
abolished increase in HA by the addition of the ET-B receptor antagonist BQ788 to low concentration
ET-1. Endothelins are also known to enhance the release of prostaglandins by stimulation of ET-B
receptors located on vascular endothelial cells [28,29], which also elevate HA production [27,30,31].
The high concentration of ET-1 may primarily affect ET-A receptors, which have been shown to increase
CD44 expression with a BQ123-sensitive mechanism [32]. We have previously demonstrated an inverse
relationship between elevated levels of surface CD44 on RMICs and supernatant HA, suggesting
increased internalization [11] and thereby reduced levels of HA in the supernatant. When the ET-A
receptor antagonist BQ-123 was included in the present study HA was elevated, not only back to
control levels, but to the levels corresponding to the low concentration of ET-1, suggesting an action
on the still active and intact ET-B receptor. When the ET-B receptor antagonist BQ788 was included,
the HA amount no longer differed from the control. The observed changes in HA in the present
study fit well with the demonstrated effects of ET-A vs. ET-B receptor activation on medullary fluid
handling. ET-B activation reduces fluid reabsorption over NO, while ET-A activation increases fluid
reabsorption [33]. This fit well with our previous finding that an intact NO-system is required for the
hydration-induced medullary HA-elevation to occur [34].
Ang II and vasopressin in combination reduced the HA content in the supernatant of cultured
RMICs and we have previously shown that vasopressin infusion in vivo reduces papillary HA [34],
presumably over the V1-receptor, since the selective V2-receptor agonist desmopressin failed to produce
such a response [3], although this may be a concentration issue. The finding of V1a receptors but not
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of the V2 subtype on RMICs [13] corroborates our suggestion. Vasopressin stimulates the activity of
Hyal in the rat renal papilla. The activation of these enzymes is associated with a decrease in the
content of HA [35]. In homozygous Brattleboro rats lacking vasopressin, the urine osmolality and
Hyal activity of renal papillary tissue were closely related after vasopressin treatment [36]. In support
of this notion, we have demonstrated that outer medullary HA content is increased in Brattleboro rats,
thus inferring reduced breakdown [3]. It has also been demonstrated that antisera against rat kidney
Hyal blocks the hydro-osmotic effect of vasopressin [37]. Furthermore, in a study by Ivanova et al. [38],
the mRNA expressions of Hyal1 and Hyal2 were increased in the medullary tissue after treatment
with a vasopressin analogue. In the present study, vasopressin alone did not reduce HA with statistical
significance, only when combined with Ang II. We have, however, in a previous study found a
reduction of HA after vasopressin treatment [34]. The discrepancy in results is not clear. The effector
mechanism underlying the reduction of HA by Ang II treatment (in combination with vasopressin)
seems to be, at least partly, due to increased Hyal activity. This would fit with previous data on
neonatal angiotensin converting enzyme (ACE) inhibition showing reduced Hyal1 mRNA expression
in the renal medulla and reduced urine Hyal activity early in the newborn rat [39]. It is also noteworthy
that these two hormones are simultaneously elevated during dehydration.
In the present study on RMICs, it is clear that the HA content is reduced after high concentration
ET-1 (ET-A receptor mediated) and the combination of Ang II and vasopressin. Furthermore, it is well
known that both Ang II and vasopressin levels in plasma are elevated during dehydration/antidiuresis
(i.e., when medullary HA levels in vivo are reduced). However, previous studies have shown that ET-1,
through its action over the ET-A receptor, and Ang II, over the AT1 receptor, increase proliferation and
extracellular matrix production (ECM) by RMICs in culture [40,41]. What could be the underlying cause
for this apparent contradiction? The standard index for ECM production (i.e., 35S-methionine/cysteine
incorporation) is not a measure of HA production, since HA does not incorporate methionine/cysteine,
being that it is a sugar compound. This index is more correct for estimating collagen-related production,
and the true relationship between different matrix components has not been demonstrated in parallel
with giving the ECM-index. It has, however, been shown that laminin production by RMICs increases
after Ang II [41]. A reduced HA content in the medullary interstitium provides favorable conditions
for an increase in the permeability of glycosaminoglycan structures adjacent to the cell surface.
Since RMICs seem to provide structural support for the renal medulla, it could be speculated that the
increase in ECM production, like laminin, would maintain structural integrity when HA levels are
reduced in parallel to increase in vivo interstitial water permeability. However, a reduced HA content
in parallel with elevation of collagen in a tissue would, during pathological conditions, provide for
fibrosis, since the HA reduction leads to reduced viscoelasticity and hydration.
CD44 is the main cell surface receptor for HA [15]. Besides providing a signal response to HA,
it participates in HA endocytosis as a scavenger receptor [42]. In the present study, RMIC surface
expression of CD44 was reduced by low media osmolality when supernatant HA content was
increased, which could provide a pathway for regulation via reduced internalization and degradation.
However, in the two other situations when CD44 expression was altered (Ang II + vasopressin and low
concentration ET-1, respectively), supernatant HA content changed in an opposite direction, which does
not enable a causal relationship. The underlying mechanism to the reduced CD44 expression after
Ang II + vasopressin and elevated expression after low concentration of ET-1 is unclear and warrants
further investigation.
The Hyal inhibitor used in the present study (L-ascorbic Acid 6-hexadecanoate, Asc-P) is a
documented potent inhibitor of different Hyal activities [43]. The importance of Hyal activity for
regulating HA turnover in RMICs is clear. When inhibiting Hyal activity during iso-osmotic conditions,
supernatant HA increases to similar levels as RMICs grown under hypo-osmotic conditions. As stated
above, this would fit well with the suggestion that the elevation in HA during hypo-osmotic conditions
occurs through a reduced activity of intracellular Hyals.
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Upon continuous hydration in the rat, the medullary HA-levels increase and peak after about 2 h
and return to control levels after about 4 h of hydration [2]. Interestingly, peak urine flow rate was
also observed after 2 h of hydration. It could be speculated that medullary HA in the rat is primarily
important for the acute and rapid exclusion of water during excessive intake.
Dwyer et al. [44] found that in obese rabbits the medullary HA is selectively elevated. It was
suggested that a possible distension could occur in the renal medulla with consequences for interstitial
hydrostatic pressure and reabsorption. Such a constitutively elevated amount of HA could therefore
result in a reduced reabsorptive capacity leading to hypohydration. Whether this can partly explain
the higher incidence of hypohydration in obese US adults remains to be established [45].
The concentrations of drugs used in the present study are generally high. However, this was done
to achieve maximum response from the systems observed. It is, furthermore, worth noting that the
various peptide receptors on RMICs are spatially close and overlapping [46] and complex interactions
may therefore occur between components of the intracellular chain of reactions which are transmitted
as the hormonal signal. How this affects the results of the present study is unknown.
In conclusion, the present study demonstrates an important regulatory influence of hormones
involved in body fluid balance on HA handling by RMICs thereby supporting the concept of a dynamic
involvement of interstitial HA on renal fluid handling.
4. Materials and Methods
4.1. Animals
All animal procedures were approved by the local animal ethics committee at Uppsala University
(Approval code C290/11, approval date 25 November, 2011). Male Sprague-Dawley rats weighing
80–90 g (Charles River, Sulzfeld, Germany) were used.
4.2. Culture of RMICs
RMICs were isolated from kidneys of young Sprague-Dawley rats as previously described [47,48].
For the first weeks, the culture is primarily epithelial, but after that it consists of a homogenous
non-epithelial population. The cells were used for experiments at passage 7 and later. The described
isolation and culturing methodology produce cells containing the characteristic lipid vacuoles.
4.3. Experimental Protocol—In Vitro
RMICs were plated at a density of about 5 × 104 cells/cm2 for 48 h in a 1:1 mixture of two media:
Roswell Park Memorial Institute (RPMI) 1640 culture medium and Dulbecco’s Modified Eagle’s Medium
(DMEM) culture medium conditioned by 3T3 mouse fibroblasts, the mixture containing a total of 15%
fetal bovine serum, as previously described [47]. The cells were then treated for 24 h with different
compounds described below. Following 24 h treatment, the supernatant was collected and analyzed
for HA content and Hyal activity. Cells were harvested and analyzed for CD44 expression and
gene expression of HAS and Hyals. The amount of protein was determined using a routine method
(DC Protein Assay, Bio-Rad Laboratories, Hercules, CA, USA). Ang II (Bachem, Bubendorf, Switzerland),
vasopressin (Sigma-Aldrich, St. Louis, MO, USA), or a combination of the two were given in concentrations
of 10−6 M. ET-1 (Sigma-Aldrich) was administrated to provide final concentrations of 10−10 M, 10−8 M,
or 10−6 M. The highest ET-1 concentration (10−6 M) was also given together with the selective ET-A
receptor antagonist BQ123 (10−6 M) (Sigma-Aldrich). The lowest ET-1 concentration (10−10 M) was also
given together with the selective ET-B receptor antagonist BQ788 (10−6 M) (Sigma-Aldrich). The Hyal
inhibitor L-ascorbic acid 6-hexadecanoate (Asc-P) was purchased from Sigma-Aldrich and administered in
a final concentration of 10−7 M. The HA synthesis inhibitor 4-methylumbelliferone (4-MU; Sigma-Aldrich)
was used in a concentration of 10−6 M. Growth media osmolality was reduced to 200 mOsm/kg H2O by
2:3 dilution with distilled water.
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4.4. Analysis of HA
HA content in supernatants from RMICs in culture was measured using a commercially available
enzyme-linked immunosorbent assay (Echelon Biosciences Inc., Salt Lake City, UT, USA) by following
the enclosed instructions and was then related to the amount of protein.
4.5. Hyaluronidase Activity in Supernatants
HA from rooster comb and all reagents for the polymerization of electrophoretic gels were
obtained from Wako Pure Chemical Industries (Osaka, Japan), Alcian blue 8GX from Fluka Chemical
(Buchs, Switzerland), and Actinase E from Kaken Pharmaceutical (Tokyo, Japan). Supernatant Hyal
activity was determined by quantitative zymography [49] with a slight modification because of its very
low activity. Briefly, three volumes of supernatant were mixed with one volume of 2× Laemmli sample
buffer containing 8% sodium dodecyl sulfate (SDS) and no reducing reagent. A control rat serum used
as a standard was diluted 200-fold with 0.15 M NaCl containing 0.1 mg/mL Bovine serum albumin
(BSA) and mixed with an equivalent volume of Laemmli sample buffer containing 4% SDS and no
reducing reagent. After incubation for 1 h at 37 ◦C, 32 μL of the supernatant mixture and 2–20 μL
of control serum mixture were applied to 7% SDS-polyacrylamide gels containing 0.17 mg/mL HA.
After electrophoretic run at 20 mA for approximately 90 min at 4 ◦C, gels were rinsed with 2.5% Triton
X-100 for 80 min at room temperature and incubated with 0.1 M formate buffer (pH 3.5 and containing
0.03 M NaCl) for 24 h at 37 ◦C on an orbital shaker. Gels were then treated with 0.1 mg/mL Actinase E
in 20 mM Tris-HCl buffer (pH 8.0) for 2 h at 37 ◦C. To visualize digestion of HA, gels were stained
with 0.5% Alcian blue in 25% ethanol: 10% acetic acid. After destaining, gels were counterstained with
Coomassie brilliant blue R-250. For the determination of Hyal activity, the stained gel was scanned
on an Image Scanner (GE healthcare Japan, Tokyo, Japan) and scans were analyzed using Image J
1.42q software (National Institutes of Health, Rockville, MD, USA). The relative band intensity (RI) of
supernatant Hyal activity was calculated from the ratio of the band intensity of Hyal activity from
0.05 μL of a control rat serum.
4.6. CD44 Analysis
Prior to CD44 analysis by western blot the surface proteins were isolated (Pierce® Cell surface
protein isolation kit, Pierce Biotechnology, Rockford, IL, USA). Molecular weight separation
was performed on 10% Tris-HCl gels with Tris/glycine/SDS buffer, the proteins transferred to
nitrocellulose membranes, and CD44 detected with sheep anti-rat CD44 (0.1 μg/mL; R&D Systems,
Minneapolis, MN, USA) and HRP-conjugated rabbit anti-sheep (1:5000; Kirkegaard and Perry Laboratories,
Gaithersburg, MD, USA). Luminescent signal was captured on an enhanced chemiluminescence
(ECL)-camera system (Kodak image station 2000; New Haven, CT, USA). β-actin was detected with
mouse anti-rat β-actin antibody (1:20,000, Sigma-Aldrich, St Louis, MO, USA) and secondary horseradish
peroxidase (HRP)-conjugated goat-anti mouse antibody (1:10,000; Kirkegaard and Perry Laboratories,
Gaithersburg, MD, USA). CD44 western blot analysis of samples from isolated surface proteins was
normalized to the β-actin expression.
4.7. Gene Expression Analysis
Total RNA was isolated from the cells (RNAquous®-4PCR, Ambion, Austin, TX, USA). cDNA was
obtained from the RNA (iScript™cDNA Synthesis Kit, Bio Rad Laboratories, Hercules, CA, USA),
and the following semi-quantitative real-time PCR was performed by LightCycler® FastStart DNA
MasterPLUS SYBR Green I (Roche Diagnostics, Mannheim, Germany) in a Lightcycler system
(Roche Diagnostics, Mannheim, Germany). PCR products were verified by agarose gel electrophoresis.
The mRNA analyzed were Hyal1 and 2, and HAS2. All values were normalized for reference genes
TATA-binding protein (TBP), β-actin (Actb), and glucose-6-phosphate dehydrogenase (G6PDH).
Values were then expressed as normalized values for the means of the reference genes by using
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the formula: 2ˆCt(reference genes) – Ct(gene of interest), where Ct is the cycle number and Ct for the
reference genes is a mean of the cycle numbers for the reference genes, which did not differ much
from each other. Primers were obtained from MWG Biotech (Ebersberg, Germany), with sequences
presented in Table 1. Primers were evaluated in terms of efficiency (Table 2), melt curves (Figure 9),
and verified product size.
Table 1. Primer sequences for HAS2, Hyal1, and Hyal2.
Gene Gene Accession Forward Primer Reverse Primer
G6PDH NM_017006.2 GTCATGCAGAACCACCTCCT ACATACTGGCCAAGGACCAC
AktB NM_031144.3 GCCCTGGCTCCTAGCACC CCACCAATCCACACAGAGTACTTG
TBP NM_001004198.1 ACCCTTCACCAATGACTCCTATG ATGATGACTGCAGCAAATCGC
HAS2 NM_013153.1 GTGACTGCACCAGTTCCGCTAA CATGTCTAATGGGACTGCACACAAG
Hyal1 NM_207616.1 TCGGACCCTTTATCCTGAAC TTCTTACACCACTCTCCACTC
Hyal2 NM_172040.2 CGTTACGTCAAGGCAGTCAG AGGTACACGGAGGGAAAGAG
Table 2. Primer efficiency for HAS2, Hyal1, and Hyal2.
Gene Ct Average NOsm (n = 8) Ct Average LOsm (n = 8) Primer Efficiency (%)
G6PDH 25.2 ± 0.2 25.5 ± 0.2 96.6
AKTB 24.4 ± 0.2 22.5 ± 0.2 98.3
TBP 17.1 ± 0.1 17.0 ± 0.2 120.1
HAS2 27.3 ± 0.2 29.0 ± 0.3 104.0
Hyal 1 27.3 ± 0.4 26.7 ± 0.4 124.5
Hyal 2 23.6 ± 0.2 24.3 ± 0.2 125.1
NOsm, normal osmolality; LOsm, low osmolality.
G6PDH AKTB TBP 
 
HAS2 Hyal1 Hyal2 
 
Figure 9. Melt curves for the primers used.
69
Int. J. Mol. Sci. 2017, 18, 2701
4.8. Statistical Analysis
Data are given as mean values ± SEM. The comparison between groups was evaluated with
one-way ANOVA followed by Fisher´s Least Significant Difference (LSD) post-hoc test. Parameters
presented as percentage in graphs were statistically evaluated using the original values. A p-value of
<0.05 was considered statistically significant.
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Abstract: Fertilization of the mammalian oocyte requires interactions between spermatozoa and
expanded cumulus extracellular matrix (ECM) that surrounds the oocyte. This review focuses on
key molecules that play an important role in the formation of the cumulus ECM, generated by the
oocyte-cumulus complex. In particular, the specific inhibitors (AG1478, lapatinib, indomethacin and
MG132) and progesterone receptor antagonist (RU486) exerting their effects through the remodeling
of the ECM of the cumulus cells surrounding the oocyte have been described. After gonadotropin
stimulus, cumulus cells expand and form hyaluronan (HA)-rich cumulus ECM. In pigs, the proper
structure of the cumulus ECM depends on the interaction between HA and serum-derived
proteins of the inter-alpha-trypsin inhibitor (IαI) protein family. We have demonstrated the
synthesis of HA by cumulus cells, and the presence of the IαI, tumor necrosis factor-alpha-induced
protein 6 and pentraxin 3 in expanding oocyte-cumulus complexes (OCC). We have evaluated
the covalent linkage of heavy chains of IαI proteins to HA, as the principal component of the
expanded HA-rich cumulus ECM, in porcine OCC cultured in medium with specific inhibitors:
AG1478 and lapatinib (both inhibitors of epidermal growth factor receptor tyrosine kinase activity);
MG132 (a specific proteasomal inhibitor), indomethacin (cyclooxygenase inhibitor); and progesterone
receptor antagonist (RU486). We have found that both RU486 and indomethacin does not disrupt
the formation of the covalent linkage between the heavy chains of IαI to HA in the expanded OCC.
In contrast, the inhibitors AG1478 and lapatinib prevent gonadotropin-induced cumulus expansion.
Finally, the formation of oocyte-cumulus ECM relying on the covalent transfer of heavy chains of IαI
molecules to HA has been inhibited in the presence of MG132.
Keywords: extracellular matrix; hyaluronan; inter-alpha-trypsin inhibitor; tumor necrosis
factor-alpha-induced protein 6; pentraxin 3; oocyte-cumulus complexes
1. Extracellular Matrix in General
The extracellular matrix (ECM) is an important structure that is present in all tissues. The ECM
interacts with cells to regulate a wide range of functions, including adhesion, proliferation, apoptosis
and differentiation. The ECM can also locally release growth factors, such as epidermal growth factor
(EGF), fibroblast growth factor and other signaling molecules such as transforming growth factor
(TGFβ) and amphiregulin [1]. Naba et al. [2] defined ECM proteins of the mammalian matrisome by
analysis of the human and mouse genome. It comprises 1–1.5% of the mammalian proteome. There are
almost 300 proteins, including 43 collagen subunits, 36 proteoglycans (e.g., aggrecan, versican, perlecan
and decorin) and ~200 complex glycoproteins (e.g., laminins, elastin, fibronectins, thrombospondins,
tenascins or nidogen). Moreover, there are large numbers of ECM-modifying enzymes, ECM-binding
growth factors, and other ECM-associated proteins [3]. Proteoglycans are important structural
macromolecules in tissues. They consist of a core protein with attached glycosaminoglycan side
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chains. There are six types of glycosaminoglycans: chondroitin sulfate, dermatan sulfate, heparin
sulfate, heparin, keratin sulfate and hyaluronan (HA). Hyaluronan is the only glycosaminoglycan
synthesized at the cell membrane and it is present in a protein-free form [4]. The size of HA depends on
the relative activity of HA-synthesizing and degrading enzymes. There are three hyaluronan synthase
isoforms (HAS1, 2 and 3) [5]. The expression of the three HAS isoforms is regulated by various stimuli,
suggesting different functions of the three proteins [6]. In contrast, hyaluronidases 1–4 degrade HA
into several fragments with size-dependent functions [7]. Dysregulation of ECM structure causes tissue
malfunction such as inflammation, infertility and cancer. The importance of the function of the ECM
is demonstrated by the embryonic lethality caused by mutations in genes that encode components
of the ECM [8,9].
2. Cumulus–Oophorus Extracellular Matrix in Ovarian Follicles: Characterization of
Essential Components
It has been shown that the complex of heavy chains of inter-alpha-trypsin-inhibitor (IαI) to HA is
the principal structural component of the cumulus ECM in ovarian follicles in mice [10,11] and pigs [12].
Genetic deletion of specific ECM proteins such as bikunin (light chain of IαI) and tumor necrosis
factor alpha-induced protein 6 (Tnfaip6-null mice were unable to transfer heavy chains from IαI to HA)
exhibit infertility in female mice [11,13]; see Table 1. Suzuki et al. [14] identified the full repertoire of
the IαI deficiency-related genes from bikunin-knockout female mice. They suggested that proteins of
the IαI family have additional effects on reproductive biology by modulating the expression of a large
number of cellular genes.
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2.1. IαI Family Proteins
It has been demonstrated that mice lacking intact IαI family proteins fail to form a stable
cumulus ECM, and the naked ovulated oocytes are not fertilized in vivo [11]. Importantly, HA-rich
oocyte-cumulus ECM does not form in IαI immune-depleted serum, while it does in the presence of
purified IαI molecules [20]. The proper structure of the cumulus ECM depends on the interaction
between HA and serum-derived proteins of the IαI family [11,12,21]. The IαI family proteins
are synthesized and assembled in the liver and secreted into the blood at high concentrations
(0.15–0.5 mg/mL of plasma) [35]. These IαI molecules consist of a small protein, named bikunin
or light chain, with a chondroitin sulfate moiety that contains one or two evolutionarily related
proteins, named heavy chains (HC1, HC2, and HC3). The first member, IαI, carries two heavy chains,
HC1 and HC2, while the next two members, pre-α-inhibitor (PαI) and inter-α-like inhibitor (IαLI)
have one heavy chain, i.e., HC, HC3 and HC2, respectively [36]. Positive bands of about 220, 130,
and 120 kDa were detected in porcine serum [12] that likely correspond to IαI (bikunin plus HC1 and
HC2), PαI (bikunin plus HC3), and IαLI (bikunin plus HC2), respectively [37,38]. In addition, porcine
follicular fluids, collected at different stages of folliculogenesis were analyzed for the presence of IαI
75
Int. J. Mol. Sci. 2018, 19, 283
proteins [12]. Importantly, the levels of IαI molecules in porcine follicular fluid did not change in
PMSG-primed follicles or in 8 h hCG-stimulated follicles, while a detectable increase in concentration
was observed at 24 h post-hCG injection. In pigs, there is no apparent barrier to the transfer of
IαI family molecules from the blood to the follicles, and the LH/hCG stimulation only facilitates
their diffusion. Inside the follicle, the heavy chains are transferred from the glycosaminoglycan of
IαI-related molecules to HA through a transesterification process [21]. To determine, whether HCs of
serum-derived IαI-related molecules are covalently linked to HA in porcine expanded OCC in vivo,
the experiments with OCC isolated from the antral follicles of pigs treated with PMSG (unexpanded
OCC) or PMSG followed by hCG for 24 h (expanded OCC) were performed [12]. The authors found that
expanded OCC contained positive bands of about 220, 130, and 120 kDa that likely correspond to IαI,
PαI and IαLI, respectively [12,37,38]. After digestion of the expanded complexes with hyaluronidase,
two additional immunopositive bands of about 85 kDa and 95 kDa were detected in the matrix extracts,
the former likely corresponding to the relative molecular mass of single HC1 and HC2, and the latter to
that of a single HC3 [36,39]. In addition, IαI proteins were detected in porcine OCC expanded in vitro
after their culture in FSH- and serum-supplemented medium [12]. Interestingly, it has been shown
that HCs from each IαI-related molecule identified in the serum are transferred and covalently linked
to HA during the cumulus expansion of OCC. Analysis of the cumulus matrix and cell extracts clearly
confirmed that the immunoreactivity was associated with the HA-rich cumulus ECM [12]. In mice
and pigs [12,15,21], it has been confirmed that the covalent linkage of the heavy chains of IαI to HA is
critical for cross-linking HA strands and stabilizing expanded HA-rich cumulus ECM.
2.2. TNFAIP6
It has been shown that the covalent transfer of heavy chains (HCs) of IαI proteins to HA does not
occur in the OCC of Tnfaip6-null mice, indicating that TNFAIP6 is actively involved in this process [13].
TNFAIP6 is an inflammation-associated protein with the ability to bind HA, IαI, and other ligands and
participate in the cumulus ECM formation and remodeling [40–42]. TNFAIP6 is produced by cumulus
and granulosa cells after an ovulatory stimulus in mice, rats and pigs [13,18,24–28]. Previously, in pigs,
four bands were detected with the antibody specific for TNFAIP6 in total and matrix protein extracts
from OCC expanded in vivo. The major positive band had an apparent molecular weight of 35 kDa
that also correlated well with the size of the free TNFAIP6 protein in mouse OCC. A doublet at
~120 kDa (HC-TNFAIP6 complex in mouse and pig) was also immunoreactive with the anti-TNFAIP6
antibody. In addition, the TNFAIP6 protein was detected in porcine OCC expanded in vitro after their
culture in FSH- and serum-supplemented medium for 24 and 42 h [26]. It has been demonstrated
that TNFAIP6, which binds to HA and interacts with heavy chains of IαI proteins, is another protein
essential for the formation and stability of expanded HA-rich oocyte- cumulus ECM in mice and
pigs [18,23,26]. Together with the high sequence similarity found among human, murine, rat, equine
and porcine TNFAIP6 [23,25,27,28] and the expression of this protein and/or the respective gene in
ovarian follicles of all of the examined species [18,23,25–28,43], it strongly supports the concept that
TNFAIP6-mediated covalent binding of HCs (of IαI proteins) onto HA is a mechanism that mammalian
OCC have in common [22].
2.3. PTX3
Experiments performed with Ptx3 knockout mice [29] have shown that complexes from
Ptx3−/−mice have defective cumulus matrix organization. Interestingly, hormone stimulation of
Ptx3−/−OCC in vitro showed that while cumulus cells synthesized HA at a normal rate they were
unable to organize this polymer in the cumulus ECM [30]. PTX3 is essential protein for organizing the
HA polymer in the cumulus ECM in mice [30–32]. PTX3 protein plays role in cumulus ECM assembly,
where HCs transferred from IαI to HA by the catalytic activity of TNFAIP6 bind distinct protomers
of multimeric PTX3 [33]. In pigs, PTX3 transcripts were significantly increased in OCC 24 h after
in vivo hCG or in vitro FSH/LH stimulation [34]. Western blot analysis with PTX3 antibody revealed
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that cumulus ECM extracts from both in vivo hCG-stimulated pigs and in vitro FSH/LH-stimulated
OCC cultured in medium supplemented either with follicular fluid or porcine serum, contain high
levels of PTX3 protein. The localization of PTX3 protein in the porcine OCC was confirmed by
immunostaining [34]. The mouse data concerning the integrity of HA-rich oocyte-cumulus ECM [30,31]
together with porcine data [34] demonstrated the importance of PTX3 protein in the ovarian follicles.
3. Effect of Specific Inhibitors (AG1478, Lapatinib, Indomethacin and MG132) and Progesterone
Receptor Antagonist (RU486) on the Formation of HA-Rich Cumulus Extracellular Matrix
3.1. Inhibition of EGFR Signaling Pathway (with AG1478) Affects Meiotic Maturation, Cumulus Expansion
and Hyaluronan and Progesterone Synthesis
Several observations support the finding that EGF-like growth factors, i.e., amphiregulin and
epiregulin, produced by granulosa cells and cumulus cells play a major role in triggering oocyte
maturation and the cumulus expansion of OCC in mice [44]. Epidermal growth factor (EGF) is
a poor inducer of porcine cumulus expansion in vitro [45]. Nevertheless, FSH pre-treatment strongly
enhances EGF response within 3 h, as evidenced by a high increase in HA production and cumulus
expansion after sequential exposure to FSH and EGF [46]. FSH itself does not affect epidermal
growth factor receptor (EGFR) concentration or the tyrosine phosphorylation of EGFR, but it enhances
the EGF-induced tyrosine phosphorylation of EGFR, indicating that the FSH signaling pathways
may stimulate or modulate specific EGFR–regulating proteins. FSH also rapidly induces porcine
OCC to express EGF-like growth factors [47] and TACE/ADAM17, a protease that cleaves and
activates the EGF transmembrane precursors [48]. It has been shown [45] that AG1478, the inhibitor
of EGFR tyrosine kinase activity, reduces 50% of the synthesis and 90% of the HA retained in the
cumulus ECM, and prevents the expansion of porcine OCC stimulated with FSH for 24 h in vitro
culture. Furthermore, although EGF does not stimulate progesterone production by porcine OCC and
granulosa cells, the pre-treatment of both cell types with inhibitor AG1478, significantly reduces the
stimulatory effect of FSH on progesterone production. This result is in agreement with the previous
finding showing that AG1478 reduced the FSH-induced expression of the steroidogenic enzyme
P450 side chain cleavage, Cyp11a1, in rat granulosa cells [49]. Importantly, the addition of AG1478
to the culture medium, irrespective of the stimulation, inhibited nuclear maturation in pigs [45,47].
Similarly, Ashkenazi et al. [50] observed that after the local administration of AG1478 inhibitor into the
rat ovary, the ratio of entrapped immature oocytes (in germinal vesicle stage) in the inhibitor-treated
ovaries was 5-fold higher than in the contralateral untreated ovaries. Thus, results in pigs [45] showing
that EGFR activation by EGF-like growth factors produced under the FSH stimulus is involved in
initiating the ovulatory events in porcine OCC are consistent with the results obtained in mice and
rats [44,50]. However, it is possible that FSH trans-activates EGFR via mechanisms independent of
EGF shedding [48]. Finally, it is important to note that the FSH-induced synthesis of both HA and
progesterone is reduced but not abolished by AG1478, indicating that other signaling pathways elicited
by FSH are operating in parallel [45].
3.2. Inhibition of EGFR Tyrosine Kinase (with Lapatinib) Affects Meiotic Maturation, Cumulus Expansion, and
Expression of Cumulus-Associated Transcripts
In the ovarian follicles, EGFR mediates the ovulatory response to LH and the sustained activity
of EGFR is an absolute requirement for LH-induced oocyte maturation and cumulus expansion [51].
However, abnormally elevated EGFR kinase activity can lead to various pathological states, including
cancer. The human epidermal growth factor receptor (HER) family consists of four closely related
transmembrane receptors: HER1 (human epidermal growth factor receptor 1, EGFR), HER2/c-Erb-B2,
HER3/Erb-B3 and HER4/Erb-B4. These members of the type I receptor tyrosine kinase family are
frequently implicated in cancer [52,53]. HER family-related downstream signaling plays a crucial role
in cell proliferation, survival, migration and differentiation [54,55]. Recently, it has been investigated
the effect of lapatinib on processes essential for ovulation, such as oocyte meiotic maturation and
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cumulus expansion, since it has been demonstrated that using of biological agents for treating cancer in
women increases the probability that some women will conceive while taking the inhibitor (lapatinib)
of growth factor signaling [56]. Lapatinib (GW572016, Tykerb/Tyverb; GlaxoSmithKline) is an orally
active small molecule that reversibly and selectively inhibits the tyrosine kinase domain of both EGFR
and HER2 [57] by binding to the ATP-binding site of the kinase, and preventing autophosphorylation
or the rapid development of resistance to monotherapies [58]. It has been found that lapatinib,
through the EGFR signaling pathway, is able to inhibit oocyte maturation in pigs [59]. In addition,
lapatinib is able to reduce the expression of cumulus expansion -related transcripts (TNFAIP6, PTGS2),
HA synthesis, cumulus expansion and progesterone secretion by porcine OCC cultured in FSH/LH
supplemented medium [59]. This is in good agreement with the previous study showing the reduction
of FSH-induced synthesis of both HA and progesterone by AG1478, another inhibitor of EGFR tyrosine
kinase activity [45].
3.3. Addition of Progesterone Receptor Antagonist (RU486) to Culture Medium Affects Meiotic Maturation; It
Does Not Affect Formation of Cumulus Extracellular Matrix Relying on the Covalent Transfer of Heavy Chains
of IαI Molecules to Hyaluronan
Progesterone is an ovarian steroid hormone that regulates key aspects of female reproduction and
acts through the progesterone receptor (PR). The progesterone receptor is a member of the nuclear
receptor superfamily and functions as a ligand-activated transcription factor. The functional roles of
PR in the ovary have been investigated with genetically modified mouse models and PR antagonist
(RU486). It has been demonstrated that PR-knockout mice do not ovulate and are infertile [60,61].
Interestingly, despite the failure of ovulation in PR-null mice, cumulus expansion proceeds normally.
However, the addition of RU486 to the culture medium with porcine OCC significantly decreases
FSH/LH-induced resumption of oocyte meiosis (~74%; p < 0.05) and progression of oocyte maturation
to the MII stage (~44%; p < 0.05) [62]. Gonadotropins stimulate cumulus expansion as well as HA
synthesis by porcine OCC during in vitro maturation [19]. The addition of RU486 did not change
FSH/LH-stimulated total HA synthesis; however, the retained amount of HA within the complexes
was significantly reduced (p < 0.05). The amount of HA retained in cumulus ECM was approximately
60% of the amount retained within the cumulus ECM of the OCC cultured with FSH/LH alone [62].
However, the immunodetection of HABP, TNFAIP6, and PTX3 proteins in FSH/LH-stimulated
OCC treated with RU486 confirmed the spatial localization of cumulus-associated components [62].
Furthermore, western blot analysis detected the heavy chains of IαI proteins in the matrix extracts
of FSH/LH stimulated-OCC, treated with RU486 [62]. Shimada et al. found [63] that porcine OCC
cultured in vitro in the presence of FSH/LH and RU486 had little developmental competence to
proceed to the blastocyst stage. Moreover, RU486 significantly impaired blastocyst development
in mice [64] and in cows [65]. Also, the administration of RU486 by intraperitoneal injection to
gonadotropin-primed mice reduced the number of ovulated oocytes [66] and in mouse follicles cultured
with hCG/EGF, in the presence of RU486, the MII rate was significantly lower (62%) [67]. Surprisingly
the addition of RU486 to the culture medium significantly increased progesterone production by
porcine OCC compared to FSH/LH alone [62]. To summarize, in pigs, the inhibition of PR with
RU486 does not affect HA synthesis, the formation of cumulus ECM and covalent linkage between HA
and heavy chains of IαI, but it appears that progesterone may be critical for maintaining an optimal
microenvironment for oocyte maturation and fertilization [62].
3.4. Addition of General COX Inhibitor (Indomethacin) to Culture Medium does not Affect Meiotic Maturation,
nor Formation of Cumulus Extracellular Matrix
In mammalian species, the preovulatory surge in gonadotropins upregulates the follicular
expression of cyclooxygenase-2 (COX-2), which elevates the levels of prostaglandins [68,69].
Mice genetically deficient in Cox-2 exhibited ovulatory failure [70,71]. In addition, Cox-2 and
prostaglandin E2 receptor subtype Ep2 null mice were infertile [72]. The administration of either general
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COX inhibitors (indomethacin) or inhibitors selective for COX-2 (NS-398, celecoxib) reduced ovulation
rates in rodents, domestic animals, and monkeys [73–75]. In porcine OCC cultured in FSH/LH
supplemented medium for 44 h, neither the resumption of meiosis (~87%) nor progression of oocyte
maturation to MII (~72%) was affected by indomethacin [62]. Concomitantly, the total HA synthesis
and retained amount of HA within the complexes was similar to those of OCC stimulated with FH/LH
alone. In addition, the covalent binding between heavy chains of IαI molecules to HA in the cumulus
ECM extracts, as well as cumulus ECM-related proteins (HABP, TNFAIP6, and PTX3) were detected
in FSH/LH-stimulated OCC treated with indomethacin [62]. In agreement, indomethacin did not
block HA synthesis induced by FSH in Graafian follicles in mice [76]. Moreover, Western blot analysis
confirmed that in cumulus cells of Cox-2 and Ep2 null mice, the TNFAIP6 protein remained covalently
associated with the heavy chains of IαI molecules. This is clear evidence that the ovaries of Cox-2
null mice maintain the capacity to produce Has2 mRNA in response to an ovulatory dose of hCG
as well as the ability to form expanded cumulus ECM [72]. Matsumoto et al. [77] showed that the
ovulatory process, but not follicular growth, oocyte maturation or fertilization, was primarily affected
in adult Cox-2 or Ep2-deficient mice. Eppig [76] suggested that PGE2 might play a role in the indirect
stimulation of cumulus expansion by LH. Interestingly, Ben-Ami et al. [78] have shown that LH may
mediate its effects on COX-2 expression in cumulus cells via the induction of the EGF-related factors
amphiregulin, epiregulin, and betacelulin produced in human granulosa cells. Similarly, in mice, these
factors bind EGF receptor in cumulus cells and induce the Cox-2 message [79]. Also Hsieh et al. [80]
have demonstrated that in mice, the LH-induction of Cox-2/Ptgs2 expression is dependent on the
activation of EGF receptor signaling in cumulus and mural granulosa cells. Moreover, it has been
shown that lapatinib, the inhibitor of EGFR tyrosine kinase activity, reduces the expression of COX-2
mRNA in porcine OCC cultured in vitro [59]. To summarize, in pigs, the inhibition of COX-2 by
indomethacin does not affect FSH/LH-stimulated HA synthesis and the formation of the covalent
linkage between heavy chains of IαI to HA nor progesterone production by cultured OCC [62].
3.5. Inhibition of Proteasomal Proteolysis (with MG132) Strongly Affects Meiotic Maturation and Formation of
Cumulus Extracellular Matrix
Protein turnover mediated by the ubiquitin-proteasome pathway plays an essential role in cell
physiology and pathology. Ubiquitin is a small chaperone protein that forms covalently linked
isopeptide chains on protein substrates to mark them for degradation by the 26S proteasome. The 26S
proteasome is a multicatalytic protease complex that specifically recognizes and hydrolyzes proteins
tagged with multiubiquitin chains. The subunits of the 26S proteasome comprise approximately
1% of the total proteome in mammalian cells; the ubiquitin-proteasome pathway serves as the
main substrate-specific cellular protein degradation pathway [81–83]. MG132 is a cell-permeable
peptide aldehyde that inhibits the chymotrypsin-like activity of the 20S proteasomal core [84,85].
The ubiquitin–proteasome pathway modulates mouse oocyte meiotic maturation and fertilization
via regulation of the MAPK-cascade and cyclin B1 degradation [86,87]. In addition, the role of the
26S proteasome in the regulation of oocyte meiosis has been described in mammals, specifically
rats, mice and pigs [83,88–90]. In pigs, the addition of MG132 to the gonadotropin-supplemented
medium prevented cumulus expansion and significantly reduced HA synthesis by the cumulus
cells. Moreover, the covalent binding between HA and heavy chains of IαI was not detected in the
MG132-treated porcine OCC [89]. The formation of expanded HA-rich cumulus ECM depends on
HA association with specific hyaluronan-binding proteins [41], such as IαI [12,20], TNFAIP6 [23–27]
and PTX3 [30,34], which all have been detected in mice and pigs. The TNFAIP6-HC complex is
likely a catalyst in the transfer of heavy chains (of IαI) onto HA [91]. This mediator reacts rapidly
with any HA, leading to the formation of heavy chain-HA and release of the TNFAIP6 catalyst.
While the mRNA expression of HAS2 and TNFAIP6 in the gonadotropin-stimulated OCC was increased
in pigs [27], mice [17,23], and rats [25], in the presence of MG132, the expression of HAS2 and
TNFAIP6 was markedly suppressed in porcine OCC. In addition no signal of HA was observed by
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immunostaining in porcine OCC [92]. Tsafriri et al. [93] used a broad-spectrum metalloprotease
inhibitor, GM6001, to find whether proteolytic activity was involved in the action of LH on the
resumption of meiosis in rats. His conclusion was that this inhibitor prevented the LH-induced
resumption of meiosis. In agreement, the inhibition of proteasomal proteolysis with MG132 arrested
90% of porcine oocytes in the germinal vesicle stage. Moreover, MG132 blocked the degradation of
F-actin-rich transzonal projections (TZPs) interconnecting cumulus cells with the oocyte and cumulus
expansion in pigs [89]. The resumption of oocyte meiosis was accompanied by the disappearance
of the zona pellucida-spanning and actin microfilament-rich TZPs, and an alteration of gap junction
communication [16,89,94]. Since the maintenance of TZPs supports an oocyte meiotic block and porcine
OCC treated with MG132 remain unexpanded, it has been suggested that proteasomal proteolysis
participates in the process of the resumption of meiosis. The terminal differentiation of cumulus
oophorus within the ovarian follicle plays a crucial role in the ability of the oocyte to resume meiosis
and reach full developmental competence [95–97]. Progesterone has been shown to enhance the
activity of proteolytic enzymes important for the rupture of the follicular wall at ovulation [98].
Gonadotropins induce PR expression in cumulus cells concomitantly with an increase in progesterone
secretion by porcine OCC [99,100]. The involvement of the proteasome in the turnover of StAR has
been described [101–103] with subsequent influence on progesterone synthesis [102]. The transfer of
cholesterol across the mitochondrial membranes is promoted by StAR [104]. In MG132-treated porcine
OCC the progesterone levels were reduced [92]. In contrast, Tajima et al. [102] found a significant
elevation in progesterone synthesis in MG132-treated rat granulosa cells. This discrepancy can be
explained by the differences in the cell culture regimen. The relation between progesterone and
proteolytic enzyme activity during ovulation in the gonadotropin-treated immature rat ovary was
studied by Iwamasa et al. [98]. Their results suggested that progesterone played an indispensable role
during the first 4 h of the ovulatory process by regulating proteolytic enzyme activities. Our results
showed that the ability of gonadotropin-stimulated porcine cumulus cells to produce progesterone to
a level comparable with control OCC was not restored when MG132 was present for 20 h of the culture,
but it was restored (50%) when MG132 was only present for 3 h. In summary, the specific proteasomal
inhibitor MG132 prevents the gonadotropin-induced resumption of meiosis and subsequent cumulus
expansion. In addition, it protects TZPs against breakdown, affects the terminal differentiation of
cumulus cells, markedly reduces the expression of HAS2 and TNFAIP6 and prevents the formation of
a covalent linkage between HA and the heavy chains of IαI [89,92].
4. Conclusions
Ovulation is controlled through multiple inputs including endocrine hormones, immune and
metabolic signals, as well as intra-follicular paracrine factors from the theca, mural and cumulus
granulosa cells and the oocyte itself. The ovulatory mediators exert their effects through remodeling
of the cumulus ECM that surrounds the oocyte. The proper structure of the cumulus ECM, which is
essential for ovulation, transport of the OCC to the oviduct and fertilization depends on the interaction
between HA and HA-associated ECM proteins. HA cross-linking within the cumulus ECM represents
an important new mechanism in the regulation of the ovulatory process in mammalian follicles.
We suggest that the structural changes in cumulus ECM affect signaling pathways and consequently
the resumption of meiosis. In addition, it is interesting to note that the synthesis of ECM molecules
is controlled by specific growth factors and the life of ECM molecules is determined by proteases.
Thus, growth factors signaling pathways and the control of ECM turnover by proteases become
possible targets for new therapies.
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TNFAIP6 Tumor necrosis factor alpha-induced protein 6
PTX3 Pentraxin 3
OCC Oocyte-cumulus complexes
COX2/PTGS2 Cyclooxygenase/prostaglandin endoperoxide synthase
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
GVBD Germinal vesicle breakdown
M I Metaphase I
M II Metaphase II
hCG Human chorion gonadotropin
PMSG Pregnant mare gonadotropin
TFGβ Transforming growth factor beta
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Abstract: Normal pregnancy is a state of hypercoagulability with diminishing fibrinolytic activity,
which is mainly caused by an increase of plasminogen activator inhibitor type 1 (PAI-1). PAI-1 is
the main inhibitor of plasminogen activators, including tissue-type plasminogen activator (tPA) and
urokinase-type plasminogen activator (uPA). In human placentas, PAI-1 is expressed in extravillous
interstitial trophoblasts and vascular trophoblasts. During implantation and placentation, PAI-1 is
responsible for inhibiting extra cellular matrix (ECM) degradation, thereby causing an inhibition of
trophoblasts invasion. In the present study, we have reviewed the literature of various reproductive
diseases where PAI-1 plays a role. PAI-1 levels are increased in patients with recurrent pregnancy
losses (RPL), preeclampsia, intrauterine growth restriction (IUGR), gestational diabetes mellitus
(GDM) in the previous pregnancy, endometriosis and polycystic ovary syndrome (PCOS). In general,
an increased expression of PAI-1 in the blood is associated with an increased risk for infertility
and a worse pregnancy outcome. GDM and PCOS are related to the genetic role of the 4G/5G
polymorphism of PAI-1. This review provides an overview of the current knowledge of the role of
PAI-1 in reproductive diseases. PAI-1 represents a promising monitoring biomarker for reproductive
diseases and may be a treatment target in the near future.
Keywords: plasminogen activator inhibitor type 1; trophoblast invasion; recurrent pregnancy losses;
preeclampsia; intrauterine growth restriction; gestational diabetes mellitus; endometriosis; polycystic
ovary syndrome
1. Introduction
The fibrinolytic system plays a role in several physiological and pathophysiological processes,
such as hemostatic balance, tissue remodeling, tumor invasion, angiogenesis and reproduction [1].
Normal pregnancy is a state of hypercoagulability with remarkable changes in all aspects of
hemostasis—an increase of clotting factors and coagulability and a decrease of anticoagulants and
fibrinolytic activity, thereby influencing placental function during pregnancy and meeting delivery’s
hemostatic challenge [2]. Fibrinolytic system is depressed during pregnancy, and this change partly
explains the higher incidence of thromboembolic complications such as recurrent pregnancy losses,
preeclampsia and intrauterine growth restriction [2]. The diminishing fibrinolytic activity is mainly
caused by a continuous increase of the major inhibitor of the fibrinolytic system: plasminogen activator
inhibitor type 1 (PAI-1) [2]. PAI-1 is responsible for approximately 60% of the PA-inhibitory activity
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in the plasma [3] and is the key inhibitor of fibrinolysis compared with PAI-2 and PAI-3 during
pregnancy [4].
PAI-1 gene deficiency shows a transient impaired placentation in mice [5], while, in humans,
PAI-1 gene deficiency is associated with abnormal bleeding after a trauma or surgery [6,7]. Transgenic
mice that overexpress PAI-1 exhibit thrombotic occlusion [8]. Former studies in humans suggest
that increased PAI-1 levels are found to be crucial mediators of vascular disease, fibrosis, tumor
metastasis, diabetes, and reproductive diseases [9–12]. PAI-1 acts as a major inhibitor of fibrinolysis,
its overexpression leads to fibrin accumulation and insufficient placentation. In this review, we focus
on the complex roles of PAI-1 in normal placentation and reproductive diseases, including recurrent
pregnancy losses, preeclampsia, intrauterine growth restriction, endometriosis and polycystic
ovary syndrome.
2. Fibrinolytic System and PAI-1 (Plasminogen Activator Inhibitor Type 1)
The prime fibrinolytic protease of the fibrinolytic system is plasminogen, which can be activated
by urokinase-type plasminogen activator (uPA) and the tissue-type plasminogen activator (tPA) [1,8].
Plasminogen can then be converted into plasmin, and eventually cleaves fibrin into cross-linked fibrin
degradation products (Figure 1) [8]. Plasminogen activator inhibitors include PAI-1, PAI-2, PAI-3,
C1-esterase inhibitor and protease nexin (Figure 1) [8]. Plasmin inhibitors are α2-plasmin inhibitor
(α2-PI), α2-macroglobulin (α2-MG) and protease nexin (Figure 1) [8]. Both uPA and tPA are serine
proteases that cleave a single Arg-Val peptide bond to transfer plasminogen to plasmin; uPA functions
mainly in pericellular proteolysis while tPA is involved in the circulation [13]. uPA plays an important
role in a variety of physiological and pathological processes including tissue destruction, inflammatory
reactions and invasion of trophoblasts [14] and cancer cells [15]. Both uPA and tPA consist of a
single-chain form and a two-chain form [4,16]. During normal pregnancy, the levels of uPA, PAI-1,
PAI-2 and α2-antiplasmin are increased and tPA levels are decreased [17].
PAI-1 is the primary inhibitor of tPA in the plasma during pregnancy [4]. It is a single-chain
glycoprotein consisting of 379 or 381 amino acids (N-terminal heterogeneity) and belongs to the serine
family of protease inhibitor, with a molecular weight of about 45 kDa. There are three different forms
of PAI-1: active, inactive and substrate form. The active form can inhibit tPA or uPA by forming a
1:1 stoichiometric complex with each enzyme and the inactive form does not react with the target
proteinase [18]. The conformational conversion from the active into the inactive form is completed by
the P1-P1’ in a reactive center loop (RCL) of the serpin cleave, followed by the insertion of the RCL
into the β-sheet A of the serpin [19]. PAI-1 gene in humans is located on chromosome 7 (q21.3-q22),
extends approximately 12.200 base pairs and consists of nine exons and eight introns [20]. PAI-1 gene
has several polymorphisms and the 4G allele of the 4G/5G polymorphism is related to high PAI-1
levels [21]. 4G polymorphism is located in the PAI-1 promotor, which is 675 bp upstream from the start
site of transcription in the promoter region [21]. Circulating PAI-1 is mainly found in platelets, whilst
a large range of cells can further express PAI-1, such as fibroblasts, smooth muscle cells, endothelial
cells, hepatocytes, inflammatory cells and placental cells [22].
Both forms of tPA are inhibited by PAI-1, whereas PAI-2 inhibits mainly the two-chain
form [23]. PAI-2 consists of two molecular forms: the low molecular weight (LMW) form with
43–48 kDa is intracellular and non-glycosylated, while the high molecular weight (HMW) form with
60 kDa is secreted and glycosylated [24]. PAI-2 is mainly expressed by placental trophoblasts and
macrophages [23]. PAI-3, also known as protein C inhibitor (PCI), is prominently expressed in male
reproductive organs and its low levels in seminal plasma are associated with infertility [25].
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Figure 1. Schematic diagram of fibrinolysis: plasminogen is activated by plasminogen activator
(tPA in blood or uPA in tissue), and then converted to plasmin. Then plasmin cleaves fibrin into
fibrin-degradation products. Plasminogen activators inhibitors are PAI-1, PAI-2, C1-esterase inhibitor
and protease nexin. Plasmin inhibitors are α2-plasmin inhibitor (α2-PI), α2-macroglobulin (α2-MG)
and protease nexin. Pro-uPA can be converted to uPA, which is catalyzed by plasmin, the product
of plasminogen.
3. Role of PAI-1 in the Female Reproduction System
During a healthy pregnancy, PAI-1 levels in the plasma gradually elevate during the second
trimester of pregnancy and reach a maximum at 32–40 weeks of pregnancy. Within 5–8 weeks after
delivery, PAI-1 levels fall again to the levels before the occurrence of pregnancy [2]. The concentration
of PAI-1 in the plasma of healthy non-pregnant women varies (55 ± 17 ng/mL) [26]. The maximum
of PAI-1 concentration during the last trimester of pregnancy is approximately 3–5 times higher than
that of non-pregnant women [26]. These temporary changes of PAI-1 during pregnancy are accounted
for hormonal influences [27]. Increases in PAI-2 levels are observed during pregnancy and during
delivery [23]. Both PAI-1 and PAI-2 decrease quickly following the placenta separation from the uterus,
but PAI-2 can still be found in the circulation up to eight weeks postpartum [2].
Trophoblasts can express PAI-1 and PAI-2 in vivo and in vitro [28]. Both PAI-1 and PAI-2
are localized in the cytoplasm of cytotrophoblasts and in the cytoplasm and plasma membrane
of intermediate and syncytiotrophoblasts [28]. PAI-1 is localized in invading trophoblasts in the human
placenta by immunostaining [29], especially in extravillous interstitial trophoblasts and vascular
trophoblasts [30]. In the human placenta, PAI-1 protein and mRNA expression exist in most extravillous
cytotrophoblast cells of the decidual layer, especially the chorionic villous tree and in cytotrophoblast
cells of the chorionic plate, basal plate and intercotyledonary septae [31]. No expression of PAI-1
has been observed in the basal plate of endometrial stromal cells, chorionic plate connective tissue
cells, septal endometrial stromal cells or villous core mesenchyme [31]. PAI-2 is the predominant
PAI accumulated in villous syncytiotrophoblasts [29]. Both PAI-1 and PAI-2 mRNAs expressions are
detected in cultured cytotrophoblasts isolated from both the first trimester and term placenta [29].
PAI-1 and PAI-2 are also expressed by uterine natural killer (uNK) cells [32].
3.1. PAI-1 Inhibits Trophoblast Invasion
Trophoblast invasion at the maternal-fetal interface is a key process during implantation and
placentation, and during this process extravillous cytotrophoblasts (EVT) acquire invasive properties,
which are able to invade and remodel maternal tissues (interstitial EVT) and uterine spiral artery
(endovascular EVT) [33]. EVT can degrade extracellular matrix (ECM) to promote cell migration to the
maternal side [33]. This process is precisely controlled by many factors expressed by maternal cells
and trophoblasts (Figure 2) [33].
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Trophoblasts and malignant tumors use the same biochemical mediators to facilitate invasion,
including extracellular matrix degradation and immunosuppression of environmental conditions.
PAI-1 can inhibit trophoblasts invasion while promoting tumor cell immigration [34,35]. PAI-1 is
a biomarker for malignancies with poor prognosis because it facilitates tumor cell migration and
invasion [35]. PAI-1/uPA/uPA receptor (uPAR)/low density lipoprotein receptor-related protein
(LRP)/integrin complexes are initiating an “adhesion–detachment–re-adhesion” cycle to promote
tumor cell migration [35,36]. Hyperinvasiveness in premalignant and malignant extravillous
trophoblasts (JAR and JEG-3 choriocarcinoma cell lines) results from a downregulation of tissue
inhibitors of metalloprotease (TIMP)-1 and PAI-1 genes [34].
EVT invasion in early pregnancy occurs in a relatively low-oxygen (3%) environment, which
is mediated by a general inhibition of the plasminogen activator system [37], as well as many
adhesion molecules, growth factors, cytokines, interleukins, ECM components, and various placental
hormones [14,33]. The anti-invasive action of EVT is caused by an upregulation of the tissue inhibitor
of TIMP-1 and PAI-1 and a downregulation of uPA [14]. PAI-1 and PAI-2 are expressed in invading
human extravillous trophoblast cells and they limit the depth of invasion [37,38]. PAI-1 is found to be
absent in the placental bed of ectopic and molar pregnancies, suggesting that no expression of PAI-1
can contribute to an uncontrolled placental invasion [30]. Expression of PAI-1 is elevated in the process
of EVT invasion treated by tumor necrosis factor α (TNF-α), and adding PAI-1-inactivating antibodies
restores migration [39].
The limitation of EVT invasion is due to reduced ECM degradation (Figure 2), which requires the
balance of promoting and restraining factors, such as metalloproteinases (MMPs) and tissue inhibitors
of MMPs (TIMPs), uPA and PAI-1 [40]. PAI-1 restrains ECM degradation in three different ways. Firstly,
PAI-1 can directly block uPA activity to constrain the proteolytic activity of plasmin [18]. Secondly,
PAI-1 binds to uPA and causes its degradation via uPAR and low-density lipoprotein receptor-related
protein (LRP) internalization [41]. The direct binding of occupied uPAR to LRP is essential for
internalization and clearance of uPA-PAI-1-occupied uPAR [42]. The activity of PAI-1 depends on
its interactions with LRP, which leads to the activation of the Janus kinase 2/signal transducer and
activator of transcription protein (Jak/-Stat) signaling pathway [43]. Lastly, an increase in the PAI-1
transcript and translation leads to the formation of keloids and fibrosis [44]. Renaud et al. (2005)
suggested that macrophages participate in decreasing the depth of trophoblast invasion by secreting
TNF-α, which couples TNFR and promotes EVT to release PAI-1 during placentation [45]. Huber et al.
(2006) further reported that TNF-α stimulates PAI-1 level of HTR-8/SVneo cells by activation of the
nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) pathway [46].
PAI-1 may also play a role in remodeling maternal uterine spiral arteries (Figure 2) [47].
PAI-1 mRNA positive cells in the maternal arteriole co-express cytokeratin, implying that PAI-1
may participate in the process of endovascular cytotrophoblast cells replacing cells of the arteriole
wall [47]. Hypoinvasion and failed placental vascular remodeling are associated with reproductive
diseases, such as recurrent pregnancy losses (RPL), preeclampsia and intrauterine growth restriction
(IUGR) and even maternal as well as fetal death [48,49]. In terms of tumor cells, PAI-1 can both
promote and inhibit tumor growth and angiogenesis. Low concentrations of PAI-1 can stimulate tumor
angiogenesis while treatment of animals with high doses of PAI-1 suppresses angiogenesis and tumor
growth [50].
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Figure 2. Schematic diagram of PAI-1’s role during trophoblasts invasion. The fetal side of the human
placenta mainly includes cytotrophoblasts and syncytiotrophoblasts, and sycytiotrophoblasts are
differentiated and fused by cytotrophoblasts. The cytotrophoblasts invade into the maternal side and
differentiate into extravillous interstitial trophoblasts, intermediate trophoblasts and endovascular
trophoblasts. Among them, extravillous interstitial trophoblasts and endovascular trophoblasts express
plasminogen activator inhibitor type 1 (PAI-1). Furthermore, cells from the maternal side take
part in trophoblast invasion, such as endometrial stromal cells, decidual cells, macrophages and
endothelial cells. Extravillous trophoblast invasion in early pregnancy is precisely controlled by many
factors expressed by trophoblasts and maternal cells, where PAI-1 is the main anti-invasive factor.
PAI-1 prevents trophoblast invasion by inhibiting extracellular matrix degradation, which leads to
fibrin accumulation in the maternal side. PAI-1 may also play a role in remodeling maternal uterine
spiral arteries.
3.2. Recurrent Pregnancy Losses
Recurrent pregnancy losses (RPL) affects approximately 1% of all couples worldwide [51], and its
latest definition is two or more consecutive failed pregnancies as documented by ultrasonography or
histopathologic examination before the 20th pregnancy week according to the Practice Committee of
the American Society for Reproductive Medicine [52]. The identifiable reasons for RPL include genetic
abnormalities, structural abnormalities, infection, endocrine abnormalities, immune dysfunction,
and thrombophilic disorders [53]. However, there are still up to 40–50% of pregnancy losses that
have unidentifiable causes [54]. PAI-1 plasma levels in RPL patients are increased in comparison
to women with healthy pregnancies [55]. Among all the thrombophilic genes, functional PAI-1-675
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4G/5G polymorphism is one of the most frequently analyzed PAI-1 genetic variants. However,
the contribution of PAI-1-675 4G/5G to unexplained RPL has remained controversial.
Gris et al. (1997) analyzed a study with 500 women with unexplained RPL and demonstrated that
increased PAI-1 levels are the most frequent hemostasis-related abnormality connected to unexplained
RPL [56]. A recent meta-analysis by Li et al. (2015) including 22 studies with 4306 cases and 3076
controls showed that PAI-1 4G/5G polymorphism is associated with an increased RPL risk (p = 0.0003),
especially in the Caucasian subgroup (p < 0.001) [57]. Khosravi et al. (2014) further found that a high
prevalence of PAI-1 -675 4G/4G existed in RPL patients as well as in implantation failure (IF) patients
(p < 0.001) [58].
Another group suggests that PAI-1-675 4G/5G alone is not responsible for RPL [59,60], and more
thrombophilic gene mutations together can help predispose RPL risk. More than three gene mutations
among the 10 thrombophilic gene mutations (factor V G1691A, factor V H1299R (R2), factor V Y1702C,
factor II pro-thrombin G20210A, factor XIII V34L, b-fibrinogen −455G > A, PAI-1 4G/5G, HPA1 a/b (L33P),
MTHFR C677T, and MTHFR A1298C) are more prevalent in RPL patients [61,62]. Endothelial PAI-1
synthesis is induced by angiotensin II, which is generated by angiotensin I-converting enzyme (ACE)
and this might be one of the main reasons of elevated PAI-1 concentrations in RPL [63].
In general, associations between PAI-1 4G/5G and unexplained RPL may have been masked
by sample-size effects, ethnicity, enrollment criteria or combinations. In order to improve our
understanding of the pathobiology of RPL, we need to identify not only novel genetic variants
and the interaction, but also how genes, proteins and the environment contribute to RPL. Thus far,
PAI-1 inhibiting fibrinolysis and fibrin accumulation are believed to be the principle reasons for RPL,
but the understanding of the mechanism of PAI-1 in RPL still has to be further analyzed.
3.3. Preeclampsia
Preeclampsia affects about 2.5% to 3.0% of pregnant women [64] and it is a leading cause of
perinatal morbidity and mortality both for the fetus and the mother [65]. Preeclampsia is a pregnancy
disorder characterized by hypertension, proteinuria and placental abnormalities [66], which are
generally manifested in the second to third trimester of pregnancy [67]. Although the mechanisms
responsible for the pathogenesis of preeclampsia are poorly understood, there is an agreement that it
is associated with hypoinvasion and failed conversion of maternal endometrial spiral arteries in the
placenta [64], both of which are related to PAI-1 and PAI-2.
Maternal PAI-1 levels in the plasma are higher in patients with preeclampsia during the second
trimester of pregnancy [67], and its mRNA levels are positively correlated with the severity of
preeclampsia during 35–41 weeks of gestation [68]. The ratio of PAI-1 to PAI-2 is increased in women
with early-onset preeclampsia (24–32 gestational weeks) in comparison to the control group, but not in
late-onset preeclampsia (35–42 gestational weeks) [69]. Estelles et al. (1989) found that both antigenic
and functional PAI-1 levels are increased while antigenic and functional levels of PAI-2 are decreased in
the third trimester (≥28 weeks) compared with healthy controls [70]. In contrast, in the first trimester
(11–13 weeks), PAI-2 in the plasma is observed to be not differently expressed in preeclampsia [71].
PAI-1 antigen levels are positively correlated to proteinuria in women with preeclampsia [72].
Therefore, PAI-1 has been considered as a potentially useful predictor of preeclampsia. Although
it is known that smoking may reduce the risk for preeclampsia [73], specifically chronic smoking
upregulates PAI-1 levels [74].
It remains uncertain whether increased PAI levels are the primary mechanism leading
to preeclampsia or a consequence of the associated endothelial and placental damage [75].
Cytotrophoblasts, which do not express Raf kinase inhibitor protein (RKIP), could be one of the
reasons for impaired migration of cytotrophoblasts in preeclampsia, because locostatin (the inhibitor
of RKIP) induces PAI-1 expression with the support of activation of NF-κB pathway and finally
contributes to an inadequate trophoblast invasion [76].
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PAI-1 expression in the plasma is increased following exposure to inflammatory cytokines,
including interleukin 1β (IL-1β) [77], vascular endothelial growth factor (VEGF), epidermal growth
factor (EGF) and fibroblast growth factor (FGF) or hypoxic conditions [78]. Hypoxia can directly
stimulate PAI-1 mRNA and protein expression [35], and can also stimulate hypoxia-inducible
transcription factors (HIF-1α and HIF-2α) to induce PAI-1 [79], both of which may also be the
mechanisms of preeclampsia. When preeclampsia occurs in combination with increased levels of
syncytial PAI-1, intervillous fibrin deposition and infarction may reduce the flow of nutrients from
mother to fetus leading to IUGR [80].
Still, there is a dispute of the correlation between PAI-1 polymorphism and preeclampsia. Gerhardt
et al. (2005) discovered that women with PAI-1 5G/5G genotype are at risk for early onset of severe
preeclampsia (17–35 gestational weeks) [81]. Morgan JA et al. (2013) found that PAI-1-675 4G/5G
polymorphism is not associated with preeclampsia with a total of 5003 women involved in the
meta-analysis [82].
3.4. Intrauterine Growth Restriction
Intrauterine growth restriction (IUGR) is defined as fetuses with pathological smallness caused by
an underlying functional problem [83], occurring in 5–10% of all pregnancies [84]. IUGR is associated
with increased risks of neonatal death or disability in the perinatal period [84,85] and predisposes
the child to a lifelong increased risk for hypertension, cardiovascular disorders and renal disease [86].
Histopathological studies of IUGR placentas indicate abnormalities of the maternal spiral arterioles,
dysregulated villous vasculogenesis, and abundant fibrin deposition, as well as oxidative stress and
apoptosis in villous trophoblast [87].
PAI-1 is a potential marker of placental insufficiency and it is associated with fetal hypoxia and
angiogenesis in IUGR [84]. PAI-1 levels in the umbilical cord blood are increased in patients with IUGR
and it is associated with the plasma’s angiogenic potency measured in vitro [84]. Cytotrophoblast cells
isolated from the placenta of IUGR pregnancies express significantly higher levels of PAI-1, with a
significant decrease in plasminogen activator activity, compared with trophoblast cells from normal
pregnancy cultured in vitro [88]. This localized increased production of PAI-1 may play an important
part in restricting endovascular trophoblast invasion in early pregnancy, increasing fibrin deposition
and reducing uteroplacental blood flow in IUGR pregnancies [88].
PAI-1 placental levels are increased in pregnancies with IUGR and preeclampsia, but not in
patients with isolated IUGR [89]. In contrast, PAI-2 expression is reduced in placentas of both IUGR
women with and without preeclampsia compared with normal placentas [89]. In the first trimester,
low PAI-2 is associated with a higher risk for the development of IUGR [90]. A significant decrease
in PAI-2 in the plasma and amniotic fluid is observed in IUGR groups in comparison with normal
pregnancies [91]. PAI-2 levels are correlated with fetal weight of IUGR pregnancies [92,93], indicating
that PAI-2 is not only the marker of the quantity and quality of the placenta tissues but also a marker
for fetal growth and development [17]. PAI-1 polymorphism (4G/5G) has not been associated with
an increased risk of IUGR in the case-control analysis [94,95].
3.5. Gestational Diabetes Mellitus
Gestational diabetes mellitus (GDM) is characterized by impaired glucose tolerance during
pregnancy, with the prevalence of 0.6–20% of pregnancies [96]. Women with GDM can have
complications including polyhydramnios, fetal macrosomia, preeclampsia, shoulder dystocia and
increased risk for operative delivery. Postpartum, patients with GDM have a more than seven-fold
increased risk of developing postpartum diabetes compared to women without GDM [97]. Insulin
resistance and chronic subclinical inflammation are the two main pathways leading to GDM and
possibly previous GDM [98]. Insulin resistance syndrome is associated with increased levels of leptin,
TNF-α, tPA, PAI-1 and testosterone [99].
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PAI-1 is partly secreted by adipose tissue, and can lead to an impairment of the fibrinolytic
system [100]. Salmi et al. (2012) reported that PAI-1 levels are higher in the serum of women with GDM
compared to healthy women during the early third trimester pregnancy [101]. Bugatto et al. (2017)
stated that PAI-1 levels in maternal uterine blood do not change in women with GDM at the third
trimester pregnancy compared to controls [102]. McManus et al. (2014) suggested that GDM women
have lower concentrations of PAI-1 in comparison to the age- and weight-matched controls in maternal
plasma, as well as in the umbilical artery and umbilical vein [103]. This study further demonstrated
that GDM offspring also have decreased PAI-1 concentrations compared to controls [103].
PAI-1 levels in women with GDM are not consistent, but PAI-1 levels have been shown to be
increased in women who had GDM during a previous pregnancy [98]. Women with previous GDM
have elevated PAI-1 levels 0.25–4 years after delivery [98]. PAI-1 levels are correlated with the insulin
sensitivity index (SI), and the PAI-1/SI ratio is increased in women with a previous GDM and impaired
insulin [104].
PAI-1 expression is significantly correlated with a variety of adiposity features, including body
mass index (BMI), total fat mass, waist circumference, visceral adipose tissue and subcutaneous adipose
tissue, total cholesterol triglycerides, fasting plasma glucose and 2 h plasma glucose in the glucose
tolerance test, insulin sensitivity as well as pancreatic beta-cell function [100,105,106]. Hyperglycemia
inhibits the expression of uPA and PAI-1 by the induction of p38 mitogen-activated protein kinases
(p38 MAPK) and peroxisome proliferator-activated receptor γ (PPAR-γ) stress signaling pathways,
which are different from the PAI-1 levels induced during preeclampsia [107].
Leipold et al. (2006) reported that the 5G allele of the PAI-1 gene is associated with normal glucose
tolerance in pregnant women independent of maternal age or BMI and it is also related to low fasting
glucose values in the oral glucose tolerance test [108]. Physical activities can lower cardiometabolic
risk in women with previous GDM and PAI-1 levels, as well as the level of C-reactive protein, leptin
and triglycerides [109].
Furthermore, Glueck et al. (2000) found that the polymorphism of PAI-1 gene is not associated
with eclampsia, abruptio placentae and intrauterine fetal death by stepwise logistic regression [110].
3.6. Endometriosis
Endometriosis is defined as the presence of endometrial-like tissue outside the uterus, causing
dysmenorrhea, chronic pelvic pain, dyspareunia, and infertility [111]. Pathogenesis of endometriosis
includes inflammation, angiogenesis, cytokine/chemokine expression and endocrine alterations
such as estrogen receptors (ESRs) and progesterone receptors (PGRs) expression [111]. PAI-1 plays
an important role in tumor cell migration and invasion [11], which is also the mechanism of
endometriotic cells invasion [112].
Ovarian endometriotic tissues have higher antigenic levels of PAI-1 than normal
endometrium [113]. Increased PAI-1 antigen levels in peritoneal fluid from patients with endometriosis
contribute to an increase of peritoneal adhesions [114]. In vitro, isolated endometriotic stromal cells
release a higher level of PAI-1 compared to the endometrial stromal and epithelial cells of women with
endometriosis and controls [112].
There exists a dispute of the association between PAI-1 gene polymorphism 4G/5G and
endometriosis [115,116]. PAI-1 4G/5G polymorphism is associated with an increased risk for
endometriosis-associated infertility [116]. However, Goodarzi et al. found that PAI-1 genotype
distribution is similar in patients with endometriosis and controls [115].
3.7. Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy of women in the
reproductive age, with a prevalence of up to 10% and symptoms include hyperandrogenism and/or
hyperandrogenemia, oligo-ovulation and polycystic ovarian morphology [117]. PCOS is associated
with infertility, RPL, type 2 diabetes mellitus and cardiovascular diseases [117]. Many studies in
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women with PCOS have reported that PAI-1 levels in the plasma are increased in both normal
weight and overweight/obese women with PCOS compared with controls with matched body
mass index (BMI) [100,118,119]. Serum PAI-1 activity is related to the BMI and homeostasis model
assessment (HOMA) score [120], insulin levels and insulin sensitivity indices [121]. PAI-1 levels
decline after treatment with sibutramine and metformin in normal weight and overweight women
with PCOS [118,122].
Oligo-ovulation (defined as delayed menses >35 days or <8 spontaneous hemorrhagic episodes
per year) is not completely understood yet [123]. uPA plays an essential role in the early growing
follicles during cell proliferation and migration, and in the early corpus luteum (CL) formation
related to ECM degradation and angiogenesis [124]. PAI-1 is localized in the granulosa and theca
cells, indicating it possibly plays a role in human ovulation, but its role in PCOS needs to be further
explained [125]. Increased PAI-1 expression in CL of rat and monkey at a later stage is correlated with
a sharp decrease in progesterone production of CL [124]. The role of PAI-1 in ovulation needs to be
studied further in humans. PAI-1 is a predominant independent risk factor for miscarriages in women
with PCOS [126]. Elevated plasma PAI-1 levels are associated with an increased risk for both type 2
diabetes mellitus and cardiovascular diseases (i.e., coronary disease/ischemic stroke) [127–129].
PAI-1 4G/5G polymorphism is associated with susceptibility to PCOS in European, Turkish,
and Asian populations [130,131].
4. Conclusions
PAI-1 is expressed in the placenta and maternal plasma of pregnant women. In the human
placenta, PAI-1 is localized in invading trophoblasts, especially in extravillous trophoblasts.
By inhibiting ECM degradation, PAI-1 plays a vital role in the prevention of trophoblast invasion in RPL,
preeclampsia and IUGR. Increased expression of PAI-1 in the plasma is found in RPL, preeclampsia,
IUGR, GDM in previous pregnancies, endometriosis and PCOS. Similar to tumor cells, PAI-1 promotes
endometriotic cells invasion during endometriosis. In PCOS, PAI-1 may regulate ovulation but this
hypothesis still requires further research. PAI-1 4G/5G polymorphism is associated with GDM and
PCOS; however, contradictory results are found in patients with RPL, preeclampsia and endometriosis.
PAI-1 expression can be reduced through physical exercise and pharmacological interventions,
such as the oral intake of thiazolidinedines (troglitazone or pioglitazone) [100], statins [100] and
metformin [118]. Altered PAI-1 levels have further been found in other pathologies. Studies on
cardiovascular diseases have displayed a strong positive correlation between PAI-1 levels in the
serum and cardiovascular risks for myocardial infarction (MI), recurrent MI, angina pectoris and
atherosclerosis [9]. In addition, PAI-1 is a pivotal mediator of vascular diseases, cancer, asthma, insulin
resistance and diabetes [100]. In the future, PAI-1 may function as a biological monitoring parameter
and possibly represents a therapeutic approach in reproductive pathologies.
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Abstract: The immense diversity of extracellular matrix (ECM) proteins confers distinct biochemical
and biophysical properties that influence cell phenotype. The ECM is highly dynamic as it is
constantly deposited, remodelled, and degraded during development until maturity to maintain
tissue homeostasis. The ECM’s composition and organization are spatiotemporally regulated to control
cell behaviour and differentiation, but dysregulation of ECM dynamics leads to the development
of diseases such as cancer. The chemical cues presented by the ECM have been appreciated as
key drivers for both development and cancer progression. However, the mechanical forces present
due to the ECM have been largely ignored but recently recognized to play critical roles in disease
progression and malignant cell behaviour. Here, we review the ways in which biophysical forces of the
microenvironment influence biochemical regulation and cell phenotype during key stages of human
development and cancer progression.
Keywords: tumour microenvironment; cancer progression; extracellular matrix; matrix remodelling;
fibrosis
1. Introduction
The extracellular matrix (ECM) is most commonly defined as the non-cellular component of
tissue that provides both biochemical and essential structural support for its cellular constituents.
Rather than serving simply as an intercellular filling, the ECM is a physiologically active component
of living tissue, responsible for cell–cell communication, cell adhesion, and cell proliferation [1].
Fundamentally, the ECM is composed of and interlocking mesh of water, minerals, proteoglycans,
and fibrous proteins secreted by resident cells. However, every organ has a unique composition of
these elements to serve a particular tissue-specific purpose [1,2]. Indeed, this unique composition
arises through dynamic biophysical and biochemical feedback between cellular components and their
evolving microenvironment during tissue development [3,4]. For any specific tissue, components
of the ECM are created and arranged by resident cells in accordance with the needs of the tissue.
The production of essential fibrous proteins, such as collagen, elastin, and laminin are controlled by the
ECM and adapt during various stages of embryonic development and disease progression. As a highly
dynamic structure, the ECM is constantly undergoing a remodelling process, by which components
are degraded and modified, facilitated primarily by ECM proteinases [5,6]. The balance between
degradation and secretion of ECM, orchestrated by ECM-modifying cells, is responsible for tensional
homeostasis and the properties of each organ, such as elasticity and compressive/tensile strength.
In vitro, most animal cells are known to only maintain viability when adhered to a substrate [7].
In this regard, cells rely heavily on their sense of touch to survive by protruding, adhering, and
spatially interacting with the surrounding ECM. Various cellular growth factor receptors and adhesion
molecules along the cell membrane, such as integrins, are responsible for the cell’s ability to adhere
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and communicate with its environment [8,9]. Indeed, cells have been shown to transduce cues
from the ECM, such as spatial context and mechanical rigidity, to coordinate crucial morphological
organization and signalling events through regulation of gene transcription. This process in which a
cell converts external mechanical stimuli into a downstream intracellular chemical signal is known as
mechanotransduction [10]. The sensitivity by which cells respond to biophysical and biochemical cues
of the ECM demonstrates the importance of tissue homeostasis in the maintenance of healthy resident
cells. Accordingly, dysregulation of ECM remodelling has been shown to contribute significantly to
cell fate through various fibrotic conditions, characterized by excess ECM deposition and increased
rigidity [11]. Due to increased interstitial pressure, unresolved loss of tissue homeostasis has been
linked to an elevated risk of various conditions, such as osteoarthritis, cardiovascular disease, and
cancer [11]. In this review, we will discuss the role of the ECM in critical physiological processes, such
as tissue development and cancer, and some potential targets for therapeutic intervention.
2. Primary Components of the Extracellular Matrix (ECM)
The ECM is composed of various proteins that give rise to different structures and properties
that exist within it. The main components of the ECM include collagen, proteoglycans, laminin, and
fibronectin. Even among these ECM components, there are subtypes that further specify their function
in the overall structure and properties of the ECM. As structure dictates function, different subtypes
and combinations of ECM molecules confer different functions that are essential for the whole body
to function.
2.1. Collagen as the Basis of ECM Architecture
Collagen is the most significant component of the ECM and the most abundant protein in
human tissue, with 28 unique subtypes discovered [12–15]. Each type is composed of homotrimers
or heterotrimers of left handed helical α chains that are twisted to form a right handed triple helix
structure [13,16]. The collagen superfamily is a large group of proteins that contain the Gly-X-Y motif,
where X and Y are usually either proline or hydroxyproline [16,17]. Despite the large amounts of
bulky proline, the right-hand helical structure is stabilized by the small glycine, interchained hydrogen
bonds, and electrostatic interactions involving lysine and aspartate [17,18]. Fibrillar collagens form
fibrous structures often found in tendons, cartilage, skin, and cornea [13,14]. Each collagen fibre is
made up of several subtypes of collagen in response to its tissue location. The most abundant type of
fibrillar collagen, type I collagen, and can be found in connective tissues ranging from skin and bone
to tendon and cornea [19]. Collagen I is involved heavily in processes such as a wound repair and
organ development.
All fibrillar collagens are first produced as precursors. The α chains are assembled together
in the rough endoplasmic reticulum to form the triple helical structure. Proline and lysine are
hydroxylated and the molecule is glycosylated to initiate the formation of the triple helical structure [20].
The procollagen is then brought to the Golgi apparatus where it is prepared for cellular export.
Processing of the procollagen happens either during or after secretion in the ECM [21–24]. The C
terminal propeptide is cleaved off by specific matrix metalloproteinases (MMPs) and if it is not
removed, it leads to high solubility of collagen that prevents it from forming fibrils [25]. For collagen
types I, II, and III, the N-propeptides are cleaved off, while for type V, XI, and other fibrillar collagens,
the N-propeptides remain (Figure 1A). This modifies the shape and diameter of the fibril without
affecting fibril formation [15,25–27]. The N-propeptides of type V and XI collagens protrude from
the gaps between collagen molecules to prevent lateral growth via steric hindrance and charge
interactions [25,26]. Type V and XI collagens are currently believed to be responsible for nucleating
and modulating the fibril formation of collagen [25,26]. It has been shown that the deletion of collagen
V in mice leads to failure of fibril assembly despite its low amounts in the total collagen content in
most tissues [28].
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Once the microfibrils are formed, these may bind with other microfibrils so that they will grow
into larger fibres. This process is mediated by other ECM proteins (Figure 1C) [29]. Small leucine
rich proteoglycans (SLRPs) such as decorin and biglycan have collagen binding motifs allowing them
to modulate fibre growth, size, morphology, and content [15,29,30]. Another subfamily of collagen
are fibril-associated collagens with interrupted helices (FACIT) that do not form fibrils themselves
but are associated with the surface of collagen microfibrils [13]. Their primary function is to mediate
the formation of a higher-order structure via binding with other extracellular matrix proteins such as
SLRPs and proteoglycans [26,31]. The supramolecular assembly of collagen is further stabilized by
lysyl oxidase (LOX), which leads to overall enhanced mechanical properties. The N terminal and C
terminal ends of individual collagen molecules are covalently cross linked by LOX both within and
between microfibres, contributing to the great tensile strength of collagen [31,32].
In addition to fibrillar and FACIT collagens, there also exist network forming collagens such as
type IV, VIII, and X. These are found in the basal lamina of basement membranes (Figure 1B) [13].
Collagen IV forms a tetramer through their 7S N-terminal domain. Each of these collagen IV molecules
is bound to another collagen IV molecule via their C-terminal NC1 domain of each α-chain, forming
a hexamer [13]. These two domains of collagen IV allow it to form a stable collagen network that
separates the basal lamina from the interstitial stroma [33]. Other ECM proteins such as laminin,
nidogen, and perlecan can be found in the basal lamina that strengthens this barrier to effectively
maintain the organization of the cells in the body (Figure 1B) [33,34].
Although different types of collagen are able to build various types of supramolecular structures
that form the basis of the architecture of the ECM, the contribution of other ECM proteins such as
proteoglycans, laminins, and fibronectin cannot be ignored. They largely influence the chemical and
physical properties of the extracellular matrix such as through their growth factor binding motifs and
innate chemical properties. Furthermore, they also serve as connectors between the cells and the ECM.
2.2. Proteoglycans as Functional Modifiers of the ECM
Proteoglycans are characterized as proteins that have glycosaminoglycans (GAGs) covalently
bonded to them. These GAGs are long chains of negatively charged disaccharide repeats that can either
be heparin sulphate, chondroitin/dermatan sulphate, hyaluronan, or keratin sulphate. Due to the
negative charge of these GAGs, proteoglycans are able to sequester water and cations, which gives them
their space-filling and lubrication functions [35]. For the purpose of this review, only transmembrane
proteoglycans and those found in the pericellular and extracellular space will be discussed.
Of the 13 transmembrane proteoglycans, four of them are syndecans, proteins thought to act as
co-receptors [35]. Syndecans have an intracellular domain, transmembrane domain, and ectodomain
(Figure 1A). The GAGs, typically heparan sulphates, are found attached to the ectodomain, which can
be shed through the action of MMPs [35,36]. The ectodomain of syndecans is intrinsically disordered,
which allows it to interact with a wide variety of molecules to perform a broad range of biological
functions (Box 1) [35]. Some of its functions involve binding to growth factors and morphogens,
facilitating exosome uptake, and being co-receptors of receptor tyrosine kinases [36–39].
One of the proteoglycans found in the pericellular area of the basement membrane is perlecan.
As a large heparan sulfate proteoglycan (HSPG), perlecan has multiple domains, each with different
binding sites and functions (Figure 1A) [40]. These heparan sulfates can bind to a variety of molecules
such as growth factors, growth factor receptors, collagen, and other ECM proteins. In the basement
membrane, perlecan binds and links collagen IV, nidogen, and laminin in order to further strengthen
the basement lamina (Figure 1B) [33,34,41].
Proteoglycans found in the extracellular space are classified into hyalectans and SLRPs.
The structure of hyalectans are identical: the hyaluronic acid binding N terminal and lectin binding
C terminal with GAGs are attached between the N and C terminal ends (Figure 1A). Hyalectans are
encoded by 4 distinct genes: aggrecan, versican, neurocan, and brevican [35]. Aggrecan is found mostly
in bone cartilage and the brain while neurocan and brevican are found in the central nervous system.
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On the other hand, versican is found in the ECM of almost all tissues and organs [42]. They can serve as
molecular bridges between the cell surface and the extracellular matrix [35]. Versican has been shown
to bind to collagen type I and fibronectin, which are both substrates of integrins [43]. The binding of
versican to fibronectin’s RGD motif leads to loss of cell adhesion as it sequesters fibronectin from the
cell’s integrins [42,43].
SLRPs make up the largest family of proteoglycans due to its 18 distinct gene products each with
multiple splice variants and processed forms [35]. These proteins have a relatively short protein core
with a central region dominated by leucine-rich repeats (LRRs). They are expressed in the ECM during
development of various tissue types, suggesting their critical involvement in directing organ size and
shape during embryonic development and homeostasis [44,45]. Decorin and biglycan are SLRPs that
have collagen-binding motifs and regulate collagen fibre assembly along with other proteoglycans
(Figure 1C) [46].
In summary, proteoglycans vary in form and structure that confer different functions in the ECM.
They are integral in the maintenance of a healthy ECM without which would lead to a non-functional
ECM and a collapse of its structure.
Box 1. Sensing the extracellular matrix’s (ECM) mechanical properties.
The ECM is sensed by the cell through transmembrane proteins such as integrins and syndecans
and other glycoproteins. Integrins are one of the most versatile transmembrane proteins as various
heterodimer combinations allows it to bind to fibronectin, laminin, and collagen [47]. Integrins themselves
are mechanosensors. Stretching has been shown to increase integrin binding to the ECM via conversion of
integrins to its high-affinity state in smooth muscle cells and fibroblasts [48]. Integrins also experience a
conformational change in their cytoplasmic domains, allowing it to activate several signalling pathways such
as mitogen-activated protein (MAP) kinases and Rho GTPases [49–51]. Syndecans can also bind to fibronectin,
resulting in a synergy between integrin and syndecan to activate signalling cascades through focal adhesion
kinase (FAK) and subsequent focal adhesion complex stabilization [52]. There are other receptors for other ECM
components such as CD44 for hyaluronan, 67 kDa laminin receptor for laminin, and discoidin domain receptors
(DDRs) for collagen [53–57].
Integrins and syndecans activate various pathways such as the MAPK and Rac1/RhoA pathways.
The selective activation of these pathways leads to context-dependent regulation of cell survival, growth,
proliferation, motility, spreading, or migration [52,58]. Integrins are connected to the actin cytoskeleton through
vinculins, talins, and other scaffold proteins while syndecans are connected to the microfilaments through
syntenin and through the actin cytoskeleton via a-actinin [52,58–61]. The adhesion complexes formed by
integrins and syndecans have been found to be mechanosensitive [9,62]. The intracellular signalling and
mechanotransduction through these receptors is still an active field of research. Much is still to be discovered
about the pathways that facilitate ECM mediated cellular responses.
2.3. Connecting the Cell to the ECM through Laminin
Laminins are trimeric glycoproteins consisting of α, β, and γ chains that are often found in the
basal lamina or some mesenchymal compartments [15]. The 12 mammalian α, β, and γ chains can
theoretically create 60 unique laminins but only 16 combinations have been observed so far [34,63].
The α chains vary in size from 200 and 400 kDa while β and γ chains have sizes from 120 to 200 kDa.
A trimer can then have a size varying from 400 to 800 kDa [63]. During rotary shadowing electron
microscopy, laminins look like cross-shaped molecules [34,64,65]. The three chains form an α-helical
coiled coil structure that forms the long arm of the cross while the three short arms are composed of
one chain each (Figure 1A) [34]. At the end of the long arm are 5 laminin G-like (LG) domains from
the α chain that serve as attachment sites for the cell. Integrins, dystroglycan, Lutheran glycoprotein,
or sulfated glycolipids bind to these LG domains [63]. At the end of each short arm are laminin
N-terminal (LN) domains that are important for laminin polymerization and basement membrane
assembly (Figure 1B) [34].
Laminins have cell type-specific functions such as adhesion, differentiation, migration, phenotype
maintenance, and apoptotic resistance [63]. Through binding of integrins, laminins are able to create a
dynamic link between the cell and the ECM (Box 1) [63]. Unique heterotrimeric laminins will have
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unique integrin heterodimers binding partners to allow the induction of signalling pathways and
organization of intracellular cytoskeleton [63,66]. Collagen IV deposition in the basement membrane
is seen as the maturation of the basement membrane that is essential for structural stability later in
development [34,67]. However, the exact mechanism by which laminins bind to collagen IV remains
unclear. Initial studies indicated that nidogen binds to laminin through the LE domains of the γ1 chain
and collagen IV, thus serving as an intermediary between the two networks found in the basement
membrane. However, recent research has indicated that nidogen might not be the major bridge in
connecting laminins and collagen IV [34]. It has been observed that the interaction between laminins
and collagen IV is directly mediated by heparan sulfates [68]. Perlecan was thought to mediate
this function, but genetic ablation of perlecan in mice did not result in collagen IV depletion [34,67].
It has since been postulated that agrin, another pericellular HSPG, serves as a compensating candidate.
In this model, both perlecan and agrin would bind to the nidogen containing laminin network and
to the collagen IV’s 7S and NC1 domains (Figure 1B) [69,70]. Laminins serve crucial roles in both
basement membrane assembly and ECM–cell interactions. Recent studies have indicated that basement
membrane assembly is initialized through laminin polymerization [53–58]. Indeed, genetic ablation of
either β1 or γ1 chains proved to be lethal due to the resultant failure of basement membrane assembly.
While collagen, proteoglycans, and hyaluronic acid comprise the major structural component of the
ECM, laminins are one of the molecules that bridge the interaction gap between the cells and the
ECM [15].
2.4. Fibronectin as the Mechanosensitive Connection Between the Cell and ECM
Fibronectin is a multi-domain protein that interacts with the various previously described
ECM components to connect the cell to the ECM [15]. It is encoded by a single gene, but it has
20 isoforms in humans as a result of alternative splicing of the mRNA [71,72]. Similar to collagen,
fibronectin forms a fibrillar network in the ECM (Figure 1C) [71]. Fibronectin naturally exists as
a dimer outside the cell, mediated by the two cysteine disulfide bonds, which is crucial for its
ability to assemble in a fibrillar fashion (Figure 1A) [71,73]. Fibronectin matrix assembly is mediated
by selective binding to α5β1 integrins through an RGD binding motif and a synergy site on the
fibronectin molecule [59,62]. Through these integrins, the compact and soluble secreted fibronectin
is unfolded revealing cryptic binding sites for other fibronectin molecules to form the fibronectin
fibrillar network (Figure 1C) [1,71,74]. Anti-integrin and anti-fibronectin antibodies have been shown
to prevent fibronectin fibril formation [71,75,76]. Fibronectin binding induces integrin clustering that
provides local high concentrations of fibronectin at the cell surface. This phenomenon promotes
fibronectin–fibronectin interactions through the N terminal assembly domains of each molecule [71].
Once fibronectin is tethered to the cell surface by integrins, the actin cytoskeleton can pull onto
fibronectin molecules to change its conformation [71,72]. This will affect the C terminal regions of
fibronectin, revealing cryptic binding sites for fibronectin, heparan sulfates, heparin, collagen, and
other ECM proteins [77–81]. It is through strong non-covalent protein-protein interactions that the
fibronectin network matures and becomes insoluble, although other ECM proteins may mediate
mature lateral interactions between fibrils [71]. These interactions stabilize the relatively weak binding
sites at individual sites. However, the turnover of the fibronectin matrix is still largely unexplored [71].
Due to fibronectin’s multiple binding sites for other ECM proteins, it has been implicated in various
functions, including a role in collagen type I assembly. It has been shown that in the absence of fibronectin,
collagen fibrils do not accumulate, suggesting a role for fibronectin in collagen assembly [82,83]. However,
this relationship may prove reciprocal as recent studies have also implicated that collagen has a role in
enhancing fibronectin assembly [71,84,85].
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Figure 1. Unique ECM molecules and their organization in the basement membrane and interstitial
stroma. Panel A (top) shows the unique components of the extracellular matrix. Panel B and C (middle)
shows how these different collagens, proteoglycans, laminins, and fibronectin are organized within the
basement membrane (B) and interstitial ECM (C). A breast acinus with epithelial cells is surrounded
by myoepithelial cells and the basement membrane. In the basement membrane, the laminin is bound
to the cell and forms a network through its long arms. It is then connected to the collagen IV network
through nidogen and proteoglycans such as perlecan and agrin. Outside the basement membrane is the
interstitial ECM where fibroblasts that produce and remodel the ECM can be found. In the interstitial
stroma, collagen fibres are made up of fibrils composed of collagen I and collagen V. The different
proteoglycans, such as decorin, biglycan, and hyalectans, holds the fibrils together to form a collagen
fibre. Fibronectin is bound to the cell via integrins and syndecans. Once fibronectin is unfolded,
it reveals cryptic binding sites for heparan sulfate proteoglycans (HSPGs) and collagen. Modified and
combined figures from Mouw et al. 2014 [15] and Hohenester and Yurchenco 2013 [34].
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3. Function of ECM
The plethora of unique ECM molecules serves several functions that influence biochemical and
biophysical processes in the cell simultaneously (Figure 2). While the ECM has been considered
for many years as an inert scaffold solely providing structure for the cells, its role in determining
the functions and phenotypes of cells has clearly emerged in the last two decades. The ECM can
serve as binding sites, controlling the adhesion and movement of cells [86]. This is emphasized in
the complex structure and composition of the basement membrane that serves as a barrier between
epithelial cells and the interstitial stroma [6,87]. In addition to structural integrity and anchorage,
the ECM components have several binding sites for growth factors, controlling their release and
presentation to target cells. This is especially important in morphogenesis as it establishes morphogen
gradients [88]. Finally, the ECM transmits mechanical signals to the cells, which activates several
intracellular signalling pathways and cytoskeletal machinery [89]. Indeed, the ECM serves several
functions and here we review the function of the ECM in the context of development and maintenance
of the stem cell niche.
The function of the ECM is best described in the context of development. The development of a
mammalian embryo from a foetus to a fully developed organism is a well-orchestrated phenomenon
that involves carefully controlled mechanisms. In such a relatively rapid process, the spatiotemporal
composition, amount, and characteristics of the ECM must be tightly regulated. Several studies have
shown that mutated ECM components lead to birth defects or embryonic lethality, which emphasizes
its role in development [2,87]. The geometry, rigidity, and other physical properties of the ECM are
sensed by the cells and ultimately direct their differentiation and the complex spatial and structural
arrangements they form in tissues (Box 1).
 
Figure 2. Functions of the ECM. The ECM serves as a point of anchorage for the cells that is essential
for maintaining tissue polarity and asymmetric stem cell division. Depending on the context, it can
impede or facilitate migration. It can sequester growth factors and prevent its free diffusion. Other
ECM components can bind growth factors and can serve as co-receptors or signal presenters, which
help determine the direction of cell-cell communication. Through the action of metalloproteinases
(MMPs), fragments of the ECM can also influence cell behaviour. The physical properties of the ECM
can be sensed by focal adhesion complexes, which lead to a variety of changes in cell phenotype such as
reorganization of the 3D genome. Figure modified and adopted from Lu, Weaver, and Werb 2012 [90].
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3.1. ECM as Tracks for Migration and Proliferation
Migration of cells is essential for tissue development and can be best illustrated by neural crest
cells, which migrate from the periphery of the neural tube to different parts of the embryo to form
parts of the heart, spinal nerve, skin, and cranium [91]. How these cells direct their migration and final
destination is a complex question that has been extensively studied.
The ECM influences the migration track and speed of migrating cells through its topography,
composition, and physical properties. The alignment of the underlying ECM has been shown to
direct cell migration and proliferation. Sharma et al. [92] previously used aligned fibres to direct
cell migration in the context of wound healing in vitro. Moreover, self-aligning materials have been
recently used to create ECM constructs for brain tissue regeneration in vivo [93].
Cells migrate from regions with lower ECM concentration to higher ECM concentration due to an
adhesion gradient in a type of cell migration known as haptotaxis [87]. However, this relationship is
nuanced. If the concentration of the ECM is too high, the adhesion force experienced by the cell is too
large from them to continue to migrate. Accordingly, the speed of migration is dependent on the ECM
concentration as well. As migration is a coordinated interplay between adhesion and deadhesion of
the cell onto the ECM, the speed of migration is characterized by a bell-shape function with respect to
ECM concentration [94].
The speed of migration is also influenced by the composition of the ECM. Hartman et al. [95] have
shown that fibroblasts cultured in rigidity gradients composed of fibronectin exhibited cell migration
while those cultured on matrices covered with either laminin or a fibronectin/laminin mixture did not
exhibit any migration. These results indicate that the ECM not only serves as a track for migration, but
also dictates cell migration due to its mechanical properties. It was previously demonstrated by Wang
et al. [96] that matrix stiffness and cell contractility also control RNA localization of genes responsible
for cellular organization and signalling to cellular protrusions. Proteases that degrade the ECM also
facilitate migration of cells through a process involving the interplay of MMPs, adamlysins, meprins,
metalloproteinase inhibitors (MMPIs), and other enzymes [2]. It is important to note that constant
ECM remodelling is occurring in development. The ECM components and their concentration are
continuously modified to dictate the developmental program.
3.2. ECM as the Dynamic Blueprint for Development
The role of ECM in structural organization is best studied in branching morphogenesis, which
involves epithelial buds and tubes invading the surrounding mesenchyme rich ECM [87]. This
process can be seen in various parts of the body, including mammary glands, salivary glands, and
kidneys [87]. Structural organization emphasizes the key functions played by the ECM and different
ECM components such as glycosaminoglycans (GAGs), collagen, and proteoglycans. Furthermore, the
ECM is constantly changing as this process occurs, highlighting the spatiotemporal control needed to
facilitate the development of these organs.
Branching in the mammary gland occurs at the terminal end buds that have a thin hyaluronic
acid-rich ECM and an accumulation of thick ECM composed of collagen IV, laminins 1 and 5,
and HSPGs at the flanks [97,98]. Thick ECM provides a structure to maintain the tubular organization
by serving as anchors for the cells while the reduced ECM at the end bud facilitates the migration
of epithelial cells, specifically the cell-budding process [87,99,100]. However, fibrillar collagen does
not only serve as a physical barrier. As it binds to discoidin domain receptors (DDRs) expressed by
mammary gland cells, it prevents hyper-proliferation possibly to maintain the tubular structure [87,101].
The architecture of the ECM serves as a guide to control how branching occurs through local
anisotropies in terms of tension as well [99]. Topographical variation in structure and elasticity of the ECM
provides a blueprint for where cells can bend, twist, and break off to form complex morphologies that are
essential for the different organs. Using micro-patterned organotypic cultures, Nelson et al. [102] showed
that tissue geometry dictates the position of the branches. Furthermore, Gjorevski and Nelson [103]
have shown that endogenous patterns of mechanical stress in the surrounding ECM specify the
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branching pattern. There are several techniques to study ECM architecture in 3D such as atomic
force microscopy (AFM) combined with second-harmonic generation (SHG) [104]. Robinson et al.
used image analyses algorithms to analyse AFM and SHG micrographs to monitor and analyse ECM
remodelling of pancreatic stellate cells. This technique could similarly be used to study how the
mechanical forces and ECM architecture continuously evolve during development.
As the end bud of the mammary gland grows, it continuously degrades the ECM, which in turn
releases factors dictating the branching direction of the growing buds [2]. ECM degradation releases
collagen fragments tumstatin and endostatin that regulate the migration, survival, and proliferation
of these cells [105]. Furthermore, the ECM’s binding sites for morphogens and growth factors, such
as Wnt glycoproteins, epidermal growth factors (EGFs) and fibroblast growth factors (FGFs), allow
them to sequester and control the release of these factors [35,106]. Through this, the ECM facilitates
the formation of a morphogen gradient, which is required for diverse types of cells and structures to
develop [88]. The growth of the bud is finally terminated through the deposition of inelastic ECM
composed of sulphated GAGs (SGAGs) and collagen I [99].
Overall, the ECM modulates the growth of tissues to form complex structures that are required
for these organs to function. The ECM provides structural organization not only through its action as a
physical barrier to growing cells, but also by activating intracellular signalling in a time and context
dependent manner. The ECM does this through growth factor distribution modulation, physical
anisotropies, and anchorage.
3.3. ECM as the Driver for Cell Fate
The ECM influences cell fate through the previously discussed morphogenetic gradient in
development. However, this is not the only mechanism by which ECM affects cell fate, as the physical
properties of the ECM also play a critical role.
The role of ECM composition on cell fate is exemplified in mammary gland differentiation.
Even with hormonal stimulation in vitro, mammary gland cells do not secrete milk proteins. However,
upon exposure of these cells to laminin-1, they begin secreting milk proteins [107]. This activation is
due to integrin binding by laminin-1 leading to phosphorylation of the prolactin receptor, an upstream
regulator of STAT5. STAT5 then activates the transcription of milk proteins β-lactoglobulin and
β-casein, indicating that an appropriate 3-D ECM microenvironment is critical for cells to function
properly [102,107].
Using a simple yet elegant approach, Engler et al. [10] demonstrated that when mesenchymal
stem cells (MSCs) are cultured on collagen matrices with various elasticities, the MSCs differentiated
into osteocytes, myocytes, and neurons on the substrates that resembled their respective native
tissue. The process by which these MSCs are able to sense the elasticity and stiffness mechanical
environment before initiating an intracellular signalling cascade to dictate cell fate is known as
mechanotransduction. This phenomenon allows the cells to sense the physical properties of the
underlying matrix and activate appropriate intracellular pathways [89]. When myosin II, a key
molecule in various mechanotransduction-signalling pathways, was blocked, MSCs became insensitive
to the matrix elasticity mediated cell differentiation [10]. This study emphasized that the ECM’s
physical properties themselves have differentiating capability.
Engler’s results indicate that environmental cues can be relayed to the nucleus biochemically
or biophysically [89]. Indeed, often biochemical and biophysical relays work in conjunction
with one another to transmit environmental information [89,108]. One prominent example of a
mechanosensitive genetic regulator is the pair of the transcription co-activators, yes-associated protein
(YAP) and transcriptional coactivator with PDZ-binding motif (TAZ). These functionally redundant
transcriptional coactivators are known to play crucial roles in critical cellular processes, such as
proliferation, wound healing, fibrosis, and other physiological processes that involve changes in
biomechanical properties [109]. Importantly, these transcription co-activators are known to be sensitive
to both biochemical and biophysical cues. The nuclear localization of YAP/TAZ is regulated by cell
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shape, stiffness, ECM topology, and shear stress [109–115]. The integrin complexes that sense this
matrix stiffness are linked to the cytoskeleton, which in turn is linked to the nucleus through the
linker of nucleoskeleton and cytoskeleton (LINC) complex, which is composed of nesprins, sun, and
lamin proteins [116,117]. This allows direct transmission of mechanical cues from the extracellular
matrix to the nucleus [117]. The extensive role of YAP/TAZ in cell processes elucidates the role of
mechanotransduction in development and diseases, such as cancer [108].
In addition to matrix stiffness, the response of the cell to the ECM’s physical properties has also
been shown to be dependent on the ligand tether length. It has been shown that the focal adhesion
sizes and cell-adhesion strengths were affected when the tether length of the ECM coating’s ligand was
varied [118]. Coating stiff ECM with RGD ligands with longer tether lengths lead to the cell sensing
a softer ECM thereby controlling mechanotransduction mediated YAP/TAZ nuclear localization in
cancer. This might be a novel effective treatment against cancer.
4. Tissue Homeostasis
The ECM is a highly dynamic structure. Even after development, ECM is constantly being
deposited, degraded and modified to maintain tissue homeostasis. This is especially important in
maintaining the phenotype of cells and in physiological processes such as wound healing, angiogenesis,
and bone remodelling [6,119,120].
To maintain tissue homeostasis, the cells in contact with the ECM sense the properties of the
ECM through receptors and focal adhesion complexes. In turn, the cell regulates the expression of
ECM components and enzymes based on the signals of the ECM. This creates a feedback mechanism
wherein the cell also influences the ECM, which results in a balance of deposition and degradation of
ECM components [116].
The response of the cells to other stimuli, including shear stresses exerted by blood flow,
are ultimately influenced by the ECM component. Chen and Tzima [121] showed that platelet
endothelial cell adhesion molecule-1 (PECAM-1), a mechanosensitive molecule, is essential for vascular
remodelling, which occurs in response to long-term changes in hemodynamic conditions. Furthermore,
Collins et al. [122] recently demonstrated that the ability of platelet endothelial cell adhesion molecule-1
(PECAM-1) to respond to mechanical forces is influenced by the type of ECM they are adhered to. This
exemplifies the complexity and importance of the feedback mechanism that exists between the ECM
and the cell to maintain tissue homeostasis.
The importance of the ECM in maintaining tissue homeostasis is exemplified by the study
performed by Weaver et al. [123] where they were able to revert the malignant breast cancer cell
phenotype to the normal phenotype. They did this by culturing breast cancer cells onto basement
membrane based 3-D substrates coated in integrin β1 blocking antibodies [123]. This study confirmed
that the ECM is able to override the mutations causing the cancer phenotype, emphasizing the ECM’s
role in maintaining the correct cell phenotype. The role of dysregulated ECM in cancer progression
will be discussed further in the next section.
That an imbalance in the deposition and degradation of the ECM leads to diseases is a hallmark
not just of cancer but also other prominent diseases including fibrosis [124–126]. Overall, the ECM’s
role in tissue homeostasis is to direct proper cell response and phenotype to maintain the tissue’s
mechanical integrity and function.
5. ECM in Cancer
5.1. Dysregulation of ECM Molecules in Cancer Progression
Traditional perspectives of cancer have shifted to reflect the important role of the ECM in
regulating cell proliferation, migration, and apoptosis. On a microscopic level, the particular
arrangement and orientation of ECM constituents form a tissue-specific microenvironment that plays a
critical role in tumour progression [11,127,128]. It is now understood that the ECM not only undergoes
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continuous active remodelling, but also elicits biochemical and biophysical cues to influence cell
adhesion and migration [129]. As such, small changes in microenvironment homeostasis can have
significant effects on the proliferation of cancer cells. As the most significant ECM component,
collagen dictates the primary functional properties of the matrix. Indeed, changes in the deposition or
degradation of collagen can lead to the loss of ECM homeostasis [130,131].
As tumour cells proliferate, the surrounding ECM undergoes significant architectural changes
in a dynamic interplay between the microenvironment and resident cells. These changes, including
increased secretion of fibronectin and collagens I, III, and IV illustrate that tumour progression demand
a continuous interaction between the ECM and tumour cells (Figure 3) [132]. Increased deposition
of matrix proteins promotes tumour progression by interfering with cell–cell adhesion, cell polarity,
and ultimately amplifying growth factor signalling [133]. However, the exact role of collagen deposition
in tumour progression is nuanced. Recent studies have shown that increased collagen cross-linking
and deposition leads to tumour progression via increased integrin signalling [134,135]. Interestingly,
however, depletion of fibrillar collagens I and III can also promote malignant behaviour, indicating
that biomechanical forces produced by collagen deposition can have both beneficial and deleterious
effects on tumour progression [136,137].
1. Regulation of Healthy Tissue Homeostasis
2. ECM Remodeling During Tumor Progression
3. Collagen Alignment Guides Cell Motility
Fibroblast
Epithelial Cell Neoplastic Cell







Figure 3. ECM remodelling during cancer progression and initiation. (1) Epithelial neoplastic cells
proliferate rapidly, inducing strain on the basement membrane. (2) Basement membrane bulges
due to mechanical strain. Adjacent cancer-associated fibroblasts increase deposition of collagen.
Stromal-derived lysyl oxidase (LOX) aligns collagen. (3) Neoplastic cells breach membrane and migrate
along aligned collagen. (Adapted from Lu et al. [6].)
Collagen cross-linking can occur in both an enzyme-mediated and non-enzyme-mediated fashion.
Regulated collagen cross-linking is coordinated primarily by LOX and the LOX family of amine oxidase
enzymes [1]. LOX, secreted by primary tumour cells, is responsible for catalysing the cross-linking
of both collagen and elastin, which in turn increases matrix stiffness and total adjacent ECM volume.
Increased ECM stiffness activates integrins and augments Rho-generated cytoskeletal tension to
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promote focal adhesion formation and cell motility [138]. Elevated LOX activity has been clinically
associated with increased collagen cross-linking, fibrosis, and elevated risk of cancer metastasis [139].
Moreover, elevated LOX activity found on invasive edges of tumours has been noted to drive actin
polymerization, cell contractility, and migration, providing a pathway for successive tumour cells to
follow [130].
Visualization of surrounding epithelial tissue during tumour metastasis has revealed localized
matrix organization and alignment along the leading edge of invasive tumours [131,140]. Indeed,
local cell invasion of these tumours has been observed to be oriented along aligned collagen fibres,
suggesting that the linearization of collagen fibres facilitates tumour invasion [141]. It is believed that
these densely aligned collagen fibres act as tracks for proliferating neoplastic cells to migrate out of the
tumour. Breast cancer serves as an important example of collagen alignment during tumour metastasis.
Although collagen within epithelial structures is typically tangled and disorganized, collagenous tissue
surrounding mammary tumours is frequently thickened, stiffened, and aligned perpendicularly to
the tumour boundary [142]. Recent studies indicate that the topography of matrix fibres increases the
efficiency of tumour migration by reducing the protrusions along the collagen fibre, and hence the
distance travelled by the migrating cell [143].
Much like collagen and LOX, elevated levels of the glycosaminoglycan hyaluronic acid in the
ECM correlates to increased likelihood of malignancy and poor prognosis [144]. As a naturally
occurring omnipresent linear polysaccharide, hyaluronic acid is critical in determining the compressive
properties of most biological tissues. The combination of tensile resistance due to collagen and
compression compliance due to hyaluronic acid creates the ideal biophysical properties for tissue
homeostasis [145]. In addition, it has been found that hyaluronic acid is both an induction signal for
mesenchymal transition and a migration substrate [146]. Accordingly, hyaluronic acid is frequently
used as a biomarker for prostate and breast cancer. While augmented levels of collagen and LOX
directly promote ECM stiffness and mechanically drive cell motility and proliferation, the exact role of
hyaluronic acid in cancer metastasis remains unclear. However, its dysregulation can serve as a key
biomarker for metastasis and cancer invasion.
5.2. Protein Unfolding Mediates Mechanotransduction
ECM signalling is a crucial cellular process that drives cell proliferation, differentiation, and
defers apoptosis [147]. In brief, if a cell cannot sense its mechanical environment, it cannot survive.
Many studies have reported that cells are capable of sensing their microenvironment through chemical
signalling, such as growth factors and metabolic precursors [148–150]. In order to detect ECM rigidity,
it is believed that cells mechanically probe their microenvironment via lamellipodia and sense the
mechanical feedback and resistance of their environment through integrin-based focal adhesions,
triggering an intracellular signalling cascade [151]. The ability for cells to probe their microenvironment
is attributed to the actin cytoskeleton, as inhibition of F-actin polymerization limits the ability of
cells to generate force, which induces a biological effect similar to plating cells on a soft substrate.
Specifically, the ability for cells to produce internal forces is derived from contractile actin bundles
and their upstream regulators, such as Rho-associated protein kinase (ROCK), which are necessary to
mechanically sense their environment [109]. While mechanical rigidity clearly has profound effects
on cell behaviour, the mechanism that translates mechanical force into gene transcription is not
fully understood.
Our recent work has illustrated the importance of protein unfolding in the transduction of
mechanical force exerted by the ECM. Indeed, talin, a prominent molecule in focal adhesion complexes
that couples focal adhesions to the actin cytoskeleton, has been shown to mechanically unfold during
force transmission [152]. Deleted in liver cancer 1 (DLC1) is a negative regulator of RhoA and cell
contractility that regulates cell behaviour when concentrated to focal-adhesion complexes bound
to talin [153]. Mechanical clamping of the R8 domain of talin prevented mechanical unfolding of
the molecule, interrupting downstream signalling of DLC1 and, consequently, cell behaviour [153].
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Moreover, single molecule force microscopy revealed that every talin rod subdomain is susceptible to
unfolding over a physiologically relevant range of forces between 10 and 40 pN [152]. Because the
observed range of talin subdomain stabilities within the focal adhesion complex depend on small
structural differences, it is possible the mechanical stability of talin rod bundles could be influenced
by a few single point mutations. These mutations could lead to misinterpretation of ECM signals,
altering cellular response. Incorrect interpretations of ECM information could influence the behaviour
of cancer cells in the tumour microenvironment, potentially triggering DLC1 deactivation, increased
cell contractility, and cell migration [152,153].
5.3. YAP & TAZ Mechanotransduction in Cancer Progression
As robust regulators of cell proliferation and survival, YAP and TAZ play critical roles in
regulating organ development, cell differentiation, and progenitor cell self-renewal [109]. During these
processes, the YAP/TAZ proteins actively shuttle between the nucleus and the cytoplasm. While in the
cytoplasm, the YAP/TAZ proteins play a relatively passive role, regulating specific signalling cascades,
such as the Wnt signalling pathway. Meanwhile, when in the nucleus, they readily interact with
DNA-binding transcription factors, particularly TEA domain family members (TEAD), to regulate
genetic expression associated with proliferation, a key hallmark of cancer [154,155]. Upon biochemical
inhibition, YAP/TAZ accumulate in the cytoplasm, suggesting that the main functionality of YAP/TAZ
is gene transcription regulation in the nucleus. Importantly, upon cell detachment from a substrate,
YAP/TAZ activity is inhibited; suggesting that YAP/TAZ translocation to the nucleus can be regulated
by the F-actin cytoskeleton and mechanical force [156]. Moreover, in mammalian systems, matrix
elasticity and cell-spreading geometry are noted to heavily regulate YAP/TAZ nuclear transport and
their corresponding physiological processes [157]. Taken together, these results suggest that focal
adhesion and cytoskeleton-mediated cell signalling of mechanical rigidity is coupled to the YAP/TAZ
pathway to induce metastasis and tumour invasion, indicating a direct chemical pathway linking
mechanical force with malignant cellular behaviour.
Although cytoskeletal tension is sufficient for YAP/TAZ nuclear translocation, there exist multiple
potential pathways and proteins that mediate YAP/TAZ nuclear translocation. For example, the
heparan sulfate proteoglycan, agrin, is most commonly known for its role in the formation of
neuromuscular junctions during embryogenesis. However, recent advances in the field have suggested
that agrin may also serve as an ECM sensor that stabilizes focal adhesions and facilitates YAP/TAZ
nuclear translocation through the lipoprotein-related receptor-4 (Lrp4) and muscle-specific kinase
(MuSK) pathway [158,159]. Activation of Lrp4 and MuSK by agrin inhibits the Hippo tumour
suppressor pathway, ultimately leading to elevated YAP/TAZ nuclear translocation [158,160]. Agrin
depletion was shown to promote the inhibitory phosphorylation of YAP, which forced nuclear YAP
to remain in the cytosol [161]. Contrarily, supplementary introduction of agrin into cells cultured on
compliant matrices was sufficient for YAP activation [161]. Multiple junctional proteins, including the
Angiomotin (AMOT) family of proteins regulate YAP/TAZ in combination with changes in actomyosin
contractility [161,162]. AMOT proteins have been shown to directly bind to YAP, inhibiting its function.
F-actin competitively binds with AMOT to disrupt YAP:AMOT complexes, releasing YAP from its
inhibitory state to translocate into the nucleus [161]. Interestingly, agrin depletion elevated YAP:AMOT
binding, which ultimately led to decreased YAP activity [159]. Moreover, recent work demonstrates
that the Ras-related GTPase, Rap2, is also a key intracellular mediator that transduces ECM rigidity
signals to influence YAP/TAZ nuclear translocation [163,164]. At low ECM stiffness, Rap2 is known to
bind and activate MAP4K4, MAP4K6, MAP4K7, and ARHGAP29, which stimulate LATS1a and LATS2
while inhibiting YAP and TAZ nuclear translocation [163]. These findings demonstrate that ostensibly
unrelated proteins, such as Rap2 and agrin, play significant roles in ECM sensing and regulation of
YAP/TAZ activity.
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5.4. ECM-Mediated Tumour Initiation and Migration
A crucial hallmark of carcinoma and other cancer cells is their ability to migrate through
surrounding tissues, penetrating the adjacent basement membrane. This dense, highly cross-linked
membrane of ECM serves not only as an anchor for epithelial cells to surrounding connective tissue,
but also as a significant barrier to epithelial cell migration [165]. However, due to the need for
cells to migrate within the body during healthy tissue homeostasis, cancer cells have adopted a few
methods of traversing the collagenous barrier [166]. One such method is the use of mechanical force.
Mechanical force has increasingly been seen as a compelling factor in triggering the breaching of
the basement membrane. As epithelial cancer cells proliferate, they are spatially constrained by the
bordering basement membrane. This burgeoning population of cancer cells significantly increases the
mechanical stress along the membrane, ultimately causing rupture and allowing cells to escape their
microenvironment (Figure 3) [167].
Another method of membrane navigation is anchor cell invasion, in which anchor cells breach the
basement membrane using protrusive, F-actin rich subcellular structures called invadopodia [168,169].
Indeed, electron micrographs of invasive tumours have demonstrated that leading invasive cells extend
a single protrusive arm into the basement membrane [170]. After initial breach by the invadopodia,
the membrane fissure widens, allowing for subsequent cells to traverse the collagen boundary [171].
However, along these breaching sites, elevated levels of collagen IV degrading products have also been
found, indicating a possible third factor in the migration of cancer cells [172]. Increased accumulation
of MMPs along the basement membrane has led to the commonly held assumption that proteases were
solely responsible for degradation of the basement membrane. However, staining of the membrane
during invasion reveal that laminin and collagen IV are in fact pushed aside by the invadopodia
rather than fully degraded [165,167]. These results indicate that MMPs may, rather, play a role in the
initial breaching of the basement membrane or in softening the matrix while anchor cell invadopodia
facilitate direct invasion [166].
5.5. Metalloproteinases (MMPs) in Tumour Progression
The role of MMPs in cancer cell invasion is multi-pronged: they not only assist in the
degradation of surrounding ECM barriers, but also release active growth factors and promote tumour
angiogenesis [148]. The ECM is known to promote cell proliferation primarily through contact with
the integrin family of cell surface receptors. However, certain ECM binding sites responsible for cell
proliferation and survival have been shown to be “cryptic” or partially hidden within the ECM. MMPs
simply unmask these hidden binding sites by degrading and loosening surrounding collagen, allowing
for integrins along the cell membrane to interact directly with the matrix [148,173].
In addition to removing physical barriers and revealing cryptic binding sites, MMP-mediated
degradation of collagen also exposes signalling components embedded within the ECM [173]. Stored
in an inactive state when embedded within collagen, various growth factors are activated upon ECM
degradation and allowed to bind with their target receptor. For example, MMP-2 mediated ECM
degradation is known to release the active form of transforming growth factor-β (TGF-β). Upon its
release, TGF-β is able to modulate cell invasion, immune response, and cell proliferation [174–176].
In effect, MMPs not only physically manipulate the surrounding ECM to allow for cell migration, but
also create a microenvironment conducive to tumour development through growth factor release and
cryptic binding site exposure. Thus, targeting MMPs could serve as a promising therapeutic approach,
despite a previous lack of success (Box 2).
Despite MMP-induced angiogenesis, vasculature networks in the tumour are frequently
disorganized with inter-capillary regions often exceeding the diffusion distance of oxygen. As such,
hypoxia, or the state in which cells are devoid of oxygen, is a hallmark of cancer. In fact, measurements
of the partial pressure of oxygen in tumours reveal that poorly oxygenated tumours strongly correlate
to increased malignancy [173]. It is believed that cancer cells are able to withstand oxygen-derived
regions by altering the transcription of various genes associated with angiogenesis. Hypoxia-inducible
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factors (HIF) are known play a crucial part in the regulating this intracellular cancer cell response
to hypoxia [177–179]. Recent studies have indicated that HIF-1α, a member of the HIF family of
transcription factors, has been associated with increased MMP and collagen production [177–179].
Importantly, HIF-1α is known to increase LOX deposition, ultimately stiffening the surrounding
matrix [180]. Finally, HIF-1α has also been shown to activate transcription factors associated with
epithelial–mesenchymal transition (EMT), the process by which cells lose their polarity and adhesion
with adjacent cells, augmenting the invasive behaviour of cancer cells [180].
Box 2. MMPs as a therapeutic target.
As the role of the ECM in tumour progression becomes more apparent, cancer therapeutic interventions have
begun to target key elements of the ECM in an attempt to limit metastasis. One key ECM component that has
been targeted is the MMP family of enzymes. Due to the significant role of MMPs during cancer progression,
the pharmaceutical industry has worked to develop safe therapies to inhibit MMP activity [181,182]. Several
groups of synthetic MMP inhibitors, such as Marimastat, Minocycline, and Matimastat, have been developed to
target broad groups of MMPs and tested in stage III clinical trials in late stage cancer patients [183].
Unfortunately, most therapies specifically targeting MMP activity demonstrated poor outcomes
during clinical trials [184]. A few possible explanations exist for the poor clinical outcomes. Firstly,
patients selected to receive the MMP-inhibiting therapies were late-stage cancer patients. As previously
discussed, MMPs are known to play a role in tumour initiation and progression. It is possible that
MMP-inhibiting agents could be more effective in early stage patients. Moreover, it is known that
specific MMPs play different roles during cancer progression. It is likely that synthetic inhibitors need
to be developed to target unique MMP subgroups at specific timeframes during cancer progression.
5.6. Role of Mechanical Stress in Tumour Growth and Treatment
As cancer progresses, tumours rapidly grow in size and stiffen due to the increased appearance of
structural components, such as ECM, cancer-associated fibroblasts (CAFs), and cancer cells. This rapid
rise in the rigidity of tumours is indeed one of the only easily detectable mechanical features of tumours
that aid physicians in predicting malignancy and prognosis [185–188]. As the tumour progresses
and stiffens, internally generated forces allow the tumour to disarrange adjacent healthy tissue and
migrate into surrounding spaces. Accordingly, tumour progression is directly facilitated by these
intratumour-generated forces and forces arising from interactions with its microenvironment [189].
These mechanical forces induce two unique types of stress on tumour cells: fluid and solid stress [190].
Generally, solid stress is created by the non-fluid components of the tumour. Initial evidence
for the existence of solid stress within tumours came from the realization that blood and lymphatic
vessels are mechanically compressed during tumour formation [191]. Growth-induced solid stress
accumulates within tumours as the cancer cells rapidly proliferate. During this rapid reproduction
process, cells grow into one another and strain the tumour microenvironment, which ultimately strains
the surrounding healthy tissue [192]. In addition to intratumour-generated solid stress, externally
generated solid stress accrues due to the adjacent tissue, which attempts to resist tumour expansion.
In brief, solid stresses directly influence tumour progression in two manners: they first apply direct
mechanical stress on cancer cells to alter genetic expression and, therefore, increase malignancy and
invasion [193]. Secondly, solid stress deforms blood and lymphatic vessels to induce hypoxia [194].
As the name suggests, fluid stresses stem from forces generated by the fluid elements of
the tumour. This includes shear stresses created by blood and lymphatic flow within the vessels,
microvasculature (capillaries), and interstitial fluid flow [195,196]. In fact, fluid stress and solid stress
are highly intertwined, as compression of blood/lymphatic vessels by solid stress greatly influences
the fluid stress exerted on the surrounding epithelial tissue [190,197,198]. Vessel constriction reduces
the cross-sectional area of the vessel to increase resistance to lymphatic flow, which in turn increases
shear stress, interstitial fluid volume, and decreases perfusion rates [199]. This decrease of perfusion
rates and flow significantly limits the ability for lymphatic vessels to remove excess fluid from the
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tumour, which ultimately increases interstitial fluid pressure in adjacent tumour tissue. Moreover,
compression of blood and lymphatic vessels has significant negative ramifications for the effectiveness












Solid Stress and Stiffness as a Function of Tumour Diameter
Figure 4. Solid stress and stiffness as a function of tumour diameter (adapted from Nia et al.) [201].
As rigidity of the ECM remains constant, an increase in tumour diameter is associated with increased
solid stress within the tumour.
Elevated solid and fluid stress within tumours place cancer cells in an entirely unique physiological
environment. Increases in tension and compression acting on the cells mechanically activates
tumourigenic pathways, increases proliferation rates, and promotes collective migration [146,148].
In addition to elevated rigidity, cancer cells produce and therefore are exposed to an elevated level of
force than adjacent tissues [202]. While the bulk rigidity of tumours is relatively simple to quantify,
measuring solid stress within tumours has proven to be a much more elusive task. Researchers have
recently begun to quantify solid stress in individual tumour cells. Nia et al. [202] has recently provided
the experimental framework for creating in-situ two-dimensional mapping of solid stress.
Researchers accomplish this mapping by releasing the solid stress within tissues in a controlled
method using predefined geometry that encapsulates the tumour in agarose gel and records
deformation after a precise incision is made. Combination of mathematical modelling and experimental
analysis has revealed a few important findings: solid stress increases linearly with tumour size while
rigidity remains constant, and adjacent healthy tissue contributes significantly to the solid stress within
the tumour. These findings suggest that rigidity of the tumour is decoupled from the solid stress
implemented on tumour cells (Figure 4).
5.7. Quantification of Tumour Cell Mechanical Stress in vivo
Tissue development, growth, and regeneration are crucially dependent on spatiotemporal
variations in microenvironment mechanics. However, most current techniques for stress quantification
utilize two-dimensional analysis that can only be performed in vitro, limiting its application for
determining microenvironment mechanics during tumour progression. To address this issue,
researchers in the Campàs group recently developed a novel oil micro droplet technique to quantify
local cell-generated mechanical stresses in tumours in a spatiotemporal manner [201,203–205].
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Figure 5. Schematic of oil micro droplet in vivo stress quantification described by Campàs et al. [203].
An oil droplet with calibrated surface tension is injected into living embryonic or cancerous tissue.
As cells proliferate, they exert force onto the micro droplet and deform it. Deformations in curvature
(red) of the oil droplet are used to calculate anisotropic stress within the tissue.
Fluorescent oil micro droplets with calibrated surface tensions are injected between tumour cells
in living tissue while fluorescence microscopy is used to image localized oil droplet deformation.
Provided droplet surface tension, measurements of curvature deformation along the oil droplet
yield precise information regarding localized anisotropic mechanical stresses exerted by adjacent
cells [201,203]. This technique of localized stress quantification shown above in Figure 5 revealed
that the magnitude of cell-generated stress varies only weakly spatially during tumour progression,
but increases dramatically over time [205]. Campàs et al. [203] further adapted the oil micro droplet
technique to incorporate a biocompatible ferrofluid magnetic micro droplets to serve as mechanical
actuators [206,207]. Using this technique, researchers are able to actively apply localized stress on
tissues while observing tissue mechanical response. Indeed, this novel ferrofluid micro droplet allows
for the simultaneous measurement of tissue mechanical properties and local cell-generated mechanical
stress [207].
5.8. Role of ECM Mechanics in Behaviour of Myofibroblastic Cells
Many aggressive malignancies, such as pancreatic ductal adenocarcinoma (PDAC),
are characterized by extensive desmoplasia and collagen deposition, which ultimately increases
the rigidity of the tumour. Myofibroblast-like cells, such as pancreatic stellate cells (PSCs), are crucial
mediators in the production of this fibrotic ECM [208]. When quiescent, PSCs are responsible for ECM
turnover and remodelling through the production of MMPs. During wound repair, PSCs become
activated by numerous soluble factors, including IL-1, IL-6, and TGF-β [141,142]. Alternatively,
PSCs in the tumour desmoplasia of human pancreatic cancers behave erratically, become chronically
activated, and create a microenvironment conducive to tumour growth [144]. It has been shown that
pancreatic tumour cells are able to induce activation of PSCs through increased secretion of TGF-β1
and PDGF [141]. However, recent studies have indicated that PSCs may be able to sustain activation
due to the mechanical properties of the microenvironment alone [209,210].
Our recent work has shown that matrix stiffness is sufficient for activation of PSCs. Upon activation,
PSCs were found to mechanically sense the increased rigidity of the environment as they produce
excess collagen [210,211]. This mechanosensing of tissue stiffness activates intracellular-signalling
pathways within the PSC, encouraging the myofibroblast-like cell to produce excess deposits collagen.
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This process of stiffness mechanosensing forms a positive-feedback loop, in which PSCs continue to
secrete collagen as the matrix becomes stiffer and stiffer [210,212]. Moreover, we also found that matrix
rigidity influences PSC migration, as PSCs migrate from adjacent soft tissue towards the stiff tumour
microenvironment [212]. Thus, as the matrix is stiffened, distant PSCs are recruited towards the stiff
tissue and become activated, further enhancing the positive feedback loop.
Inactivating the mechanosensing and remodelling capability of PSCs may be an effective
therapeutic strategy. All-trans-retinoic acid (ATRA) has been shown to suppress PSC mechanosensing
by downregulating MLC-2 actomyosin contractility. This leads to PSC inactivation and turns off the
positive feedback loop of increased matrix rigidity and PSC activation [213]. By inactivating PSC’s
ability to sense the mechanical environment, ATRA reduces fibrosis and suppresses cancer invasion.
Furthermore, inactivation of PSC’s ECM remodelling capability prevents its ability to mechanically
liberate TGFβ from Latent TGFβ Binding Protein (LTBP) [214].
These results indicate that the mechanical environment is a powerful regulator of PDAC
progression via PSC activation and ECM remodelling, suggesting that reprogramming of PSCs and
other resident cells may be a viable therapeutic target to alleviate tumour growth. A review of the role
of mechanical rigidity and mechanical stress in tumour proliferation can be seen in Box 3.
Box 3. Rigidity and stress influence cell behaviour.
As discussed in the previous three sections, mechanical stiffness and stress of the tumour both play extremely
important yet distinct roles in influencing cancer cell behaviour. Although there is significant overlap in effects
of rigidity and mechanical stress, the points below highlight certain differences:
Tumour Rigidity
 Caused by elevated ECM deposition
 Mechanically activates pancreatic stellate cells (PSCs) to produce ECM
 Induces EMT in epithelial cells
 Amplifies growth-factor signalling
Tumour Stress (Solid and Fluid)
 Caused by increased cell proliferation and blood flow
 Induces hypoxia in tumours
 Augments cell proliferation
 Increases chemo resistance
5.9. Seed and Soil
For many years, the scope of study regarding cancer metastasis had primarily focused on cancer
cells and their migration through the vasculature. However, as the complex interplay between the
ECM and cancer progression became apparent, the perspective on cancer progression to distant
organs evolved. In 1889, surgeon Stephen Paget posited that cancer metastasis is dependent on
complex interactions between the migrating tumour cells (the “seed”) and its microenvironment
(the “soil”) [208,209]. Despite doubt over the course of the twentieth century, Paget’s hypothesis
was strengthened in the 1970s when Isaiah Fidler’s research demonstrated that successful tumour
migration could only occur at certain organ sites [215].
Further research demonstrated that primary tumours have the ability to induce the formation of a
microenvironment at distant organ sites that are conducive to tumour growth [209,213]. This newly
formed distant microenvironment, known as the pre-metastatic niche (PMN), promotes tumour
growth through a variety of methods, including increased inflammation, vascular permeability,
immunosuppression, and tissue stiffness [215–217]. Studies have indicated a variety of molecules
and mechanisms involved with the generation of the PMN, such as tumour-derived secreted factors
(TDSFs) and tumour-derived extracellular vesicles (EVs) [218,219].
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Figure 6. Illustration of pre-metastatic niche formation in the liver. (1) The primary tumour located in
the pancreas emits tumour-derived secreted factors (TDSFs) and extracellular vesicles (EVs). (2) TDSFs
and EVs migrate through the vasculature and bone marrow to the secondary organ. While in the
bone marrow, TDSFs and EVs recruit bone marrow-derived stem cells (BDSCs), such as hematopoietic
stem cells, to the secondary organ site. (3) TDSFs and EVs induce immune cell recruitment and ECM
remodelling through LOX and cancer-associated fibroblasts at the pre-metastatic site. [220]
One primary form of tumour-derived EV is the exosome, which has a diameter ranging from
30–100 nm [218]. Exosomes containing proteins, mRNAs, and unique ECM-binding integrins are first
secreted from the primary tumour and travel through the vasculature, promoting vessel leakiness in
distant organ sites. EVs and TDSFs, such as TGF-β and MMP-9, then alter local resident cells and
fibroblasts [219,221]. Fibroblasts altered by exosomes recruit more inflammatory cytokines, such as
TGF-β, and dramatically increase collagen deposition to stiffen tissue in the PMN [222]. Just as in
primary tumour tissue, elevated collagen deposition and inflammation increase interstitial stress within
the tissue to induce hypoxia [220]. Finally, TDSF-mediated recruitment of non-resident cells, such
as bone marrow-derived cells (BMDCs) and immune suppressor cells, ultimately attracts circulating
tumour cells (CTCs) to the site (Figure 6) [223]. CTCs traveling through the vasculature are able to
easily permeate into the PMN due elevated vasculature leakiness and collectively migrate through the
organ toward the stiffer tissue, in a process known as durotaxis [224,225].
Interestingly, the notion of the PMN proposes that critical changes to the ECM, typically associated
with primary tumour formation, can occur prior to the arrival of tumour cells [226,227]. The Seed
and Soil process closely mirrors the process of primary tumour ECM remodelling, with one critical
difference: it occurs in the absence of cancer cells. Furthermore, it specifies that TDSF and EV-mediated
ECM remodelling is crucial in facilitating cancer metastasis. However, many aspects of the mechanism
regarding PNM formation remain elusive.
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Although exosomes have been known to play a crucial role in PMN development, why cancer
cells only metastasize to specific organs, a process known as organotropism, has remained unclear.
Recent research in the Lyden laboratory has demonstrated that exosomes secreted by primary
tumour cells have specific integrin expression patterns that dictate organotropism. Indeed, exosome
proteomics revealed that exosomal integrins α6β4 and α6β1 are closely linked with lung metastasis,
while exosomal integrin αvβ5 is associated with liver metastasis [220]. Targeting of these specific
integrins decreased exosomal uptake by resident cells and decreased lung and liver metastasis,
respectively. These results suggest that exosomal integrin expression could be used to predict
organ-specific metastatic sites. Moreover, there is an implication that cancer therapies may be most
beneficial if tailored to distinct metastatic sites (lung, liver, etc.) and each stages of cancer metastasis:
pre-metastatic and post-metastatic [215].
6. Challenges and Future Perspectives
In this review we have discussed the complex and nuanced role of the ECM in tissue development
and cancer progression. Over the past 20 years, studies have revealed the importance of the ECM
in regulating crucial physiological processes such as stem cell lineage specification, cell migration,
and proliferation [138–140]. Accordingly, perspectives have shifted to address cancer not only as
a disease of uncontrolled cell proliferation, but also of dysregulation of the microenvironment.
The ostensibly static ECM actively undergoes dynamic remodelling during all stages of cancer
progression in a complex interplay between cancer cells, resident cells, and non-cellular components.
Advances in understanding of the role of ECM in cancer progression have provided hope and revealed
promising therapeutic targets for mitigating cancer’s ability to metastasize. However, a lack of success
in targeting broad ranges of proteins, such as MMPs and collagen, reveals the temporal sensitivity and
specificity needed to effectively limit the spread of the tumour cells.
As neoplastic cells proliferate rapidly in tumours, they experience an increase in mechanical
stress, which mechanically activates tumourigenic pathways, increases migration, and induces hypoxia.
An essential region of future cancer research will be to ascertain the mechanism by which increased
mechanical stress in tumours relates to malignant behaviour and angiogenesis. These signalling
pathways relating to exogenous mechanical stress and malignant behaviour serve as an auspicious
therapeutic target to resist cancer progression. Moreover, understanding the relationship between
increased solid stress and angiogenesis mechanisms would elucidate possible advancements for drug
delivery. Recent developments in in vivo cell stress quantification techniques may provide novel
insights into the relationship between ECM-generated stress and hypoxia [213–216].
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Abstract: Cancer patients experience a four-fold increase in thrombosis risk, indicating that cancer
development and progression are associated with platelet activation. Xenograft experiments and
transgenic mouse models further demonstrate that platelet activation and platelet-cancer cell
interaction are crucial for cancer metastasis. Direct or indirect interaction of platelets induces
cancer cell plasticity and enhances survival and extravasation of circulating cancer cells during
dissemination. In vivo and in vitro experiments also demonstrate that cancer cells induce platelet
aggregation, suggesting that platelet-cancer interaction is bidirectional. Therefore, understanding
how platelets crosstalk with cancer cells may identify potential strategies to inhibit cancer metastasis
and to reduce cancer-related thrombosis. Here, we discuss the potential function of platelets in
regulating cancer progression and summarize the factors and signaling pathways that mediate the
cancer cell-platelet interaction.
Keywords: cancer metastasis; platelet; biomarker; cancer therapy
1. Introduction
During tumor progression, a small number of cancer cells invade into surrounding tissue
from the primary lesion and get into the circulation system through the intravastation process [1].
These circulating tumor cells (CTCs) were first identified by Thomas Ashworth in 1869 [2]. Given the
recent progress in CTC isolation, the association between CTC and cancer metastasis or prognosis has
been identified in many types of cancer, including lung cancer [3,4], breast cancer [5], colon cancer [6]
and castration-resistant prostate cancer [7]. In fact, multiple clinical trials have been done or are ongoing
to test whether CTC counts can be used as a prognosis marker. The roles of CTCs in cancer metastasis
and cancer relapse are well established in animal models [8,9]. Single cell RNA sequencing data show
that CTCs exhibit the epithelial-to-mesenchymal transition (EMT) [10] and stem cell phenotypes [11,12],
suggesting that CTCs are the driver of cancer metastasis.
CTCs directly interact with red blood cells [13], platelets, macrophages [14], and many other immune
cells [15–17]. CTCs also encounter shear stress induced by blood flow [18]. These interactions play
important roles in the colonization of CTC at distant organs. It has been shown that CTCs induce the
differentiation of macrophages. Cytokines secreted by the differentiated macrophage, in turn, enhances
CTC-inflammatory cell interaction, stroma breakdown, and CTC invasion [19,20]. Clinical data show
that the number of CTC is negatively associated with CD3+ T cells and cytotoxic (CD8+) T cells [21],
suggesting that T cell-mediated immunity is abnormal in patients with high CTC counts [16]. In addition,
programmed death-ligand 1 (PD-L1) expression has been detected on the surface of CTCs, which may
contribute to the immune escape from T cells and promote cancer metastasis [22].
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Clinical evidence and mouse models demonstrate that platelet-cancer cell interaction is crucial
for cancer metastasis [23]. Platelets, originally derived from megakaryocytes in the bone marrow [24],
are the key regulator of thrombosis [25,26]. The major function of platelets is to prevent bleeding
and reduce blood loss in case of vascular injury [27]. It has been reported that platelet count is
associated with metastasis and poor prognosis in cancer patients [28,29]. Consistently, with the clinical
evidence, the size and number of tumor nodules are reduced by halving the platelet count in the
murine model of ovarian cancer [30]. In addition, long-term application of low-dose anti-platelet
drugs, such as aspirin, inhibits cancer metastasis and significantly reduces cancer incidence [31,32].
Together these results suggest that platelet activation is a potential target and prognosis marker for
cancer treatment [29,33,34].
In this review, we discuss the function and regulation of cancer cell-platelet interaction during
cancer development and progression. We also summarize the factors and pathways mediating the
interaction and potential targets to halt platelet-induced cancer progression.
2. Roles of Platelets in Cancer Development and Progression
2.1. Roles of Platelets in Tumor Development
Platelet activation by physiological agonists results in secretion of a variety of cytokines and growth
factors in the platelet releasates (molecules released after platelets activating) [35,36]. Platelet releasates,
induced by the agonists of the thrombin receptors, protease activated receptor-1 (PAR1) and PAR4 [37],
promote the proliferation of MCF-7 and MDA-MB-231 breast cancer cells and angiogenesis via the
phosphoinositide 3-kinase/protein kinase C (PI3K/PKC) pathway [38]. Platelet activation induced by
other agonists, including the adenosine diphosphate (ADP) (through its receptor P2Y12 and P2Y1) also
promotes tumor growth in ovarian cancer and pancreatic cancer [39,40]. Recently, the relationship between
P2Y12 and cancer was reviewed by Ballerini et al. indicating the important role of P2Y12 in malignant
cells [41].
Many of the platelet-derived factors involved in cancer progression are important components
of tumor microenvironment, such as transforming growth factor beta (TGF-β), vascular endothelial
growth factor (VEGF), and platelet-derived growth factor (PDGF) [42–44]. TGF-β1, a member of
the TGF-β family, can be secreted during platelets activation [45]. A recent study showed that
platelet-derived TGF-β1 promotes the growth of primary ovarian cancer in murine models [46].
Incubation of platelets with TGF-β1-blocking antibody or downregulation of TGF-βR1 receptor
expression in cancer cells with siRNA inhibits proliferation in ovarian cancer cells [47]. It has been
shown that platelet extracts induce hepatocellular carcinoma growth [48] by suppressing the expression
of Krüppel-like factor 6 [49], a tumor suppressor in many cancers [50]. Protein levels of VEGF,
PDGF and platelet factor 4 (PF4) in platelets are elevated in colorectal cancer patients compared
to healthy control [51]. VEGF and PDGF are the well-characterized angiogenesis regulator [52,53].
It has been shown that platelets induce tumor angiogenesis by releasing platelet-derived growth
factor D and VEGF, and subsequently promotes the tumor growth [54]. PF4 accelerates Kras-driven
tumorigenesis in lung cancer [55]. Interestingly, PF4 has also been identified as a chemokine that
exhibits anti-angiogenesis activity [56] and may inhibit tumor growth through anti-angiogenesis [57].
PF4 may bind to VEGF or basic fibroblast growth factor (bFGF), thereby inhibiting receptor binding
and bFGF dimerization [58,59]. These results suggest that the function of PF4 in cancer development
is context-dependent.
Platelet-derived microRNA has recently been identified as a regulator of tumor development.
Lawrence E. Goldfinger showed that platelet-derived microparticles transfer miR-24 into cancer
cells. Platelet miR-24 subsequently targets mt-Nd2 and Snora75, modulates mitochondrial function,
and inhibits tumor growth [60]. Although most data support that platelets promote cancer progression,
especially in metastatic dissemination [61,62], this study suggest that the platelets suppress tumor
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development at the initiation stage. Therefore, the function of platelets in cancer progression may be
stage- and context-dependent.
2.2. Roles of Platelets in Cancer Metastasis
About 90% cancer related death is due to cancer metastasis [63]. Depletion of platelets or inhibition
of platelet activation inhibits cancer metastases [64,65], indicating that platelets are required for cancer
metastasis. During metastasis, cancer cells must detach from the primary tumor and intravasate into
circulation, where tumor cells encounter immune cells and experience fluid shear stress. The shear
force can sensitize both colon and prostate cancer cells to TNF-related apoptosis-inducing ligand
(TRAIL)-induced apoptosis [66]. It has been speculated that binding of platelets to cancer cells protects
cancer cells from shear-induced damage and facilitates cancer colonization [67].
EMT, characterized by disruption of cell-cell adhesion and expression of mesenchymal markers,
provides cancer cells with the increased cell plasticity and stemness required for colonization and
metastasis [68,69]. Platelet-cancer cell interaction promotes EMT in tumor cells and enhances
the rate of tumor extravasation in vivo through the TGF-β/Smad and NF-κB pathways [70,71].
Platelet microparticles (PMPs) are the most abundant microparticles in the blood, which may transport
miRNA and many other factors promoting EMT. For instance, miR-939 in PMPs promotes the EMT by
downregulating E-cadherin and claudin by targeting the 3′UTR region of these genes [72]. In addition,
the platelet receptor C-type lectin-like receptor 2(CLEC2) binds to Aggrus expressed in cancer cells
and induces the EMT phenotype and cancer metastasis [73]. Tissue factor (TF) is a transmembrane
receptor that initiates the extrinsic coagulation pathway. TF is highly expressed in many cancers,
and the expression is associated with cancer metastasis [74]. Co-culturing patient-derived ovarian
cancer cells with platelets increases the EMT/stemness biomarker and TF protein levels in cancer cells.
TF further enhances platelet recruitment and tumorsphere formation [75]. Platelet-released PDGF can
also enhance Cyclooxygenase (COX)-2 expression and induce the EMT markers [76]. These studies
suggest that platelets promote the EMT process through multiple pathways.
Platelet activation and adhesion depend on integrin signaling [77]. Five integrins, including α2β1,
α5β1, α6β1, αIIbβ3 and αvβ3, have been identified in platelets, which bind preferentially to collagen,
fibronectin, laminin, vitronectin, and fibrinogen, respectively [78]. It has been shown that platelet α6β1
mediates the platelet-cancer cell interaction by binding to metalloproteinase (ADAM) 9 on tumor cells,
and subsequently induces platelet activation and cancer cell extravasation. Deletion of integrin α6β1
on platelets reduces lung metastasis [79]. Knockout mouse experiments show that platelet β3 integrin
contributes to cancer bone metastasis [80]. Treatment with the αIIbβ3 antagonist significantly reduces
the bone metastasis of breast cancer in mice though depletion of platelet derived lysophosphatidic
acid (LPA) [81]. Interestingly, αIIbβ3 expression is also detected on tumor cells [82]; however, roles of
the tumor cell αIIbβ3 in cancer metastasis remains unclear.
Anoikis is a programmed cell death induced by cell detachment [83]. Anoikis resistance is
required for CTC survival and colonization in distant organs. Platelet interaction protects cancer
cells from anoikis [84]. RhoA-(myosin phosphatase targeting subunit 1) MYPT1-protein phosphatase
(PP1)-mediated Yes-associated protein 1 (YAP1) dephosphorylation and nuclear translocation are
induced by platelets, resulting in apoptosis resistance [85]. Apoptosis signal-regulating kinase 1
(Ask1) is a stress-responsive Ser/Thr mitogen-activated protein kinase kinase kinase (MAP3K) in
the Jun N-terminal kinases (JNK) and p38 pathways [86]. Once the Ask1 is deficient in platelet,
activating phosphorylation of protein kinase B (Akt), JNK, and p38 is reduced, and tumor metastasis is
attenuated [87].
Acid sphingomyelinase (Asm) is another secreted protein mediating the interaction between
cancer cells and platelets. Asm released from activated platelets induces the production of ceramide.
Ceramide activates the α5β1 integrin on melanoma cells and promotes metastasis in vivo [88].
Treatment with exogenous Asm activates p38 kinase pathway in melanoma cells. Activation of
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p38 is required for tumor cell adhesion and metastasis in vivo [89]. This evidence suggests that
platelets promote cancer metastasis through direct and indirect interactions.
2.3. Impact of Platelet on the Anti-Tumor Immunity
In order to survive in circulation, CTCs need to overcome not only the shear force-induced damage,
but also attacks from immune cells. Antitumor immunity activity is well-characterized in NK cells [90].
Depletion of NK cells significantly promotes cancer metastasis in mouse [91]. It has been shown that
binding of platelets protects CTCs from NK cells [92]. MHC class I is usually downregulated in tumor
cells [93]. Platelet-derived MHC class I is transferred to tumor cells upon interaction, subsequently reducing
the NK cells’ antitumor reactivity [94]. In addition, TGF-β released by platelets inhibits the anti-tumor
activity of NK cells by reducing the expression of natural-killer group 2, member D on NK cells [95].
Platelet-derived TGF-β has multiple functions in suppressing the antitumor immunity. TGF-β1 is
required for converting conventional CD4+ T (Tconv) cells into induced regulatory T (iTreg) cells [96].
In the hemophilia A mice, TGF-β1 along with other platelet contents induces Foxp3 expression in
Tconv cells, and then converts them into functional iTreg cells [97]. Treg cells have the ability of
killing activated T cells through a granzyme B (GzmB)-dependent mechanism [98,99]. In addition,
platelets constitutively express the non-signaling TGF-β-docking receptor glycoprotein A repetitions
predominant (GARP) [100]. Platelet-intrinsic GARP may facilitate TGF-β activation in tumor tissue
and subsequently constrains the T cell function in the cancer microenvironment [101]. These data
support the hypothesis that platelets promote cancer metastasis by repressing immune response.
3. Cancer Induces Platelet Activation
The interaction between platelets and cancer cells is bidirectional, and cancer cells have profound
effects on platelet generation and activation. Cancer patients often have an abnormal platelet count
and activation. More than five-fold increase of thrombosis and thromboembolism incidences have been
detected in cancer patients compared with normal person [102]. Furthermore, the extracellular vesicles
derived from breast cancer cell lines induce tissue factor-independent platelet activation and aggregation,
providing a potential mechanism for cancer-associated thrombosis [103]. Fiorella Guadagni et al. showed
that the cancer-associated oxidative stress also contributes to persistent platelet activation [104].
Cathepsins K (CAT K) is a protease up-regulated in many cancers [105,106]. It has been shown that
platelet aggregation is induced by CAT K in a dose-dependent manner through proteolytically-activated
receptors (PAR) 3 and 4. During this process, sonic hedgehog, osteoprotegerin, parathyroid
hormone-related protein, and TGF-β are released, which, in turn, induce downstream signaling pathways
in breast cancer cells [107]. This study further suggests that cancer cells have profound impacts on
platelet activation.
Levels of lipid phosphate phosphatase 1 (LPP1), the key enzyme in phospholipid biosynthesis
pathways, is reduced in platelet derived from ovarian cancer patients. The reduction of LLP1 may
contribute to the increased risk of thrombosis in cancer patient [108]. However, plasma levels of
β-thromboglobulin and PF-4, two markers of platelet α granule secretion and platelet aggregation,
have little difference between ovarian cancer patient and patients with benign ovarian tumors.
In addition, platelets derived from ovarian cancer patients do not exhibit an enhanced aggregation
response to ADP or collagen [109]. These findings suggest that platelet hyperactivation in cancer
patients is cancer-type dependent.
4. Platelets, a Potential Therapeutic Target and Biomarker for Cancer Treatment
4.1. Platelet Is a Potential Target to Suppresses Cancer Metastasis
Given the crucial roles of platelets in cancer progression, targeting cancer cell-platelet interaction
is considered a promising strategy for cancer prevention and treatment. In fact, many compounds
that target platelets exhibit anti-tumor activities. Aspirin is the traditional drug to reduce fever,
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pain, and inflammation [110]. It is also widely used in patients with a high risk of heart disease
and thrombosis because of its unique ability to inhibit platelet COX-1 [111]. Treatment with aspirin
suppresses the function of platelets in promoting cancer metastasis in mice [112]. Population and
clinical studies also demonstrate that aspirin significantly reduces the risk of colon cancer development
and inhibits cancer growth and invasiveness [113,114]. Tamoxifen is used widely as antiestrogen
therapy for breast cancer [115]. Interestingly, one study shows that tamoxifen and its metabolite,
4-hydroxytamoxifen, directly inhibit platelet-mediated metastasis [116]. Specifically, delivery of the
platelet aggregation inhibitor ticagrelor to tumor tissue also inhibits the EMT phenotypes and cancer
metastasis in vivo [117].
The compound 2CP, a derivative of 4-O-benzoyl-3-methoxy-beta-nitrostyrene, binds to the CLEC-2
and inhibits the platelet aggregation and cancer metastasis in vivo [118]. Phosphodiesterases (PDEs)
regulate cyclic nucleotide signaling by catalyzing cyclic adenosine monophosphate (cAMP) and cyclic
guanosine monophosphate (cGMP) to the inactive form. PDE2, PDE3, and PDE5 expression is detected
in platelets [119,120]. Selective PDE inhibitors, such as caffeine and theophylline, inhibit platelet
aggregation and cancer cell invasion, and enhance anti-cancer drug efficiency in vivo [121–123].
Glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists inhibit platelet aggregation, and a pre-clinical study
shows that treatment with GPIIb/IIIa antagonists significantly decreases tumor nodules in lung
metastasis [124].
4.2. Targeting Platelets Is a Potential Strategy to Overcome Drug Resistance
The chemotherapeutic response in human epidermal growth factor receptor 2-negative breast
cancer is significantly associated with that platelets surround primary tumor [125]. Clinical data show
that primary tumor cells surrounded with platelets are less responsive to neo-adjuvant chemotherapy.
In addition, platelets promote EMT in cancer cells, which is associated with chemoresistance [126,127].
It has been reported that platelet-derived ADP and ATP increase the level of EMT inducer Slug and
cytidine deaminase, and enhances gemcitabine resistance. The P2Y12 inhibitor abolishes the survival
signal induced by platelet-derived ADP and ATP [39]. These data suggest that targeting platelets is a
potential strategy to overcome chemoresistance.
4.3. Platelets in Anti-Cancer Drug Delivery
Platelets, and their secreted vesicles, are potential drug delivery vehicles [128]. Platelets have
little effect on drug activity, and using them as drug delivery vehicles may reduce side effects [129].
The platelet-loaded drugs are protected from clearance and, thus, can circulate in blood for a relatively
long time [130]. A recent study shows that platelet membrane-coated particles specifically deliver
drugs to CTC and reduce cancer lung metastases in mice [131]. Current drug delivery systems
depend on unique cancer markers and tumor-specific microenvironment cues, such as pH and hypoxia.
However, the microenvironment of CTCs is different from the solid tumor. Platelets may provide an
effective delivery system to target CTCs and inhibit cancer metastasis.
5. Conclusions and Future Direction
Platelet-cancer cell interaction promotes cancer cells metastasis by enhancing CTC survival
and extravasation (Figure 1). Growth factors, metabolites, and microRNA released by activated
platelets induce EMT and enhance cancer cell stemness, which is crucial for cancer cell colonization
at the distant organs (Table 1). Importantly, cancer cells also induce platelet activation and
aggregation, and subsequently elevate the risk of thrombosis. Therefore, targeting platelet-cancer cell
interaction is a potential strategy to reduce both cancer metastasis and cancer-associated thrombosis.
Nevertheless, targeting platelets has not been utilized for cancer therapy in the clinic because the cancer
cell-platelet interaction is still not completely understood. For instance, the key factor that regulates
cancer cell-platelet interaction has not been identified; roles of platelets in tumor initiation and primary
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tumor development remained to be determined. We believe that addressing these questions may help
to achieve the goal of targeting platelet-cancer interaction for cancer therapy.
 
Figure 1. The interaction between cancer cell and platelet. Circulating tumor cells induce platelet
activation and aggregation. Activated platelets release a variety of factors, which promote primary
tumor growth and cancer metastasis. Binding of platelets also protects CTCs from flow shear force and
immune cell attacks.
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Abstract: Nonalcoholic steatohepatitis (NASH) is the critical stage of nonalcoholic fatty liver disease
(NAFLD). The persistence of necroinflammatory lesions and fibrogenesis in NASH is the leading cause
of liver cirrhosis and, ultimately, hepatocellular carcinoma. To date, the histological examination of
liver biopsies, albeit invasive, remains the means to distinguish NASH from simple steatosis (NAFL).
Therefore, a noninvasive diagnosis by serum biomarkers is eagerly needed. Here, by a proteomic
approach, we analysed the soluble low-molecular-weight protein fragments flushed out from the
liver tissue of NAFL and NASH patients. On the basis of the assumption that steatohepatitis leads
to the remodelling of the liver extracellular matrix (ECM), NASH-specific fragments were in silico
analysed for their involvement in the ECM molecular composition. The 10 kDa C-terminal fragment
of the ECM protein vitronectin (VTN) was then selected as a promising circulating biomarker in
discriminating NASH. The analysis of sera of patients provided these major findings: the circulating
VTN fragment (i) is overexpressed in NASH patients and positively correlates with the NASH activity
score (NAS); (ii) originates from the disulfide bond reduction between the V10 and the V65 subunits.
In conclusion, V10 determination in the serum could represent a reliable tool for the noninvasive
discrimination of NASH from simple steatosis.
Keywords: nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; liver fibrosis; secretome
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is by now the most common liver disease in the
developed and developing countries with a global estimated median prevalence of 20% [1]. Most
NAFLD patients have simple steatosis or nonalcoholic fatty liver (NAFL) with low inflammation,
Int. J. Mol. Sci. 2018, 19, 603; doi:10.3390/ijms19020603 www.mdpi.com/journal/ijms151
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tissue damage, or liver fibrosis. However, 13% to 31% of the cases develop definite nonalcoholic
steatohepatitis (NASH), characterized by hepatic steatosis and inflammation with ballooning, with or
without fibrosis [2]. The prognosis is poorer in patients with NASH, and NASH patients can progress
to liver cirrhosis and ultimately hepatocellular carcinoma (HCC) [3]. Therefore, it is crucial to obtain a
prompt diagnosis of NAFLD patients with NASH for an effective clinical management.
Currently, the differentiation of NAFL from definite steatohepatitis and liver fibrosis in the whole
spectrum of NAFLD is still based on the histological examination of liver biopsies to assign a grade
and stage through scoring systems [4]. The NAFLD Activity Score (NAS) is widely accepted and
used in clinical practice [5]. To stage fibrosis, the NASH Clinical Research Network system is one of
the most validated systems currently available and defines four fibrosis stages [5,6]. Nevertheless,
although the histological evaluation of liver biopsies addresses the full spectrum of lesions of NAFLD,
this procedure remains invasive and limited by sampling error, diagnostic accuracy, and hazard to the
patients [7].
Serum biomarkers offer a noninvasive and cost-effective alternative to liver biopsy both for
patients and clinicians. Previous studies on NAFLD subjects described some circulating proteins and
metabolites with a potential for discriminating between NASH and NAFL [8–11]. Nevertheless, the
feasibility, specificity, and sensitivity of these candidate biomarkers are relatively low or, in some cases,
only reflect one aspect of NAFLD progression instead of the overall condition. There is, therefore,
an increasingly pressing need to identify NAS-related serum biomarkers that can reflect the grade
of the disease. In this regard, low-abundance peptides in the serum may represent a reservoir
of NASH-specific products originating from leakage as a result of cell death, extracellular matrix
remodelling, or damages [12]. Unfortunately, one of the challenges in proteomic-based serum marker
discovery is that serum samples are dominated by high-abundance proteins whose presence obscures
less abundant products. In particular, the high concentrations of albumin and immunoglobulins (Igs)
in serum samples prevent the successful identification of low-abundance biomarkers in studies based
on top-down peptidomic approaches. Moreover, methods developed for depleting the high-abundance
proteins, while eliminating the most of albumin and Igs, lead to the impoverishment of minor products.
Therefore, identifying potential circulating markers of NASH straight from serum samples still remains
an ambitious challenge.
In this study, to overcome this issue, we firstly performed a proteomic analysis of soluble
low-molecular-weight (LMW) polypeptides flushed out from liver biopsies of NAFLD patients.
The 10 kDa subunit (V10) of vitronectin was identified as upregulated in the flush-out samples
of the NASH liver sample group. Hence, our aim has been to provide a proof of concept regarding
the possible correlation of serum vitronectin fragments with histopathology in patients affected by
NAFLD and its putative role in the assessment of disease severity.
2. Results
2.1. Characteristics of the Patients
The group of NAFLD patients included 50 subjects (24 males and 26 females). Among them,
27 subjects did not present definite steatohepatitis (NAFL group) while 23 subjects displayed
definite steatohepatitis (NASH group). The fibrosis stage in NASH patients was more advanced
than in those affected by NAFL. The patient’s age did not statistically differ between NAFL
and NASH groups. The body mass index (BMI), aspartate aminotransferase (AST), and alanine
aminotransferase (ALT) levels were significantly higher in subjects with NASH than in those with
NAFL. Gamma-glutamyltransferase (GGT) levels and AST/ALT ratio were not significantly different
between the groups. The clinical and serological characteristics of the patients are summarized in
Table 1.
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Table 1. Clinical characteristics of NAFL and NASH populations.
NAFL NASH p Value
All 27 23
Gender (male/female) 14/13 10/13 0.55
Nas 2.81 ± 1.04 5.43 ± 0.99 <0.001
Fibrosis 1/2/3/4 11/12/4/0 3/5/9/6 <0.001
AGE at enrolment (years) 52.3 ± 14.4 51.7 ± .9.8 0.44
Body mass index (kg/m2) 28.7 ± 4.1 30.5 ± 3.9 0.067
AST (U/L) 37.6 ± 17.8 61.9 ± 40.9 0.005
ALT (U/L) 69.3 ± 36.1 97.1 ± 56.1 0.024
GGT (U/L) 62.4 ± 41.5 80.7 ± 86.7 0.18
AST/ALT ratio 0.56 ± 0.18 0.68 ± 0.31 0.07
Data are reported as Means ± Standard Deviation; p values <0.05 are reported in bold; AST (Aspartate transaminase);
ALT (Alanine transaminase); GGT (Gamma-glutamyl transferase).
2.2. Identification of LMW Polypeptides in NAFL and NASH Samples
The LMW polypeptides released from the liver tissue are an essential part of the NASH
microenvironment and represent a reservoir of early promising and specific biomarkers firstly
detectable in the NASH-specific secretome and, subsequently, circulating in the blood as
low-abundance products. Therefore, a comparative proteomic analysis of enriched LMW polypeptides
flushed out from the liver biopsies of NAFLD patients could represent a powerful alternative strategy
for the discovery of circulating subnanomolar biomarkers.
Secretomes from the liver biopsies were individually collected, and equal amounts of proteins
from patients having a diagnosis of simple steatosis (NAFL group) and definite steatohepatitis
(NASH group) were pooled. One hundred micrograms of proteins from each pool was separated by
non-reducing SDS-PAGE with a buffer system specific for the resolution of low-molecular-weight
polypeptides. Each gel lane was cut into seven sections ranging from 3 to 20 kDa, and the polypeptides
in each gel section were digested and submitted to nLC–MS-based proteomic analysis. A total of
235 and 119 proteins in NASH and NAFL groups, respectively, were identified (Table S1). Aiming at
selecting peptides originating from the fragmentation of whole proteins, we used the electrophoretically
derived molecular weight (MWexp) of the protein as the identification constraint. On the basis of
the assumption that the MWexp of a protein should correlate with its theoretical molecular weight
(MWcal) obtained from the database search, 63 and 23 identifications resulted as protein fragments
in NASH and NASL groups, respectively (Table S1). Interestingly, by comparing these two datasets,
7 protein fragments were identified in the NAFL group, 16 were commonly identified, and 47 were
found exclusively in the NASH group, thus confirming that the disease progression leads to increased
protein fragmentation (Figure 1).
Figure 1. Venn diagram of the overlap of identified protein fragments in NASH and NAFL groups.
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2.3. In Silico Analysis of NASH-Specific Fragments
In response to inflammatory stimuli, NASH leads to changes in the composition of the liver
extracellular matrix (ECM), where high levels of ECM protein fragments are generated and released into
the circulation at low concentrations [13]. Therefore, it is conceivable that liver-specific ECM circulating
peptides may be the one of the most suitable candidates as circulating NAS-related biomarkers for
assessing grade and stage in NASH patients.
The 47 proteins, whose fragments were found exclusively in the NASH group, were then analysed
for their involvement in the ECM molecular composition by interrogating the MatrisomeDB 2.0
(http://matrisomeproject.mit.edu/proteins/), a searchable database that integrates experimental
proteomic data on ECM and ECM-associated proteins from the ECM Atlas [14]. As shown in Table 2,
seven proteins were found to be associated with liver ECM, five of which as minor components or
regulators (i.e.: LGALS3, LGALS4, CTSB, SERPINB1, SERPINC1), and the vitronectin (VTN) and
fibrinogen alpha chain (FGA) as main structural components. Since several reports demonstrated
that the VTN is upregulated in the ECM of fibrotic liver [15–18], it is reasonable to hypothesize that
this protein may be subjected to turnover and degradation. Accordingly, we decided to challenge the
detection of the VTN fragment directly in the sera of patients.
Table 2. ECM and ECM-associated components analysis of NASH fragments by MatrisomeDB 2.0.
Gene Symbol Name Matrisome Division Category
FGA Fibrinogen alpha chain Core matrisome ECM Glycoproteins
VTN Vitronectin Core matrisome ECM Glycoproteins
LGALS3 Galectin-3 Matrisome-associated ECM-affiliated Proteins
LGALS4 Galectin-4 Matrisome-associated ECM-affiliated Proteins
CTSB Cathepsin B Matrisome-associated ECM Regulators
SERPINB1 Leukocyte elastase inhibitor Matrisome-associated ECM Regulators
SERPINC1 Antithrombin-III Matrisome-associated ECM Regulators
2.4. Correlation between Circulating VTN Fragments and Liver HistoMorphology
Mature vitronectin is a multifunctional plasma and extracellular matrix protein of 459 amino acids
with a MWcal of 52 kDa; the observed MWexp of the glycosylated form is 75 kDa [19]. We identified
the VTN fragment in the 12–7 kDa SDS-PAGE-displayed molecular weight range. Interestingly, by
tandem mass spectrometry analysis, we found that the sequence of the tryptic peptides, originated
from the digestion of the VTN fragment, matched with the C-terminal end of the protein (Table S2).
To detect this fragment in the sera of our cohort of patients, a non-reducing western blotting analysis
was performed by using an antibody that recognizes the vitronectin C-terminal end. As expected,
the 75 kDa form of VTN (V75) was detected in the serum of NAFLD patients (Figure 2). Moreover,
an additional signal of approximately 10 kDa (V10) was detected, thus confirming the existence of a
circulating C-terminal fragment. Surprisingly, the V10 level of expression did not reflect the expression
level of the circulating mature form. We then analysed the serum levels of V10 and V75 in the frame
of NASH by densitometry. As shown in Figure 3, NASH patients displayed increased levels of V10
compared to the NAFL group (p = 0.027). On the contrary, lower amounts of V75 were measured in
the serum of NASH patients (p = 0.013) and in patients with a fibrosis score >2 compared to patients
with a fibrosis score =1 (p < 0.01). Then, we further extended the analysis by using the V10/V75
ratio (Figure 3). Interestingly, the V10/V75 ratio was significantly higher in NASH compared to
NAFL patients (p = 0.003). By bivariate analysis (Figure 3), V10, V75, and V10/V75 ratio significantly
correlated with the NAS score (respectively: r = 0.311, p = 0.028; r = −0.318, p = 0.024; r = 0.399,
p = 0.004) but not with clinical–serological parameters (i.e., BMI, ALT, AST); only the V75 fragments
correlated with the fibrosis score (r = −0.424; p = 0.002). To further assess whether these results could
be actually due to the reported differences in BMI, ALT, and AST between the two groups (NAFL and
NASH), a linear regression analysis was performed by two models using NAS or, alternatively, fibrosis
154
Int. J. Mol. Sci. 2018, 19, 603
as independent variables. The ratio V10/V75 resulted a predictor of NAS (beta = 0.354; p = 0.010)
but not of fibrosis (beta= 0.166; p = 0.248), independently from the above-mentioned parameters
(i.e., BMI, ALT, AST); moreover, the V75 fragment resulted a predictor of fibrosis (beta= −0.292;
p = 0.034) but not of NAS (beta= −0.279; p = 0.051), independently from BMI, ALT, AST. Given the low
beta value, we further tried to individuate a possible cut-off value for the V10/V75 ratio by analysing
sera from healthy subjects (N = 6). The V10, V75, and V10/V75 ratio values resulted significantly
higher in NAFLD patients compared to healthy subjects (p < 0.05). For the V10/V75 ratio, we assumed
the highest value obtained in healthy subjects as a possible cut-off (0.27) to be used as a threshold for
NAFLD patients. The binary logistic regression demonstrated that NASH diagnosis was associated
with a V10/V75 ratio over (>0.27) the identified threshold (OR: 5.254; CI 95%: 1.142–24.163; p = 0.033)
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Figure 2. Western blotting analysis of 10 kDa VTN fragment levels in NAFLD patients. Dilutions (1:10)
of the serum samples were separated on a non-reducing SDS polyacrylamide gel and probed with an
antibody specific for the vitronectin C-terminal end (C-VTN). Total protein staining by Ponceau S on
the nitrocellulose membrane is shown. Patient IDs are indicated. These images are representative of
experiments carried out in triplicate
155
Int. J. Mol. Sci. 2018, 19, 603
Figure 3. V10 and V75 levels are increased in NASH patients’ serum. (A) Densitometry analysis
of the V10 and V75 blots imaged in Figure 2. The total lane density detected from the Ponceau S
staining of the transferred protein in the blots was used for normalization. Patients with definite
steatohepatitis (NASH group) have higher V10 and lower V75 levels compared with patients without
definite steatohepatitis (NAFL group); * = p < 0.05. (B) Histogram showing that the V10/V75 ratio was
higher in NASH compared to NAFL group (left); * < 0.05. The scatter plot graph on the right shows the
correlation between the V10/V75 ratio and the NAS score. (C) The histogram on the left shows V75
serum levels in patients divided according to the fibrosis (F) score; * < 0.01 versus F1 group. The scatter
plot graph on the right shows the correlation between V75 levels and the fibrosis score. (D) Sirius red
stains in liver biopsies are representative of F1 and F3 stages, respectively. Scale bar = 100 μm.
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2.5. Circulating V10 Originates by the Reduction of VTN Clipped Form
VTN is produced and secreted by the hepatocytes in two molecular forms of 75 kDa: a single,
non-cleaved chain and a furin-mediated clipped form composed of two chains of 65 and 10 kDa which
are held together by a disulfide bond [19]. Consequently, we wondered whether the increased level
of the C-terminal fragment of vitronectin in the sera of patients with NASH may be related to the
degradation of vitronectin by proteases overproduced in NASH or to the reduction of the disulfide
bond between the two vitronectin subunits.
The degradation of vitronectin occurs by means of matrix metalloproteinases (MMPs)-1, -2, -3, -7,
and -9 [20]. Since MMP-2 and -9 are found extensively upregulated in NASH [21], we first sought to
determine whether in vitro digestion of circulating VTN by these MMPs gave rise to increased levels of
V10. As indicated in Figure 4A, the proteolytic activity generated fragments ranging from 37 to 45 kDa.
Nevertheless, the 10 kDa signals were found at lower levels with respect to the control, thus suggesting

















































Figure 4. The 10 kDa VTN fragment originates from the reduction of the disulfide bond between the
V65 and V10 subunits. (A) C-VTN non-reducing western blotting analysis of 1:10 dilutions of a NASH
serum sample in the presence or absence of MMP-2 and -9. Total protein staining by Ponceau S on the
nitrocellulose membrane is shown. (B) C-VTN western blotting analysis of 1:10 dilutions of a NASH
serum sample in the presence or absence of a sample-reducing agent (SRA). Total protein staining by
Ponceau S on the nitrocellulose membrane is shown. (C) Non-reducing western blotting analysis of
1:10 dilutions of a NASH serum sample probed with antibodies specific for the vitronectin C-terminal
(C-VTN) and N-terminal (N-VTN) ends. These images are representative of experiments carried out
in triplicate.
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Then, we verified the hypothesis that V10 originated by the releasing of the 10 kDa subunit from
the vitronectin clipped form by means of disulfide bond reduction. Firstly, we proved that the addition
of a reducing agent generated a signal corresponding to the same molecular weight of V10 (Figure 4B).
Then, we analysed the presence of the free circulating 65 kDa subunit (V65) by using an antibody
that recognizes the vitronectin N-terminal end. As reported in Figure 4C, in addition to the 75 kDa
signal, the immunoblot after non-reducing electrophoresis highlights the presence of a further band
corresponding to the V65 subunit, thus suggesting that the circulating 10 kDa fragment could be the
result of the disulfide bond reduction.
3. Discussion
Our analysis on sera of NAFLD patients showed that: (i) circulating V10 is overexpressed in
NASH patients compared to NAFL patients and positively correlates with NAS; (ii) circulating V75 is
underexpressed in NASH patients compared to NAFL patients and negatively correlates with NAS
and liver fibrosis; (iii) the V10/V75 ratio is a predictor of NAS score, independently from BMI, ALT,
and AST; (iv) circulating V10 originates from the disulfide bond reduction of the V75 clipped form.
The aim of the present study was to identify circulating serum markers which could be helpful in
distinguishing patients with high NAFLD activity or with advanced fibrosis. For this purpose, we
focused our attention on those peptides originated by the fragmentation of mature proteins that may
reflect valuable disease-related information. However, the proteomic screening for these fragments
was performed on liver biopsy secretomes to overcome complexity and detection problems associated
with peptide analysis of serum or plasma. Serum and plasma proteins are present at concentrations
that are likely to extend over 10 orders of magnitude [22]. In addition, the 22 major proteins, including
albumin and immunoglobulins, representing 99% of total serum polypeptides, are preferentially
sequenced by mass spectrometry [23]. Therefore, the identification of the remaining 1%, consisting
of thousands of LMW proteins and peptides, remains challenging despite the proposed strategies
for peptide extraction from serum [24,25]. Here, by enriching LMW polypeptides flushed out from
the liver specimens of patients, we generated NAFL- and NASH-specific data sets of LMW protein
fragments whose comparison highlighted an increased tissue protein turnover during the progression
of the disease from the simple steatosis to the steatohepatitis. To gain insights on the specific valence
of the protein fragments found in NASH, we focused our attention on the liver ECM specific products
which may reflect the pathological matrix remodelling in steatohepatitis. Five ECM-derived fragments
were found, and, among these, we restricted the experimental observations to the vitronectin 10 kDa
C-terminal fragment.
Vitronectin has been extensively studied in the frame of liver fibrosis in chronic liver diseases
such as viral hepatitis B and C infections and HCC. Particularly, the ECM-associated vitronectin is
found at low concentrations in normal liver and markedly increases in the cirrhotic liver, while the
circulating 75 kDa form follows an opposite trend [15–18].
Here, for the first time, we analysed the expression of circulating VTN in the frame of NAFLD.
We demonstrated that in NASH patients, VTN undergoes molecular remodelling that releases the
two subunits from the clipped form. Since the small subunit V10 was found at high concentrations
in NASH, while the V75 form was found to be decreased, the ratio V10/V75 might be a suitable
serological indicator helpful for discriminating the presence of steatohepatitis in NAFLD patients.
A 10 kDa vitronectin C-terminal fragment has been previously identified as a serum marker of
HCC [26]. Nevertheless, while in HCC the V10 is produced by the catalytic activity of MMP-2 on
the V75 non-cleaved form, we demonstrated that in NASH it originates from the disulfide bond
reduction of the clipped form. Oxidative stress has been extensively demonstrated to be a major factor
in the development of NASH [27–29]. Particularly, it has been shown that the production of reactive
oxygen and nitrogen species in a context of liver steatosis promotes lipid peroxidation which, in turn,
supports the necroinflammatory milieu and leads to the stimulation of collagen synthesis in hepatic
stellate cells [30,31]. To counteract the oxidative stress, mammalian cells activate thioredoxin (Trx),
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which maintains a reducing environment by catalysing an electron flux from nicotinamide adenine
dinucleotide phosphate to Trx through Trx reductase, which reduces its target proteins using highly
conserved thiol groups [32]. Therefore, it is conceivable that the oxidative stress-induced elevated
serum [33] and tissue (Table S1) Trx levels in NASH patients may be responsible for the free V10
production. Moreover, since increased hepatic vitronectin expression favors fibrogenesis by recruiting
lymphocytes within the inflamed liver tissue and promoting a wound-healing response [19,34], the
oxidative stress-induced reduction of the functional V75 clipped form may be the consequence of
a pathophysiological response for counteracting liver fibrosis and the disease progression. Further
experiments may challenge the robustness of these insights.
The validation and clinical availability of serum biomarkers of NASH are desirable to aid clinicians
in the discrimination of NAFLD patients with steatohepatitis from simple steatosis and for the
noninvasive monitoring of disease progression and response to therapy. To date, the most promising
proposed serum biomarkers (i.e.: cytokeratin-18 M30 fragment [8], fibroblast growth factor 21 [35],
interleukin 1 receptor antagonist [36], pigment epithelium-derived factor [11], osteoprotegerin [37]),
showed a potential in diagnosing NAFLD and NASH. However, taken individually, they reflect only
one aspect of the NAFLD pathological scenery, i.e., hepatocyte apoptosis, inflammation, fibrosis,
insulin sensitivity, and steatosis. Moreover, some of them, showing low sensitivity and accuracy, need
to be validated in a larger cohort [38]. However, it has been demonstrated that tests performed by
combining these biomarkers improved the accuracy in the diagnosis of NASH [38]. Thus, we believe
that the measurement of V10 in blood could be a further useful tool for detecting NASH by means of a
panel of markers. However, the present study represents a proof of concept regarding the possibility
to detect vitronectin fragments in the serum of patients affected by NAFLD and a possible correlation
with histomorphology. Thus, our results should be replicated in a larger cohort of NAFLD patients
to validate their eventual clinical relevance. In addition, it has, in general, several limitations: (i) a
sampling bias may have originated as liver biopsy was used as gold standard for assessing the use of
V10; (ii) the samples were all selected within the Italian population; (iii) the lack of validation based on
a gel-free quantitative immunoassay able to discriminate the C-terminal V10 from the V75; (iv) the
specificity of the V10 fragment in relation to hepatocyte injury in NASH has not been challenged in
patients with other liver diseases. Moreover, since the presence of threonine rather than methionine at
position 381 was proposed to be responsible for the susceptibility of VTN to cleavage at Arg379–Ala380
for subunits production [19], a genetic SNP analysis of the VTN gene may be considered for those
NASH patients with low levels of circulating V10.
In conclusion, our findings suggest that the circulating VTN 10 kDa subunit may be a reliable tool
in the discrimination of patients with NASH.
4. Materials and Methods
4.1. Patient Characteristics
The study was approved by the Institutional Ethic Committee of Sapienza University of Rome
(prot. 873/11, Rif. 2277 approved on 13 October 2011) and conforms to the ethical guidelines of the
1975 Declaration of Helsinki. The population for the current study consisted of 50 well-characterized,
biopsy-proven adult NAFLD patients. To be eligible for the study, NAFLD patients had to fulfill
the following criteria: ultrasound evidence of fatty liver (defined according to Hamagouchi criteria),
absence of current or past excessive alcohol drinking as defined by an average daily consumption of
alcohol >20 g for women and >30 g for men; negative tests for the presence of hepatitis B surface antigen
and antibody to hepatitis C virus. Percutaneous liver biopsy was performed under ultrasound guidance
in fatty liver patients with clinical suspicion of NASH by their treating hepatologists. The decision
to perform the biopsy was individualized and based on a persistent elevation of serum alanine
aminotransferase levels (>1.5 above normal values) for more than 6 months and the presence of risk
factors for NASH. A single operator performed ultrasound-guided liver biopsies. The pathologist who
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examined the biopsy specimens was blinded to patients’ identity or clinical information. Diagnosis
of definite steatohepatitis (i.e., NASH) was defined using standard criteria [4], and NAFLD activity
score (NAS) was calculated on the basis of separate scores for steatosis, hepatocellular ballooning,
and inflammation [5]. Fibrosis was scored on a scale of 0–4 [5]. Blood samples from six control (healthy)
subjects was analysed. Control subjects (three male and three female) with age = 49 ± 13 years
(mean ± standard deviation) were included; these subjects had a BMI < 25, did not have metabolic
risk factors, (e.g., diabetes, hypertension), were negative for viral hepatitis markers, had normal liver
serological tests, and had no sign of liver steatosis at ultrasound. A written informed consent was
obtained from all subjects.
4.2. Liver Secretome, Protein Digestion, and Peptide Purification
Secreted proteins from fresh liver biopsies were obtained by overnight shaking (600 RPM) in
Washing Buffer (0.5 M NaCl, 10 mM Tris Base pH 7.5, 1× protease inhibitor cocktail (Sigma Aldrich,
St. Louis, MO, USA)) at 37 ◦C. After centrifugation at 13,000 rpm for 1 min, the supernatants were
collected, and protein concentrations were measured by Bradford assay. Equal amounts of samples
were individually collected to generate pools of 100 μg. The samples were then separated on 12%
gels (Life technologies, Thermo Fisher Scientific, Waltham, MA, USA) by SDS-PAGE with MES
running buffer (Life technologies). The gels were stained by Simply Blue Safe Stain (Life technologies),
and seven sections for each gel lane were cut. Protein-containing gel pieces were washed with
100 μL of 0.1 M ammonium bicarbonate (5 min at RT). Then, 100 μL of 100% acetonitrile (ACN) was
added to each tube, and the tubes were incubated for 5 min at RT. The liquid was discarded, the
washing step repeated once more, and the gel plugs were shrunk by adding ACN. The dried gel
pieces were reconstituted with 100 μL of 10 mM DTT/0.1 M ammonium bicarbonate and incubated
for 40 min at 56 ◦C for cysteine reduction. The excess liquid was then discarded, and the cysteines
were alkylated with 100 μL of 55 mM IAA/0.1 M ammonium bicarbonate (20 min at RT, in the dark).
The liquid was discarded, the washing step was repeated once more, and the gel plugs were shrunk by
adding ACN. The dried gel pieces were reconstituted with 12.5 ng/μL trypsin in 50 mM ammonium
bicarbonate and digested overnight at 37 ◦C. The supernatant from the digestions was saved in a fresh
tube, and 100 μL of 1% TFA/30% ACN was added to the gel pieces for an additional extraction of
peptides. The extracted solution and digested mixture were then combined and vacuum-centrifuged
for organic component evaporation. The peptides were resuspended with 40 μL of 2.5% ACN/0.1%
TFA, desalted, filtered through a C18 microcolumn ZipTip, and eluted from the C18 bed using 10 μL of
80% ACN/0.1% TFA. The organic component was once again removed by evaporation in a vacuum
centrifuge, and the peptides were resuspended in a suitable nanoLC injection volume (typically
3−10 μL) of 2.5% ACN/0.1% TFA.
4.3. NanoLC Analysis and Mass Spectrometry Analysis
An UltiMate 3000 RSLC nano-LC system (ThermoFisher Scientific, Waltham, MA, USA) equipped
with an integrated nanoflow manager and microvacuum degasser was used for peptide separation.
The peptides were loaded onto a 75 μm NanoSeries C18 column (ThermoFisher, P/N 164534) for
multistep gradient elution (eluent A 0.05% TFA; eluent B 0.04% TFA in 80% ACN) from 5% to 20%
eluent B within 10 min, from 20% to 50% eluent B within 45 min, and for further 5 min from 50% to 90%
eluent B with a constant flow of 0.3 μL/min. After 5 min, the eluted sample fractions were continuously
diluted with 1.2 μL/min a-cyano-4-hydroxycinnamic acid (CHCA) and spotted onto a MALDI target
using a HTC-xt spotter (PAL SYSTEM) with an interval of 20 s resulting in 168 fractions for each
gel slice. Mass Spectrometry Analysis MALDI-TOF MS spectra were acquired using a 5800 MALDI
TOF/TOF Analyzer (Sciex, Concord, ON, Canada). The spectra were acquired in the positive reflector
mode by 20 subspectral accumulations (each consisting of 50 laser shots) in an 800−4000 mass range,
focus mass 2100 Da, using a 355 nm Nb:YAG laser with a 20 kV acceleration voltage. Peak labeling
was automatically done by 4000 Series Explorer software Version 4.1.0 (Sciex) without any kind of
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smoothing of peaks or baseline, considering only peaks that exceeded a signal-to-noise ratio of 10 (local
noise window 200 m/z) and a half maximal width of 2.9 bins. The calibration was performed using
default calibration originated by five standard spots (Mass Standards kit for Calibration P/N 4333604).
Only the MS/MS spectra of preselected peaks (out of peak pairs with a mass difference of 6.02, 10.01,
12.04, 16.03, and 20.02 Da) were integrated over 1000 laser shots in the 1 kV positive ion mode with
the metastable suppressor turned on. Air at the medium gas pressure setting (1.25 × 10−6 Torr) was
used as the collision gas in the CID-off mode. After smoothing and baseline subtractions, spectra were
generated automatically by 4000 Series Explorer software. The MS and MS/MS spectra were processed
by ProteinPilot Software 4.5 (Sciex) which acts as an interface between the Oracle database containing
raw spectra and a local copy of the MASCOT search engine (Version 2.1, Matrix Science, Ltd.).
The Paragon algorithm was used with identification as the Sample Type, iodacetamide as cysteine
alkylation, with the search option “biological modifications” checked, and trypsin as the selected
enzyme. MS/MS protein identification was performed against the Swiss-Prot database (number
of protein sequences: 254757; released on 20121210) without taxon restriction using a confidence
threshold of 95% (Proteinpilot Unused score ≥ 1.31). The monoisotopic precursor ion tolerance was
set to 0.12 Da and the MS/MS ion tolerance to 0.3 Da. The minimum required peptide length was set
to six amino acids.
4.4. Immunoblotting Analysis
Dilutions 1:10 of the serum samples were separated in 12% gels (Life technologies) by SDS-PAGE
with MES running buffer (Life technologies) and electroblotted onto nitrocellulose (GE, Healthcare,
Little Chalfont, UK) membranes. The blots were incubated with primary and secondary antibodies.
The antibodies were revealed using ECL (Millipore). To control for equal protein loading and transfer,
the membranes were stained with Ponceau S solution (Sigma). The following antibodies were used:
anti-C-VTN (Abcam, Cambridge, UK, ab113700), anti-N-VTN (Santa Cruz Biotechnology, Dallas,
Texas, USA, sc-15332); the secondary anti-rabbit peroxidase-conjugated antibody was from Jackson
ImmunoResearch. The chemiluminescent blots were imaged with the ChemiDocTM Touch Imaging
System (Bio-Rad Laboratories, Hercules, CA, USA), and vitronectin band densities were quantified by
ImageLab software version 5.1.2 (Bio-Rad). Total protein lane densities by Ponceau S staining were
used for normalization.
4.5. In Vitro Degradation of Vitronectin by Metalloproteases
MMP-2 (ab81550) and MMP-9 (ab82955) were from Abcam. Before incubation with the serum
sample, pro MMP-9 was activated by incubation with 4-aminophenylmercuric acetate 1 mM (Sigma,
St. Louis, MO, USA) overnight at 37 ◦C. The digestion of vitronectin was carried out by incubation of
the substrate at 37 ◦C for 24 h with MMPs in an enzyme-to-substrate ratio of 1:20 in 50 mMTris-HCl,
pH 7.5, containing 0.15 M NaCl, CaCl2 10 mM, 0.05% Brij 35 and 0.02% NaN3.
4.6. Statistics
Outcome measures for between-group comparisons of patient characteristics (Age, body mass,
AST, ALT, GGT, V10, and V75) were reported as mean and standard deviation or median and
interquartile range, as appropriate. The Student t test or Mann–Whitney U test were used to compare
groups for normally or not normally distributed data, respectively. The Pearson correlation coefficient
or the Rho Spearman nonparametric correlation test were used. All tests are two-tailed, and a p-value
of <0.05 was considered as statistically significant.
Linear multiple regression analyses were performed to identify factors independently associated
with NAS and liver fibrosis. A further multiple logistic regression analysis was carried out to test the
independent factors associated with the V10/V75 ratio above the upper normal value (0.27) found in
healthy controls. The analyses were performed using SPSS software v.23 (IBM, Milan, Italy).
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Abstract: Porcine mammary fatty tissues represent an abundant source of natural biomaterial for
generation of breast-specific extracellular matrix (ECM). Here we report the extraction of total ECM
proteins from pig breast fatty tissues, the fabrication of hydrogel and porous scaffolds from the
extracted ECM proteins, the structural properties of the scaffolds (tissue matrix scaffold, TMS),
and the applications of the hydrogel in human mammary epithelial cell spatial cultures for cell
surface receptor expression, metabolomics characterization, acini formation, proliferation, migration
between different scaffolding compartments, and in vivo tumor formation. This model system
provides an additional option for studying human breast diseases such as breast cancer.
Keywords: porcine; breast cancer; extracellular matrix; hydrogel; tissue matrix scaffold; scaffold;
3D culture
1. Introduction
Hydrogel is a gel formed by networks of polymer chains, which have the ability to retain the
water and gelatinize easily through various cross-linking processes. It has a wide range of applications
ranging from biomedical research, tissue engineering, and clinical utilization to drug delivery [1–4].
Hydrogels are commonly classified into two major categories, synthetic and natural, based on the
origin and biochemical properties of the source materials used to produce the gel. Although synthetic
hydrogels have been used in research fields for decades owing to many advantages, including long
service life, high capacity of water absorption, high gel strength, easy availability, low cost, comparably
simple fabrication process, adjustable signaling inputs by integration of different extracellular matrix
(ECM) proteins or polypeptides, and experimental reproducibility [3], a growing trend of using
hydrogels derived from natural, especially tissue-specific native biomaterials in biomedical and
bioengineering applications has become increasingly robust recently [5].
Among native tissue-derived hydrogels, collagen and the laminin-rich ECM (lrECM or
Matrigel) [6,7] have been extensively used in various bioassays and experiments for phenotypic
and mechanistic studies of human diseases as well as for tissue engineering [8–11]. These studies have
contributed substantially to our understanding of cell biology on substrata that resemble those existing
in native environments, which are beyond the supporting capacity of plastic and synthetic polymeric
surfaces. The compositional differences of the substrata that cells live on are important for cell
adhesion, migration, and growth since different cell surface receptors are expressed in response to their
interacting proteins or particles within the matrices for extracellular and intracellular signaling and
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other biological functions. To this end, collagen and the compositionally under-defined mouse sarcoma
lrECM may induce cellular phenotypes different than those seen in cells grown on tissue-specific
matrices since the levels and types of collagen and other components within ECM of different organs
or tissues are quite distinct [12–14].
In an effort to promote tissue-specific scaffolding tools available to study breast cancers,
we recently reported a tissue matrix scaffold (TMS) system generated using mouse mammary fat
pad (MFP) ECM [15]. Both hydrogel and porous TMS were derived from the same ECM source and
used in spatial breast tumor modeling and drug testing, representing an ideal platform for consistent
studies from in vitro to in vivo without switching to different culturing matrices. In this current work,
we present the biochemical composition of the ECM of female porcine breast fatty tissues and introduce
the fabrication of hydrogel and porous scaffold using the purified ECM. Finally, select applications of
the scaffolds in breast cancer research are exhibited.
2. Results and Discussion
2.1. Extraction and Identification of Porcine Breast Tissue ECM Proteins
Proper handling of fresh tissues is critical for minimal degradation and maximal identification of
native proteins within the tissues. Homogenization of the fresh porcine breast fatty tissues directly
obtained from local slaughter house was conducted in a precooled homogenizer, with the container
holding the tissues embedded in ice and sliced tissues mixed with ice-cold water as described in
the materials and methods. The homogenized tissues were then decellularized with the non-ionic
detergent triton X-100 or the zwitterionic detergent CHAPSO to remove the cellular contents while
preserving the native and active states of the ECM proteins. Since porcine breast tissues contain
rich fat that is difficult to remove compared to that within the mammary tissues of mice and human,
we applied lipase in the detergent solution to maximize lipid removal and the decellularization
efficiency (Figure 1a). The detergents and lipase were removed with multiple rounds of washing with
ddH2O. The resulting ECM dry weight was about 2% of the total fresh tissues used for the extraction.
Whole ECM protein extraction from the ECM was carried out using a gradient of concentrations of
urea and thiourea solutions to solubilize proteins that could be dissolved under different urea solution
conditions due to their sizes and native conformational states. After dialysis and concentration of the
protein extract, the total protein amount within the extract was measured at about 90% of the ECM
used for the extraction.
The proteomic composition of the porcine ECM was identified using liquid chromatography
coupled with tandem mass spectrometry (LC-MS/MS). The majority of ECM proteins detected were
different types of collagen, representing about 70% of the major proteins listed (Figure 1b), with collagen
I and III being the most abundant (~77% based on single chain ratios) among the total collagen content.
While the sum of glycoproteins and proteoglycans accounted for about 5% of the ECM major proteins,
the content of myosin and tropomyosin was about 19%, with other ECM proteins comprising the
remaining 6%. Interestingly, when we compared these data with the proteomic profiles of mouse
normal MFP ECM that we reported previously [15], the ECM of rat mammary tissues [12] and the
ECM of human breast tissues adjacent (considered to be normal) to tumors [16], it appeared that
the ECM total collagen content of the human breast tissue ECM (about 80–85%) was in between of
that of the porcine breast ECM and the rodent mammary ECM (about 85–90%). Another intriguing
result was that higher myosin and tropomyosin content was detected in the porcine breast ECM
compared to that of the rodent mammary ECM (less than 0.5%) and of the human breast ECM (about
1%) [16]. The amounts of the overall glycoproteins and proteoglycans within the ECM of porcine,
rodent, and human were similar at about 5–7%. These ECM compositional differences of the porcine,
mouse, and human breast tissues could be due to the anatomical and physiological natures of the
native tissues that are related to the functions of the tissues in each specific species. It is noteworthy
that the reproductive cycle seems to play a role in mammary tissue ECM compositional changes [12,17].
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Additionally, the differences in the buffers and methods used to extract native ECM proteins clearly
have an impact on the types and amounts of proteins identified [12,15,16,18]. Future proteomic
analyses of mammary ECM compositions of the aforementioned and additional species using the same
extraction and analytical methods will potentially identify novel discrepancies upon cross comparing
the data sets obtained from the same experiments.
Figure 1. Extracellular matrix (ECM) protein extraction and identification from porcine breast fatty
tissues. (a) Outline of the major steps of the breast ECM protein extraction and downstream applications.
(b) The major ECM proteins of porcine breast fatty tissues.
2.2. Generation and Characterization of the Porcine Breast ECM Hydrogel Scaffold
To assess the impact of storage temperature of the ECM hydrogel on polymerization, the gels
(8 mg/mL) directly stored at 4, −20, −80 ◦C, and flash froze in liquid nitrogen followed by storing at
−80 ◦C were thawed on ice and dropped onto the bottom of a 100 mm tissue culture dish, which was
then placed in a 37 ◦C incubator for polymerization. After 30 min of incubation, the gels from the
different stocking conditions all gelatinized (Figure 2a). When the polymerized gels were submersed
in 1× PBS or DMEM, they retained their initial shapes and remained undissolved during the 10-day
testing period (Figure 2b). To maximize the preservation of the ECM proteins in their native forms
and avoid protein degradation, we used liquid nitrogen flash freezing followed by storing at −80 ◦C
as a standard approach for long-term stocking of the hydrogel solutions at different concentrations.
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Short-term storage on ice or at 4 ◦C for up to four weeks did not seem to affect the polymerization of
the hydrogel and its performance in experiments as described below.
Generation of porous TMS using the ECM hydrogel was achieved using a combination of a
gas foaming method [19] and a freeze-gelation approach [20] with modifications as described in the
methods. This technique not only induced gelation of the hydrogel but also allowed production of
interconnecting porous structures within the solidified gel. The sustainability of the fabricated porous
scaffolds under regular tissue culture conditions (37 ◦C, 5% CO2) was evaluated in 1× PBS or DMEM
for 7 days. Our results showed that the porous scaffolds were stable and retained their shape during
the period of testing (Figure 2c,d). Hematoxylin and eosin (H&E) staining of the cross sections of the
scaffolds showed inter-connective pores at the sizes of about 100–200 μm (Figure 2e, left panel), highly
resembling those of the decellularized porcine breast fatty tissue ECM (Figure 2e, right panel).
Figure 2. Physical and structurally properties of the porcine breast ECM hydrogel and porous TMS.
(a) The ice-cold ECM hydrogel stored under different conditions (hydrogels kept in −20 ◦C and −80 ◦C
were thawed in ice at 4 ◦C) dispensed on the clean and dry plate before polymerization tested and
subjected for polymerization at 37 ◦C for 30 min. (b) The polymerized hydrogel was immersed in
1× PBS or DMEM and placed in 37 ◦C incubator (5% CO2) for stability test. Scale bars, 4 mm for (a,b).
(c,d) The sustainability of the porous scaffolds generated from the ECM hydrogel was assessed by
submersing the scaffolds in PBS or DMEM and incubation at 37 ◦C (5% CO2) for 7 days. Scale Bars,
6 mm. (e) H&E staining of the cross sections of the porous scaffolds and decellularized porcine
breast fatty tissue ECM. Scale bars, 100 μm. (f) AFM measurement of the mechanical properties of
porcine native breast tissues, decellularized breast ECM, and porous TMS: (i) Young’s moduli of the
samples; (ii) and (iii) Illustrations of the positions of the probe tips on the decellularized ECM and
TMS samples, respectively.
In order to evaluate the mechanical resemblance of the reconstituted scaffolds to that of the matrix
of native tissues, we used AFM to measure native porcine breast tissues, decellularized porcine breast
ECM, and porous scaffolds generated using porcine breast ECM hydrogel. The AFM testing method on
the stiffness of biological tissue structures, cells, and specific regions of ECM is not standardized. Thus,
previous reports have shown different results depending on their individual testing conditions [21,22].
On a large scale, measurements of decellularized organ matrices with AFM have been reported [23,24].
On a fine scale, mechanical properties of breast cancer cells and their structures have been investigated
using AFM [25]. The probe tip size, indentation rate, and maximum force applied to samples should be
optimized based on the mechanical strength of the samples. Thus, we optimized our testing parameters
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specifically for the breast tissues as described in the methods. The positioning of the probe tip for
indention on the decellularized ECM and TMS has been illustrated in Figure 2f-ii,f-iii.
Our AFM results showed that the average Young’s modulus of the native porcine breast tissues
was 0.243 ± 0.027 kPa (Figure 2f–i), which corresponded to a similar range of the compliance of
human normal breast tissues [25,26] and is about 45–50% higher than that of mouse normal mammary
tissues [27,28]. The Young’s modulus of the decellularized porcine breast ECM was 0.366 ± 0.061 kPa
(Figure 2f–i), which is about 50% higher than that of the porcine breast native tissues and stiffer than
decellularized mouse normal mammary fatty tissues [28]. A similar trend of higher Young’s modulus
in decellularized tissues than in native tissues was observed in AFM measurement of human liver
samples [29]. Porous TMS generated using ECM hydrogel at the concentration of 40 mg/mL (data for
the concentrations of 20 mg/mL and 60 mg/mL were not shown) demonstrated an average Young’s
modulus of 0.411 ± 0.180 kPa (Figure 2f–i), which is close to that of the decellularized porcine breast
ECM. These data collectively indicate that the structural and mechanical properties of the reconstituted
porous TMS highly resemble those of the decellularized native ECM and are suitable for spatial tissue
cultures that closely mimic native breast tissue microenvironment.
2.3. ECM Support of Cell Surface Receptor Expression and Metabolomes in Spatial Culture
Our proteomics data showed that collagen I and III were the major protein components, whereas
the main basement membrane protein laminin only accounted for a minimal amount of the porcine
breast tissue ECM. Therefore, we carried out immunofluorescence (IF) staining of integrin β1 and β4
plasma membrane receptors for collagen I/III and laminin, respectively, in MM231 cells grown on the
breast ECM hydrogel-coated glass coverslips for 24 h. The expression of focal adhesion kinase (FAK)
on the surface of the cells was also immunostained to serve as an indicator of the adhesion sites of
the cells. Our confocal fluorescence microscopy results showed that high levels of integrin β1 and
low levels of integrin β4 were observed in the cells cultured on the hydrogel matrix (Figure 3a,b),
indicating that the cells attached to the matrix through integrin β1 and collagen I/III interactions.
To assess the capability of the porcine breast ECM hydrogel in capturing the metabolites secreted
from cells grown on it, 4% porcine breast ECM hydrogel was added into the wells of 96-well plates at
a thickness of 4 mm, followed by inserting porous TMS illustrated in Figure 2c (2-mm thick, 6-mm
diameter, 100-μm pore size) into the surface section of the gel before its polymerization in a 37 ◦C
incubator. A total of 1.0 × 104 MM231 cells per well were seeded on the top of the porous scaffold and
cultured in RPMI 1640 medium (Corning; 1×; 2 g/L of D-glucose; 10% FBS) under optimal conditions
(37 ◦C, 5% CO2) for 3 days. The hydrogel samples underneath the porous scaffolds were collected, cross
sectioned (Figure 3c, left panel) and processed for mass spectrometry (MS) analysis of the metabolites
collected within the gels as described in the methods.
Based on our MS spectral data, metabolite distribution patterns and relative abundance levels
were determined using the SCiLS Lab MS imaging analysis software, which also grouped compounds
(detected as ions with specific m/z values) into distinct ion distribution patterns across the scaffolds for
comparison. A total of 41 distinct chemical features (i.e., the mass over charge ratios detected in MS)
were selected based on their abundance distribution profiles and the positive scores (close to 1) resulted
from the receiver operating characteristic (ROC) curve analyses in the MM231 cell culture-laden
hydrogel samples compared to the medium-containing blank hydrogel samples. As illustrated by one
of the forty-one results, the compound with m/z 663.024 was absent from the blank scaffold (Figure 3c,
right panel, top) but showed high accumulation with a distinct pattern of being more abundant near
the edges of the ECM hydrogel scaffold than in the center. This compound had a ROC value of close
to 1 (highly positive; Figure 3d, top panel). The box plot for this compound (Figure 3d, bottom panel)
further demonstrated its preferential accumulation within the hydrogel samples of the MM231 cell
cultures. Similar results were found in all 41 ions (data not shown), i.e., higher specific chemical
abundances were detected in the hydrogel samples of the MM231 cell cultures with high ROC scores.
Four box plots for the ions with top ROC scores from the 41 individual groups were shown in Figure S1,
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which had m/z ratios at 663.024, 531.060, 839.043, and 768.371 with the ROC scores of 0.995, 0.996,
0.994 and 0.988, respectively. Together, these data demonstrate that the porcine breast ECM hydrogel
scaffolds support matrix-associated cell membrane receptor expression and secretion of metabolites
from the cells grown in the tissue-mimicking 3D space.
Figure 3. Membrane surface receptor expression and metabolomic analysis of cells grown on porcine
breast fatty tissue ECM hydrogel. Integrin β1 (a) or β4 (b) receptor (green) and FAK (red) expression in
MM231 cells cultured on the ECM hydrogel-coated coverslips were assessed by IF. Phalloidin staining
(white) of F-actin was used to contour the cells. Scale bars, 10 μm. (c) MS imaging of cross sections of
the medium-conditioned blank (upper panels) and MM231 cell culture-laden (bottom panels) hydrogel
scaffolds. (d) Examples of ROC (upper) and box-and-whiskers (bottom) plots from the MS imaging
analysis, showing data for a compound with m/z 663.024, where differences between the hydrogel
samples cultured with or without MM231 cells are clearly evident.
2.4. Applying Porcine Breast ECM Scaffold in Support of Spatial Cell Proliferation, Coculture of Cancer Cells
and Stromal Cells, and Tumor Formation
To evaluate the proliferation of mammary epithelial cells on porcine breast ECM hydrogel, normal
MCF10A or MM231 cells were seeded in 96-well plates coated with or without the porcine breast
ECM hydrogel, collagen, and Matrigel, and cultured under optimal conditions (37 ◦C; 5% CO2) for
7 days. Cell proliferation was measured using WST-1 reagent (Sigma-Aldrich, St. Louis, MO, USA)
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at different time points (Day 1, 3, 5, 7). Our results showed that both type of the cells proliferated
faster on Matrigel compared to those on collagen and ECM hydrogel (Figure 4a), possibly due to the
compositional nature of Matrigel, which contains growth factors and underdefined cellular components
derived from Engelbreth–Holm–Swarm (EHS) sarcoma sources [15,30]. In contrast, the growth of the
cells cultured on the porcine breast ECM hydrogel is even slower than those on collagen but at
comparable levels, suggesting certain degree of similarities of the two types of gels on supporting cell
population expansion.
Figure 4. Applications of porcine breast ECM hydrogel and porous scaffolds in proliferation, migration,
and tumor formation experiments. (a) Proliferation of MCF10A or MM231 cells on the porcine breast
ECM hydrogel. Error bars, mean ± SD. (b) MCF10A cell acini formation within the ECM hydrogel.
(c) Compartmental culture of MM231 cells and HUVECs to assess cross-compartmental migration
of different types of cells. (d) The vasculature of a whole mount cross section of breast tumors from
mice MFP implanted with MM231 cell-laden porous TMS derived from the porcine ECM hydrogel.
(e) H&E staining of the cross sections of mice breast tumors developed from the cancer cell-laden TMS.
Black arrows in d and e indicate blood vessels. Scale bars, 50 μm for (b); 1 mm—upper first panel (c) &
500 μm—lower three panels (c); 200 μm for (d,e).
The spatial growth and proliferation of mammary epithelial cells within the breast ECM hydrogel
were further assessed using an acini formation assay. Briefly, 1 × 104 MCF10A cells were mixed
into 200 μL of 2% porcine breast ECM hydrogel and cultured on 8-well chamber slide under optimal
conditions as described above for 7 days. Acini formation was assessed using light microscopy, and the
structures of the acini were characterized with phalloidin and DAPI IF staining followed by confocal
microscopy. Our results showed that MCF10A cells formed acini at different sizes, with larger ones
having hollow centers (Figure 4b). Compared to the traditional acini formation assay using Matrigel,
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the current method applies fewer matrix materials, simplified procedures, and shorter culture times.
Importantly, the purified porcine total ECM hydrogel contains neither growth factors nor tumor cell
products and has well-defined ECM proteins, lending promise for low background tissue cultures and
adjustable options for adding desired culturing components within culture medium.
In order to observe the spatial expansion of cancer cell population and recruitment of stromal
cells, we have devised a coculture system using the porcine breast ECM hydrogel and porous TMS
(Figure 2c,d) derived from the hydrogel. 1 × 104 GFP-MM231 cells were seeded on the porous
scaffold (round, 2 mm thick, 4 mm diameter) placed in a well of 96-well plates. A layer of the
ECM hydrogel (8 mg/mL) containing 1 × 104 RFP-HUVECs (human umbilical vein endothelial
cells) was covered on top of the porous scaffold (Figure 4c, top panels). After polymerization of
the gel, 100 μL of 1× DMEM containing 10% FBS was added into the well (replicate samples were
prepared). The two types of cells within the different yet mutually accessible compartments were
cultured for 14 days. The distribution and migration of the cells within the co-culture system were
imaged over time using confocal microscopy. Our data showed that both MM231 cells and HUVECs
progressively increased their numbers and migrated out of their initial living compartment into
adjacent areas (Figure 4, middle and bottom panels). The interaction of the two types of cells was
also increased, as exhibited by the yellow overlapping regions. Clearly, this compartmental culture
approach using hydrogel and porous scaffold derived from the same native tissue ECM allows for
the observation of certain cellular phenotypes, such as spatial cell migration and interaction, in an
advanced tissue-mimicking environment that could be difficult to be captured in live tissues or other
nontissue-specific culture models.
We next tested the efficiency of the porcine breast ECM scaffold in supporting tumor formation
in vivo. 1 × 105 MM231 cells were seeded on a spherical porous TMS (4 mm diameter) and cultured for
24 h under optimal conditions as described before. Triplicate samples were prepared for the experiment.
Then, the scaffolds were implanted separately into the mammary fat pad (MFP, 4th nipple region
from the rostral side) of eight-week-old nulliparous NOD/SCID female mice. Tumor development
was observed over a period of 4 weeks. The sizes of the tumors were dynamically measured using
a caliper and reached an average of about 2-cm diameter at the end of week 4 post-implantation,
at which point the tumors were collected, formalin fixed, cross-sectioned (10 μm thick), and H&E
stained for histological examination as we reported previously [15]. Our histological data showed that
visible blood vessels had been grown into the tumors in most of the regions of the outer half of the
tumor bodies (Figure 4d,e, arrows), which were filled with mixtures of cancer cells and stromal cells
clustered within or overlapped with ECM structures (Figure 4e). This data indicates that the porcine
breast ECM-based scaffold represents another tissue-specific platform, in addition to mice ECM-based
scaffolds [15], to support consistent formation of breast tumors in animals.
3. Materials and Methods
3.1. Tissue Collection and Decellularization
The fresh mammary tissues from female pigs were collected aseptically from a local slaughter
house, where the research purpose of using the designated tissues was informed. The animal use
protocol (#04965) has been approved (01/30/2017) by WSU Institutional Animal Care and Use
Committee (IACUC). The tissues on ice were immediately transferred to the lab, sliced into small
pieces, and homogenized in sterilized ice-cold deionized distilled water (ddH2O). After centrifugation
(10,000 RPM/17,000 RCF; 30 min) at 42 ◦C (Pig fat is relatively sticky and melts only above 37 ◦C) of
the homogenized tissues, the supernatant together with the fat were discarded. The centrifugation
process was repeated for a couple of rounds to maximally remove the fat until there was visible
oil droplets on the surface of the supernatant. The homogenized tissues were then mixed with a
sufficient amount (at least 10 times more than the homogenized tissue volume) of 0.1% Triton X-100
or 4% CHAPSO with constant agitation at room temperature for 12 h and centrifuged as described
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above. This decellularization process was repeated one more time. The pelleted ECM was transferred
into 50 mL conical tubes containing 0.1% Triton X-100, cOmplete mini protease inhibitor cocktail
(Sigma-Aldrich, St. Louis, MO, USA), and lipase (1 mg/g of ECM), and incubated at 37 ◦C with
constant rotation for 12 h, followed by several rounds of washing with ddH2O and centrifugation to
ensure complete removal of Triton X-100, protease inhibitors, and lipase from the samples. The ECM
was lyophilized and assessed for decellularization efficiency using the removal of DNA content (<50 ng
per milligram of dried ECM) and the maximal retention of collagen and glycosaminoglycan (GAG)
within the ECM as parameter references as described previously [15].
3.2. Extraction of Porcine Breast Tissue ECM Proteins
The lyophilized ECM was pulverized by grinding in liquid nitrogen, followed by treating the
ECM powder twice with 3.4 M NaCl buffer (99.25 g NaCl, 6.25 mL of 2 M Tris Base, 0.75 g EDTA,
and distilled water to 500 mL, final pH 7.4) at 4 ◦C for 15 min. The ECM was pelleted by centrifugation
and homogenized in 2 M urea buffer (60 g Urea, 3.025 g Tris Base, 4.5 g NaCl, distilled water to 500 mL,
pH 7.4) at 4 ◦C overnight. The sample was then centrifuged at 13,000 RPM/28,720 RCF for 30 min.
The supernatant was collected and kept on ice. Further homogenization of the remaining ECM was
followed using 4 M and 6 M urea buffer, respectively, and the supernatant from each extraction was
collected and stored as described above. The remaining insoluble ECM was treated with increasing
concentration of urea/thiourea (6 M/0.5 M; 6 M/2 M; 7 M/0.5 M; and 7 M/2 M) for 12 h at 4 ◦C,
and supernatant collected as before. The insoluble ECM sediment was further homogenized with 8 M
urea, and then with 2% of n-octyl β-D-glucopiranoside (OG) overnight at 4 ◦C. Again, the supernatant
was collected after centrifugation at 13,000 RPM/28,720 RCF for 30 min. The urea concentrations of the
different batches of the supernatants were brought to 2 M. Then the tissue ECM protein extracts were
pooled together and dialyzed in cold TBS (6.05 g Tris Base, 9.0 g NaCl, total volume of 1 L, pH 7.4,
with 5 mL of chloroform) for at least 2 h. Dialysis was repeated twice in cold TBS without chloroform
for 12 h. Further dialysis with serum free 1× DMEM medium is optional. The sterile ECM protein
solution was then concentrated using polyethylene glycol (PEG) and stored at −80 ◦C for future use.
3.3. Identification of the ECM Proteins and Data Analysis
Identification of the extracted ECM proteins was conducted as reported previously [15] . Briefly,
the ECM proteins were solubilized in 8 M urea solutions containing 1% ProteaseMAX (Promega),
subjected to Dithiothreitol (DTT) reduction, iodoacetamide (IAA) alkylation, trypsin digestion,
followed by LC-MS/MS. The raw data was converted to mgf files, which were used to search against
Sus Scrofa amino acid sequence database with decoy reverse entries and a list of common contaminants
(81,280 total entries with 40,602 pig proteins from UniProt database downloaded 11_28_2017) using
in-house Mascot search engine 2.2.07 (Matrix Science, Boston, MA, USA) with variable methionine
and proline oxidation, and with asparagine and glutamine deamidation. Peptide mass tolerance was
set at 15 ppm and fragment mass at 0.6 Da. Protein annotations, significance of identification and
spectral based quantification was performed with the help of Scaffold software (version 4.4.1, Proteome
Software Inc., Portland, OR, USA). Protein identifications were accepted if they could be established at
greater than 80.0% probability within 1% false discovery rate and contained at least two identified
peptides. Protein probabilities were assigned by the ProteinProphet algorithm [31].
3.4. Generation of Porous Scaffold Using the ECM Hydrogel
The porcine breast ECM hydrogel at the concentration of 40 mg/mL was mixed with sodium
bicarbonate (final concentration 1 mg/mL), filled in desired culture vessels (for example 96-well plates),
flash-frozen in liquid nitrogen, and stored in −80 ◦C overnight. The frozen hydrogel blocks were
then immersed into precooled (−80 ◦C) ethanol bath containing 0.1 M acetic acid until there was no
bubbles arising from the solidified gel (the processing time depends on the size of the frozen gel).
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The ethanol was replenished, and the scaffolds remained immersed for at least 24 h. Before cell culture,
the scaffolds were washed three times with 1× PBS or tissue culture medium.
3.5. Atomic Force Microscopy (AFM)
AFM (Dimension Icon ScanAsyst, Santa Barbara, CA, USA) was used to determine the Young’s
moduli of the samples. Three different types of samples were prepared for this study: porcine breast
native fatty tissues, decellularized ECM of porcine breast native fatty tissues, and porous TMSs
generated using hydrogel extracted from the decellularized ECM of porcine breast native fatty tissues
as described above. Samples were embedded in optimal cutting temperature (OCT) compound and
frozen in ethanol-dry ice bath, cross sectioned into 20 μm of thickness, mounted on silane-coated
slides, and rinsed with 1× PBS and ddH2O to remove OCT. The samples were kept at 4 ◦C until AFM
measurement. Before AFM, the samples were allowed to warm up to room temperature in a sealed
plastic bag to prevent drying. AFM measurement of the mechanical properties of the samples was
conducted through borosilicate spherical-shaped tips (Novascan, Boone, IA, USA) with a size of 5 μm
and 0.06 N/m spring constant [25]. The spring constant of cantilever was matched with the stiffness
of the porcine breast tissues or decellularized ECM samples to be tested. During AFM measurement,
the maximum force was set to 2 nN. The total indentation depth was 1 μm with an indentation rate of
20 μm/s. For the native tissue samples, data points were collected by every 10 μm along the x-axis.
For decellularized ECM and TMS, due to the porous structures of the samples, the data points were
collected by manually selecting areas of interest to avoid probing inside pores. At least 7 different
points were measured for each sample. The data was processed using Hertz’s model with Poisson’s
ratio of 0.5 to determine the Young’s moduli of the samples.
3.6. Cells and Tissue Cultures
Human breast cancer epithelial cells MDA-MB-231 (MM231) and normal breast epithelial cells
MCF10A were purchased from ATCC, and GFP-MM231 cells and RFP-HUVECs were from Cell Biolabs
and ANGIO-PROTEOMIE, respectively. The cells were cultured in optimal medium under 37 ◦C and
5% CO2 conditions as described previously [15,32].
3.7. Immunofluorescence Staining (IF)
IF staining of the cells cultured on coverslips coated with porcine breast tissue ECM hydrogel and
confocal microscopy were carried out as described previously [33]. Integrin β1 (#MAB17782), integrin
β4 (MAB4060), and FAK (#NBP1-84750) antibodies were purchased from Novus Biologicals (Littleton,
CO, USA). Alexa Fluor 663 Phalloidin probe was purchased from ThermoFisher Scientific (#A22284)
(Waltham, MA, USA).
3.8. Metabolome Analysis
The hydrogel samples collected from the tissue cultures were flash frozen, cross sectioned (10-μm
thick) and mounted onto the cold indium tin oxide (ITO)-coated microscope slides (Figure 3c, left panel).
Three experimental replicates were prepared, and three consecutive sections from an individual
replicate were collected. A matrix solution of 2,5-dihydroxybenzoic acid (DHBA, 20 mg/mL) dissolved
in water and methanol mixture (50:50 in volume) was applied to the tissue sections on the different
slides using a TM-Sprayer. The DHBA-coated slides were analyzed using a Bruker SolariX 9.4T
MALDI FTICR mass spectrometer (Bruker Daltonics, Billerica, MA, USA) to scan ions within a mass
range of 150–3000 Da. Imaging acquisition was carried out using FlexImaging (Bruker Daltonics).
The spectral analyses were performed using DataAnalysis (Bruker Daltonics) and SciLS Lab (SciLS,
Bremen, Germany).
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3.9. Cell Proliferation Assay
The growth and proliferation of the cells on TMS scaffolds were measured using WST-1 reagent
as described previously [19,32]. Briefly, 2% of porcine breast ECM hydrogel, 100 μL was dispensed
into each well of a 96-well culture plate and incubated at 37 ◦C for cross linking as described above,
forming TMS scaffolds. MCF10A or MDA-MB-231 suspended in the respective culture media were
seeded on the scaffolds (1 × 104 per scaffold) and allowed to attach for 45 min as we described in
our previous paper [19]. 100 μL of respective culture medium was then added and cultured under
the optimal conditions (37 ◦C, 5% CO2), replacing media in every alternate day. The proliferation of
the cells grown on the scaffolds was measured using WST-1 (Sigma-Aldrich) at the points indicated
(1st, 3rd, 5th and 7th day). WST-1 solution (10 μL) was added at a 1:10 dilution into the cultures and
incubated for 2 h. The supernatants of the cultures were collected and the colorimetric reactions that
reflect the proliferation status were measured using a Synergy 2 microplate reader (BioTek, Winooski,
VT, USA) for the absorbance at 490 nm. Error bars represent standard deviations (SD) of the means of
three independent experiments.
3.10. Data Availability
The MS proteomics and metabolomics data have been deposited to the ProteomeXchange
Consortium via the PRIDE partner repository with the data set identifier PXD011011 (proteomics) and
PXD010960 (metabolomics), respectively.
4. Conclusions
Porcine mammary ECM contains abundant collagen as well as other structural or compositional
proteins similar to those in mouse [15] and human breast ECM [16]. Additionally, the physical
structures of the decellularized mammary ECM of these different native tissue materials are also
close to each other. These physicochemical resemblances of the native ECM across the different
mammalian species potentially benefit our research involving the applications of the ECM in
phenotypic, mechanistic, or pharmacological response studies of human diseases relevant to the
ECM source organs or tissues. The tissue-specific native ECM-based studies will provide valuable and
clinically relevant insights into the development of human cancers and other diseases. We expect to see
a steady growth of using tissue-specific biomatrices to address disease-specific questions in the future.
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Abstract: Exploring the complicated development of tumors and metastases needs a deep
understanding of the physical and biological interactions between cancer cells and their surrounding
microenvironments. One of the major challenges is the ability to mimic the complex 3-D tissue
microenvironment that particularly influences cell proliferation, migration, invasion, and apoptosis in
relation to the extracellular matrix (ECM). Traditional cell culture is unable to create 3-D cell scaffolds
resembling tissue complexity and functions, and, in the past, many efforts were made to realize
the goal of obtaining cell clusters in hydrogels. However, the available methods still lack a precise
control of cell external microenvironments. Recently, the rapid development of microfabrication
techniques, such as 3-D printing, microfluidics, and photochemistry, has offered great advantages
in reconstructing 3-D controllable cancer cell microenvironments in vitro. Consequently, various
biofunctionalized hydrogels have become the ideal candidates to help the researchers acquire some
new insights into various diseases. Our review will discuss some important studies and the latest
progress regarding the above approaches for the production of 3-D ECM structures for cancer and
other diseases. Especially, we will focus on new discoveries regarding the impact of the ECM on
different aspects of cancer metastasis, e.g., collective invasion, enhanced intravasation by stress and
aligned collagen fibers, angiogenesis regulation, as well as on drug screening.
Keywords: microfabrication; extracellular matrix; cancer; metastasis
1. Introduction
The lethality of cancer lies in its ability to form metastases that accounts for about 90% of cancer
deaths according to the available statistics [1,2]. The phenomenon of cancer metastasis has been
investigated extensively in the last decade [3–5], and the neighboring microenvironment of cancer
cells, i.e., the extracellular matrix (ECM), has been found to significantly impact tumor and metastasis
development [6–10].
Cancer cells are not isolated, and their complicated cell–cell communications, development,
metastases, and functions are always closely connected with the ECM microenvironment [11–13],
e.g., tumor cells must break through the ECM, a critical step for cancer metastasis, to be able to
reach the lymphatic or vascular system [14]. Therefore, an in-depth understanding of the interactions
between cancer cells and ECM, from both physical and biological perspectives, is necessary to uncover
the mechanism of cancer metastasis. This may also help to find potential therapeutic strategies to
control malignant cancer. To achieve this goal, constructing a realistic in vitro cell culture system,
particularly involving cell proliferation, migration, invasion, and apoptosis in relation to the ECM,
becomes imperative.
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In fact, the structure of the ECM in vivo is a complicated system, especially around a neoplastic
tissue. The 3-D structure of the ECM in healthy, perilesional, and neoplastic tissues is different.
The ECM in a healthy area shows a homogeneous distribution of structure, proteins, and glycoproteins,
with collagen fibers intersecting to form a random network. Conversely, the ECM in perilesional
and neoplastic areas shows a heterogeneous distribution of the structure, with a dense matrix,
irregular shape, and asymmetric profile. The heterogeneous degree of glycoproteins distribution
and the parallel degree of collagen fibrils become more obvious closer to the neoplastic tissue [15,16].
In addition, the degree of stiffness of the ECM is an important parameter related to the occurring lesions.
The increased stiffness of perilesional areas may represent a new predictive marker of invasion [17].
Traditionally, cells have been cultured in Petri dishes that can only provide a two-dimensional
(2-D) extracellular environment: cells can only attach to the surface of the medium and cannot
form any 3-D scaffolds to mimic the real tissue complexity and functions [18–20]. Although some
important discoveries have been made by using 2-D cancer cell culture systems, they are still insufficient
for understanding the complex interactions between cancer cells and the ECM. Numerous studies
have indicated that cell morphology, signaling patterns, and cellular functions are different in 3-D
tissue microenvironments in vitro compared to 2-D Petri-dish systems [21,22], e.g., 2-D cell cultures
do not fully support the recovery of the cellular phenotypes found in tissues in vivo [23]; also,
when addressing drug toxicity effects, pharmacokinetic studies performed in 2-D polarized intestinal
cells showed distinct features compared to those from toxicology screening tests conducted in a
3-D system composed of interconnected channels and chambers representative of distinct tissue
types [24,25].
Realizing a 3-D tissue microenvironment similar to the one found in vivo, is one of the major
challenges, but also the key factor to bridge the gap. In the past, many efforts were made to mimic the
complex 3-D tissue microenvironment and particularly its influence on cell proliferation, migration,
invasion, and apoptosis in relation to the ECM, for example by embedding cell clusters in a low-density
Matrigel to form a lumina to mimic the in vivo epithelial layer [26], or by aggregating cells into 3-D
spheroidal structures on a low-adhesion surface of a 2-D culture system [27]. However, a precise
control of cell morphology (including size, density, and shape) is still lacking, and quantitatively
adjustments of the external microenvironment, such as the medium and nutrition gradient, cannot be
achieved [28].
In this review, we will discuss some commonly used, modern microfabrication techniques for the
effective reconstruction of 3-D cell culture microenvironments in vitro that mimic real tissue structures
or systems in vivo. On the basis of the available literature and the latest progress, we will elaborate on
how these specifically designed 3-D cells–ECM microenvironments in vitro are applicable to the study
of cancer, including metastasis, tumor angiogenesis, and drug screening, as well as of other diseases.
2. Microfabrication Techniques in the Effective Reconstruction of 3-D ECM Microenvironments
In Vitro
Recently, the rapid development of microfabrication techniques, such as 3-D printing [29–32],
microfluidics [33,34], photopolymerization, photochemistry, photoreaction [35–40], mold-based
Diskoid In Geometrically Micropatterned ECM (DIGME) [41,42], as well as the corresponding cell
culture approaches, have made it possible to precisely design and construct sophisticated controllable
tissue models in vitro that mimic the 3-D architectures and physiological conditions present
in vivo [28,43]. Consequently, various biofunctionalized hydrogels, such as collagen, fibronectin,
and Matrigel, have become ideal candidates [12,44–50]. Furthermore, combined with advanced
modern biomicroscopic tools, the direct and clear observation of cell morphology, motility, and other
behaviors has become much easier, thereby helping the researchers acquire new insights into various
diseases. Some commonly used methods and materials to engineer 3-D cancer or other disease models
and the strengths and limitations of each technique are summarized in Tables 1 and 2, respectively.
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Table 1. Methods and materials used to engineer 3-D cancer or other disease models.
Technique Method Material
3-D bioprinting
















FLDW (femtosecond laser direct writing) [38]
DMD-PP process(digital micromirror




Polyethylene glycol (PEG) [37]
Poly(ethylene glycol) diacrylate (PEGDA) [37]
Methacrylamide-modified gelatin or hydrogel [39]
Table 2. Strengths and limitations of each technique.
Technique Strength Limitation
3-D bioprinting Flexible
Unable to achieve accuracy at less than 50 μm (the highest accuracy is
inkjet printing in publishing).
The temperature is not easy to control precisely.
High cost.
microfluidics High precisionStable Structures are limited, e.g., multilayers, lumen.
photochemistry Curing fastHigh precision
Limited by optical characteristics.
Must be combined with other technologies, e.g., 3-D printing,
to achieve high accuracy and flexible structure.
2.1. Microfabrication Techniques Contribute to the Construction of Special Structures, Such as Interface,
Regions of Oriented Collagen Fibers, and Vascular Structures in the ECM
Metastasis usually involves the infiltration of cancer cells through aligned collagen fibers in the
ECM and their subsequent penetration through the basement membrane to reach the blood or lymph
vessels [14]. Moreover, characteristic changes in the orientation of the collagen fibers in the ECM are
usually accompanied by the initiation and progression of tumors and are labeled as tumor-associated
collagen signature. This collagen signature has served as an early diagnostic marker in various
pathological processes related to cancer [60]. To mimic such processes, such as the ECM infiltration and
collagen signature in in vitro cell culture systems, a successful reconstruction of the special structures
of the ECM becomes significantly important. Microfabrication techniques seem to be ideal tools to
realize this goal.
Zhu et al. [34] created a 3-D heterogeneous Matrigel structure, i.e., an ECM system with an
interface inside it, to simulate the nonhomogeneous ECM microenvironment in vivo by curing
two Matrigel sections of identical concentration at different times. Brin M. Gillette et al. [61] also
fabricated a stable collagen fiber-mediated interface by micropatterning and gelling 3-D ECMs of
flexible composition to mimic the nonhomogeneous and anisotropic properties of the native tissue.
Besides the realization of interfaces, microfabrication provides a new way to establish aligned
collagen fiber structures. Liu et al. [14] created a 3-D sandwiched ECM microenvironment in a
microfluidic chip with pillar-like inner structures by injecting collagen I in a fluid state into the
Matrigel. Collagen I showed a specific orientation, perpendicular to the heterogeneous interface,
induced by the internally developing strain during the solidification of the composite ECM, as shown
in Figure 1A. Such aligned collagen fibers might resemble the highly oriented collagen fiber bundles
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found in cancer patients. Alexandra et al. [62] also varied the alignment of individual fibers and their
network by using a microfabrication-based 3-D culture approach to investigate the dynamics of ECM
alignment around tissues of defined geometry.
Figure 1. Diverse microfabrication techniques to recreate 3-D ECM microenvironments in vitro.
(A) Microfluidics is used to build 3-D sandwiched ECM formed by collagen and Matrigel (i). An aligned
collagen fiber zone is established at the surface (ii) [14]; (B) A multiscale vascular system with collagen
as ECM is produced by using the 3-D bioprinting technology [63]; (C) Photochemistry is used to build
3-D patterned hydrogels as scaffolds with a range of different geometries (i). The size and shape of the
cells is controlled inside microniche chambers (ii). Scale bar: 100 μm [23]; (D) A glucose gradient is
established in the microfluidic chip, with collagen as the ECM. The system is used to study the trend of
collective invasion of cancer cells. The cartoon of device is shown in (i), and the corresponding 3-D view
is shown in (ii) [64]. All figures shown here are reproduced with permission from copyright owner.
Other complex structures, such as in vascular or multicomponent systems, can also be
reconstructed with modern microfabrication techniques. Lee et al. [63] developed a 3-D bioprinting
platform, as illustrated in Figure 1B, to construct large-scale fluidic vascular channels with an
adjacent capillary network within a 3-D hydrogel through a natural maturation process, as seen
for angiogenic endothelial cells sprouting from a large channel edge and branching out into the
collagen matrix. Their model can help to engineer desired 3-D vascular niches or thick vascularized
tissues. Yong Da Sie et al. [38] adopted multiphoton excitation photochemistry to fabricate a complex
3-D multicomponent microstructure by inserting human fibronectin at specific locations on the 3-D
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scaffold formed by bovine serum albumin (BSA). Their model can be used to test the role of single
factors in cell growth and metastasis.
2.2. Advanced Microfabrication Techniques Can Realize a Systematic and Quantitative Regulation of Cell
Geometry, Such as Density, Volume, Size, Shape, and Location, in a Complex 3-D ECM Setting for Long
Periods of Culture
Geometric cues are also considered to affect cellular functions, e.g., cell survival, self-renewal,
and differentiation, in 3-D ECM microenvironments [23,65]. A precise control of cellular geometry in
a complex 3-D scaffold, for long periods of culture, can be achieved effectively through the modern
microfabrication techniques.
Lee et al. [66] fabricated a 3-D spheroid culture-based system with transparent and cell-repulsive
polyacrylamide hydrogel, for testing nanoparticle toxicity. In their system, the sizes and shapes of the
cells were accurately controlled by constraining the cells inside the pores. In 2011, Cheri Y. Li et al. [67]
fabricated a 3-D cell-laden hydrogel microtissue with a photocurable hydrogel as the ECM. This system
could control the cell size as well as the cell type. They made the microtissues functional by
surface-encoding DNA. Through this system, they achieved multiple types of microtissues with
multiplexed patterns. Several years later, Bao et al. [23] provided a more robust method to encapsulate
single cells within 3-D matrix structures using the photopolymerization technique, for example in
hydrogel microniches, which allows both cell adhesion and nutritional permeability, as shown in
Figure 1C. These microniches were prism-shaped, with a controlled geometry of the bottom plane,
and had precisely defined volumes, which could constrain the cell size and geometry in a systematic
and quantitative manner. This device could also be easily combined with a confocal microscope to
acquire images rapidly.
2.3. Modern Microfabrication Techniques Can Help to Control Precisely the Concentration Gradient of the
Medium, with Respect to Growth Factosr, Nutrients, and Drugs, in the ECM
Metastasis is an energy-consuming process, and cancer cell invasion cannot be achieved without
a driving force, such as growth factors, nutrition, or drugs [66,68]. Microfabrication techniques can
help us to setup a concentration gradient inside the ECM to further investigate the complex metastasis
process in vitro.
Liu et al. [64] designed a 3-D mesoscopic ecology by drilling a hole into a glass slide and filling
it with 4.7 mg/ml collagen solution. A stable glucose gradient was established through the gel with
low-glucose medium at the top and high-glucose medium at the bottom of the device, as demonstrated
in Figure 1D. This device can help to test chemotaxis and trophotaxis of metastatic cells towards
glucose or growth factors in a 3-D homogeneous ECM microenvironment. Ashley A. Jaeger et al. [56]
also fabricated a 3-D bioreactor using Matrigel as the ECM. Their system could quantitatively control
the oxygen gradient mimicking the tumor microenvironment, and could potentially be applied to
study gas exchanges in cancer cell cultures.
Multiple concentration gradients can also be realized. Fan et al. [18] constructed a 3-D microfluidic
system with an array of hollow microchambers in collagen I for cell culture, by employing the
micromoulding and microfluidic techniques. This delicately designed microfluidic system could realize
up to four controlled biochemical and drug gradients, simultaneously, through four independent
microchannels encompassing the central collagen platform, and offered a robust platform for
high-throughput drug and biochemical screening studies.
In conclusion, on the basis of the advanced microfabrication techniques, e.g., 3-D printing,
microfluidics, and photochemistry, reconstructing a 3-D cells–ECM microenvironment in vitro,
which perfectly mimics tissue morphology and functions in vivo, becomes an attainable goal.
Especially, these techniques prove to be very useful in forming a special morphology, such as interface,
oriented collagen fiber region, and vascular structures, or in quantitatively regulating cellular geometry
and precisely controlling concentration gradients in the ECM.
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3. New Discoveries about Cancer and Other Diseases, Based on 3-D ECM Systems In Vitro
Because of the rapid development of advanced microfabrication techniques, numerous novel
discoveries, related to cancer and other diseases, have arisen in the last decade. In this section of
the review, we will discuss some important studies and latest progress in the field of cancer and
other diseases, based on 3-D in vitro cell–ECM microenvironments. We will especially focus on
cancer metastasis—new discoveries of the impact of the ECM, e.g., collective invasion, intravasation
enhancement by stress and aligned collagen fibers, angiogenesis regulation, as well as drug screening.
3.1. The Impact of Tumor Biotic Factors and Secretion on Normal Tissues and Cells via 3-D
ECM Microenvironments
Cancer cells are reported to be able to affect normal tissues and cells by secreting biotic factors,
which are transferred through the neighboring ECM. Therefore, a comprehensive understanding of
the complicated interactions between cancer cells and normal tissues via a 3-D ECM would be of great
benefit for a better control of malignant cancers.
Eliza Li Shan Fong et al. [69] established a 3-D Ewing sarcoma model using an electrospinning
apparatus ex vivo. They found that Ewing sarcoma cells cultured in porous 3-D electrospun
poly(ε-caprolactone) exhibited remarkable differences in the expression pattern of the insulin-like
growth factor-1 receptor/mammalian target of rapamycin pathway, and they were more resistant to
traditional cytotoxic drugs compared to the cells grown in a 2-D monolayer culture system. Jia et al. [29]
fabricated a 3-D ECM-like substrate with arbitrary micropatterns by combining inkjet printing and
electrospinning. They found a close spatiotemporal interaction between breast cancer cells and stromal
cells through transforming growth factor (TGF)-β1, which is secreted by breast cancer cells and can
induce spatial differentiation of fibroblasts, as shown in Figure 2A1,A2.
Figure 2. Cont.
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Figure 2. New discoveries about cancer and other diseases based on 3-D ECM systems in vitro.
(A1) Spatiotemporal interactions between breast cancer cells and stromal cells are studied in a coculture
system established by 3-D bioprinting technology. Cancer cells could recruit the stromal cells by
differentiating into α-SMA positive cells, dashed line circle indicates the colony formed by cancer
cells. (A2) Cancer cells (MCF-7) and stromal cells are co-cultured with high seeding density on the
polycaprolactone nanofiber matrices. (i-iii) show the fluorescence images after co-cultured for 1 week to
3 weeks. The control seeding, without cancer cells, shows that only a small part of stromal cells became
α-SMA-positive cells (iv) Scale bar: 100 μm [29]; (B) Using a 3D ECM of collagen, a glucose gradient
is established for studying the collective invasion of cancer cells. Scale bar: 150 μm [64]; (C) A 3-D
funnel-like Matrigel interface is created inside the ECM microenvironment. Through the complex and
heterogeneous 3-D ECM microenvironment, ECM heterogeneity is proved to be an essential element in
controlling collective cell invasive behaviors, red dashed circle indicates the network and connection of
invading cells with other invading branches, and black arrow shows the cell plane. [34]; (D) A complex
concentration gradient of specific biological molecules is built in a 3-D microfluidic system including
microchamber arrays. Matrix Metalloproteinases (MMPs) produced by cancer cells are proven to
play a dominant role in determining cellular behavior through the control of E-cad expression [18];
(E) Using a system made by bioprinting, cancer cells are shown to regulate angiogenesis through
secretion. Cancer cells and endothelial cells are seeded far from each other (E1). Endothelial cells are
found to sprout toward the cancer clusters. (E2) The fluorescence images of coculture of cancer cells
and endothelial cells (i), and the control group of endothelial cells only (ii). Scale bar: 100 μm [29].
All figures shown here are reproduced with permission from copyright owner.
3.2. The Collective Invasion of Cancer Cells into a Homogeneous ECM System Driven by Medium, Nutrients,
and Growth Factor Gradients
During metastasis in vivo, cancer cells are commonly found to migrate to distant locations
collectively. Extensive investigations have indicated that the intercellular and cell–ECM interactions
have significant impacts on this collective invasion behavior.
Liu et al. [64] constructed a 3-D mesoscopic ecology to investigate the process of invasion of
metastatic cells into an elastic medium in the presence of a glucose gradient. They showed that human
breast cancer cells seeded on the top surface of the gel with low-glucose medium could invade into the
3-D collagen matrix cooperatively from the top to the bottom, where the glucose medium concentration
was high. This collective invasion of cancer cells was found to be similar to that seen in the case of
exchanging leaders in the invading front, as shown in Figure 2B. John Casey et al. [40] fabricated 3-D
microwell arrays of defined geometry and dimension using photoreactive hydrogels to study cell
migration out from cell aggregates over time. They concluded that spheroids within PEG 20 kDa
microwells had the narrowest diameters as the cells tended to condense and cluster together.
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Brendon M. Baker et al. [57] used the sacrificial channel template approach to fabricate another
ECM structure, composed of collagen gel, which contained microfluidically ported microchannels.
A stable diffusion gradient of soluble angiogenic growth factors dependent on the structure of the
microfluidic network, was established. They showed that human umbilical vein endothelial cell
(HUVEC) invasion and angiogenic sprouting occurred at the locations with the strongest gradients.
3.3. Intravasation of Cancer Cells into a Heterogeneous ECM Structure with the Help of Gradients, Stress, or
Aligned Collagen Fibers
The intravasation of cancer cells into the lymphatic or vascular systems involves the key
process of the cancer cells breaking through the basement membrane to get into the vessels.
With modern technology, the important and puzzling question concerning tumor metastasis, i.e.,
how the heterogeneous ECM structures, such as aligned collagen or interface, influence cell infiltration
and the subsequent break into the basement membrane during metastasis, is slowly getting answered.
In 2012, Ioannis K. Zervantonakis et al. [70] designed and constructed a 3-D tumor–endothelial
intravasation microfluidic-based assay by interconnecting two independently addressable microchannels
via a 3-D ECM hydrogel. Tumor and endothelial cells were seeded, respectively, in these two channels
to mimic tumor cell invasion through 3-D ECM, in response to externally applied growth factor,
such as epidermal growth factor (EGF), or biochemical gradients. Their experiments, aimed at
addressing how tumor cells interact with normal epithelial cells, showed that breast carcinoma cells
could invade through a HUVEC monolayer in the presence of macrophages, and the endothelial
barrier impairment was associated with a higher number and faster dynamics of tumor–endothelial
interactions. Several years later, Zhu et al. [34] used their system of 3-D heterogeneous ECM
microenvironment in vitro to mimic the environment in vivo. Breast cancer cells were found to
exhibit strikingly different invasive behaviors in homogenous and heterogeneous Matrigel with
interior interfaces. As shown in Figure 2C, the interface in a heterogeneous ECM microenvironment
guided cell invasion at an early stage, and the cells showed strong collective finger-like invasive
behaviors. Liu et al. [14] used their 3-D ECM structure, as introduced in Section 2.1, to study cancer
cell infiltration. They showed that the aligned collagen fibers were able to significantly enhance
tumor metastatic potential, since metastatic breast cancer cells could accelerate their infiltration into
rigid Matrigel by following the alignment direction. Epithelial–mesenchymal transition (EMT) is also
a prominent signal of deterioration of tumors. Once a cancer cell undergoes a phenotypic change
through EMT, it will obtain greater migratory and invasive ability, directing cells to penetrate into the
vessels [71]. Sharmistha Saha et al. [72] combined the technology of electrospun and microfabrication
to create fibrous scaffolds with random or aligned fiber orientation mimicking the complex ECM
microenvironment in tumors. They found that the aligned fiber scaffold can guide EMT in cancer cells
accompanied by the upregulation of TGF β-1.
3.4. Biophysical and Mechanical Properties of the ECM, such as Geometry, Density, Stiffness, Contractility,
and Crosslinking of Collagen Fibers, Influence Tumor Angiogenesis Both Directly and Indirectly
Recently, ECM stiffness has progressively become a significant mechanical cue that precedes
disease and drives its pathological progression by altering cellular behavior or influencing tumor
angiogenesis [73]. Abnormal vessel growth and function are usually the hallmarks of cancer
or inflammatory diseases and contribute to disease progression [74]. Tumor cells and tissues
need to establish a blood supply, primarily through angiogenesis, from a pre-existing vascular
network, to satisfy their increasing demand for nutrients and oxygen to perform metabolic
functions, similar to the normal tissues [74,75]. Angiogenic programming of tumor tissues is a
multidimensional process, regulated by cancer cells, stromal cells, their bioactive products, as well as
ECM microenvironments [76].A few years ago, Mason et al. [77] took advantage of the tunable
mechanical properties of collagen-based scaffolds to investigate the effects of matrix stiffness on 3-D
microenvironments. They observed a significant increase in cellular spreading and extension with
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increasing matrix stiffness, and these effects lasted throughout the entire course of the cell culture
period. Recently, Jia et al. [29] showed cancer-regulated angiogenesis by factors secreted from the
cancer cells, which guided the sprouting of endothelial cells toward cancer clusters, by using their 3-D
ECM structure with arbitrary micropatterns, as shown in Figure 2E1,E2.
3.5. 3-D Microenvironments for Drug Screening
Conventionally, pharmacokinetic studies are performed in rodents or in 2-D polarized intestinal
cells before clinical administration, nevertheless, several compounds have still proven toxic to humans,
despite such testing [9]. Advanced microfabrication techniques have proven their suitability in creating
3-D cell–ECM microenvironments in vitro that can be perfectly used for screening drugs.
Lee et al. [66] showed that the toxicity of CdTe and Au was significantly reduced in their system
with a 3-D microenvironment, compared to that in 2-D cultures. In 2017, Fan et al. [18] used their
complex gradient microfluidic system, which allowed incorporating multiple chemical, temporal,
and spatial gradients within a 3-D micropatterned collagen scaffold in vitro, to test the role of matrix
metalloproteinases (MMPs) in inhibiting cancer cells aggregation. As shown in Figure 2D, MMPs
inhibitors were found to depress the abilities of the cancer cells to disrupt the structure of the
surrounding lumen-like cell clusters; the down regulation of E-cad expression, due to the MMPs
produced by invasive breast cancer cells, played a dominant role in determining the cellular behavior.
3.6. Other Diseases (Wound Healing, Clonal Acinar Development, Differentiation of Embryoid Bodies,
Neurodevelopmental Processes, Cartilage Defects) Related to 3-D Cells–ECM Microenvironments
Besides cancer metastasis, 3-D cell–ECM microenvironments fabricated by modern microfabrication
techniques can also be applied in the study of many other diseases or biomedical processes, including,
but not limited to, wound healing, clonal acinar development, differentiation of embryoid bodies,
neurodevelopmental processes, and so on.
The idea of the 3-D bioprinting of skin cells was considered adequate for transitioning the
technology to clinical settings. For example, Skardal, A. et al. [78] used the bioprinting technology
to deposit two layers of a fibrin–collagen gel containing endothelial cells to treat full-thickness skin
wounds in mice.
In 2015, Dolega et al. [79] constructed a 3-D cell culture system based on a flow-focusing
microfluidic chip that encapsulates cells in Matrigel microbeads. Each individual microbead acts
as a single-cell culture compartment, generating one acinus per bead, on an average. They used this
3-D cell culture system to investigate acinar development, by tracing the microbead under temporally
and spatially controlled conditions. They found that acinar development proceeds through clonal
growth from single cells, which are self-sufficient to differentiate in a Matrigel environment.
In studying the differentiation of embryoid bodies, Fung et al. [80] presented a 3-D microfluidic
platform, using biocompatible materials, based on a Y-channel device with two inlets for two different
culturing media, to study the differentiation of embryoid bodies by in vitro aggregation of embryonic
stem cells. They found that the differentiation of the same embryonic stem cells into different
specialized cell lineages can be achieved by applying the microfluidic technology.
In the treatment of cartilage defects, the differentiation of stem cells into chondrocytes is an
important cue [81]. Many physical and mechanical characteristics of the ECM, such as hypoxia, stiffness,
topography, and pore size, are closely related to the interdifferentiation process of chondrocytes and
stem cells [82]. Kuan-Han Wu et al. [81] used gelatin as ECM in a microfabrication process to create a
scaffold with different sizes of microbubbles and pores. They found that the size of microbubbles and
pores can impact chondrogenesis, and a larger pore size is required for inducing mature chondrogenesis.
Xiaobin Huang et al. [83] chose pH-degradable Poly(vinyl alcohol) (PVA) hydrogel as an ECM scaffold
to study the effects of oxygen tension on chondrogenesis. They found that the degree of hypoxia affects
the expression of many cytokines (e.g., MMP13, ALPL, COL10A1, ELISA), which has a further influence
on chondrogenesis. For example, hypoxia in 2.5% O2 would promote cartilage matrix production.
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Recently, Lancaster et al. [84] developed a 3-D cerebral organoid culture system for deriving brain
tissues to study human neurodevelopmental processes in vitro. This method recapitulated not only
the fundamental mechanisms of mammalian neurodevelopment, but also displayed a wide range of
characteristics of human brain development.
4. Conclusions
The significant progress of microfabrication in the last decade has advanced our understanding
of cancer and other diseases. In this review, we have discussed some important findings and latest
developments of the above approaches with respect to cancer and other diseases in 3-D ECM scaffolds.
We stress that these 3-D ECM microenvironments are closely related to the process of cancer metastasis
that presents multiple aspects, such as collective invasion and intravasation, tumor angiogenesis
regulation, as well as drug screening.
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BSA Bovine serum albumin
TGF Transforming growth factor
HUVEC Human umbilical vein endothelial cells
MMPs Matrix metalloproteinases
EGF Epidermal growth factor
DIGME Diskoid In Geometrically Micropatterned ECM
EMT Epithelial-mesenchymal transition
PEG Polyethylene glycol
PEGDA Poly(ethylene glycol) diacrylate
DMD-PP Digital micromirror device-based projection printing
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Abstract: Historically, increased numbers of mast cells have been associated with fibrosis in numerous
cardiac pathologies, implicating mast cells in the development of cardiac fibrosis. Subsequently,
several approaches have been utilised to demonstrate a causal role for mast cells in animal models of
cardiac fibrosis including mast cell stabilising compounds, rodents deficient in mast cells, and
inhibition of the actions of mast cell-specific proteases such as chymase and tryptase. Whilst
most evidence supports a pro-fibrotic role for mast cells, there is evidence that in some settings
these cells can oppose fibrosis. A major gap in our current understanding of cardiac mast cell
function is identification of the stimuli that activate these cells causing them to promote a pro-fibrotic
environment. This review will present the evidence linking mast cells to cardiac fibrosis, as well as
discuss the major questions that remain in understanding how mast cells contribute to cardiac fibrosis.
Keywords: heart; protease; tryptase; chymase; TNF-α; collagen; extracellular matrix; histamine
1. Introduction
Mast cells (MCs) are non-circulating immune cells that develop only once bone marrow-derived
precursors have reached their target tissue. These tissue MCs then go through several stages of
maturation driven primarily by the c-kit ligand, stem cell factor, with the final MC phenotype being
highly dependent on the microenvironment in which they reside. There is now a substantial amount
of evidence supporting a role for MCs in cardiac remodeling and heart failure [1]. In fact, MC
numbers increase in the heart both in humans and in experimental animals in a wide variety of
cardiac pathologies including myocardial infarction (MI) [2–4], hypertension [5–7], transplantation [8],
myocarditis [9], volume overload [10,11], and in the failing heart [12]. Many of the effects of cardiac
MCs involve regulation of the extracellular matrix (ECM), whether it be inducing ECM degradation or
promoting increased ECM synthesis. The latter characterises cardiac fibrosis, which is a characteristic
of almost all cardiac pathologies and is the focus of this review article. Cardiac MCs can influence
fibrosis by direct effects on fibroblasts, as well as indirect effects, both brought about by the many
proteases, cytokines, growth factors, and other products manufactured by these multi-faceted cells.
This review article will discuss the evidence supporting a role for MCs in cardiac fibrosis by presenting
studies that have utilised MC stabilizing compounds, rodents deficient in MCs, and specific inhibitors
of MC proteases. This review will also discuss important unanswered questions in the field, including
the elusive mediators that activate cardiac MCs causing them to promote fibrosis.
2. Studies Associating Mast Cells with Cardiac Fibrosis
MCs were first linked to cardiac fibrosis more than 50 years ago with the observation that these
cells were increased in human hearts with endocardial fibrosis [13]. Since then, there have been
numerous other observations that have associated MCs with cardiac fibrosis arising from multiple
etiologies. In 1988, increased MCs were found to be associated with areas of fibrosis in biopsies
obtained from 92 human diseased hearts by Turlington et al. [14]. In 1989, Olivetti et al. [6] observed
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an increased number of MCs in the right ventricle (RV) of rats following constriction of the pulmonary
artery, a technique that results in RV fibrosis. Subsequently, Li et al. [8] reported that MCs were
increased in human hearts following transplantation and that MC number correlated with fibrosis
(r = 0.63). Strengthening this relationship was the observation that patients with high numbers of MCs
at two weeks post-transplantation showed a 17% increase in fibrosis by week 3, whilst those patients
with lesser numbers of MCs had only a 3.5% increase in fibrosis. Perhaps not surprisingly, patients in
the high MC group also scored higher on the rejection scale.
Levels of the MC-specific amine, histamine, were reported to be elevated in experimental Chagas’
disease induced by infection of mice with Trypanosoma cruzi virus [15], with MCs in these mice
appearing in areas of fibrosis [16]. Further, MC degranulation occurs soon after infection of mice
with experimental myocarditis induced by coxsackievirus [17]. MC density also increases [18] in
myocarditis and very strongly correlates with collagen volume fraction (r = 0.946) [19].
MCs were also linked to fibrosis in the hypertensive left ventricle (LV) when Panizo et al. [5]
observed an increase in MC density in the LV of spontaneously hypertensive rats (SHR) that strongly
correlated with collagen volume fraction (r = 0.87). Shiota et al. [7] also reported increased MC densities
across the lifespan of the SHR. Even in stenotic aortic valves, MCs contained increased cathepsin G,
which correlated with expression levels of collagen I and III [20]. More recently, Luitel et al. [21]
confirmed in mice the earlier findings of Olivetti [6] in rats that MC density and degranulation increase
in the RV following constriction of the pulmonary artery. Whilst these studies clearly show a strong
association between MCs and fibrosis in the heart from varying etiologies, these associations do not
establish causality. These studies are summarized in Table 1.
Table 1. Summary of in vivo studies associating mast cells (MCs) with cardiac fibrosis.
Species Model/Pathology Outcome Heart Chamber References
Human Fibrosis ↑ MC LV [13,14]
Rat Pulmonary hypertension ↑ MC RV [6]
Human Transplantation MC number correlated with fibrosis LV [8]
Mouse Myocarditis ↑ histamine, ↑ MC correlated with fibrosis LV [15,19]
Rat Hypertension ↑ MC correlated with fibrosis LV [5]
Mouse Pulmonary hypertension ↑ MC RV [21]
LV = Left ventricle, RV = Right ventricle.
3. Evidence for the Causal Involvement of Mast Cells in Cardiac Fibrosis
3.1. Studies with Mast Cell Stabilizers
MC stabilizers prevent the release of MC mediators (e.g., histamine). This stabilization may
ultimately involve blocking calcium channels, without which MC granules cannot fuse to the cell
membrane and be exuded. Several studies have used this approach to examine the role of MCs in
cardiac fibrosis. Palaniyandi et al. [19] demonstrated that the MC stabilizer disodium cromoglycate
(also known as cromolyn) could dramatically reduce fibrosis in a model of myocarditis, whereby
rats were injected with porcine cardiac myosin emulsified with complete freund’s adjuvant with
Mycobacterium tuberculosis H37RA. A subsequent study confirmed the anti-fibrotic effect of cromolyn in
myocarditis in rats [22]. We provided the first causal evidence that MCs play a role in cardiac fibrosis
in the hypertensive heart [23]. SHR were treated with the MC stabilizing compound nedocromil
(30 mg/kg/day) from 8 weeks of age (prior to the development of fibrosis) through to 24 weeks of age.
This resulted in complete prevention of fibrosis in the LV, as determined by collagen volume fraction
(Figure 1A). This included the observation that MC stabilization prevented macrophage recruitment
and normalized cytokine profiles (IFN-γ, IL-4, IL-6 and IL-10). Interestingly, we found that IL-10
was dramatically decreased in untreated SHR, and was returned to normal after MC inhibition. In a
previous study, Palaniyandi et al. [24] had demonstrated that IL-10 inhibited acute myocarditis-induced
pathological changes in the heart, and that this likely involved the inhibition of MCs since histamine
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levels and MC density were reduced by IL-10. Thus, IL-10 may represent an endogenous MC inhibitor,
with a loss of IL-10 leaving MCs susceptible to activation stimuli. Confirming the pro-fibrotic role
of MCs in the pressure overloaded heart, Kanellakis et al. [25] showed that cromolyn prevented
LV fibrosis in mice with transaortic constriction. Similarly in the atria, the MC stabilizer, cromolyn,
prevented fibrosis following transaortic constriction-induced pressure overload on the heart [26]. Even
in STZ-induced diabetic hearts, nedocromil was able to reduce cardiac fibrosis [27]. More recently,
Li et al. [28] found that nedocromil (30 mg/kg/day) prevented fibrosis from developing in rats
following five weeks of transaortic constriction. Thus, the MC stabilzer studies strongly argue for a
role for MCs in cardiac fibrosis. However, one must be aware of possible off target effects of these
compounds, such as inhibition of sensory nerves. These studies are summarized in Table 2.
 
Figure 1. MC stabilization with nedocromil, or MC deficiency prevents cardiac fibrosis.
(A) Quantification and representative picrosirius red-stained images (20× magnification) for left
ventricle (LV) collagen volume fraction for Wistar Kyoto rats (WKY), spontaneously hypertensive rats
(SHR), and SHR treated with the MC stabilizer, nedocromil (Ned, 30 mg/kg/day), * = p < 0.05 vs
WKY, † = p < 0.05 vs SHR; (B) representative images of picrosirius red stained LV collagen in control
mice (LM/c-kit+/−), TNF-α overexpressing mice (MHCsTNF/c-kit+/−), and TNF-α overexpressing
mice crossed with MC-deficient mice (MHCsTNF/c-kit−/−); (C) quantification of collagen volume
fraction in control LM//c-kit+/− mice, MHCsTNF/c-kit+/− mice, and MHCsTNF/c-kit−/− mice; and
(D) LV pressure-volume relationship for control LM//c-kit+/− mice, MHCsTNF/c-kit+/− mice, and
MHCsTNF/c-kit−/− mice. * = p < 0.05 vs LM/c-kit+/−, † = p < 0.05 vs MHCsTNF/c-kit+/−. (Copied
with permission from Levick et al., Hypertension, 2009;53:1041–1047 (A); and Zhang et al., Circulation,
2011;124:2106–2116 (B–D)).
Table 2. In vivo studies establishing cause and effect between MCs and cardiac fibrosis.
Species Intervention Pathology Outcome Heart Chamber Reference
MC Stabilizers
Rat Cromolyn Myocarditis ↓ fibrosis LV [19,22]
Rat Nedocromil Hypertension ↓ fibrosis LV [23]
Mouse Cromolyn Transaortic constriction ↓ fibrosis LV [25]
Mouse Cromolyn Transaortic constriction ↓ fibrosis Atria [26]
Mouse Nedocromil STZ-induced diabetes ↓ fibrosis LV [27]
Rat Nedocromil Transaortic constriction ↓ fibrosis LV [28]
MC-deficient Rodents
Mouse KitW/Wv Abdominal aortic banding ↓ perivascular fibrosis LV [29]
Mouse KitW/Wv Transaortic constriction ↓ fibrosis Atria [26]
Mouse KitW/W-sh TNF-α overexpression
↓ fibrosis, ↓ diastolic
dysfunction LV [30]
Rat Ws/Ws Hyperhomocysteinemia ↑ fibrosis LV [31]
Rat Ws/Ws Radiation ↑ fibrosis LV [32]
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Table 2. Cont.





↓ collagen I and III
mRNA, ↓ fibrosis LV [33]
Rat Chymase inhibitor(NK3201) Myocardial infarction
↓ collagen I and III
mRNA, ↓ fibrosis, ↓ E/A LV [34]
Mouse Chymase inhibitor(NK3201) Intermittent hypoxia ↓ perivascular fibrosis LV [35]
Rat PAR-2 antagonist(FSLLRY, tryptase) Hypertension ↓ fibrosis LV [36]
Mouse H2R−/− Transaortic constriction ↓ fibrosis, ↑ systolicfunction LV [37]
LV = Left ventricle, RV = Right ventricle, PAR-2 = Protease activated receptor-24. MC products.
3.2. Studies with Mast Cell-Deficient Rodents
3.2.1. Types of Mast Cell-Deficient Rodents
There are several mutant mice that have been utilized as models of MC-deficiency to study MC
function in vivo including KitW/W-v and KitW/W-sh mice [38–41]. These mouse strains carry spontaneous
loss of function mutations at both alleles of the dominant white spotting locus (W, i.e., c-kit). This
mutation exhibits a significant reduction in c-kit tyrosine kinase-dependent signalling, hence disrupting
normal MC development and survival [39,42]. The different mutant alleles of c-kit reflect the variable
non-MC-related effects that these mice display. The mutated W allele gives rise to truncated c-kit
without the transmembrane domain, resulting in no protein expression on the cell surface [43].
Alternatively, the Wv mouse has a point mutation at the tyrosine kinase-encoding domain of c-kit.
Unlike the W mouse, KitW/W-v mice still express the c-kit protein on the cell surface, although with
reduced tyrosine kinase activity [43,44]. KitW/W-v mice have no detectable MCs in multiple organs by
the time they reach 6 to 8 weeks of age [39]. However, due to malfunction of the c-kit protein, these mice
display phenotypic abnormalities such as macrocytic anaemia, infertility, impaired melanogenesis,
lack of intestinal cells of Cajal, spontaneous dermatitis, gastric ulcers and duodenum dilatation [45–53].
This strain has traditionally been the most popular strain used to study MC-deficiency.
The W-sash (KitW/W-sh) mutation is an inversion mutation in the transcriptional regulatory
elements, upstream of the c-kit transcription start site of mouse chromosome 5, resulting in functionally
impaired c-kit protein [54]. This mutation was first described 23 years ago from crossing two inbred
strain mice (C3H/HEH × 101/H), although it is only fairly recently that this strain has gained
popularity as a model of MC-deficiency in vivo [40,55]. Adult KitW/W-sh mice are MC-deficient
at multiple anatomical sites [56], however, unlike the KitW/W-v mouse, they are fertile and not
anaemic [40,57]. They also exhibit normal levels of myeloid cells, B cells, T cells, dendritic
cells, and basophils [58]. Importantly, like the KitW/W-v mouse, KitW/W-sh mice can be successfully
reconstituted with bone marrow derived mast cells with normal c-kit expression by adoptive transfer
via intraperitoneal, intradermal or intravenous injection [55,56,58]. A comprehensive study by
Grimbaldeston et al. [58] details the advantageous of KitW/W-sh mice over KitW/W-v mice.
Another mutant mouse that can be used to study MC biology is the steel-Dickie (Sld) mouse.
This mutation occurs due to a 4.0 kilobase intragenic deletion and truncates the Sl coding sequence.
Mast cell growth factor (MGF) is encoded by the Sl gene, hence this mutation results in soluble
truncated growth factor that lacks both transmembrane and cytosplasmic domains [59]. Sld mice carry
a homozygous mutation in the Sl gene as a complete deletion of Sl alleles, resulting in the complete
absence of MGF and is lethal [60–62]. Phenotypically, Sld mice exhibit melanocytes defects, severe
anaemia and sterility [63].
There is also a MC-deficient rat. The Ws/Ws rat has a 12-base deletion in the tyrosine kinase domain
of c-kit, the receptor for stem cell factor. The Ws/Ws phenotype is otherwise normal except for white
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spotting of the skin and macrocytic anemia that is spontaneously ameliorated by 10 weeks of age [41].
Therefore, these rats do not exhibit the severe anemia seen in some MC-deficient mouse strains.
3.2.2. Pro-Fibrotic Role for Mast Cells
Hara et al. [29] were the first to use MC-deficient mice to evaluate cardiac fibrosis in any form.
They used male KitW/Wv mice exposed to abdominal aortic banding for 15 weeks and found that whilst
perivascular fibrosis occurred in WT mice with banding, collagen levels were normal in KitW/Wv mice.
To definitively confirm the role of MCs in MC-deficient mice, MCs must be replaced by adoptive
transfer. Unfortunately, Hara et al. were unsuccessful in their attempt to replenish MCs in KitW/Wv
mice, thus, could not confirm that a lack of MCs was solely responsible for the resistance to adverse
remodelling. The inability to reconstitute MCs to the hearts of these mice may have been due to
beginning reconstitution just 2 days before initiating banding. Typically, it takes 6 to 8 weeks for
injected MCs to reconstitute to the heart. Liao et al. [26] used the KitW/Wv mouse to investigate the
contribution of MCs to atrial fibrosis following transaortic constriction. These authors reported that
mice deficient in MCs were protected against atrial fibrosis, however, they also did not perform
MC reconstitution experiments. In an interesting study, Zhang et al. [30] investigated the role of
MCs in cardiac fibrosis in a model of TNF-α overexpression. Mice with cardiac-restricted TNF-α
overexpression were crossed with KitW/W-sh mice. While fibrosis developed in the hearts of TNF-α
overexpressing mice, this did not occur in MC-deficient TNF-α overexpressing hearts, indicating that
MCs mediate the pro-fibrotic actions of TNF-α in this setting (Figure 1B,C). Further, the lack of MCs
restored normal diastolic function as indicated by normalisation of the LV pressure volume relationship
(Figure 1D). This study shows that in the setting of elevated TNF-α, MCs mediate the pro-fibrotic
actions of TNF-α and that MC-mediated cardiac fibrosis contributes to diastolic dysfunction. This
study offers probably the most conclusive evidence to date that MCs contribute to cardiac fibrosis,
however, the caveat here is that this is an artificial up-regulation of TNF-α, which may or may not be
relevant to conditions such as hypertension. These studies are summarized in Table 2.
3.2.3. Anti-Fibrotic Role of Mast Cells
Despite the evidence that MCs are pro-fibrotic in the heart, there does appear to be some
exceptions. Martin Hauer-Jensen’s laboratory has used the Ws/Ws MC-deficient rat to identify some
of these exceptions. In one study, Joseph et al. [31] fed Ws/Ws rats a diet high in homocysteine for
10 weeks to induce hyperhomocysteinemia that causes perivascular and interstitial cardiac fibrosis,
without concomitant cardiomyocyte hypertrophy. Both forms of fibrosis were further increased in
Ws/Ws rats fed homocysteine, indicating that MCs were protective in this setting. In another study on
cardiac injury caused by radiation (single dose at 18 Gy), Boerma et al. [32] found that MC-competent
rats had increased collagen III compared to rats deficient in MCs. However, this was not the case for
collagen I. These studies are summarized in Table 2.
The reasons why MCs appear to be pro-fibrotic except in the instances of hyperhomocysteinemia
and radiation are not clear. One tempting explanation is the use of MC-deficient rats in the studies
indicating an anti-fibrotic role versus MC-deficient mice in the studies supporting a pro-fibrotic role.
However, MC stabilisers in rats appear to be anti-fibrotic, arguing against this hypothesis. It may be that
MCs are directed to take on a pro-fibrotic phenotype when the stimulus involves altered cardiovascular
hemodynamics (e.g., hypertension) or infection (e.g., myocarditis), whereas remodelling not related to
these types of stimuli invoke an anti-fibrotic MC phenotype. Deeper analysis of the types of mediators
released by MCs in each of these settings will be required to confirm or refute this hypothesis.
4. MC products
Figure 2 indicates specific mediators released by MCs and their potential contributions to cardiac
fibrosis. These mediators are discussed below.
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Figure 2. Schematic depicting potential MC activation stimuli and interactions with other cell types that
lead to cardiac fibrosis. Candidates for cardiac MC activation include IgE, TNF-α, and C5a. These then
cause the release of MC mediators including the proteases tryptase and chymase, TNF-α, histamine,
and TGF-β1. These mediators can then have direct effects on cardiac fibroblasts, but may also contribute
to an inflammatory response that then activates cardiac fibroblasts via numerous cytokines. IL-10 and
estrogen likely oppose cardiac MC activation/degranulation.
4.1. Proteases
Cardiac MC phenotype has not been well studied. However, cardiac MCs, like MCs in general,
store large amounts of specific proteases. Cardiac MCs fall under the connective tissue type MC
phenotype since they contain both chymase and tryptase (Figure 3). On the other hand, mucosal MCs
are tryptase+, but chymase-. Most of the work pertaining to cardiac MC products that contribute to




Figure 3. Immunolabelling of chymase (A, green) and tryptase (B, red) in cardiac mast cells isolated
from rats (400× magnification; Copied with permission from Morgan et al., Inflamm Res, 2008;57:1–6).
4.1.1. Chymase
Chymase is a chymotrypsin-like serine protease stored in the granules of MCs. In a mouse
model of transaortic constriction, Hara et al. [29] observed an increase in Mcp5 in the heart, one of the
mouse genes for chymase. Chymase activity in the heart was reported to increase 5.2-fold in hamsters
with hypertension induced by the two-kidney, one-clip approach [64]. Similarly, there is evidence of
chymase up-regulation in humans, with chymase mRNA and protein increased in patients with aortic
stenosis undergoing valve replacement surgery [65].
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The first study to demonstrate a causal role for chymase in cardiac fibrosis was by
Matsumoto et al. [33]. In this study, heart failure was induced by rapid pacing in beagles (270 bpm,
22 days). Dogs with heart failure were treated with the chymase inhibitor SUNC8257 (10 mg/kg,
orally twice a day), with chymase inhibition reducing collagen I and III mRNA levels and fibrosis
as determined by picrosirius red staining (Figure 4). In the setting of MI-induced remodelling in
rats, the chymase inhibitor, NK3201 reduced collagen I and III levels as well as fibrosis following
4 weeks post-MI, although it was unclear whether this analysis only included the infarct region
or the entire LV [34]. Intriguingly, whilst there was a small improvement in diastolic function with
chymase inhibition, as determined by E/A ratio, LV dilatation and systolic function were not improved.
In an interesting study, Matsumoto et al. [35] investigated the role of chymase in cardiac remodelling
caused by intermittent hypoxia mimicking sleep apnoea. Mice were placed in chambers that delivered
intermittent hypoxia (30 s of 4.5% to 5.5% O2 followed by 30 s of 21% O2 for 8 h/day during the
daytime) or normoxic conditions for 10 days. In addition to other remodelling parameters, perivascular
fibrosis was increased by hypoxia and reduced by the chymase inhibitor, NK3201.
Figure 4. Picrosirius red-stained images of perivascular fibrosis in normal, paced (vehicle), and paced
plus the chymase inhibitor SUNC8257 (Chy-I) dog hearts (100× magnification; Copied with permission
from Matsumoto et al., Circulation, 2003;107:2555–2558).
In the Matsumoto study in dogs, TGF-β1 mRNA was reduced by chymase inhibition whereas
ACE mRNA was not. Further, Shimizu et al. [66] observed that aortic banding in male Syrian hamsters
induced an increase in chymase activity and a decrease in angiotensin converting enzyme (ACE)
activity, while causing cardiac fibrosis. The authors concluded that this indicated that chymase was
primarily responsible for angiotensin II formation in this setting. These studies reflect the two known
mechanisms likely to underlie chymases role in promoting fibrosis (i.e., angiotensin II and TGF-β1).
Evidence has shown that chymase plays a role in the formation of angiotensin II in a non-canonical
pathway of the renin angiotensin system (RAS). Chymase acted as an angiotensin-(1–12) converting
enzyme in generating angiotensin II in SHR neonatal myocytes [67]. Chymase was also found to be
responsible for this bio-conversion in the left atria of patients undergoing surgery for treatment of
resistant atrial fibrillation or LV of normal patients dying from motor vehicle accidents [68,69]. Further
supporting this, cardiac angiotensin II formation was reduced by the chymase inhibitor NK3201 in a
mouse model of intermittent hypoxia [35]. Thus, one mechanism by which chymase exerts pro-fibrotic
actions is via angiotensin II. Although, one needs to be aware of species differences in the contribution
of chymase versus ACE to the cardiac angiotensin II pool. Balcells et al. [70] have noted that the human
heart has dramatically more angiotensin II than other species, with dog being second, followed by
mouse, rabbit, and rat. Human cardiac angiotensin II was almost entirely accounted for by chymase
activity, as was also the case in the dog [70]. Approximately 25% of cardiac angiotensin II formation in
the rat was attributed to chymase, whereas the contribution was less again in the rabbit and mouse.
Akasu et al. [71] found similar results. They reported that angiotensin II was almost entirely accounted
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for by chymase in human, hamster, dog, and marmoset hearts. Pig and rabbit hearts showed ACE as
the primary mechanism for angiotensin II synthesis. Interestingly, and in contrast to Balcells et al. [70],
Akasu et al. [71] found that chymase was the primary determinant of angiotensin II formation in the
rat heart. The mouse heart was not investigated.
The other pathway by which chymase exerts pro-fibrotic actions involves TGF-β1. At a cellular
level, treatment of isolated neonatal cardiac fibroblasts with chymase (15–30 ng/mL) for 24 h resulted
in cell proliferation [72]. This was accompanied by increased mRNA and protein levels of TGF-β1.
Chymase up-regulation of TGF-β1 was independent of angiotensin II since blockade of AT1 and
AT2 receptors did not alter TGF-β1 production. The proliferative and collagen producing effects of
chymase could be reduced by a neutralising antibody to TGF-β1. The downstream mediator of TGF-β1
was Smad2/3 and not p38 or ERK pathways. In vivo, cromolyn reduced TGF-β1 levels in rats with
myocarditis [19]. Shiota et al. [7] demonstrated that activated MCs were a major source of TGF-β1 and
were localised to areas of fibrosis in 12 month and 20 month old SHR that were in advanced stages of
LV hypertrophy and heart failure, respectively. In a mouse model of TNF-α overexpression, crossing
these mice with MC-deficient mice reduced TGF-β1 levels as well TGF-β receptors in the heart [30].
4.1.2. Tryptase
Tryptase is a serine protease also stored in the granules of MCs. Fewer efforts have focused on
the role of tryptase in cardiac fibrosis, even though tryptase levels increase in fibrotic hearts [23,28].
Mice with encephalomyocarditis virus-induced myocarditis show up-regulated mRNA levels of Mcp6,
the gene for tryptase, 14 days after infection, which tracked with an increase in collagen I gene
expression [18]. Using an in vitro approach, we demonstrated that tryptase could increase ECM
synthesis by cardiac fibroblasts after 72 h [23]. Interestingly, proliferation was induced much more
rapidly (24 h), suggesting that a fibroblast proliferative response might be the primary action of tryptase.
In a follow-up study, we demonstrated that the effects of tryptase on cardiac fibroblasts were mediated
by protease activated receptor-2 (PAR-2), which induced selective MAP kinase pathways with ERK1/2
mediating the pro-fibrotic actions of tryptase on cardiac fibroblasts, with no involvement from p38 or
JNK [36]. This pathway also mediated cardiac fibroblast conversion to the myofibroblast phenotype.
Critically, blockade of PAR-2 with FSLLRY (10 μg/kg/day) in SHR prevented fibrosis from occurring,
independent of blood pressure. Thus, the role of tryptase appears to be more direct than is the case for
chymase. In another follow-up study, we identified an autocrine/paracrine response by cardiac MCs
mediating their own protease release. Inhibition of tryptase with nafamostat mesilate (5 mg/kg/day)
reduced plasma chymase levels in rats with transaortic constriction [28]. To investigate this further,
sections of rat LV were cultured in a novel tissue culture system and treated with tryptase. Tryptase
caused the release of chymase into the media and a concomitant increase in collagen production that
could be reduced by the chymase inhibitor chymostatin. These results suggest that tryptase also acts
in an autocrine/paracrine manner to induce chymase release from MCs, and subsequent fibrosis.
4.2. Other Mast Cell Products
MCs release many products other than proteases that are capable of influencing the ECM. Several
of these will be discussed below. However, it is important to recognize that many of these products
can be produced by other cell types, and the relative contribution of the MCs to the overall pool of
some of these products is unclear.
4.2.1. Histamine
The human heart contains considerable amounts of histamine (1035 ± 65 ng/g of atrial
tissue) [73]. Histamine is the classic MC product mediating hypersensitivity reactions, and this
is also true in the heart, which participates in anaphylaxis. However, histamine can also contribute
to cardiac remodelling [74]. In the most direct assessment to date, Zeng et al. [37] performed
transaortic constriction on H2 histamine receptor deficient mice (H2R−/−, Table 2). After four weeks,
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H2R−/− mice showed reduced cardiac fibrosis and slightly improved systolic function, indicating
a role for histamine in cardiac fibrosis. The investigators performed additional studies in isolated
cardiac fibroblasts and determined that both histamine and the H2R-selective agonist amthamine
dihydrobromide increased protein levels of calcineurin; this was prevented by the H2R antagonist
famotidine. Importantly, H2R activation also up-regulated myofibroblast conversion, fibronectin
production, and procollagen I and III up-regulation at the gene level. Calcineurin was subsequently
shown to mediate fibroblast proliferation, fibronectin production, and collagen gene regulation in
response to H2R activation. This study clearly shows the capability of histamine to have direct effects on
cardiac fibroblasts. Interestingly though, the actions of histamine may extend beyond this. Of the four
known histamine receptors, three (H1, H2 and H3) are found in the heart. Due to their localisation, the
actions of these receptors in the heart are extremely complex. H1R and H2R are present in the sinoatrial
and atrioventricular nodes of the heart, suggesting regulation of heart rate [75]. H1R modulates cardiac
autonomic nerve function [76,77]. Interestingly, histamine enables noradrenaline release in the rat
heart via H2R [78]. Given the pro-fibrotic properties of noradrenaline, this raises the possibility that
MC-mediated release of noradrenaline via H2R could promote fibrosis. In fact, a recent clinical study
linked H2R antagonist use to a 62% reduced risk of heart failure [79]. Cardiac sensory nerves possess
H3R. Our recent findings that the sensory nerve neuropeptide substance P plays a critical role in
cardiac fibrosis in the hypertensive heart raises the possibility that MC histamine could be responsible
for its release [80]. If this is the case it sets up an interesting feed forward mechanism since we have
data indicating that substance P and its cognate receptor the neurokinin-1 receptor are responsible
for the increase in MC density observed in the hypertensive heart, but neurokinin-1 receptors do not
contribute to MC activation in this setting. Thus, other stimuli activate MCs, potentially resulting in
histamine release and amplification of the substance P response.
4.2.2. Components of the Renin Angiotensin System
Renin is the first enzyme in the RAS, its role being to cleave angiotensinogen to angiotensin I,
which in turn can be cleaved by ACE or chymase to active angiotensin II. In 2004, Roberto Levi’s group
demonstrated that rat cardiac MCs contain renin [81]. Extrapolating the relevance of this finding to
humans, Levi’s group also showed that the human MC line HMC-1 produced active renin that could
convert angiotensinogen to angiotensin I. Subsequently, Hara et al. [82] confirmed the presence of renin
mRNA in HMC-1 cells and further identified angiotensinogen mRNA in these cells. Interestingly, these
authors identified pre-formed angiotensin II in HMC-1 cells that was released in response to calcitonin
gene-related peptide. Although MC-derived renin contributes to ischaemia-induced arrhythmias in
the heart [83], no specific evidence shows directly the role of MC-derived components of the RAS
in cardiac fibrosis. However, given the known pro-fibrotic effect of angiotensin II, it is reasonable to
assume that MC RAS contributes at least to some degree to cardiac fibrosis.
4.2.3. TNF-α
Immunolabelling indicates that MCs are likely the main source of TNF-α in the heart [84,85].
MC stabilizers such as ketotifen and cromoglycate prevented TNF-α release in hearts undergoing
ischemia reperfusion, further supporting this supposition [86]. MC-derived TNF-α has been shown to
stimulate collagen production by dermal fibroblasts [87], however, the extent to which MC-derived
TNF-α contributes to cardiac fibrosis has not yet been investigated.
4.2.4. TGF-β
The role of MCs in generating TGF-β via chymase has already been discussed in Section 4.1.1,
however, direct production of TGF-β by MCs could also contribute to organ fibrosis. Inhibition of
TGF-β1 has been shown to mediate the pro-fibrotic effects of MCs on dermal fibroblasts in culture [87].
Although this suggests effects of MC-derived TGF-β, the alternate possibility cannot be ruled out
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that chymase induced activation of TGF-β produced by fibroblasts. There are no studies directly
investigating the contribution of MC-derived TGF-β to cardiac fibrosis.
4.2.5. Matrix Metalloproteinases
Investigation of MCs in airways of dogs found that these cells produce matrix metalloproteinase
(MMP)-2 and -9 (gelatinase A and B) [88]. Stem cell factor selectively up-regulated MMP-9 [88].
Interestingly, TGF-β opposed the actions of stem cell factor on MMP-9. The significance of MMPs is
their ability to regulate the ECM, whether it be by initiating degradation, or alternatively, inducing
pro-fibrotic responses [89]. While MC regulation of MMPs has been established in cardiac volume
overload [10,90], this results in ECM degradation in that setting. The contribution of MCs to MMPs
has not been investigated in relation to cardiac fibrosis. However, conditioned media from MCs was
able to increase MMP-2 activation in neonatal cardiac fibroblasts [91]. Additionally, chymase inhibition
prevented MMP-9 activation in pigs undergoing ischemia reperfusion [92].
5. Important Questions
While there is accumulating evidence that MCs contribute to cardiac fibrosis, there are several
important questions that remain unanswered.
5.1. What Activates Cardiac Mast Cells?
Probably the most pressing question is what are the stimuli that activate these cells causing them
to promote fibrosis? There are several good candidates still to be investigated. These are depicted in
Figure 2.
5.1.1. Immunoglobulin E
Like all MCs, cardiac MCs possess the IgE receptor, FcεRI. This is evidenced by their degranulation
in response to antibody against FcεRI in vitro [93]. Interestingly, FcεRI activation causes release of
histamine and tryptase, as well as leukotriene C4 and prostaglandin D2 by isolated human cardiac
MCs [94]. As discussed earlier, MC histamine and tryptase are linked to cardiac fibrosis. Surprisingly,
the role of IgE and FcεRI in causing cardiac fibrosis has not yet been investigated.
5.1.2. TNF-α
TNF-α receptor I (TNFRI) and TNF-α receptor II (TNFRII) mediate the actions of TNF-α. TnfrI−/−
mice have improved cardiac remodelling responses (including fibrosis) following MI, while TnfrII−/−
mice have worse fibrosis. Thus, TNFRI exacerbates remodelling leading to heart failure, whereas
TNFRII has cardioprotective actions. The evidence implicating TNF-α and TNFRI comes from studies
that crossed TNF-α overexpressing mice with MC-deficient mice. TNF-α overexpressing mice develop
fibrosis; this fibrosis is reduced in mice lacking MCs. This indicates that MCs mediate the pro-fibrotic
effects of TNF-α, implying that TNF-α plays a role in activating MCs. What is not clear from that study
is whether this is direct activation of MCs by TNF-α via TNFRI or whether the activation is indirect
with TNF-α up-regulating other mediators that then activate cardiac MCs. This question requires
MC-specific deletion of TNFRI. Also, whether MC-derived TNF-α represents a viable treatment target
is questionable given the failure of targeting TNF-α in heart failure patients.
5.1.3. Complement 5a
Patella et al., demonstrated more than 20 years ago that isolated human cardiac MCs degranulate
in response to the complement factor, C5a [93]. The response to C5a was more rapid than to IgE and
reached the same maximal response as IgE. However, Füreder et al. [95] subsequently reported that
only 5% to 15% of human cardiac MCs that they examined possessed the C5a receptor and that human
cardiac MCs did not release histamine in response to C5a. Nevertheless, coronary infusion of C5a
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(500 ng) in pigs undergoing MI led to an increase in coronary histamine levels indicating MC activation
by C5a [96]. It will require MC-specific deletion of the C5a receptor to help resolve this question.
5.2. What Are the Specific Mechanisms by Which Mast Cells Cause Cardiac Fibrosis?
Despite clear evidence from multiple animal models that MCs are involved in cardiac fibrosis and
that MC proteases mediate these actions along with possible contributions from other MC mediators,
we know very little about the specifics. One example is the temporal involvement of MCs in cardiac
fibrosis. Our own belief is that these cells are important in initiating fibrosis, but may not be involved
continually throughout the process. This somewhat stems from our experience in MC regulation of the
ECM in volume overload models where MC density increases in the first few days following initiation
of volume overload, before returning to normal [90]. This suggests that MCs are important early
to initiate processes that then continue throughout the remodelling process. Supporting this, MCs
density is increased in the young SHR [7] and continued to be increased at 8 and 12 weeks of age, when
fibrosis develops, before returning to normal levels by 16 weeks of age once fibrosis is established.
Interestingly, MC density increases again around the age that heart failure develops in the SHR [7].
Also undetermined are the specifics of MC interactions with cardiac fibroblasts. In vitro it has
been shown that MCs can act directly on cardiac fibroblasts to induce myofibroblast conversion,
proliferation, and excess collagen synthesis [36,72], however, do these direct interactions actually
occur in vivo, and to what extent? While cardiac MC number does vary between species, overall
there are very few MCs in the heart. Clearly, although few in number they have a significant impact,
however, it does raise the question of how many cardiac fibroblasts and MCs can actually interact in a
paracrine manner in vivo. This we do not know. We do not even know whether released MC products
circulate in the heart, giving them the opportunity to reach fibroblasts from remote parts of the heart,
or whether they just act locally. Figure 5 depicts local versus distant interactions between MCs and
cardiac fibroblasts.
 
Figure 5. Schematic depicting the possible interactions between MCs and fibroblasts in the heart. (Left)
MCs may act in a paracrine manner to signal only to fibroblasts in their local area. This would limit
direct MC-fibroblast interactions as a mechanism by which MCs cause fibrosis; (Right) Alternatively,
MC products may be taken up in the general coronary circulation allowing their products to be
distributed to fibroblasts throughout the heart. This would allow for greater MC-fibroblast interactions.
Also likely important in MC modulation of cardiac fibrosis are interactions with other
inflammatory cells (Figure 2), especially if direct MC-fibroblast interactions are minimal. Conditioned
media from bone marrow-derived MCs activated with the calcium ionophore A23187 (500 ng/mL)
dramatically up-regulated VCAM-1, ICAM-1, P-selectin, and E-selectin in mouse heart endothelial cells,
suggesting a role for MCs in inflammatory cell recruitment [97]. In support of this, we had observed
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reduced numbers of macrophages in the SHR LV following treatment with nedocromil compared
to untreated SHR [23]. This qualitative assessment suggests a role for MCs in the recruitment of
macrophages to the fibrotic heart, however, quantitative assessment of this effect is still lacking. Should
MCs regulate macrophage recruitment, then it should be determined as to whether this is a direct effect
on macrophages, or whether other cells are involved (i.e., MC activation of endothelial cells). We also
reported that MC stabilization reduced IFN-γ and IL-4 production, demonstrating the contribution of
MCs to the overall cytokine pool, whether directly or indirectly.
Very little work has investigated MC-cardiomyocyte interactions. In our own studies, we did not
observe any significant effect on cardiac hypertrophy, either by MC stabilization with nedocromil or
inhibition of tryptase with FSLLRY [23,36]. Chymase appears to be able to induce cardiomyocyte death
by entering these cells and inducing translocation of nuclear receptor subfamily 4A1 (NR4A1) from
the nucleus to the cytoplasm. This was identified in ischemia reperfusion injury; the significance of
this to cardiac fibrosis has not been explored. Media from cultured MCs can invoke death in cultured
neonatal cardiomyocytes, with a neutralizing antibody against chymase opposing this effect [98].
Cardiomyocyte death is a stimulus for cardiac fibrosis. Thus, MC interactions with cardiomyocytes
could be a stimulus for fibrosis, however, this is yet to be established.
5.3. What Is the Cardiac Mast Cell Phenotype and Are There Gender Differences?
A large amount of the work contributing to our understanding of the role of MCs in adverse
cardiac remodeling has come from the laboratory of Joseph Janicki. Recently, the Janicki lab
produced evidence indicating that differences in MC phenotype may underlie cardioprotection in
pre-menopausal females. Intact and ovariectomised (ovx) female rats were exposed to pressure
overload induced by transaortic constriction. LV MC density did not increase in intact females, but did
increase in oxv rats [99]. Further, whilst there was a small increase in LV chymase levels in intact rats,
the increase was greater in ovx animals. This was also the case for TGF-β1, presumably related to the
increase in chymase. When oxv female rats were treated with estrogen, MC density, LV chymase, and
TGF-β1 were reduced, as was fibrosis. This suggests that estrogen in pre-menopausal females provides
a level of protection from cardiac fibrosis by reducing the ability of MCs to either: (1) respond to
activation stimuli and therefore reduce levels of MC proteases that contribute to fibrosis in males; or (2)
reduce production of mediators responsible for promoting fibrosis. Essentially, phenotypic differences
exist between male and female MCs and this may underlie pre-menopausal cardioprotection in females
(Figure 2). This is an extremely interesting concept that needs to be further explored.
These potential phenotypic differences between male and female MCs leads to another gap in our
cardiac MC understanding; very little is known about the cardiac MC phenotype in general. This is an
area that has been badly neglected. We know that cardiac MCs are tryptase+/chymase+ (Figure 3),
as well as containing histamine and TNF-α [84,94,100]. Patella et al. [94] have demonstrated that
isolated human cardiac MCs produce leukotrienes in response to activation by C5a. Beyond these
few mediators, essentially nothing is known about cardiac MC phenotype. Whether cardiac MC
sub-populations exist, as is the case for macrophages and T cells, is currently unknown, but should
become a focus of investigation.
6. Conclusions
There is strong experimental evidence that MCs contribute to cardiac fibrosis, at least in part
through the release of MC-specific proteases. However, the specifics of how MCs promote fibrosis is
not clear, including the role of non-protease MC products, the stimuli that activate cardiac MCs,
how cardiac MCs and fibroblasts interact in vivo, and specifics of cardiac MC phenotype (e.g.,
sub-populations and gender differences). These questions must be answered if targeting MCs is
to eventually become a therapeutic approach in humans.
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SHR Spontaneously Hypertensive Rat
ECM Extracellular Matrix
Sld Steel Dickie
ACE Angiotensin Converting Enzyme
PAR-2 Protease Activated Receptor 2
H1R Histamine Receptor 1
H2R Histamine Receptor 2
H3R Histamine Receptor 3
H4R Histamine Receptor 4
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HMC-1 Human Mast Cell Line 1
MMP Matrix Metalloproteinase
TNFRI Tumor Necrosis Factor Receptor I
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Abstract: Thrombospondins (TSPs) represent extracellular matrix (ECM) proteins belonging to the
TSP family that comprises five members. All TSPs have a complex multidomain structure that
permits the interaction with various partners including other ECM proteins, cytokines, receptors,
growth factors, etc. Among TSPs, TSP1, TSP2, and TSP4 are the most studied and functionally
tested. TSP1 possesses anti-angiogenic activity and is able to activate transforming growth factor
(TGF)-β, a potent profibrotic and anti-inflammatory factor. Both TSP2 and TSP4 are implicated
in the control of ECM composition in hypertrophic hearts. TSP1, TSP2, and TSP4 also influence
cardiac remodeling by affecting collagen production, activity of matrix metalloproteinases and
TGF-β signaling, myofibroblast differentiation, cardiomyocyte apoptosis, and stretch-mediated
enhancement of myocardial contraction. The development and evaluation of TSP-deficient animal
models provided an option to assess the contribution of TSPs to cardiovascular pathology such
as (myocardial infarction) MI, cardiac hypertrophy, heart failure, atherosclerosis, and aortic valve
stenosis. Targeting of TSPs has a significant therapeutic value for treatment of cardiovascular disease.
The activation of cardiac TSP signaling in stress and pressure overload may be therefore beneficial.
Keywords: thrombospondins; cardiac remodeling; cardiac hypertrophy; heart failure; atherosclerosis;
myocardial infarction; cardiac fibrosis
1. Introduction
The function of the extracellular matrix (ECM) is not only limited by providing structural
support and immobilization of cells. Functional significance of the ECM also relies in mediating
cell-cell and cell-matrix contacts, signaling conduction, and triggering cell adhesion, motility, and
differentiation. The composition and functional properties of the ECM vary depending on the
cell type and tissue/organ specificity. For example, in the cardiovascular system, the ECM is
involved in maintaining structural continuity of the heart and blood vessels, providing an essential
scaffold for cell attachment and functioning, control of cell growth, viability and death, regulation
of diastolic stiffness, and performing tissue repair/remodeling in a case of cardiovascular damage
and inflammation [1]. In the ECM, structural changes induced by local microenvironment can lead
to functional matrix alterations. Changes in the matrix may be then conducted to adjacent cells and
affect their activity and behavior. For example, the cardiovascular ECM mediates blood flow-induced
mechanotransduction [2,3] and adaptive responses of vascular cells and cardiomyocytes to various
stress stimuli [4,5].
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In cardiovascular pathology such as atherosclerosis, arterial restenosis or heart failure,
ECM-associated responses are frequently maladaptive and may lead to adverse tissue remodeling
and fibrosis [6,7]. Inflammatory, profibrotic, prooxidant, hypoxic, and other pathological stimuli may
induce substantial modifications and impair matrix turnover, which in turn may cause qualitative
and quantitative changes in matrix architecture and composition by increasing content of certain
ECM proteins and decreasing amount of other matrix components [8,9]. For instance, in failing hearts
of patients with dilated cardiomyopathy, significant changes in the content of some non-fibrillar
matrix and matricellular proteins were found. Implementation of the mechanical unloading of the left
ventricle by left ventricular assist device resulted in the restoration of the fibrillar ECM and basement
membrane and improved clinical outcome [9].
Matricellular proteins comprise non-structural ECM proteins that modulate cell function and
behavior. Matricellular proteins include thrombospondins (TSPs), tenascins, periostin, osteopontin,
CCN proteins, and osteonectin/secreted protein acidic and rich in cysteine (SPARC) [10]. Tenascins
contain three members (tenascin C, tenascin R, and tenascin X) that are especially abundant
in developing embryonic tissues like cartilage, tendon, bone, and nervous system where these
proteins promote migration, proliferation, and differentiation of stem and lineage-specific progenitor
cells [11,12]. Periostin plays multiple physiological and pathogenic roles including regulation of
mesenchymal differentiation in the developing heart, tissue repair, and involvement in cancer and
valvular heart disease [13–15]. Osteopontin triggers biomineralization, bone remodeling, and immunity
as well as pathological ectopic calcification [16–18]. Osteonectin is a Ca2+-binding protein whose
primary function is to contribute to osteogenesis by conducting biomineralization of the bone and
cartilage [19]. CCN proteins include at least six members (CCN1–6) with a complex multidomain
structure that provides an option to bind numerous ligands and participate in a variety of biological
processes such as angiogenesis, inflammation, tissue repair, fibrosis, and carcinogenesis [20]. Like CNN
proteins, TSPs have several functional domains and indeed are able to interact with multiple partners.
TSPs are abundantly distributed in various tissues and organs including the cardiovascular system.
At steady state, TSP expression is low but can be up-regulated in response to wounding. TSPs are likely
to contribute to post-injury tissue repair and remodeling [21]. In this review, we consider structural
and functional aspects of the TSP protein family in relation to cardiovascular disease.
2. Thrombospondins Structure
The TSP family contains five members (TSP1–5) that represent multimeric glycoproteins, which
bind Ca2+, interact with other ECM proteins, and contribute to the associations between cells and
between cells and ECM. TSMs divided to two subgroups: trimeric subgroup A (TSP1 and TSP2) and
pentameric subgroup B (TSP3, TSP4, and TSP5). TSPs have a complex multidomain structure (Figure 1).
The C-terminal domain, type III repeats and epidermal growth factor (EGF)-like repeats are present in
all TSPs and underline the TSP family. The oligomerization domain can be also found in all family
members but it is more variable compared with other shared structures [22]. The subgroup A has three
EGF-like repeats and type I repeats (also known as thrombospondin repeats; TSRs), von Willebrand
factor type C (vWC) domains, and the N-terminal domain. The subgroup B contains four EGF-like
repeats but vWC domains and TSRs are missing. While TSP3 and TSP4 have the N-terminal domain,
TSP5 has not [23].
The evolutionary analysis showed that the subgroup B is evolutionary younger than the
subgroup A [24]. In fish, a TSP4-like sequence, an ortholog of the tetrapod TSP5 gene is found [25].
The TSP5-coding sequence evolved more quickly from the TSP4-like sequence as an innovation in the
tetrapod lineage. Thus, all TSP genes show conservation of synteny between fish and tetrapods. In
humans, the TSP1, TSP3, TSP4 and TSP5 genes reside within paralogous regions and are the result of
gene duplications [24].
211
Int. J. Mol. Sci. 2017, 18, 1540
Figure 1. Structure of thrombospondins (TPSs). TSP family includes five members: TSP1–5. Subgroup
A comprises TSP1 and TSP2 that form pentamers while subgroup B contains trimeric TSP3–5. TSPs
have a complex multidomain architecture that provides an option to bind various ligands. For example,
C-terminal domain contains CD47-binding site. Type III repeats are involved in Ca2+ binding while
Type I repeats are responsible for the interaction with CD36, a receptor for TSP1 and TSP2, and
inhibition of matrix proteinases (MMPs). Type II EGF-like domains are involved in the regulation of
various signaling pathways such Notch and others. C-terminal domain, Type III repeats and Type II
epidermal growth factor (EGF)-like repeats share high homology in all TSPs and represent a signature
of the TSP family. Von Willebrand factor type C (VWc) domain is cysteine-rich and is implicated
in binding members of the transforming growth factor-β (TGF-β) superfamily. The oligomerization
(coiled-coil) domain drives formation of TSH homooligomers. The N-terminal domain, which is present
in TSP1–4 and absent in TSP5, is less conservative. This domain regulates structure and stability of the
coiled-coil region and binds heparin.
Due to the availability of various structural domains, TSPs can interact with different surface
receptors and ECM proteins. In the TSP molecule, EGF-like domains are employed for binding of
integrins and Ca2+, TSPs are needed to bind transforming growth factor (TGF)-β and CD36, while the
N-terminal domain is required for binding heparin and integrins [26]. The C-terminal domain contains
a binding site for CD47, an essential TSP receptor [27]. TSP-mediated effects indeed depend on the
availability of the binding partner and local microenvironment that explains cell- and tissue-specific
actions of TSPs. In addition, TSPs display different cellular distributions, different temporal expression
profiles and have distinct functional responsibilities and modes of transcriptional regulation.
TSP1 that was identified first represents the most studied thrombospondin. TSP1 and TSP2 are
expressed by several cell types in response to damage or during remodeling [28,29]. TSP1 is known due
to the functional significance in the control of angiogenesis and thrombosis and capacity to increase
bioavailability TGF-β by liberating this cytokine from its latent form [23]. In the heart, TSP2 contributes
to maintaining of cardiac matrix integrity via its actions on matrix metalloproteinases (MMPs) [30].
The highest expression levels of TSP3 and TSP5 were detected in the vascular wall and tendon [31].
However, both these TSPs are the least studied among TSP family members. TSP4 has a role in vascular
inflammation [31], regulation of myocyte contractility, angiogenesis, and ECM remodeling [32,33].
In our understanding of TSP functions, the most profound recent progress was made in
studying the cardiovascular system. Genetic studies showed association between single nucleotide
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polymorphisms (SNPs) in TSP1, TSP2, and TSP4 genes with cardiovascular pathology [34–39]. All TSP
disease-associated SNPs are functional. For example, the A387P polymorphism of TSP4 and N700S
polymorphism of TSP1 alter Ca2+-binding sites [40]. Ca2+ binding is essential for TSP structure
and function. The TSP1 S700 variant had significantly less capacity to bind Ca2+ compared to
the N700 allele. In fact, the P387 variant of TSP4 represents a gain-of-function allele because it
acquired an additional Ca2+-binding site absent in the A387 allele [40]. A recent meta-analysis showed
that the N700S polymorphism of TSP1 is associated with coronary artery disease (CAD) especially
in Asian populations (heterozygote model: odds ratio (OR) = 1.57 [95% confidence interval (CI):
1.01–2.44]; dominant model: OR = 1.56 [95% CI: 1.00–2.43]). The TSP4 A387P polymorphism is
associated with increased CAD risk in American population (homozygote model: OR = 1.29 [95% CI:
1.04–1.61]; recessive model: OR = 1.27 [95% CI: 1.02–1.58]). No association was shown for the THS2 3′
(untranslated region) UTR polymorphism and higher CAD risk [41].
3. Cardiac Integrity
Expression of all TSP family members was found in the heart. In cardiac remodeling, TSP1, TSP2,
and TSP4 are up-regulated [42–45]. In pressure overload, myocardial expression of TSP3 and TSP5
was shown to be also increased [46].
TSP1, TSP2, and TSP4 are involved in cardiac fibrosis but possess opposite effects. While TSP1
and TSP2 promote fibrosis [47,48], TSP4 inhibits profibrotic mechanisms as was shown in animal
models [49,50] and human heart allografts [43,48]. In human allografts, increased levels of TSP1 and
TSP2 suggested for induction of both the fibrotic response and allograft rejection [43,48]. In TSP1
or TSP2-deficient murine cardiac remodeling models (i.e., those affected with doxorubicin-induced
cardiomyopathy [51], diabetic cardiomyopathy [52,53], dilated cardiomyopathy [54], or MI [44,55,56]
the profibrotic role of both TSPs was confirmed. Mechanistically, profibrotic effects of TSP1 and TSP2
in the heart lead to the stimulation of TGF-β, a key inducer of cardiac fibrosis [48,57,58], suppression
of MMPs [48,59], and inhibition of angiogenesis [43,47,55]. Profibrotic activity of TSP1 can be also
mediated the calreticulin/low density lipoprotein receptor-related protein 1 (LRP1) complex whose
stimulation results in the activation of prosurvival protein kinases such as PI3K and migration of
fibroblasts [60,61]. The N-terminal domain of TSP1 has the calreticulin-binding site to stimulate
association of calreticulin with LRP1 to the signal focal adhesion disassembly and providing signal
into the cytoplasm [62].
TSP2 expression was observed only in biopsy specimens from the hypertrophic hearts of rats
that rapidly developed heart failure suggesting for a possible value of TSP2 to serve as a marker of
early onset of heart failure [59]. TSP2-deficient mice were extremely vulnerable to rapid progression
from angiotensin II-induced cardiac hypertrophy to cardiac failure and fatal rupture since 70% of
animals died from cardiac rupture whereas the rest of them progressed to heart failure [59]. These data
therefore indicate a role of TSP2 as an essential regulator of cardiac integrity.
In the heart, lack of TSP4 leads to advanced fibrosis [49,50] suggesting for the anti-fibrotic role.
TSP4 also triggers heart stress adaptation by increasing intracellular Ca2+ content in cardiac muscle
cells and enhancing contractility [63]. TSP4-induced adaptive response against ER stress also protects
cardiomyocytes from pressure overload [1]. In TSP4-deficient mice, tendon collagen fibrils were found
to be significantly larger than in wild-type mice suggesting for the negative TSP4-dependent regulation
of collagen synthesis in ligaments [64]. However, it is unknown whether this TSP inhibit cardiac
collagen production.
The reason of profound differences in the actions of TSP4 and TSP1/TSP2 on myocardial fibrosis
may rely on the structural differences between these TSPs. TSP4 lacks domains responsible for the
control of MMP function, angiogenesis and TGF-β stimulation. These domains are present in TSP1
and TSP2 [23]. Thus, in order to recognize effects of every TSP in heart remodeling, it is necessary to
monitor expression of each TSP in various steps of remodeling and adaptive reaction to heart damage.
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Expression of TSP1–4 was found in human aortic valves [65]. In fibrosclerotic and stenotic valves,
TSP2 production was increased. TSP2 was up-regulated in myofibroblasts and some endothelial cells
(ECs) and was associated with myofibroblast proliferation and neovascularization. TSP2 activation
was followed by suppression of Akt and NF-κB [65]. Cardiac-related expression of TSP4 was highest
in the valves suggesting for a potential activity in these regions [32,50].
4. TSPs in Angiogenesis
Angiogenesis is an essential physiological process involved in the developmental vasculogenesis
and tissue repair after injury. In pathology, formation of neovessels occurs in vascular proliferative
diseases such as atherosclerosis and in tumors. The anti-angiogenic properties of TSP1 and TSP2 are
established and confirmed in different models of angiogenesis [66,67]. The anti-angiogenic activity of
TSP1 and TSP2 may be especially attractive in the context of anti-tumor therapy because both TSPs are
able to inhibit tumor-associated angiogenesis and suppress tumor growth [68,69]. Studying of TSP1
effects on tumor neovessel formation provided new insights into a specific role and a power of this
TSP in preventing angiogenesis. It became obvious that tissue expression of TSP1 is able to define fate
of angiogenesis even without influencing by pro-angiogenic signals [70].
A phenomenon of dormant tumors that have a microscopic size and do not expand is associated
with high expression and inhibitory effects of TSP1 and tissue inhibitor of matrix proteinases
TIMP-1 [71]. Down-regulation of TSP1 and reduced tumor sensitivity to angiostatin leads to
proangiogenic switch and induction of rapid growth and tumor expansion [72]. MicroRNA (miR)-467
was reported to function as a negative regulator of TSP1 expression [73]. This miRNA is induced by
high glucose and leads to the sequestration of TSP1 mRNA in the non-polysomal fraction of tumor cells
and induction of angiogenesis. Inhibition of miR-467 suppresses tumor growth and angiogenesis [74].
The anti-angiogenic activity of TSP1 is attributed to a structural domain known as the TSP type
I repeat [75]. This domain serves as a single Ca2+-binding site for endothelial receptor CD36 that is
essential for mediating anti-angiogenic effects of TSP1 and TSP2 [76,77]. Histidine-rich glycoprotein
(HRGP), a circulating protein, contains a CD36 homology domain and blocks TSP-dependent
anti-angiogenic effects by binding to either TSP1 or TSP2 [75,78]. Another TSP-1-dependent
anti-angiogenic mechanism is consisted of the engagement of CD47 that disrupts CD47 interaction
with vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) and blunts VEGFR2-mediated
proangiogenic signaling associated with activation of endothelial NO synthase (eNOS) and soluble
guanylate cyclase (sGC) [79]. In silico analysis showed that TSP1 binding to CD47 can also enhance
VEGFR2 degradation [80]. By contrast, in TSP1-deficient mice, phosphorylation of endothelial VEGFR2
is up-regulated thereby providing a stimulatory signal to Akt or Src that in turn activate eNOS
through phosphorylation [79]. Another suppressive mechanism, by which TSP1 can inhibit myristic
acid-stimulated eNOS-dependent signaling that leads to the induction of increased adhesion properties
of ECs and vascular smooth muscle cells (VSMCs), is dampening of the CD36-mediated uptake of free
fatty acids or engagement of CD47 [81,82].
TSP1 can also diminish the sGC/3′, 5′-cyclic GMP (cGMP) signaling by limiting cGMP-dependent
activation of the downstream cGMP-activated kinase (PKG) [83]. The inhibitory effect of TSP1 on
eNOS/cGMP signaling in ECs are more potent than that of TSP2 suggesting for a role of TSP1 as a
dominant regulator of NO/cGMP signaling pathway through CD47 [84].
NO is essential for activation sGC that contains a heme responsible for NO binding [85].
NO-dependent stimulation of sGC leads to intensive production of cGMP, a signaling messenger that
is involved in the vascular tone regulation by relaxation of VSMC contractility [86], inhibiting platelet
aggregation [87] and blood cell adhesion to the endothelium [88]. Except for limiting NO bioavailability,
inhibitory effects of TSP1 on sGC activity and cGMP production can also involve suppression of
the hydrogen sulfide (H2S)-mediated signaling through blocking activity of H2S-biosynthesiting
enzymes, cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE) [89]. Another inhibitory
mechanism may involve TSP1-dependent stimulation of reactive oxygen (ROS) and nitrogen species
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production [90], which in turn inactivate sGC via covalent enzyme modification [91] or heme
nitrosylation [92].
Compared to TSP1 and TSP2, TSP4 exerts proangiogenic properties [93]. TSP4 was detected in the
lumen of neovessels. TSP4-deficient mice have diminished angiogenesis in comparison with wild-type
mice. Mice transgenic for the CAD-associated human TSP4 P387 variant displayed more intensive
angiogenesis compared with mice bearing the A387 allele of TSP4. Pulmonary ECs derived from
TSP-lacking mice exhibited reduced adhesion and migratory properties in contrast to wild-type ECs. In
addition, recombinant TSP4 was shown to stimulate vessel development and EC motility/proliferation
through binding to integrin-α2 and gabapentin receptor α2δ-1 [93].
5. TSPs in Atherosclerotic Blood Vessels
Vascular expression was shown for all TSPs [31]. In blood vessels, TSP1, TSP2, and TSP4
are involved in the functional and structural regulation of the vascular wall and interactions with
blood-borne cells. In diabetic rats, TSP1 levels were increased after vascular wounding [94]. In rats
with balloon-induced injury, blockade of TSP1 in carotid artery with antibody resulted in enhanced
reendothelization and decreased neointima formation [95]. In apolipoprotein E (ApoE)-deficient
mice, an atherosclerotic animal model, inhibition of TSP1 and TSP4 caused delayed atherosclerosis
progression and less inflammatory conditions. However, at late atherogenic stages, the plaques
developed proinflammatory content and had the same size as lesions in control mice [31,96]. TSP-1
or TSP4 did not alter intraplaque lipid content but induced dramatic changes in macrophages counts
within the plaque by influencing either function (TSP1) or infiltration (TSP4) of macrophages to the
lesion. In advanced lesions, TSP2 plays an anti-atherogenic role by stimulating phagocytic function of
macrophages needed to perform clearance of apoptotic and necrotic cells and cell debris [96].
In ApoE-deficient mice, TSP4 depletion does not affect lesional matrix deposition [31] while TSP1
deficiency leads to the formation of more fibrotic lesions of less size but also increases inflammation
associated with enhanced activity of macrophages [96]. These macrophages are involved in intensive
degradation of the fibrous cap associated with increased accumulation of MMP-9 in the cap but display
altered phagocytosis that finally results in increase of the necrotic core and plaque destabilization.
It appears that TSP1 promotes atherogenesis in early stages through induction of endothelial
dysfunction, stimulation of VSMC proliferation and inhibiting collagen deposition. However, in
late stages, TSP1 switches this role to the anti-atherogenic function by repressing lesional maturation
via stimulation of the phagocytic activity of macrophages and reducing necrosis [97].
In ApoE-deficient mice fed on high-fat diet, strong plaque TSP1 expression was detected in fibrous
cap-associated VSMCs and inflammatory cells in the shoulder of the plaque and foam cells. Weak
TSP1 expression was found in the adventitia and media of the atherosclerotic wall [96]. Expression
of TSP2 was found in human arterial VSMCs [98] but was not detectable in the endothelial plaque
lining and intraplaque neovessels [99]. TSP3, TSP4, and TSP5 are all also linked to atherosclerotic
plaques. Expression of TSP3 was detected in the tunica media and tunica adventitia, on the luminal
endothelial surface, and in the plaques in ApoE-deficient mice [31]. TSP4 exerts proatherosclerotic
and proinflammatory effects in vessels since TSP4-knockout mice developed less inflammatory
lesions with lowered macrophage content, diminished activation of ECs, and reduced production
of proinflammatory cytokines [31]. TSP4 stimulates adhesion and movement of macrophages and
neutrophils in an integrin αvβ3-dependent manner [13,40]. The CAD risk-associated TSP4 P387 variant
was shown to enhance leukocyte attachment to ECs and motility and promote proinflammatory
signaling in vascular and blood-borne cells likely due the ability to bind more Ca2+. This ability leads
to conformational changes in the mutant TSP4 molecule and provides better interaction with cell
surface receptors [13,40].
TSP5 protein was histochemically detected in normal and affected (i.e., atherosclerotic and stenotic)
human arteries where it is produced by VSMCs [100]. In ApoE-deficient mice, TSP5 expression is
associated with tunica media and a few plaque cells [31]. TSP5 is involved in maintaining VSMC
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quiescence and contractile phenotype via interaction with integrin α7β1 [101]. A disintegrin and
metalloproteinase with thrombospondin motifs 7 (ADAMTS7) that is also expressed in VSMCs can
degrade TSP5 and promote VSMC migration and recruitment for neointima formation [102].
CD47 (also known as the integrin-associated receptor; IAP) is the receptor for TSP1 [103].
After stimulation with TSP1, CD47-mediated pathway is involved in the control of leukocyte
functions, vascular resistance, and intracellular signaling in ECs and VSMCs [104]. TSP1 binding
to CD47 has global functional consequences by inhibiting endothelial nitric oxide (NO) production,
controlling vascular tone, and maintaining systemic hemodynamics and cardiac dynamics in stressful
conditions [105–108]. The interaction between TSP1 and CD47 also regulates thrombosis/hemostasis,
immune responses, and mitochondrial function [109]. CD47-binding capacity can be shared between all
TSP family members since CD47-binding site is located in the C-terminal region, which is homologous
in all TSHs.
TSP1-mediated overactivation of NADPH oxidase may exert important pathogenic effects in
cardiovascular pathology. TSP1 is able to stimulate Nox1 and Nox4 through CD47-dependent signaling.
In VSMCs, TSP1 binding to CD47 leads to phospholipase C (PLC)-catalyzed biosynthesis of diacyl
glycerol, a stimulator of protein kinase C (PKC) that in turn phosphorylates the NADPH oxidase
core subunit p47phox followed by activation of Nox1. Nox1 overactivity enhances ROS formation that
further inhibits VSMC-dependent vasorelaxation and induces vascular dysfunction by promoting
oxidative stress [90]. In ischemic VSMCs, TSP1 can also increase ROS generation via stimulation of the
cell surface receptor signal-regulatory protein-α (SIRP-α) and subsequent recruitment of the p47phox
subunit [110].
TSP1-induced Nox4 up-regulation stimulates ROS-dependent proliferation of VSMCs and
neointimal formation, a hallmark of the proatherogenic arterial remodeling [111,112]. In addition,
TSP1/CD47-dependent stimulation of Nox1 enhances micropinocytosis of non-modified low density
lipoprotein (LDL) by macrophages and promotes their transformation to foam cells, another key
characteristics of atherogenesis. In macrophages, Nox1 overactivity induces dephosphorylation of
actin-binding protein cofilin, PI3K-dependent activation of myotubularin-related protein 6 (MTMR6)
followed by cytoskeletal rearrangements and increased LDL uptake [113]. Thus, TSP1-mediated
stimulation of ROS-dependent signaling and oxidative stress have numerous pathogenic consequences,
which promote atherogenesis.
6. TSPs in Myocardial Infarction
Myocardial injury initiates the post-MI tissue repair response aimed to restore cardiac conduction
and contractility, blood supply, and replace necrotic cardiomyocytes in the infarct with a scar [114].
After MI, cardiomyocyte necrosis occurs early in post-MI remodeling of the infarct area while apoptosis
occurs in the infarct and distant cardiac regions both in the early and late stages of remodeling [115].
In the early stage of cardiac repair, infiltrated inflammatory cells release MMPs, particularly MMP-2/9,
to degrade ECM in the injured myocardial area and adjacent regions [116]. In parallel with ECM
destruction, transformation of cardiac fibroblasts to myofibroblasts associated with their proliferation
and migration to the site of injury begins. In response to profibrotic signals, myofibroblasts produce
collagen and other ECM components, which are deposited in the cell-free infarcted zone that was
cleared by macrophages from necrotic cells [117]. In the proliferative stage of myocardial repair, the
collagen amount quickly rises in the injured region while collagen fibers undergo cross-linking in the
maturation stage [118]. Collagen can be also accumulated in the non-infarcted area that can initiate
reactive myocardial hypertrophy [116].
Compared to pressure overload, post-MI reperfusion in TSP1-deficient mice leads to more
intensive and long-term heart inflammation in the infarct border zone and excessive remodeling [55].
These observations allow to suggest that TSP1 exerts a barrier function in the infarct border zone to
limit propagation of inflammation and fibrosis into the non-injured cardiac regions. The mechanisms of
this effect are not well studied. TGF-β-dependent up-regulation of TSP1 production may be involved
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in this process [55,56]. TSP1 also enhances apoptosis of activated T cells through CD47-dependent
activation of proapoptotic Bcl-2 family member BNIP3 that primarily links it to inflammation [119,120].
TSP1 inhibits both eNOS-dependent NO production and NO-mediated signaling that stimulates
vascular relaxation and angiogenesis [107]. These data may suggest for a putative contribution of TSP1
to heart ischemia and/or MI [121]. However, TSP1 also exhibit cardioprotective effects by activating
TGF-β, an anti-inflammatory cytokine [56]. Indeed, inhibition of CD47 represents a more attractive
therapeutic target than inhibition of TSP1. In ischemic mouse models, exposure to CD47-blocking
agents results in significant improvement of tissue survival and decreased vasculopathy, an evidence
of the therapeutic value of CD47 suppression to treat cardiovascular disease [122]. In MI or ischemia,
down-regulation of CD47 may have unpleasant sequela such as diminished apoptosis of inflammatory
macrophages, which can result in elevated levels of proinflammatory cytokines [123]. Enhanced TSP1
production may be involved in NO resistance observed in aging and ischemic heart disease [122].
Indeed, therapeutic targeting of vessel NO signaling through TSP1/CD47 can be valuable [121].
Compared with TSP1, our knowledge of a role of TSP2 in MI is constrained. TSP2 and TSP4 do not
involved to the control of NO signaling [106]. However, TSP2 shares with TSP1 many anti-angiogenic
properties, promotes CD36-mediated apoptosis of ECs, and initiates cell cycle arrest [68]. TSP2-deficient
mice exhibited increased angiogenesis that was associated with MMP-9 up-regulation [123]. Similarly,
TSP2 deficiency was shown to induce enhanced angiogenesis and delayed skin wound contraction
accompanied with increased MMP-2/9 and soluble VEGF production [124]. These findings indicate
that anti-angiogenic effects TSP2 can be released through multiple mechanisms. TSP2 deletion in
mouse was shown to induce increased vascularity and defects in connective tissue formation due to
impaired collagen fibrillogenesis [125,126] indicating that cardiac TSP2 may be involved in post-injury
heart remodeling and repair through the control of fibrillogenesis [127]. In favor of the involvement of
TSP2 into cardiac repair, the ability of TSP2 to positively modulate function of human cardiomyocyte
progenitor cells (hCMPCs) in hypoxic conditions was demonstrated [128]. In mice, short-term exposure
to hypoxia stimulates migratory and invasive properties of hCMPCs while prolonged exposure
activates proliferation, angiogenesis, and blocks migration likely due to TSP2 actions [129]. Limitation
of migratory activity of hCMPCs is necessary to induce proliferation and differentiation of progenitor
cells into cardiomyocytes in the infarcted region.
Post-MI and in cardiac hypertrophy, TSP4 expression was shown to be chronically up-regulated
in the heart, especially in the left ventricle [45]. TSP4 mRNA levels directly correlated with the rate of
left ventricular remodeling indicating the role of TSP4 in post-MI cardiac remodeling [130]. TSP4 plays
a cardioprotective role by diminishing cardiac ER stress. Furthermore, cardiac TSP4 overproduction is
protective against MI [63]. Further studies showed that the type III repeat domain and the C-terminal
domain of TSP2 are involved in Atf6α binding and regulation of ER stress response [131]. ATF6α is
an ER stress-regulated transcription factor that drives expression of ER chaperons needed to initiate
the unfolded protein response and prevent ER stress [132]. TSP4 cardiac-specific transgenic mice was
resistant to myocardial infarction (MI) while TSP4-deficient mice exert cardiac maladaptation.
In the pilot genetic study, an association of the TMP1 N700S and TMP4 A387P variants with higher
risk familial premature MI was demonstrated. The TMP2 T/G 3′UTR polymorphism was associated
with lower risk of familial MI [34]. A global meta-analysis confirmed association with CAD only for the
TMP1 N700S and TMP4 A387P polymorphisms but not for the TMP2 T/G 3′UTR [41]. The TSP4 A387P
polymorphism was associated with increased coronary risk in post-MI subjects who had elevated
levels of high density lipoprotein (HDL) cholesterol and C-reactive protein (CRP), an inflammatory
marker [39]. Accordingly, the TT genotype of the TMP2 T/G 3′UTR variant showed association with
plaque erosion independently of age, gender, and cigarette smoking in cases of sudden death [133].
Lesional erosion that is induced by intimal injury and does not lead to plaque rupture is a frequent
cause of sudden death [134]. However, the results of case-control studies were contradictory since no
significant association of the TMP1 N700S, TMP2 T/G 3’UTR, and TMP4 A387P genetic variants, and
with both CAD and MI were found in other studies [135–138]. Possible reasons of such an inconsistency
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may be referred to the different patients’ selection criteria, insufficient size of the population samples
tested, racial differences, etc. For example, the frequency of the TSP1 N700S variant was reported to
be extremely low in the Chinese Han population [138]. This therefore underlines the need to recruit
case-control cohorts of a larger size to provide a sufficient statistical power that is critical to the success
of genetic association studies to detect causal genes of human complex diseases such as CAD.
7. TMPs in Cardiac Hypertrophy
Cardiac hypertrophy can be induced by chronic pressure overload (for instance, by essential
hypertension) and is characterized by extensive growth of cardiac muscle cells, proliferation of cardiac
fibroblasts, increased ECM deposition (i.e., fibrosis), and intensive cell death. Heart fibrosis occurs
due to the massive production and deposition of collagens type I and type III, which exceeds their
degradation. Fibrosis is resulted from the up-regulation of collagen synthesis, down-regulation of
collagen destruction, or both [139]. In heart hypertrophy, cardiac matrix composition is altered due
to collagen redistribution and increased cross-linking that can lead to changes in ECM functional
properties [140]. MMPs is the most frequent type of enzymes involved in matrix remodeling. Except
for matrix degradation, MMPs also promote ECM synthesis by liberating growth factors and other
profibrotic messengers from the matrix [141]. In the heart, chronic hypertension stimulates apoptosis
of cardiomyocytes [142] and inflammation [143].
In hypertensive cardiac disease, levels of TSP1, TSP2, and TSP4 are elevated [45,59,144]. Pressure
overload stimulates heart expression of TSP1 and TSP4 [45,144]. TSP2 up-regulation was observed in
hypertrophic hearts of rats that overexpressed renin and further progressed to heart failure [59].
In mice, TSP1 deficiency led to early onset of heart hypertrophy and enhanced late dilatation
in response to pressure overload. Degenerative morphological changes in cardiomyocytes were
observed due to the sarcomeric loss and rupture of sarcolemma. Cardiac remodeling was abnormal
and accompanied with abundant infiltration of defective fibroblasts. The fibroblast-to-myofibroblast
transdifferentiation was impaired. Collagen synthesis was reduced due to the perturbed TGF-β
signaling. Furthermore, myocardial production of MMP-3 and MMP-9 was up-regulated [144]. Indeed,
TSP1 loss in the heart leads to adverse consequences by impairing response to pressure overload
and inducing aberrant tissue remodeling. TSP1 activation in the pressure-overloaded myocardium
is critical in the control of the fibroblast phenotype and heart remodeling through up-regulation of
TGF-β-dependent pathway and cardiac matrix preservation through inhibition of MMPs. However,
no significant changes in inflammatory responses was detected [144] that is rather paradoxical since
TGF-β exerts anti-inflammatory properties. In an ischemia-reperfusion model, TSP1 deletion was
associated with prolonged post-MI inflammatory response and increased release of proinflammatory
factors such as chemokine (C-C motif) ligand 2 (CCL2), chemokine (C-X-C motif) ligand 10 (CXCL10),
interleukin (IL)-1β, IL-6, macrophage inflammatory protein-1α (MIP-1α) [55]. In experimental diabetic
cardiomyopathy complicated with abdominal aortic coartaction, implementation of LKSL, a peptide
that antagonizes TSP1-dependent TGF-β activation, had beneficial actions on the myocardium by
inhibiting TGF-β-driven fibrosis [52]. Hence, from the pharmacological point of view, antagonizing
TSP1-dependent activation of TGF-β looks more attractive and efficient than blockade of TSP1 signaling
in heart hypertrophy.
Reduced vascularity because of decreased angiogenesis is supposed to promote progression of
heart hypertrophy to heart failure [145]. The inhibitory actions of TSP1 on cancer angiogenesis
were broadly investigated. However, there are contradictory results of studies that examine
microvascular effects of TSP1 in the heart. Global deletion of TSP1 was reported to induce the
development of dense cardiac capillary network and higher cardiac mass [146]. These findings were
not confirmed [144]. Up-regulation of MMPs in TSP1-deficient mice may substantially contribute to
enhanced angiogenesis [144].
In response to vasoactive stress, TSP1-deficient mice responded by increased heart rate and
changes in blood pressure by elevation of central diastolic and mean arterial blood pressure
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and reduction of peripheral blood pressure and pulse pressure. In response to epinephrine, the
hypertensive response was diminished in both TSP1-deficient or CD47-deficient mice [105]. These
data indicate an important role of TSP1 and its receptor CD47 in the acute regulation of blood
pressure, which possess vasoconstrictor effects to hold global hemodynamics under vasoactive
stress. By inhibiting NO-dependent vasorelaxation, TSP1 maintains blood pressure under stressful
conditions [107]. Since CD47 is crucially involved in TSP1-mediated regulation of blood pressure,
pharmaceutical targeting of the TSP1/CD47 mechanism may be useful for treatment of hypertension.
In cardiac hypertrophy, TSP2 and TSP4 activities are rather oriented to the control of matrix
composition. In pressure overload, TSP2-lacking mice developed cardiac rupture or heart failure
accompanied with higher activities of MMP-2/9 indicating that TSP2 contributes to the control of
cardiac integrity in hypertrophic hearts [59]. The up-regulation of TSP2 was recognized as a useless
effort to rescue the integrity in pressure overload. In response to experimentally induced transverse
aortic constriction (TAC), TSP4-deficient mice exhibited advanced heart hypertrophy and fibrosis
along with left ventricular dilation, decreased systolic and impaired diastolic function. These cardiac
changes resembled age-dependent hypertrophy and fibrosis [50]. TAC-induced interstitial fibrosis was
accompanied with up-regulated collagen production, increased MMP expression, lowered microvessel
density and was not associated with apoptosis of cardiac muscle cells and inflammation [147]. However,
it is unclear whether decrease in myocardial capillary density is the effect of fibrosis or angiogenesis.
TSP4-lacking hearts failed the ability to respond properly to acute pressure overload by enhanced
heart contractility or by activation of stretch-response pathways (Akt- and ERK1/2-dependent). In
addition to missing capacity to reply normally to acute pressure overload, TSP4-deficient mice also
failed the ability to perform an appropriate adaptive response to chronic press overload that induces
cardiac dilation, greater myocardial mass, and decline in heart function. However, no changes in
interstitial fibrosis was detected. Pressure overload affected cardiac contractility of a whole cardiac
muscle, not in separate cardiomyocytes [49]. Therefore, TSP4 can serve as a cardiomyocyte-interstitial
mechano-sensing molecule, which regulates adaptive myocardial contractile reactions in response to
acute stress. Stable and stressed ECM is likely to negatively regulate function of cardiac muscle cells,
which is confronted by TSP4 in normal conditions [49].
8. TSPs in Heart Failure
The aberrant remodeling leads to myocardial overwork that if untreated can progress to
heart failure. Structural changes associated with right or left heart failure are differentiated [148].
Right failure is characterized by intensive collagen degradation and cross-linking disruption and
off-center hypertrophy. In left failure, cardiomyocyte hypertrophy is concentric while interstitial
collagen content and cross-linking is increased [149]. Heart remodeling is accompanied by substantial
cardiomyocyte loss, which is supposed to represent one of the major mechanisms of heart failure
progression. Apoptosis, necrosis, and autophagy mediate the cardiomyocyte death [150,151].
Cardiac inflammation also contributes to heart failure through enhanced production of TNF-α and
other inflammatory cytokines that exhibit adverse effects on the myocardium [152].
TSP1 levels were decreased in human failing hearts and positively correlated with TGF-β levels
indicating that cardiac fibrosis is an attribute of early stages of heart failure [153]. In rats with
artificially induced heart failure, TSP1 production was up-regulated [154,155]. The TSP1/CD47
signaling seems to play a central role in promoting left ventricular hypertrophy and heart failure [155].
Up-regulation of histone deacetylase 3 (HDAC3) and Ca2+/calmodulin protein kinase II (CaMKII)
stimulates hypertrophy of the left ventricle. Accordingly, blockade of either CD47, HDAC3 or CaMKII
has beneficial cardiac effects by reducing hypertrophy and softening heart failure [155] thereby
underlining a value of the TSP1/CD47 pathway in the pathogenesis of heart failure.
In a murine model of age-related heart failure, a modulatory role was shown for miR-18/19, both
are members of the aging-associated miRNA cluster 17–92 that targets TSP1 and connective tissue
growth factor (CTGF) [156]. In age-related heart failure, expression of cluster 17–92 miRNA members
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was down-regulated. Accordingly, TSP1 and CTGF were increased. Importantly, these expression
changes occurred only in cardiomyocytes, not in fibroblasts. Indeed, miR-18/19 protect heart against
age-related heart failure. With aging, expression of the cluster 17–92 declines while expression of TSP1
and GTCF grows, a phenomenon that predisposes to heart failure [156].
In aged mice, TSP2 production is also increased and is attributed to the ECM surrounding cardiac
muscle cells [54]. In older animals, TSP2 deficiency was associated with severe dilated cardiomyopathy,
cardiac fibrosis, altered systolic function, and inflammation. Cardiomyocytes were subjected to
increased cellular stress and death. Cardiac capillary density was not affected. MMP-2 expression was
up-regulated and tissue transglutaminase-2 was down-regulated that led to aberrant cross-linking.
Cardiac expression of the TSP2 transgene prevented dilated cardiomyopathy in aged rats [54].
The cardioprotective action of TSP2 was confirmed in a model of doxorubicin-induced
cardiomyopathy. Deletion of TSP2 in mice caused higher death rate in response to doxorubicin
while survived animals has diminished heart function associated with intensive apoptosis of cardiac
muscle cells and ECM destruction because of MMP-1/9 activation [51]. As shown in a model of viral
myocarditis-induced heart failure, TSP2 deficiency also stimulates heart inflammation suggesting for
the involvement of TSP2 in the regulation of inflammatory response [157]. Lack of TSP2 is related to
reduced activation of regulatory T cells, advanced necrosis and fibrosis, heart dilation, and diminished
systolic function. TSP2 overexpression prevents heart failure and reduces mortality through attenuating
heart inflammation, inflammation, and virus-induced cardiac death. TSP2 was also up-regulated in
the myocardial biopsy samples from subjects affected with viral myocarditis [157]. Overall, these data
demonstrate protective effects of TSP2 against heart failure.
The up-regulation of cardiac TSP4 expression was observed in the heart of rats with pressure
overload-induced heart failure [45,158] and in rats with heart failure induced by the volume overload
after aortocaval fistula [159]. Interestingly, there were no significant changes in systolic function and
expression of genes responsible for Ca2+ homeostasis, neurohumoral regulation, contractility, and
cytoskeleton organization during transition from left ventricular hypertrophy to heart failure [158].
Only, expression of ECM proteins such as TSP4 and matrix Gla protein was elevated indicating
that progression from hypertrophy to heart failure is regulated by ECM remodeling. In the heart of
TSP4-deficient mice subjected to TAC to increase left ventricle load, massive ECM depositions, higher
cardiac mass, decreased microvessel density, abnormal heart function, and inflammation, but no signs
of apoptosis were observed [50]. These observations show that increase of cardiac TSP4 expression
is an adaptive response to pressure overload. TSP4 display cardioprotective effects by regulating
myocardial remodeling in pressure overload to prevent progression to heart failure.
9. TSPs in Calcific Aortic Valve Disease
The ECM and factors that control ECM composition and remodeling are implicated in the
pathogenesis of calcific aortic valve disease (CAVD). Inflammation and angiogenesis, both are regulated
by TSPs, also closely linked to the pathogenesis of aortic stenosis [160]. CAVD is characterized by
increased proliferation of myofibroblasts, neovasculogenesis, and valvular calcification. Expression
of TSPs 1–4 was detected in stenotic valves, with up-regulation of TSP2 [65]. TSP2 expression was
permanently increased in neovessels during progression from early valve remodeling to adverse
stenosis indicating a role of TSP2 in the control of CAVD-associated neovascularization [65]. Further
studies are required to discover a precise mechanism underlining a role of TSP2 in calcified
aortic valves.
10. TSPs in other Pathologies
The involvement of TSP1 to hypoxia-induced pulmonary hypertension was shown. This disorder
is characterized by increased pressure in the pulmonary artery, pulmonary vein, and lung vasculature.
Pulmonary hypertension is accompanied by narrowing of lung-associated vessels due to thickening of
the tunica intima and tunica media as a result of pathogenic vascular remodeling. Increased workload
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of the heart causes hypertrophy of the right ventricle that can finally progress to the right heart
failure [161].
Chronic lung ischemia induces overexpression of TSP1 in the pulmonary artery as was shown in
a pig model of experimental pulmonary hypertension. TSP1 overactivity correlated with increased
death of ECs and endothelial dysfunction likely due to the proapoptotic effects of TSP1 [162]. Similarly,
up-regulated levels of various matricellular proteins including TSP1, TSP2, and TSP4 were detected in
the right ventricle of monocrotaline-induced pulmonary hypertensive rats [163]. In humans affected
with pulmonary hypertension, elevated levels of circulating TSH1 were also reported [164]. Deletion
of TSP1 in mice was related to increased arterial VSMC hyperplasia, proliferation, and growth, less
advanced vascular remodeling, lowered right ventricular hypertrophy and right ventricle systolic
pressure compared with wild-type counterparts exposed to chronic hypoxia. In fact, TSP1-deficient
animals showed increased resistance to hypoxia-induced pulmonary hypertension [165].
Mechanistically, TSP1-induced activation of TGF-β promotes VSMC hyperplasia and proliferation
in the pulmonary artery and lung arteries of less caliber [166]. In hypoxia-induced human pulmonary
artery VSMCs, TSP1 activation also up-regulates production of the NADPH oxidase subunit, Nox4,
that can be inhibited by the peroxisome proliferator-activated receptor γ (PPARγ) or its agonist,
rosiglitazone [167]. In hypoxic VSMCs, TGF-β acts in an autocrine manner stimulating insulin-like
growth factor binding protein-3 (IGFBP-3) activation via the Akt/PI3K mechanism. IGFBP-3 then
increases Nox4 expression, which induces VSMC proliferation and transformation of cardiac fibroblasts
to myofibroblasts through ROS-dependent signaling and therefore aggravates lung arterial thickening
and right ventricular hypertrophy [168–170]. Cardiovascular protective effects of PPARγ are mediated
through inhibition of hypoxia-induced binding of the transcription factor NF-κB to the Nox4 promoter
that prevents transcription [171]. On the other hand, hypoxia was shown to down-regulate PPARγ
in pulmonary arterial VSMCs via the ERK1/2- NF-κB-Nox4 mechanism [172]. In summary, these
observations suggest for a pathogenic role of both TSP1 and TGF-β in pulmonary hypertension
that cooperate in induction of abnormal tissue remodeling associated with increased arterial VSMC
hyperplasia/proliferation and hypertrophy of the cardiac right ventricle.
In addition to the involvement of coronary atherosclerosis and post-MI cardiac remodeling, a role
of TSPs in cerebrovascular ischemic disease and ischemic stroke was reported. After stroke, increased
production of TSP1 and TSP2 was observed in experimental models of ischemic stroke [173,174]. The
post-stroke activation of TSPs is necessary to promote an adaptive response to brain injury in order to
the recover synaptic plasticity and motor function [175] and regulate angiogenic and platelet-mediated
prothrombotic mechanisms [176]. In the resolution phase of the repair of brain infarct, TSP-1/CD36
interaction is important to activate clearance of dead and apoptotic cells by macrophages in response to
stimulation by IL-4 or monocyte colony-stimulating factor (M-CSF) [174,177]. Thus, these data indicate
protective effects of TSP1 and TSP2 on brain function during healing of ischemic cerebral injury.
TSP1 plays a protective role in non-ischemic neurological pathology such as Alzheimer’s disease
(AD), fragile X syndrome, and Down syndrome, both are associated with serious mental impairments
and reduced synaptic plasticity. Decreased expression of TSP1 was shown in a subset of cortical
pyramidal neurons and astrocytes that are prone to AD [178,179]. TSP1 was shown to protect neurons
against β-amyloid-induced synaptic degeneration [179]. On the other hand, β-amyloid inhibits release
of TSP1 by astrocytes that in turn attenuates expression of synaptic proteins such as synaptophysin
and PSD95 followed by aberrations in the morphology of dendritic spines and reduction of synaptic
plasticity [180]. Similar abnormalities such as spine malformations and reduced synaptic density were
observed in Down syndrome astrocytes, astrocytes from animal models of fragile X syndrome, and
astrocytes from TSP-deficient mice indicating a pathological role of TSP1 deficits [181,182]. In the
AD brain, prostaglandin E2, an inflammatory messenger, reduces astrocytic expression of TSP1 by
induction of miR-135 that targets the TSP1 mRNA. Binding of prostaglandin E2 to its receptor EP4
leads to protein kinase A (PKA)-dependent stimulation of the CCAAT/enhancer-binding protein δ
(CEBPD), a transcriptional coactivator that up-regulates expression of miR-135 in astrocytes [183].
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In summary, these findings suggest for a key role of TSP1 in astrogenesis and maturation, spine
development, and synaptogenesis. Thus, decreased TSP1 activity is linked to neurodegenerative,
neurodevelopmental, and mental pathology associated with dysfunction of dendritic spines and
aberrations in synaptic plasticity.
Thrombospondins may contribute to the pathogenesis of congenital heart defects (i.e., congenital
heart disease) associated with structural heart anomalies presented at birth. In children with congenital
ventricular septal defect characterized by the perforation of the ventricular septum, serum levels
of TSP1 were dramatically increased and showed positive correlation with the risk of ventricular
septal defect [184] thereby suggesting for a potential value for early diagnosis of this cardiac defect. A
pathologic role of TSP1 up-regulation in the ventricular septal defect is unclear but may be related to
the constitutive impairment of the TGF-β signaling associated with alterations of migration of neural
crest cells [185] that contribute to the formation of the septum part, which separates the pulmonary
circulation from the aorta [186].
Depletion of the Hect domain E3 ubiquitin ligase Nedd4 in mice resulted in detrimental
abnormalities in heart development associated with the formation of double-outlet right ventricle
and atrioventricular cushion defects that was fatal for developing embryos [187]. TSP1 expression
was markedly up-regulated in Nedd4-deficient mice. Nedd4 is involved in the ubiquitination of a
variety of ion channels, membrane transporters, growth factors and their receptors [188] followed
by proteosomal degradation. Interestingly, VEGFR2 is a Nedd4 substrate [189] whose degradation
is promoted by TSP1. Indeed, Nedd4-deficient mice experience adverse problems in cardiogenesis
and vasculogenesis associated with letal developmental deviations likely due to the defects in protein
trafficking machinery, ER stress, and heart malformations due to enhanced and deregulated growth
factor signaling. In addition, Nedd4 deficiency may induce the premature control loss of the activity
of sodium channels such as cardiac voltage-gated channel Nav1.5 [190] and peripheral neuronal
channels Nav1.2 and Nav1.7 [191], which is rather lethal because of the inability to support heart
conduction/contractility and cardiac/neuronal connectivity in a proper manner.
Some cardiac congenital aberrations such as for example the Holt-Oram syndrome are
accompanied by alterations in electrical conduction [192]. The role of TSPs in the regulation of
myocardial electrophysiology and contraction is widely unclear. Direct evidence for the involvement
to the cardiac muscle contractility was obtained only for TSP4 that modulates heart contraction in
response to stress induced by enhanced blood flow [49]. In TSP1-deficient mice, no difference in heart
contractility was observed compared to the wild-type counterparts [193]. Although TSPs are able
to bind many Ca2+ cations, this property may be primarily essential for Ca2+-dependent signaling.
However, there are some evidence in favor of a potential involvement of TPSs in the control of muscle
contraction. As mentioned above, the TSP1/CD47 mechanism is implicated in CaKMII-mediated
cardiac hypertrophy [155]. In differentiated SMCs, CaKMII controls cell contractility [194]. In
peripheral sensory nerves, painful nerve injury interrupts Ca2+ signaling by stimulating plasma
membrane Ca2+-ATPase (PMCA) activity and inhibiting sarco-endoplasmic reticulum Ca2+-ATPase
(SERCA) activity that results in depletion of ER-associated Ca2+ depots and increase of cytoplasmic
Ca2+ levels. Injury-induced TSP4 up-regulation resembles effects of painful injury on Ca2+ homeostasis
by reducing Ca2+ current (ICa) via high-voltage-activated Ca2+ channels and stimulating ICa through
low-voltage-activated Ca2+ channels in dorsal root ganglion neurons. This leads to the PMCA
activation, SERCA depression, increase of store-operated Ca2+ influx, and Ca2+ signaling disruption
through TSP4-dependent stimulation of the voltage-gated Ca2+ channel α2δ1 subunit (Cavα2δ1) and
PKC-mediated signaling [195]. It would be interesting to examine whether TPSs contribute to the
regulation of cardiomyocyte-specific Ca2+ handling and activity of SERCA and CaKMII that are
primarily involved in the myocardial contractility and electric conductivity.
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11. Therapeutic Potential of Thrombospondins
The multidomain structural architecture of TSP molecules defines their diverse functions and
pleiotropic actions. TSPs have a capability to bind a variety of proteins such as cytokines, growth
factors, receptors, and proteases that emphasizes their function in a tissue- and cell type-specific
manner [23]. So far, the antiangiogenic activity of TSP1 and TSP2 in cancers inflamed an interest to
use these molecules for anti-cancer therapy [196]. Peptides mimicking the anti-angiogenic domains of
TSPs and recombinant proteins were developed [197,198].
As known, in TSP1 and TSP2, the anti-angiogenic function is related to the properdin
(type-1) repeats located at the N-terminal stalk region [22]. Small peptides derived from this
region exhibited only weak inhibitory effects on angiogenesis. However, a single D-amino acid
substitution (D-isoleucine) of a particular properdin-region heptapeptide was found to strengthen the
anti-angiogenic activity by 1000-fold [199]. Finally, a potent anti-angiogenic TSP1 mimetic nonapeptide
analog of this substituted heptapeptide named ABT-510 was constructed [200]. In preclinical studies,
ABT-510 showed an ability to efficiently inhibit VEGF-induced migration of microvascular ECs and
exhibited anti-angiogenic and anti-tumor activity in several mouse and human xenograft models [201].
In humans, ABT-510 alone or in combination with cytotoxic agents was tested in several Phase
I clinical trials to treat a variety of advanced solid and soft cancers [202–207]. Overall, ABT-510
administration was safe and well-tolerated, with modest adverse effects with injection-site reactions
and fatigue as the most frequent. The anti-tumor effect of ABT-510 varied depending on the cancer type.
In principal, treatment with ABT-510 alone had a modest efficiency. However, combinational therapy
with cytotoxic agents improved the efficiency of anti-cancer therapy. In Phase II trials [208–210],
ABT-510 monotherapy led to stabilization of tumor growth and inhibition of tumor expression of
proangiogenic factors. In overall, treatment with ABT-510 alone showed a moderate efficiency in Phase
II clinical studies by providing only a modest prolongation of overall survival of patients. Thus, based
on the results of Phase II trials, clinical application of ABT-510 in combination with other anti-cancer
agents was recommended.
In the context of cardiovascular therapy, anti-angiogenic approaches tested in tumors may
be helpful in graft atherosclerosis. Mapping of salutary and deleterious effects to different TSP
domains will provide an option to construct other TSP-targeting agents for widespread cardiovascular
pathology such as MI and heart failure. In heart hypertrophy, atherosclerosis, heart failure, and MI, the
down-regulation of the TSP/CD47 axis to enhance angiogenesis and restore NO-dependent signaling
would be beneficial [121]. CD47 blockade with a monoclonal antibody was preclinically tested in
animal models of ischemia resulted in improvement of angiogenesis and great increases in tissue
survival [109,211].
So far, assessment of therapeutic effects CD47 blockade with a monoclonal antibody undergoes
transition from the preclinical phase to clinical evaluation. The main purpose of these Phase I clinical
trials is to check biosafety/tolerability of a CD47 antibody CC-90002 and find an optimal dose for
treatment of advanced hematological neoplasms in combination with Rituximab, an anti-CD20
monoclonal antibody (trial NCT02367196) or for monotherapy of acute myeloid leukemia and
high-risk myelodysplastic syndrome (trial NCT02641002). Another humanized anti-CD47 monoclonal
antibody, Hu5F9-G4, will be clinically tested alone for treatment of recurrent/refractory acute myeloid
leukemia (trial NCT02678338) and advanced solid malignancy or lymphoma (trial NCT02216409) [212].
At present, patients are enrolled for these clinical studies. Expected beneficial effects of this
immunotherapy involve the inhibition of tumor angiogenesis and invasion, decrease of tumor-induced
macrophage apoptosis and functional impairment, and depletion of CD47-expressing cancer stem
cells that are key contributors to tumor relapse and chemoresistance [213]. In a case of the evident
tolerability to antibodies, these trials will proceed to the Phase II.
In order to target a profibrotic activity of TSP1 through the activation of TGF-β, the activation
sequence (LKSL) in the TSP1 molecule essential for the interaction with the latency-associated peptide
(LAP) was mapped [214] and an LKSL peptide was developed [215]. The peptide antagonizes TSH1
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binding to LAP and inhibits TGF-β liberation from the latent complex with LAT. The anti-fibrotic
activity of the LKSL peptide was demonstrated in various animal models including experimental
models of liver fibrosis [216], unilateral ureteral obstruction [217], diabetic nephropathy [218], and
post-hemorrhagic hydrocephalus [219]. Regarding cardiovascular pathology, cardioprotective effects of
LKSL peptide-mediated inhibition of TGF-β activation were observed in TAC-induced cardiomyopathy
in type 1 diabetic rats. Diabetic rats treated with the LKSL peptide did not develop cardiac fibrosis and
had improved heart function [52]. However, in a recent study, detrimental effects of implication of
this peptide to treat angiotensin II-induced abdominal aortic aneurysm in ApoE-deficient mice were
observed [220]. LKSL-dependent suppression of TGF-β activation further aggravated abdominal aortic
aneurysm associated with increase of aortic diameter, adverse atherosclerosis within the aortic arch,
and aortic elastin fragmentation due to down-regulation of the TGF-β-target gene lysyl oxidase-like
1 (LOXL1), an enzyme involved in cross-linking of elastin [221]. These data suggest for protective
role of TGF-β against aortic aneurism. Inhibition of TGF-β signaling may therefore have deleterious
consequences by impairing vascular ECM repair and promoting aortic infiltration of inflammatory
cells. However, in overall, LKSL-mediated suppression of TSH1-dependent TGF-β activation showed
beneficial results in inhibition of tissue fibrosis and should be further explored to prevent or diminish
the advanced profibrotic response in hypertrophic hearts or in post-MI cardiac repair.
Since the regenerative potential of human heart is limited, MI-induced loss of cardiomyocytes can
result in heart failure and death. Stem cell therapy has emerged as a promising strategy for healing
cardiac injury, directly or indirectly, and seems to offer functional benefits to patients. Cardiac stem
cell therapy involves using of hematopoietic, mesenchymal, and cardiac stem cells for regenerative
purposes. However, a common challenge is to increase the retention and survival of engrafted cells at
the injured site in order to strengthen their chances for proliferation and differentiation to functional
cardiomyocytes [222]. To enhance the regenerative and prosurvival capacity, stem cells are subjected
to ischemic/pharmacological preconditioning before transplantation. For example, regenerative
properties of CD34+ hematopoietic progenitor cells from diabetic patients with atherosclerosis are
frequently reduced and impaired. Treatment of CD34+ progenitors with TSP1-derived peptide
RFYVVMWK promotes expression of TSP-1, integrins, and P-selectin that in turn increases adhesion
capability and retention of the autologous progenitor cell engraft although do not affect apoptosis
and viability [223]. Hypoxic exposure of adipose tissue-derived mesenchymal cells from aged mice
improve their functionality by decreasing expression of anti-angiogenic, prothrombotic, and profibrotic
molecules such as TSP-1, plasminogen activator inhibitor-1 (PAI-1), and TGF-β [224]. Preconditioning
of mesenchymal stem cells with oxytocin significantly stimulates their therapeutic potential, angiogenic
properties, and resistance to hypoxia and apoptosis through induction of various prosurvival and
anti-apoptotic factors including TSP-1 [225].
12. Conclusions
Effects of TSPs on the mechanisms of cardiac remodeling are represented in Figure 2. Table 1
recapitulates TSP-dependent actions in the cardiovascular system. In summary, TSP1, TSP2, and
TSP4 possess protective properties against heart hypertrophy since their deletion in animal models of
pressure overload results in aberrant remodeling [49,50,59,144,147]. Lack of TSP1 and TSP2 activates
MMP production and causes dilation of the left ventricle whereas altered TSP1-dependent TGF-β
activation disturbs conversion of fibroblasts to myofibroblasts and down-regulates cardiac matrix
synthesis [144]. In a murine pressure overload model, loss of TSP4 resulted in increased cardiac
mass and fibrosis [50]. TSP4 also protects from abnormal heart remodeling through induction of
stretch-mediated enhancement of myocardial contraction in pressure overload and prevention of the
ER stress in cardiomyocytes [49,63]. On the basis of the role in heart hypertrophy, TSP1 and TSP2
would be suggested to influence post-MI remodeling but their effects are needed to be evaluated.
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Figure 2. The role of thrombospondins (TSPs) in cardiovascular pathology. TSP1, TSP2, and TSP4
are the best preclinically studied TSPs in experimental models of cardiovascular pathology involving
knockout or overexpression of these TSPs. Sharp arrows define stimulatory effects. Other type of
arrows defines inhibitory effects.
Table 1. The role of thrombospondins in cardiovascular physiology and pathology
Characteristics TSP1 TSP2 TSP3 TSP4 TSP5
Expression in the vascular wall Yes Yes Yes Yes Yes
Expression in the atherosclerotic
plaque Yes Yes Yes Yes Yes
Cardiac expression Yes Yes No? Yes Unknown
Angiogenesis in the myocardium Inhibition Inhibition Unknown Activation Unknown
Up-regulated expression in
cardiac remodeling Yes Yes Yes Yes Yes
Inhibition of MMP-2/3/9 Yes Yes No No No
Cardiac fibrosis Activation/Inhibition Inhibition Unknown Inhibition Unknown
VSMC proliferation/ hyperplasia Activation Activation Unknown No effect Inhibition
Blood pressure Vasoconstriction Vasoconstriction Unknown Unknown Unknown








Unknown Unknown Recruitment tothe plaque Unknown
Plaque progression Activation Unknown Unknown Activation Unknown
Oxidative stress Activation Unknown Unknown Unknown Unknown
Cardiomyocyte apoptosis Inhibition Inhibition Unknown Unknown Unknown
Cardiac contractility No effect Unknown Unknown Activation Unknown
Cardiac hypertrophy Inhibition Inhibition Unknown Inhibition Unknown
Heart failure Inhibition? Inhibition Unknown Inhibition Unknown
Abbreviations: MMP, matrix metalloproteinase; TSP, thrombospondin; VSMC, vascular smooth muscle cell.
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In failing hearts, TSP2 and TSP4 protect cardiac ECM from adverse remodeling. In TSP-deficient
ageing heart, systolic function is altered while fibrinogenesis and cardiac dilatation are activated [54].
Also, an advanced cardiac muscle cell death, inflammation, MMP-2 activation and aberrant collagen
cross-linking was observed [54]. TSP2 possess cardioprotective properties against heart failure in
viral myocarditis by repressing inflammation, fibrotic response, and cardiomyocyte death [157].
In doxorubicin-induced cardiomyopathy, the anti-hypertrophic activity of TSP2 is related to the
inhibition of apoptosis of cardiac muscle cells and preserving ECM from the damage [51]. As in
a case of TSP2, TSP4 deletion results in fibrosis, altered diastolic function, and depressed systolic
function denoting the involvement of TSP4 in the regulation of ECM composition [50]. Finally, TSP4
appears to possess the proatherosclerotic activity since ApoE-deficient mice lacking TSP4 had reduced
macrophage accumulation in the plaques due to reduced proinflammatory activation of ECs and
decreased recruitment of inflammatory leukocytes to the endothelium [31].
So far, the most comprehensive functional assessment of the physiological and pathological roles
was done only for TSP1, a founder member of the TSP family. Less complete results were obtained
for TSP2 and TSP4. From the scientific literature, there is a profound data deficit about the function
of TSP3 and TSP5. Although TSP3 is expressed by VSMCs at significant levels, its expression in the
homeostatic myocardium seems to be absent [42]. However, stimulation of cardiac fibroblasts with
a peptide matricryptin generated by a limited proteolysis of collagen Iα1 by MMP-2/9 results in
the induction of TSP3 expression. Along with TSP3, matricryptin induces production of many ECM
structural and regulatory proteins that contribute to post-MI cardiac repair and promote scar formation
and angiogenesis [226]. This effect of matricryptin has a therapeutic promise and therefore should
be further evaluated. Since TSP1 and TSP2 inhibit proteolytic activation of MMP-2 and MMP-9 [227],
these TSPs can potentially suppress cardiac expression of TSP3. Therefore, assessing reciprocal TSP
regulation would be intriguing. Thus, future prospects in the thrombospondin-related research may
ultimately concern investigation of TSP3 and TSP5 functions. Further, TSPs have a variety of binding
partners and the number of TSP ligands is growing. However, regulatory mechanisms of binding these
ligands are widely unknown. Actually, ligand binding is spatially and temporally regulated, and it
would be of great interest to reveal these regulatory patterns and recognize their functional significance.
Overall, studies involving knockout mice indicate that deficiency of TSP1, TSP2, and TSP4 appears
to be deleterious in cardiovascular pathology. Therefore, enhancing of cardiac TSP-dependent signaling
in stressful settings such as pressure overload may be profitable. Precise analysis of the relationship
between the TSP structure and function, identification of new receptors, and functional mapping of
various domains will be useful for the development of novel drugs to target TSPs and promote the
gain in TSP-dependent signaling pathways.
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Abstract: Pulmonary vascular remodeling is a pathophysiological feature that common to all
classes of pulmonary hypertension (PH) and right ventricular dysfunction, which is the major
prognosis-limiting factor. Vascular, as well as cardiac tissue remodeling are associated with a
re-expression of fetal variants of cellular adhesion proteins, including tenascin-C (Tn-C). We analyzed
circulating levels of the fetal Tn-C splicing variants B+ and C+ Tn-C in serum of PH patients to
evaluate their potential as novel biomarkers reflecting vascular remodeling and right ventricular
dysfunction. Serum concentrations of B+ and C+ Tn-C were determined in 80 PH patients and
were compared to 40 healthy controls by enzyme-linked immunosorbent assay. Clinical, laboratory,
echocardiographic, and functional data were correlated with Tn-C levels. Serum concentrations of
both Tn-C variants were significantly elevated in patients with PH (p < 0.05). Significant correlations
could be observed between Tn-C and echocardiographic parameters, including systolic pulmonary
artery pressure (B+ Tn-C: r = 0.31, p < 0.001, C+ Tn-C: r = 0.26, p = 0.006) and right atrial area (B+ Tn-C:
r = 0.46, p < 0.001, C+ Tn-C: r = 0.49, p < 0.001), and laboratory values like BNP (B+ Tn-C: r = 0.45,
p < 0.001, C+ Tn-C: r = 0.42, p < 0.001). An inverse correlation was observed between Tn-C variants
and 6-minute walk distance as a functional parameter (B+ Tn-C: r = −0.54, p < 0.001, C+ Tn-C:
r = −0.43, p < 0.001). In a multivariate analysis, B+ Tn-C, but not C+ Tn-C, was found to be an
independent predictor of pulmonary hypertension. Both fetal Tn-C variants may represent novel
biomarkers that are capable of estimating both pulmonary vascular remodeling and right ventricular
load. The potential beneficial impact of Tn-C variants for risk stratification in patients with PH needs
further investigation.
Keywords: fetal tenascin-C; pulmonary hypertension; vascular remodeling; right ventricular dysfunction
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1. Introduction
Pulmonary hypertension (PH) is a clinical entity consisting of different conditions with elevated
mean pulmonary arterial pressure (PAP) that is above 25 mmHg and is quantified by invasive
measurements [1]. Elevation of PAP is associated with increased morbidity and mortality rates [2].
According to the classification used by current guidelines [1], five entities of PH are distinguished
according to etiology. Group 1, pulmonary arterial hypertension (PAH), mainly includes the idiopathic
and hereditary forms, as well as PH that is associated with connective tissue disease and drug intake.
Group II is defined as PH due to left heart disease. Group III covers PH due to lung diseases and/or
hypoxia. Group IV includes those conditions where chronic thromboembolic pulmonary events
result in PH (CTEPH). Lastly, Group V covers miscellaneous disorders that lead to an increase in the
pulmonary arterial pressure. However, significant overlap in clinical features and etiology exists [1].
Despite the diversity in PH etiology, certain pathophysiological processes occur in all forms of
pulmonary hypertension. These include vasoconstriction, microthrombi formation, and pulmonary
vascular remodeling, including structural and functional rebuilding of the extracellular matrix
(ECM) [3]. Pathological tissue remodeling is known to be accompanied by the re-occurrence of
fetal variants of matrix proteins, like tenascin-C (Tn-C), which are absent in non-diseased mature
tissues. This effect has been repeatedly demonstrated for remodeling of cardiac tissue [4–9], but also
occurs during vascular remodeling [10]. The cell adhesion molecule Tn-C is known to play a pivotal
role in the regulation of cell adhesion, activation, differentiation, and migration in inflammation and
tissue remodeling [11]. Different so-called fetal variants of this protein are generated by alternative
splicing of the pre-mRNA, in particular B and C-domain, containing Tn-C (B+ and C+ Tn-C) [12,13].
These variants are expressed during embryonic development and under pathological conditions, while
being virtually absent in healthy adult organs [14].
Because of the close association of fetal Tn-C variants and tissue, as well as vascular remodeling,
the aim of the present study was to investigate the serum concentrations of B+ and C+ Tn-C in patients
with pulmonary hypertension as compared to healthy control persons. Additionally, the assessment
of echocardiographic, standard laboratory and functional parameters were performed to enable
correlation analyses with circulating Tn-C to elucidate the possible role of these protein variants as
novel biomarkers for diagnosis and risk stratification in patients with PH.
2. Results
2.1. Baseline Characteristics
For these investigations, 80 patients with PH and 40 apparently healthy subjects were recruited.
Baseline characteristics of the included PH patients, as well as controls are reported in Table 1.
PH patients had more co-morbidities, such as hyperlipidemia, coronary artery disease, diabetes
mellitus, and chronic kidney disease. Medical therapy of the PH patients included more frequent
intake of statins and glucocorticoids. Laboratory analyses revealed higher BNP, CRP, and creatinine,
and lower LDL cholesterol and hemoglobin. The lower LDL cholesterol is at least in part explained by
the higher intake of statins in the PH patients but also the chronic inflammatory state.
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Table 1. Clinical data: Cardiovascular risk factors and medication of the study groups. In (A)
presented for patients with pulmonary hypertension irrespective the etiology and control patients,
in (B) presented for patients with pulmonary hypertension that are subdivided according to the etiology
and control patients.
(A)
Clinical Parameter Control Persons (n = 40) PH Patients (n = 80) p-Value
Age (years) 66 ± 7 70 ± 13 n.s.
BMI (kg/m2) 27.9 ± 4.7 28.6 ± 6.0 n.s.
Gender, male (%) 33 39 n.s.
Systolic BP (mmHg) 146 ± 33 146 ± 33 n.s.
Diastolic BP (mmHg) 81 ± 17 78 ± 13 n.s.
Functional class 1.5 ± 0.6 2.6 ± 0.8 <0.001
Laboratory:
BNP (pg/mL) 56 ± 70 445 ± 584 <0.001
CRP (mg/L) 2.7 ± 2.6 11.7 ± 17.5 0.002
Creatinine (μmol/l) 76 ± 16 111 ± 50 <0.001
LDL (mmol/l) 3.6 ± 1.0 2.7 ± 1.0 <0.001
Haemoglobin (mmol/l) 8.7 ± 0.8 7.9 ± 1.3 <0.001
Leukocytes (Gpt/l) 7.1 ± 1.4 7.5 ± 2.2 n.s.
Co-Morbidities:
Hypertension (%) 95 83 0.03
Hyperlipidemia (%) 88 56 <0.001
Obesity (%) (BMI>30 kg/m2) 42 38 n.s.
CAD (%) 0 26 <0.001
CKD (%) (GFR < 50 mL/min) 8 50 <0.001
Diabetes (%) 20 50 0.002
Smoking (%) 29 52 0.027
Medication:
ASA (%) 25 18 n.s.
Beta blocker (%) 63 60 n.s.
ACE Inhibitor/Sartans (%) 85 78 n.s.
Statins (%) 38 59 0.026
Prednisolon (%) 0 11 0.027



















Age (years) 66.0 ± 6.8 64.5 ± 11.5 75.1 ± 8.1 58.5 ± 22.3 69.8 ± 11.5 74.9 ± 7.9 <0.001
BMI (kg/m2) 28.0 ± 4.7 29.0 ± 8.4 27.9 ± 3.9 25.9 ± 7.5 30.6 ± 5.2 29.9 ± 6.5 n.s.
Functional class 1.5 ± 0.6 2.6 ± 0.8 2.6 ± 0.7 2.4 ± 1.1 2.3 ± 0.7 2.8 ± 0.7 n.s.
Laboratory:
BNP (pg/mL) 56 ± 70 113 ± 82 635 ± 678 469 ± 469 111 ± 87 627 ± 731 0.021
CRP (mg/L) 2.7 ± 2.6 7.8 ± 10.7 13.8 ± 21.0 10.5 ± 12.9 5.2 ± 5.8 16.1 ± 22.0 n.s.
Creatinine (μmol/L) 76 ± 16 88 ± 44 127 ± 59 93 ± 24 99 ± 40 121 ± 47 n.s.
LDL (mmol/L) 3.6 ± 1.0 2.5 ± 1.0 2.5 ± 1.0 3.0 ± 1.0 3.0 ± 0.9 2.7 ± 1.2 n.s.
Haemoglobin (mmol/L) 8.7 ± 0.8 7.7 ± 1.5 7.5 ± 1.2 8.5 ± 1.0 8.9 ± 1.4 7.6 ± 1.6 0.012
Leukocytes (Gpt/L) 7.1 ± 1.4 6.7 ± 2.4 7.6 ± 1.7 8.3 ± 1.5 7.4 ± 1.8 7.7 ± 3.4 n.s.
Data are presented as mean ± standard deviation or percentage. ACE = angiotensin-converting enzyme,
ASA = acetyl-salicylic acid, BMI = Body mass index, BNP—brain natriuretic peptide, CHD = coronary heart disease,
CKD = chronic kidney disease, CRP = C-reactive protein, LDL = low-density lipoprotein, n.s. = not significant.
2.2. Serum Levels of B+ and C+ Tn-C
Both fetal splicing variants of Tn-C were higher in patients with PH (B+ Tn-C: 752 (CI 520–1110)
ng/mL versus 368 (CI 238–616) ng/mL, p < 0.001, Figure 1A; C+ Tn-C: 79 (CI 48–125) ng/mL versus
66 (CI 44–82) ng/mL, p = 0.034, Figure 1B).
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Figure 1. Increased serum levels of B+ and C+ Tn-C in patients with pulmonary hypertension (PH)
compared to healthy controls. (A) shows the results for B+ Tn-C; (B) for C+ Tn-C; (C,D) show the
subgroup analyses with respect to the PH etiology, PH classes are named according to the classification
of the current guidelines. The box plots indicate the median (line inside the box), 25 and 75 percentile
(lower and upper boundary of the box), 10 and 90 percentile (whiskers outside the box) as well as
outlier values (dots). Cl. = class, Tn-C = Tenascin C.
For B+ Tn-C, analysis with respect to the PH etiology revealed significant elevations compared
to healthy controls for all classes investigated: class I (780 (CI 559–1350) ng/mL, p = 0.002), class II
(778 (CI 530–1191) ng/mL, p < 0.001), class III PH (811 (CI 447–1324) ng/mL, p = 0.001), and class IV
(624 (CI 489–829) ng/mL, p = 0.018). Similar results were found for PH of mixed genesis, including PH
resulting from lung and cardiac diseases (class II and class III) (706 (CI 478–1089) ng/mL, p = 0.002)
(Figure 1C). For C+ Tn-C, significantly elevated concentrations were observed in patients with PH
when compared to controls, but subgroup analysis only revealed a significant difference in patients
with PH class II as compared to healthy controls (PH class II: 83 (CI 54–142), p = 0.030) (Figure 1D).
2.3. Correlation of Tn-C Serum Levels with Echocardiographic Parameters
For both patients’ groups, echocardiographic parameters were obtained (Table 2) and were
correlated with the serum concentrations of Tn-C. For both variants of Tn-C, a significant correlation
between the serum concentration and the systolic PAP was observed (B+ Tn-C: r = 0.31, p < 0.001,
C+ Tn-C: r = 0.26, p = 0.006). Additionally, a significant correlation between the serum levels of B+ and
C+ Tn-C and the right atrial area was found (B+ Tn-C: r = 0.46, p < 0.001, C+ Tn-C: r = 0.49, p < 0.001).
These correlations are demonstrated in Figure 2. No significant correlation was observed between
Tn-C variants and TAPSE or TDI of the RV as markers of right heart dysfunction.
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& III (n = 14)
LV-EF (%) 68 ± 7 63 ± 7 56 ± 13 63 ± 9 60 ± 6 52 ± 12
IVSDd (mm) 12 ± 2 12 ± 3 13 ± 3 13 ± 2 11 ± 2 12 ± 2
RVd basal (mm) 35 ± 2 41 ± 9 46 ± 7 47 ± 10 44 ± 7 49 ± 9
TAPSE (mm) 25 ± 2 22 ± 5 15 ± 3 19 ± 7 18 ± 3 16 ± 4
TDI-S’ (RV) (cm/s) 14 ± 2 12 ± 1 8 ± 1 9 ± 0 11 ± 1 9 ± 2
RA area (cm2) 15.4 ± 2.3 20.8 ± 8.3 27.9 ± 9.6 19.7 ± 8.8 22.2 ± 5.2 31.0 ± 13.7
PAP sys (mmHg) 21 ± 4 59 ± 22 52 ± 16 57 ± 22 50 ± 20 56 ± 16
Data are presented as mean ± standard deviation. IVSDd = intraventricular septum diameter in diastole,
LV-EF = left ventricular ejection fraction, PAP sys = systolic pulmonary arterial pressure, RA = right atrium,
RVd = right ventricular diameter in diastole, TAPSE = tricuspid annular plane systolic excursion, TDI-S’ (RV) = tissue
doppler imaging, right ventricle. PH classes given in this table correspond to the PH groups defined in the
current guidelines.
Figure 2. Correlation analyses between the serum concentration of B+ and C+ Tn-C and
echocardiographic parameters. The correlation analysis graphs demonstrate significant correlations
between B+ and C+ Tn-C and the systolic pulmonary artery pressure (A,B), as well as the area of the
right atrium (C,D). PAP sys = systolic pulmonary arterial pressure, RA = right atrium, Tn-C = tenascin C,
p-value = level of significance, r-value = correlation coefficient.
2.4. Correlation of Tn-C Serum Levels with BNP
Serum concentration of Tn-C correlated with BNP as a standard laboratory parameter of heart
failure. For both Tn-C variants, a significant correlation could be demonstrated (B+ Tn-C: r = 0.45,
p < 0.001; C+ Tn-C: r = 0.42, p < 0.001, Figure 3).
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Figure 3. Correlation analyses between the serum concentration of B+ (A) and C+ (B) Tn-C and the
brain natriuretic peptide (BNP). BNP = brain natriuretic peptide, Tn-C = tenascin C, p-value = level of
significance, r-value = correlation coefficient.
2.5. Correlation of Tn-C Serum Concentrations with the 6-Minute Walk Distance
An inverse correlation was observed between serum levels of the two Tn-C variants and the
6-minute walk distance (B+ Tn-C: r = −0.54, p < 0.001; C+ Tn-C: r = −0.43, p < 0.001) as a parameter
reflecting functional capacity (Figure 4).
Figure 4. Correlation analyses between the serum concentration of B+ (A) and C+ (B) Tn-C and the
6-min walk distance. Tn-C = tenascin C, p-value = level of significance, r-value = correlation coefficient.
2.6. Impact of Clinical Parameters on Tn-C Serum Levels
Because of significant clinical differences in the patient groups that were enrolled in our study,
we performed further analyses investigating possible confounding variables. To verify the predictive
value of Tn-C serum concentration for the probability of pulmonary hypertension, a multivariate
analysis was performed. Age, diabetes mellitus, CAD, CKD, statin medication, C-reactive protein levels,
and the serum concentration of the two Tn-C variants were entered into the analysis as independent
variables. After backward elimination, only CKD (Wald: 9.529, OR: 12.316, 95% CI: 2.501–60.647,
p = 0.002), C-reactive protein (Wald: 4.414, OR: 1.199, 95% CI: 1.012–1.420, p = 0.036), and B+ Tn-C
(Wald: 7.854, OR: 1.002, 95% CI: 1.001–1.004, p = 0.005), but not age, diabetes mellitus, CAD, statin
medication, and C+ Tn-C were found to be independent predictors of pulmonary hypertension.
3. Discussion
Pathological tissue and vascular remodeling is associated with a variety of cardiovascular
disorders results in the re-occurrence of fetal variants of extracellular matrix and cell adhesion
modulating proteins like Tn-C, which are virtually absent in non-diseased adult organs [14].
The re-expression of fetal Tn-C variants like B+ and T+ Tn-C was repeatedly demonstrated to
reflect the extent of cardiovascular remodeling and disease severity for several heart diseases [6,7,9].
Therefore, these molecules have been suggested as novel biomarkers not only for diagnosis and
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prognosis estimation, but also for therapeutic surveillance since serum levels also reflect reverse
remodeling [4–6,9,15,16]. Fetal Tn-C re-occurrence has also been demonstrated with special regard to
vascular remodeling processes [17,18].
In an animal model using monocrotaline-injected rats, Rabinovitch and colleagues demonstrated
that the development of pulmonary arterial medial hypertrophy was accompanied by Tn-C expression
in co-localization with proliferating smooth muscle cells [17]. Additionally, it could be shown
that iloprost inhalation results in a reversion of the remodeling process reflected by a decrease
in Tn-C occurrence [18]. Furthermore, Correira-Pinto et al. also demonstrated an overexpression
of Tn-C in cardiac tissue of monocrotaline-induced pulmonary hypertension in an animal model
reflecting PH-induced cardiac, and in particular, right ventricular pressure overload [19]. However,
these observations have only been made for Tn-C found in tissue, not serum, and it is well known that
lung tissue from PH patients is not available in daily routine because taking biopsies is not indicated
in these patients and will not be an option, even in the future, due to the high risk associated with this
invasive procedure.
In the present study, we investigated fetal Tn-C variants as serum biomarkers of tissue and
vascular remodeling in human PH. We demonstrate that fetal Tn-C levels are increased in PH when
compared to healthy controls. Elevated Tn-C concentrations in patients suffering from PH have
previously been described by Schumann et al. [20]. The authors, however, did not analyze different
fetal Tn-C variants [20]. Therefore, our data are the first to demonstrate both B+ and C+ Tn-C as
functionally most important fetal splicing variants of the protein with prognostic significance in PH.
Subgroup analyses of the present study revealed that an elevated serum concentration of B+ Tn-C
occurs in PH due to different etiologies as compared to healthy controls. For C+ Tn-C, subgroup
analysis revealed significant differences only between PH class II and the control group. It has to
be mentioned, that in this PH class, the highest number of patients has been included. Besides
this, the intake of glucocorticoids might diminish statistical significance in PH due to lung diseases.
An influence of glucocorticoids on Tn-C expression has been previously described in the literature [21–23].
Interestingly, Tn-C serum concentrations could be shown to correlate with echocardiographic
parameters, such as systolic PAP and the area of the right atrium. This demonstrates significant
correlations between the fetal variants of the matrix glycoprotein and parameters reflecting right
ventricular load. This finding is supported by former studies that found PH-induced cardiac
remodeling with an increased Tn-C occurrence [19]. This idea is supported by a publication
investigating a patient cohort with acute pulmonary thromboembolism describing a correlation
between Tn-C and systolic PAP [24]. Additionally, similar effects have been described in an
animal model. Monocrotaline-induced right ventricular failure was shown to be associated with
an up-regulation of Tn-C gene expression and results in significantly elevated plasma levels. However,
in this model, a significant correlation could be observed for right ventricular ejection fraction and
Tn-C [25]. In our present study, as markers of right ventricular function, TAPSE and TDI were
echocardiographically measured but no significant correlation between these parameters and Tn-C
were observed.
Another interesting finding of the present study was a significant positive correlation between
serum BNP and both, B+ and C+ Tn-C levels. This reflects prior findings in human studies of patients
with acute PH due to pulmonary thromboembolism [24], as well as animal models [25]. Besides PH,
this correlation has also repeatedly been described in other cardiovascular diseases [16]. However,
the present study was not only able to demonstrate a correlation between the fetal Tn-C variants and
laboratory parameters, but also with functional data reflecting the physical capability of PH patients
assessed by the 6-min walk test. This association was found for both Tn-C variants and is a novel
finding of the current study.
There are certain limitations of our study. First, due to the small numbers of patients, statistical
analyses underestimate the differences. Second, heterogeneity with respect to the clinical data of
PH patients and the controls has to be mentioned. Moreover, significant differences in the subgroup
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analyses can be explained by the PH etiology. The highest mean BNP value is found in the PH class II,
reflecting PH due to left heart disease. This is possibly due to the increased cardiac load not only of the
right heart, but also the left heart occurring in the course of the underlying disease.
4. Material and Methods
4.1. Patients
We enrolled 80 patients with PH admitted to the Department of Internal Medicine I, Jena University
Hospital, Friedrich Schiller University of Jena, Germany. 40 apparently healthy control subjects were
recruited within the same department. Controls were enrolled after invasive exclusion of coronary
artery disease [26]. Further exclusion criteria were malignant or autoimmune disease, hyperthyroidism,
infection, history of pulmonary embolism or stroke, peripheral artery disease, and medical treatment,
including corticosteroids or immunosuppressive agents. All of the patients underwent transthoracic
echocardiography and a 6-minute walk test. Blood samples were collected for routine laboratory
analyses, including serum brain natriuretic peptide (BNP) levels. Serum was stored using special
low binding tubes (Protein LoBind Tubes, Eppendorf AG, Hamburg, Germany) and stored at −80 ◦C
after snap freezing in liquid nitrogen to reduce artificial protein degradation. Moreover, repeated
freeze-thaw cycles were strictly avoided.
The investigation conforms with the principles outlined in the Declaration of Helsinki (Br Med J
1964; ii: 177) and was approved by the local ethics committee (registration number: 4732-03/16,
11 April 2016). All patients gave written informed consent before inclusion into the study.
4.2. Quantification of Serum Tn-C Levels and Standard Laboratory Values
Serum levels of B+ and C+ Tn-C were determined using enzyme-linked immunosorbent assay
(ELISA). Well-established and validated ELISA assays are commercially available (Tenascin-C
Large (FNIII-C) ELISA and Tenascin C Large (FNIII-B) ELISA, both IBL International GmbH,
Hamburg, Germany). Routine standard laboratory parameters were measured according to standard
hospital procedures.
4.3. Investigation of Echocardiographic Parameters and 6-Minute Walk Test
For each patient, a transthoracic echocardiography was performed to determine standard
parameters, including left ventricular ejection fraction (EF), diastolic diameter of the interventricular
septum (IVSDd), or relevant valve abnormalities. Moreover, special effort was made to carefully
assess the parameters representing right heart morphology and dysfunction. Here, especially tricuspid
annular plane systolic excursion (TAPSE), tissue doppler imaging of the right ventricle (TDI RV),
the area of the right atrium (RA), and systolic pulmonary arterial pressure were measured. Moreover,
6-minute walk distance was documented for each patient.
4.4. Statistical Analysis
Statistical analysis was performed using SPSS (version 20.0, IBM Inc., Armonk, NY, USA) and
SigmaPlot (version 12.0, Systat Software Inc., San Jose, CA, USA). The Kolmogorov Smirnov test
was used to test the normal distribution of all the variables. When normally distributed, values are
reported as mean ± standard deviation. When not normally distributed, the values are reported as
median (25–75% Confidence Interval). The non-parametric Mann-Whitney Rank Sum Test was used to
compare the number of different cells between two different study groups. To compare more than two
groups, the Kruskal Wallis test was used. Bivariate correlations between parametric variables were
assessed by the Spearman rank correlation test. To test the predictive value of Tn-C concentrations
on the probability of the occurrence of pulmonary hypertension, a multivariate regression analysis
was performed using a binary logistic model (backward elimination method: Wald). The presence of
pulmonary hypertension was defined as the dependent variable. Age, diabetes mellitus, CAD, CKD,
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C-reactive protein, statin treatment, and the two Tn-C variants were included into the first step. Then,
multistep backward elimination (removal threshold p > 0.10) of independent variables was carried out.
p < 0.05 was considered statistically significant.
5. Conclusions
In conclusion, the present study demonstrates that there is an increase of serum of B+ and C+
Tn-C in patients with PH. For B+ Tn-C, this is visible for all PH classes. This is an important novel
finding, because most of the studies in the field of PH have been conducted in PAH, which is a rare
disease [27]. The prevalence of especially class II and class III PH is more frequent. For this reason,
research in this field is necessary to improve diagnostic and therapeutic approaches.
Based on our findings, both the investigated Tn-C splicing variants, but especially B+ Tn-C,
can be suggested as promising novel biomarkers in human PH, which merits further investigation and
validation in larger patient cohorts. Fetal Tn-C variants are functionally involved in vascular and tissue
remodeling associated with PH probably irrespective of the particular etiology. This should be further
investigated both in vivo and in vitro and raises the question, whether functional blocking strategies
might be a therapeutic approach for PH treatment in the future. In this context, the availability
of human recombinant antibodies specific to fetal Tn-C variants might be of certain interest since
these antibodies can serve as vehicles for targeted delivery of both, bioactive molecules, such as
immunocytokines and antibody-drug-conjugates. Further, this might have diagnostic potential for the
development of novel radionuclides or molecular imaging strategies [28–30] to visualize pathologic
lung tissue and vascular remodeling.
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BMI Body mass index
BNP Brain natriuretic peptide
CAD Coronary artery disease
CKD Chronic kidney disease
CRP C-reactive protein
ECM Extracellular matrix
IVSDd Intraventricular septum diameter in diastole
LDL Low-density lipoprotein
LV-EF Left ventricular ejection fraction
PH Pulmonary hypertension
PAH Pulmonary arterial hypertension
PAP Pulmonary arterial pressure
RA Right atrium
RV Right ventricle
TAPSE Tricuspid annular plane systolic excursion
TDI Tissue doppler imaging
Tn-C Tenascin C
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Abstract: The ADAMTS5 metzincin, a secreted zinc-dependent metalloproteinase, modulates the
extracellular matrix (ECM) during limb morphogenesis and other developmental processes. Here, the
role of ADAMTS5 was investigated by knockdown of zebrafish adamts5 during embryogenesis.
This revealed impaired Sonic Hedgehog (Shh) signaling during somite patterning and early
myogenesis. Notably, synergistic regulation of myod expression by ADAMTS5 and Shh during
somite differentiation was observed. These roles were not dependent upon the catalytic activity of
ADAMTS5. These data identify a non-enzymatic function for ADAMTS5 in regulating an important
cell signaling pathway that impacts on muscle development, with implications for musculoskeletal
diseases in which ADAMTS5 and Shh have been associated.
Keywords: metalloproteinase; extracellular matrix; ADAMTS; somite; muscle; zebrafish
1. Introduction
The A Disintegrin-like and Metalloproteinase domain with Thrombospondin-1 motifs (ADAMTS)
metalloproteinases have important functions during developmental morphogenesis and are also
implicated in chronic disease. The proteoglycanase subfamily of ADAMTS1, 4, 5, 8, 9, 15 and
20 have broad functions, many attributed to their ability to remodel extracellular matrix (ECM)
components, such as the chondroitin sulphate proteoglycans versican and aggrecan. For example,
Adamts20 deficient bt/bt mice have defects in melanoblast survival [1] and Adamts9 haplo-insufficient
mice on an Adamts20 deficient (bt/bt) background present with a secondary cleft palate [2], in each
case associated with reduced versican proteolysis. Furthermore, ADAMTS1 has been implicated in
promoting atherosclerosis [3] and ADAMTS15 acts as a tumor suppressor in breast carcinoma [4],
potentially through proteoglycan proteolysis. However, non-enzymatic roles for several ADAMTS
family members have been described [5–7].
ADAMTS5 has been implicated in classic morphogenesis during development as well as in
chronic diseases such as arthritis and atherosclerosis. For example, combinatorial knockout of Adamts5,
Adamts9 and Adamts20 in mice prevented generation of bioactive fragments of versican that are
necessary for interdigital tissue apoptosis during development [8,9]. Adamts5 knockout mice also
developed myxomatous heart valves [10]. Furthermore, ADAMTS5 is considered one of the most
important aggrecan-degrading enzymes in arthritis [11,12] and may also promote lipoprotein binding
in atherosclerosis [13].
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ECM remodeling is crucial to many developmental and disease processes, in part due to its role
in controlling cell signaling. Heparan sulphate proteoglycans bind fibroblast growth factors (FGFs),
thereby regulating their bioavailability to their receptors (FGFRs) [14] during developmental processes
such as myogenesis [15], as well as acting as co-receptors for Sonic Hedgehog (Shh) signaling [16].
A recent study identified Adamts9 as necessary for umbilical cord vascular development due, at least
in part, on its facilitation of Shh signaling [17]. Furthermore, levels of Hedgehog (Hh) signaling
correlate with the severity of osteoarthritis, which is potentially mediated by a pathway involving
ADAMTS5 [18]. Combined, these studies are suggestive of a complex interplay between the ECM and
crucial cell signaling pathways that involves ADAMTS proteoglycanases.
This study identifies a role for ADAMTS5 during zebrafish embryogenesis. Abrogation of adamts5
expression disrupted Shh signaling during somite differentiation and reduced the expression of
the myogenic regulator myod. Importantly, somite differentiation was synergistically dependent
upon Shh and ADAMTS5. Moreover, these functions of ADAMTS5 were independent of catalytic
function. These data indicate that ADAMTS5 plays an important non-enzymatic role in regulating the
Shh pathway during embryogenesis that impacts on muscle development. This may be relevant in
conditions where ADAMTS proteins interact with the Shh signaling pathway, such as osteoarthritis and
umbilical cord vascular complications, as well as disorders where the myogenic program is disrupted,
such as muscular dystrophies.
2. Results
2.1. The Secreted Metalloproteinase ADAMTS5 Is Expressed in Zebrafish Embryos
We have previously elucidated a role for ADAMTS5 during myoblast fusion in post-natal
skeletal muscle from Adamts5−/− mice [19]. To investigate this further, zebrafish was employed
as a highly manipulable model of vertebrate development, which possesses a strongly conserved
adamts5 gene that is maternally inherited and then dynamically expressed in early-stage embryos [20].
To obtain a detailed understanding of ADAMTS5 protein expression in zebrafish, whole-mount
immunohistochemistry (IHC) was performed with a previously described anti-ADAMTS5 antibody
directed to its pro-domain [21], which is highly conserved in ADAMTS5 across vertebrates [20,22].
At 8 h post fertilization (hpf) (~80% epiboly), ADAMTS5 was strongly expressed in the dorsal
mesoendoderm at the animal pole with variable expression ventrally at the vegetal pole (Figure 1A).
At 18 and 24 hpf, after the commencement of somitogenesis, ADAMTS5 was expressed in the rostral
neural tube (floor plate) and bilaterally in the prosencephalon (Figure 1A).
2.2. Silencing of ADAMTS5 Expression
To explore adamts5 function, the gene was targeted using two independent morpholino antisense
oligonucleotides (MOs) that were directed to either the AUG translation start site (AUG-MO) or the
splice site at the exon 2/3 boundary (2/3-MO) (Figure 1B), since exon 3 encodes for the catalytic
domain of ADAMTS5 in human, mouse and zebrafish [22]. ADAMTS5 protein expression was found
to be reduced upon adamts5 AUG-MO injection as shown by IHC and immunoblotting (Figure 1C).
To confirm altered splicing of adamts5 transcripts after administration of the 2/3-MO, RT-PCR was
performed followed by sequencing analysis (Figure 1D). This indicated a 71% reduction of correctly
spliced adamts5 transcript and identified an alternate adamts5 transcript retaining the 569-bp intron
between exons 2 and 3 that results in inclusion of several premature stop codons (Figure 1D).
The AUG-MO was subsequently used throughout the study to ensure translation of the entire gene
was disrupted, as well as to guarantee the maternal transcripts for this gene [20] were also affected;
however, similar data was obtained with the adamts5 2/3-MO [23].
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Figure 1. Expression and silencing of adamts5 in zebrafish embryos. (A) ADAMTS5 expression in 8,
18 and 24 hpf wild-type embryos. Note strong early expression in the dorsal mesoendoderm (8 hpf,
arrows) and variable expression ventrally (8 hpf, arrowhead), with later expression in the floor plate
of the neural tube (18 and 24 hpf, arrows) and bilaterally in the prosencephalon (24 hpf, arrowheads).
Asterisks = prosencephalon in no primary antibody control. Scale bar = 250 μm; (B) Schematic
representation of the adamts5 gene structure targeted with antisense morpholino oligonucleotides
(MO), and its subsequent splicing, indicating the primers used for RT-PCR and the size of the
resultant products; (C) Reduced ADAMTS5 expression is seen in adamts5 AUG-MO injected embryos
(asterisk) versus control (arrow) by whole-mount antibody labelling (left-hand panel) and Western blot
(right-hand panel) showing the 120 kDa ADAMTS5 species (asterisk) with a region of the Coomassie
blue stained gel shown below, demonstrating even loading; (D) RT-PCR of adamts5 mRNA obtained
from 24 hpf embryos following injection of the adamts5 2/3-MO at the 1-cell stage, showing amplicons
a and b (asterisk). β-actin was used as a house-keeping gene.
2.3. Notochord Morphology Is Perturbed in adamts5 Morphant Embryos
Shh signaling from the notochord has been previously demonstrated to be important for adaxial
and paraxial mesoderm formation and myod expression during myogenesis [24], while no tail (ntl)
is an independent marker for axial mesoderm (notochord) [25]. Expression of shh and ntl remained
unchanged in 12 hpf adamts5 morphants compared to controls [23]. However, at 18 hpf the pattern of
shh (Figure 2A,D) and ntl (Figure 2B,E) staining was altered revealing disrupted notochord morphology.
2.4. Skeletal Muscle Formation Is Disrupted in adamts5 Morphant Embryos
Notochord perturbation is linked with defective somitic muscle formation and morphogenesis [24].
Therefore, the disrupted notochord morphology in the adamts5 morphants suggested that skeletal
muscle development might be affected. This is also consistent with previous observations indicating
a skeletal muscle developmental defect in Adamts5 knockout mice [19]. Reduced or absent paraxial
mesodermal myod expression was also observed at 18 hpf (Figure 2C,F). To analyze potential myofiber
defects, adamts5 AUG-MO was administered to double-transgenic embryos, in which myofiber thin
filaments were labeled with Lifeact-GFP whereas the sarcolemma and t-tubules of the myofiber
were marked with mCherryCaaX via the CaaX-tag [26]. In control injected 3 dpf double-transgenic
larvae, Lifeact-GFP revealed the typical striation of the highly organized myofibril and mCherryCaaX
indicated regularly spaced t-tubules and ordered fiber membranes within chevron-shaped somites
(Figure 2Ga–a′ ′ ′). In contrast, the somites of adamts5 morphants were U-shaped, which resembled a
phenotype previously reported in shh mutant embryos [27] (Figure 2G(b)), confirming shh availability
as a potential cause. In addition, myofibril striation within myofibers of adamts5 morphants was
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partially lost and the sarcolemma appeared irregular, indicating disrupted muscle organization
(Figure 2Gb–b′ ′ ′).
Figure 2. Notochord morphogenesis and muscle fiber formation is perturbed in adamts5 morphant
embryos. (A) Expression of shh in the notochord of 18 hpf control (a,a′, arrows) and adamts5 morphant
(b,b′, open arrowheads) embryos, with medio-lateral deviation in the adamts5 morphants (b,b′), with
anterior indicated (*); (B) Expression of ntl in the notochord of 18 hpf control (a,a′, arrows) and
adamts5 morphant (b,b′, open arrowheads) embryos, with medio-lateral deviation in the adamts5
morphants with anterior indicated (*); (C) Expression of myod in adaxial and paraxial mesoderm
of 18 hpf control embryos (a,a′) and its perturbation in adamts5 morphants (b,b′, open arrowheads)
with anterior indicated (*); (D) Quantitation of affected notochords in control and adamts5 morphant
embryos demarcated by shh in Figure 2A; (E) Quantitation of affected notochords in control and adamts5
morphant embryos demarcated by ntl in Figure 2B; (F) Quantitation of embryos with perturbed myod
expression in control and adamts5 morphant embryos demarcated in Figure 2C; (G) Double-transgenic
Tg(acta1:lifeact-GFP)/Tg(acta1:mCherryCaaX) embryos, in which thin filaments are marked green and
sarcolemma red, reveal loss of muscle integrity in 3 dpf adamts5 morphants. Muscle fibers of control
injected larvae feature the typical striation of the myofibril and regular myofibers within chevron-shape
somites, indicated by a dashed line (a). The boxed area in a is magnified in a′–a′′′. Myofibril striation
is partially lost within adamts5 morphants (arrowhead in b′) and the sarcolemma of the myofibers
disrupted (arrow in b′′). The boxed area in b is magnified in b′–b′′′. Scale bar = 50 μm.
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To further analyze myofiber differentiation, myod expression was examined. Reduced or absent
paraxial mesodermal myod expression was observed at 12 hpf (Figure 3A(a,b)), whereas expression of
adaxial mesodermal myod was largely unaffected (Figure 3A(a,b)). Similar observations were made
with the adamts5 2/3-MO (Supplementary Figure S1) or upon co-injection of a p53 morpholino with
the adamts5 AUG-MO (Supplementary Figure S2B). To ensure that the specificity of the phenotype was
due to reduced adamts5 expression, mRNA encoding either wild-type or catalytically-inactive (E411A)
ADAMTS5 were co-injected, with both able to partially rescue the reduced paraxial mesodermal myod
expression (Figure 3A(c,d), respectively, and Figure 3B). This indicated that the enzymatic function of
ADAMTS5 was not necessary to induce the reduced myod expression.
Figure 3. Loss of paraxial mesodermal myod expression in adamts5 morphant embryos. (A) Expression
of adaxial and paraxial myod in 12 hpf embryos injected with control MO (a, arrowheads), with adamts5
morphant embryos showing substantial loss of paraxial expression (b, open arrowheads), as well as
mild loss of paraxial myod expression (b, open arrowheads). Rescue of paraxial myod expression in
adamts5 morphants co-injected with mRNA encoding wild-type (c, arrows) or catalytically-inactive
E411A (d, arrows) ADAMTS5. Control embryos injected with ADAMTS5 mRNA encoding wild-type
ADAMTS5 show unaffected myod expression in paraxial mesoderm (e, arrows). Scale bar = 100 μm;
(B) Quantitation of embryos showing present or absent myod patterning represented in (A).
2.5. Receptor-Mediated Sonic Hedgehog Signaling Is Affected in adamts5 Morphants
We hypothesized that reduced ADAMTS5 could lead to an altered extracellular environment that
might disrupt Shh signaling, and that since adaxial mesoderm is in closer proximity to the notochord
it might be less disrupted compared to the paraxial mesoderm. Therefore, cyclopamine, an antagonist
of Smoothened (Smo), a receptor in the Shh signaling pathway [28] was used to understand whether
Shh signaling through Smo was impaired in adamts5 morphants. The presence of 5 μM cyclopamine
did not affect adaxial myod expression at 12 hpf in wild-type embryos (Figure 4A(g–I),B). However,
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treatment of adamts5 morphants with 5 μM cyclopamine severely affected adaxial expression of myod
(Figure 4A(j–l),B) compared to untreated adamts5 morphant embryos (Figure 4A(d–f),B). In a reciprocal
experiment, the Smo agonist, SAG, was used to confirm the dependency of Shh signaling on adamts5
expression. Administration of SAG on wild-type embryos disrupted paraxial myod expression in a
similar manner to adamts5 morphants (Figure 5A(d–I),B). However, the same concentration of SAG
partially rescued the loss of paraxial myod patterning in the adamts5 morphants (Figure 5A(g–l),B).
These experiments collectively suggest an interaction between ADAMTS5 and Shh, such that they act
synergistically to stimulate myod expression in adaxial mesoderm (Figure 6).
Figure 4. Combinatorial inhibition of Shh signaling and adamts5 disrupt paraxial and adaxial myod
expression. (A) Adaxial and paraxial myod expression in 12 hpf embryos treated with vehicle control
(a–c, arrows denote paraxial myod expression), vehicle + adamts5-MO (d–f, arrows denote absent
paraxial myod expression), 5 μM cyclopamine (g–i, arrowheads represent similar paraxial myod staining
compared to control group) and 5 μM cyclopamine + adamts5-MO (j–l, open arrowheads represent
absent adaxial myod expression and arrowhead represents absent paraxial myod staining compared to
adamts5 MO group). Scale bar = 200 μm; (B) Quantitation of embryos showing present or absent myod
patterning represented in (A).
Figure 5. Combinatorial activation of Shh signaling and inhibition of adamts5 rescues paraxial myod
expression. (A) Adaxial and paraxial myod expression in 12 hpf embryos treated with vehicle control
(a–c, arrows), 10 μM Smoothened agonist (Smo agon.) (d–f, arrow/open arrowhead represent
present/absent myod expression in paraxial mesoderm), vehicle + adamts5-MO (g–i, arrow/open
arrowhead represents present/absent myod expression in paraxial mesoderm) and 10 μM Smo agon.
+ adamts5-MO (j–l, arrows indicate myod expression present in paraxial mesoderm). Scale bar = 100 μm;
(B) Quantitation of embryos showing present or absent myod patterning represented in (A).
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Figure 6. Model of interaction between Shh and ADAMTS5. Hypothetical model showing
ADAMTS5 and Shh expression synergistically regulate downstream activation of MyoD in adaxial and
paraxial mesoderm.
3. Discussion
Zebrafish myogenesis is controlled by multiple pathways [29–31]. Signaling from the notochord
specifies slow-twitch muscle precursors in the adaxial mesoderm [24], which migrate laterally after
somite formation to the most lateral muscle layer [32]. Myotomes develop following elongation and
fusion of somitic cells and their attachment to the somite boundary, with the boundaries between
myotome forming the critical myotendenous junctions that are the primary sites of force generation [33].
ECM–cell adhesion has been shown to be essential for multiple steps in this process [34]. This study has
identified a novel non-catalytic function of the ECM protein ADAMTS5 in regulating Sonic Hedgehog
signaling that impacted on somite differentiation, with reduced expression of myod in the paraxial
mesoderm and disrupted myotome boundaries.
The phenotypes induced by the adamts5 morphants were rescued with mRNA encoding both
wild-type and catalytically-inactive ADAMTS5. Although unexpected, there is some precedence
for ADAMTS family members demonstrating non-catalytic functions as reviewed recently [35].
For texample, ADAMTS1 has been shown to bind to VEGF through its C-terminal thrombospondin
repeats and spacer domain to block VEGFR2 activation [5]. Moreover, both wild-type and
catalytically-inactive (E363A) ADAMTS15 were able to reduce breast cancer cell migration on matrices
of fibronectin or laminin [6]. Furthermore, enzymatic activity was not required for enhancement
of neurite outgrowth by ADAMTS4, which was instead dependent upon MAP kinase cascade
activation [7]. ADAMTSL family members, which are structurally similar to ADAMTS family members
but lack the N-terminal propeptide and catalytic domain, may also offer some important insights into
non-catalytic functions of ADAMTS family members. Most notably, mutations of human ADAMTSL2
have been causally linked to the musculoskeletal disorder Geleophysic Dysplasia [36], where patients
present with severe short stature, joint immobility and cardiac valvular abnormalities. Collectively,
this suggests a role of ADAMTS5 in zebrafish muscle development is likely not related to its enzymatic
function. However, mouse studies have highlighted considerable redundancy amongst ADAMTS
members [35] suggesting that combinatorial targeting might be required to identify additional functions
that may be dependent on enzymatic activity.
Shh is an important regulator of musculoskeletal development, given its role in somite and neural
tube patterning. Duplication, and presumed overexpression, of Shh is associated with congenital
muscular hypertrophy in humans [37]. Shh also enables the formation of the cranial musculature [38]
and polarizes the limb during early morphogenesis [39,40]. Shh has also been demonstrated to mediate
the patterning of somites [41,42]. Shh has the ability to activate myogenesis in vitro and in vivo [43]
with expression and secretion of Shh from the notochord able to induce slow muscle fiber formation
in vivo via myod [24]. The adamts5 morphants displayed altered myod expression in the paraxial—but
not adaxial—mesoderm despite levels of shh expression in the notochord being unaffected. This might
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be explained by reduced bioavailability of Shh in the absence of ADAMTS5. Since the adaxial
myod-positive cells represent the slow muscle precursors that subsequently move through the fast
muscle region where they impact on fast muscle differentiation [44], it would be of interest to examine
the relative distribution of slow and fast twitch muscle fibers in the adamts5 morphants.
The results obtained using agonists and antagonists of the downstream Smo pathway suggest that
ADAMTS may work both upstream, as well as in parallel with Shh signals. Wnt/β-catenin signaling
has been shown to act in co-operation with Shh (and BMPs) in embryonic myogenesis [31]. This could
be mediated, at least partially, via ADAMTS5 since Wnt/β-catenin has been shown to act upstream
of ADAMTS5 in other developmental situations, such as chondrocyte maturation and function [45].
Similarly, defects in Delta/Notch can affect somite boundary formation [46], with this pathway also
shown to induce ADAMTS5 in joint cartilage, providing another potential upstream regulator of
ADAMTS5 during somite differentiation.
Defective notochords have been identified in mutants of ECM components, such as fibrillin [47],
collagen [48], the basement membrane proteins laminin alpha [49], beta and gamma [50], as well
cell-associated molecules such as integrins [46]. A number of these defects are due to disrupted
morphogenesis that results from perturbed ECM-cell interactions [49]. This suggests that altered
morphogenesis as well as disrupted patterning may contribute to the perturbed notochord in adamts5
morphants. In addition, U-shaped myotome boundaries have also been observed in mutants of ECM
components, such as fibronectin [51] and laminin [52], or the alternative ECM processing enzyme
MMP-11 [53], providing precedence for ADAMTS5 impacting on the myotome boundary.
This study has identified a new function for the metzincin ADAMTS5. By exploring the role of
ADAMTS5 in zebrafish, understanding has been gained of a potential non-catalytic function in the
regulation of muscle development and maintenance via interaction with the Sonic Hedgehog signaling
pathway. Since both ADAMTS5 and Shh have independent—as well as potential combinatorial—roles
during musculoskeletal development, the complex interplay between ADAMTS and Shh could be
relevant to the development of musculoskeletal diseases, such as muscular dystrophies and arthritis.
Further biochemical and functional characterization of potential interactions between ADAMTS5 and
Shh in such diseases may reveal new insights into the development and progression of these diseases.
Given that treatment options for these diseases are limited, this knowledge could then be applied to the
development of novel therapeutics that specifically modulate this interaction to slow the progression
of these debilitating conditions.
4. Materials and Methods
4.1. Zebrafish Lines and Maintenance
Wild-type and Tg(acta1:lifeact-GFP)/Tg(acta1:mCherryCaax) [26] zebrafish were maintained, raised
and staged according to standard protocols [54]. Embryos were obtained by mating trios or using a
mass embryo production system (MEPS) (Aquatic Habitats) and raised at 28.5 ◦C. Experiments were
approved by the Deakin University Animal Ethics Committees (G14/2013, 15/05/2013).
4.2. Embryo Microinjection and Other Treatments
Morpholino antisense oligonucleotides (MOs; Gene Tools) targeting the ATG start codon (5′-
atgctgtcgaaattacaggagtttggcgcgtat) and exon 2/3 splice site (5′-ctatcattgaggacgacggcctgcacgctg
ccttcactgtggctcatgagatc) of zebrafish adamts5 (GenBank: JF778846.1) were used to ablate the adamts5
gene. MOs were solubilized in 1× Danieau buffer and 1 nL injected at a concentration of
1 mg/mL into one-cell stage embryos, as previously described [55]. Alternatively-spliced adamts5
species were confirmed by Sanger sequencing (Australian Genome Research Facility, Melbourne,
Australia) of RT-PCR amplicons generated with flanking primers (5′-ggcggatgtaggaactgtgt and
5′-ttacgcacctcacactgctc). Capped RNA encoding full-length wild-type or catalytically-inactive (E411A)
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ADAMTS5 [21] were synthesized using the T7 mMessage mMachine kit (Thermofisher Scientific,
Scoresby, Victoria, Australia) and 40 pg was microinjected into one-cell stage embryos.
For other studies, injected embryos were treated with 5 μM cyclopamine (Sigma-Aldrich, St. Louis,
MO, USA) in DMSO or 10 μM Smoothened agonist SAG (CAS 364590-63-6) (Merck Millipore,
Darmstadt, Germany) in water, along with the corresponding vehicle control at 5.5 hpf and fixed at
12 hpf in 4% PFA/PBS.
4.3. Whole-Mount In Situ Hybridization and Immunofluorescence
Whole-mount in situ hybridization was performed as described [56]. The following antisense
digoxigenin-labelled mRNA probes were synthesized by in vitro transcription: shha and myod [57],
and no-tail (ntl) [58]. Immunofluorescence performed on whole embryos with polyclonal rabbit
anti-propeptide ADAMTS5 (Cat# ab39203-100, Abcam, Pak Shak Kok, New Territories, Hong Kong,
China) at 1:200 followed by anti-rabbit Alexa fluor 594 secondary antibody at 1:500 (Life Technologies,
Carlsbad, CA, USA). Histochemical methods were performed as previously described [59].
4.4. Western Blotting
Cell lysates were extracted from 24 hpf embryos and subjected to Western blotting as described
previously [60], using the polyclonal rabbit antibody against propeptide ADAMTS5 described above
at 1:5000 followed by an anti-rabbit HRP antibody (Cell Signaling Technologies, Danvers, MA, USA) at
1:10,000. Protein concentrations were measured using the Bradford assay and equal loading of protein
confirmed by Coomassie blue staining on duplicate SDS-PAGE gels.
4.5. Statistics
Two-tailed paired t-tests were performed between all treatment groups compared to the respective
control groups with scoring performed blind. Significance was achieved at a p-value ≤ 0.05, with
Gaussian distribution assumed in all cases.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/3/
766/s1.
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Abstract: In Duchenne muscular dystrophy (DMD), a dysregulated extracellular matrix (ECM)
directly exacerbates pathology. Glucocorticoids are beneficial therapeutics in DMD, and have
pleiotropic effects on the composition and processing of ECM proteins in other biological contexts.
The synthesis and remodelling of a transitional versican-rich matrix is necessary for myogenesis;
whether glucocorticoids modulate this transitional matrix is not known. Here, versican expression
and processing were examined in hindlimb and diaphragm muscles from mdx dystrophin-deficient
mice and C57BL/10 wild type mice. V0/V1 versican (Vcan) mRNA transcripts and protein levels were
upregulated in dystrophic compared to wild type muscles, especially in the more severely affected
mdx diaphragm. Processed versican (versikine) was detected in wild type and dystrophic muscles,
and immunoreactivity was highly associated with newly regenerated myofibres. Glucocorticoids
enhanced C2C12 myoblast fusion by modulating the expression of genes regulating transitional
matrix synthesis and processing. Specifically, Tgfβ1, Vcan and hyaluronan synthase-2 (Has2) mRNA
transcripts were decreased by 50% and Adamts1 mRNA transcripts were increased three-fold by
glucocorticoid treatment. The addition of exogenous versican impaired myoblast fusion, whilst
glucocorticoids alleviated this inhibition in fusion. In dystrophic mdx muscles, versican upregulation
correlated with pathology. We propose that versican is a novel and relevant target gene in DMD,
given its suppression by glucocorticoids and that in excess it impairs myoblast fusion, a process key
for muscle regeneration.
Keywords: Duchenne muscular dystrophy; fibrosis; glucocorticoids; myogenesis; mdx mouse; versican
1. Introduction
Duchenne muscular dystrophy (DMD) is a fatal hereditary disease affecting ~1:3500 boys, with
glucocorticoid therapy being the only treatment with clinical efficacy [1]. DMD is caused by mutations
in the dystrophin (DMD) gene, which renders dystrophic skeletal muscles vulnerable to ongoing
contraction-induced injury, resulting in excessive inflammation, impaired regeneration and fibrosis [2].
Whilst fibrosis is usually thought of as a disease endpoint, it is important to note that endomysial
extracellular matrix (ECM) accumulation precedes overt muscle degeneration in DMD [3], and is
thought to actively contribute to the degeneration of dystrophic muscles [4–6].
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The composition and processing of the ECM influences global cell behaviour, including cellular
processes necessary for effective muscle repair [7–9]. Aberrant ECM synthesis and processing is
observed in dystrophic muscles from patients with DMD [10] and in mdx mice [11], compromising
regenerative myogenesis and exacerbating inflammatory processes [12]. TGF-β is considered to be
a key cytokine driving fibrosis in DMD [13], and its levels are elevated in dystrophic muscles and in
circulation [14].
The mature ECM of normal skeletal muscle is composed of glycoproteins, collagens
and proteoglycans containing heparan sulphate and chondroitin sulphate/dermatan sulphate
glycosaminoglycan (GAG) side chains [15]. Endomysial fibrosis in DMD is associated with the
increased expression of not only mature ECM proteins [16,17], but also transitional ECM proteins
such as hyaluronan and versican [18]. These transitional matrix proteins, through their synthesis
and remodelling, regulate cell behaviour during normal development and regeneration, as well as
functioning as a scaffold for mature ECM deposition [8,19]. ECM proteases are also upregulated in
dystrophic muscles [20]. Strategies to limit aberrant ECM synthesis and remodelling in DMD are
of therapeutic interest. Given the importance of a transitional matrix in tissue repair, versican is
an especially relevant ECM protein [18].
Versican is a chondroitin sulphate proteoglycan (CSPG) [19], localised to pericellular regions of
the basement membranes and interstitial matrices [9,21,22]. In skeletal muscle, the V0 and V1 splice
variants of versican are the most abundant [9]. V0/V1 versican is comprised of the G1 and G3 globular
domains at the N- and C-terminus respectively, with each of their core proteins sharing a common
GAG-β domain and V0 versican containing an additional GAG-α domain. Chondroitin sulphate
moieties on V0/V1 versican bind growth factors, cytokines and adhesion molecules, such as CD44
(cluster of differentiation 44), to regulate downstream signalling pathways [23]. The C- and N-termini
of versican bind various ECM molecules [24], including hyaluronan [25], a large non-proteinaceous
GAG of variable size which has been linked to myogenesis and muscle growth [8,26]. Hyaluronan is
synthesised by hyaluronan synthases (HAS) and degraded by hyaluronidases (HYAL), with HAS2,
HYAL1 and HYAL2 being the predominant skeletal muscle isoforms [26].
Recent studies have highlighted the role of versican in myoblast proliferation and myotube
formation, processes critical for regenerative myogenesis [9,27]. In developing chick skeletal muscle,
versican is synthesised early in myogenesis [27] and is localised to the pericellular matrix of developing
myotubes [28]. V1 versican is cleaved at the Glu441-Ala442 peptide bond within the GAG-β domain by
specific A Disintegrin-like And Metalloproteinase Domain with ThromboSpondin-1 repeats (ADAMTS)
proteoglycanases [29], which include ADAMTS1, -4, -5, -9, -15 and -20 [30], and presumably ADAMTS8,
however this has not yet been proven [31]. This produces the bioactive G1-DPEAAE fragment known
as versikine [19], which in other biological contexts can be pro-apoptotic [32] or pro-inflammatory [33].
Using C2C12 myoblasts as an in vitro model of regenerative myogenesis, we have shown that the
processing of a versican and hyaluronan rich transitional, pericellular matrix by ADAMTS5 or -15
facilitated myotube formation [9].
Glucocorticoids delay disease progression in DMD by improving muscle strength, respiratory
function, and increasing ambulation by up to four years [34,35]. These beneficial effects may be due
to membrane stabilisation, decreased muscle necrosis and fibrosis, modulation of inflammation,
and/or improved regeneration [12,36]. In dystrophic mdx mice, high dose treatment with the
glucocorticoid deflazacort increased the proliferation and/or fusion of muscle precursor cells during
myotube formation following crush injury, as well as enhancing the growth of intact myotubes [37].
More recently, when mdx mice were treated with prednisone or VBP15 (vamorolone; a dissociative
glucocorticoid [38]) TGF-β related networks were suppressed, this included reduced gene expression
of various collagen isoforms (1A1, 3A1 and 6A1), leading to improved muscle repair [12]. In vitro,
glucocorticoids also enhanced myotube formation in primary wild type and dystrophic mdx myoblasts,
as well as in C2C12 cells [39,40].
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Given the importance of transitional matrix synthesis and remodelling for myofibre formation and
that glucocorticoids can enhance myogenic differentiation [1,8,41], the effects of glucocorticoids on the
ECM during myogensis and myoblast differentiation should be better characterised. In other disease
models associated with a heightened pro-inflammatory state, glucocorticoids do modulate ECM
composition and degradation with the specific effects being tissue and context dependent. In cultured
rat mesangial cells, glucocorticoids decreased secreted and cell associated chondroitin sulphate and
dermatan sulphate proteoglycan content by 50% [42]. In cultured airway fibroblasts stimulated with
serum, glucocorticoids decreased versican gene and protein expression by 50% [43]. Hyaluronan
content in skin and dermal fibroblasts was also reduced following glucocorticoid treatment [44],
due to decreased Has2 mRNA transcription and stability, and thus reduced hyaluronan synthesis [45].
Given their clinical usage in DMD and the ECM expansion observed in dystrophic muscles,
understanding the transitional ECM gene targets regulated by glucocorticoids in skeletal muscle
cells is an important step towards improving therapeutic outcomes for strategies targeting fibrosis
in dystrophy.
Here, we show that V0/V1 versican mRNA transcript abundance and protein levels are elevated
in diaphragm and hindlimb tibialis anterior (TA) muscles from dystrophic mdx mice when compared
to C57BL/10 wild type mice. We identify a novel mechanism mediating the glucocorticoid stimulated
increase in myoblast fusion and myotube formation in C2C12 cells. Specifically, in differentiating
myoblasts, low doses of glucocorticoids (25 or 100 nM dexamethasone) modulated the expression of
genes associated with the synthesis and processing of a versican–hyaluronan rich transitional matrix.
This effect is dependent on versican, as glucocorticoid treatment improved myotube formation in the
presence of excess versican. As a whole, these findings offer novel insight into the relevance of versican
in dystrophic skeletal muscle pathology.
2. Results
2.1. Versican Expression Is Increased in Dystrophic Muscles and Correlate with the Severity of Pathology
The pathology of TA muscles from adult mdx mice is moderate compared to the human
disease. Specifically, in hindlimb muscles from mdx mice there is minimal fibrosis, lower levels of
inflammation and more effective regeneration as indicated by the presence of centrally nucleated
fibres [46] (Figure 1B); although, muscle strength is compromised [47]. The pathology of mdx diaphragm
muscles is more representative of DMD, with greatly impaired contractile function and high levels
of endomysial fibrosis [48,49] (Figure 1D). V0/V1 Vcan mRNA transcript abundance was greater
in dystrophic compared to wild type muscles (Figure 1I). To support this gene expression data,
the immunoreactivity of full length V0/V1 versican and its cleaved bioactive fragment, versikine,
was assessed in TA and diaphragm muscle cross-sections from mdx and wild type mice (Figure 2).
V0/V1 versican protein levels were upregulated in TA and diaphragm muscles from mdx
mice (Figure 2B,D) compared to wild type mice (Figure 2A,C, and as quantified in Figure 2I).
In concordance with the more severe pathology, versican immunoreactivity was greatest in the mdx
diaphragm. In dystrophic muscles, versican staining was localised to regions of mononuclear infiltrate,
which includes myoblasts, inflammatory cells and fibroblasts (Figure 2B,D; as indicated with a white
asterisk). Versican staining was also associated with endomysial fibrosis in TA (Figure 3A–D) and
diaphragm muscles (Figure 2D).
264
Int. J. Mol. Sci. 2017, 18, 2629
 
Figure 1. Muscle architecture and fibrosis in wild type and mdx mice. (A–D) Muscle architecture
can be determined from the H and E-stained muscle cross-sections, and (E–H) areas of fibrosis can
be observed by examining wheat germ agglutinin (WGA) stained cross-sections. (I) Versican (V0/V1
Vcan) mRNA transcript abundance was increased in mdx compared to wild type mice (* p = 0.026;
main effect genotype; 2-way general linear model (GLM) ANOVA). Arrows denote areas of fibrosis
and mononuclear infiltrate. Gene expression analysis was determined from n = 3 wild type mice and n
= 3 mdx mice. Scale bar = 100 μm. Error bars = S.E.
Remodelling of V1 versican by ADAMTS proteoglycanases (e.g., ADAMTS1, -5 and -15) yields
the bioactive versikine fragment [19]. Versikine immunoreactivity was predominantly localised to the
pericellular region of myofibres, and did not differ between dystrophic and wild type TA or diaphragm
muscles (Figure 2E–H, and as quantified in Figure 2J). In mdx TA and diaphragm muscle cross-sections,
versikine staining was also associated with regions of mononuclear infiltrate (Figure 2F,H; as indicated
with a white asterisk). When this association of versikine with mononuclear infiltrate was further
interrogated in mdx TA muscle cross-sections by specifically assessing areas of regeneration, high levels
of versikine immunoreactivity were co-localised with desmin positive, newly regenerated myofibres
(Figure 3E–H). Furthermore, nuclear localisation of versikine (but not versican) was observed in muscle
fibres and mononuclear infiltrate (Figure 3I,J).
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Figure 2. Versican and versikine expression in TA and diaphragm muscles from wild type and mdx
mice. Representative images of (A–D) versican and (E–H) versikine immunoreactivity from TA and
diaphragm muscles from wild type and mdx mice. (I) Quantification of versican immunoreactivity
revealed an upregulation in TA (* p = 0.001) and diaphragm muscles (# p = 0.0001) from mdx mice when
compared to wild type mice. (J) Versikine immunoreactivity was similar in mdx and wild type TA or
diaphragm muscles. White asterisks denote areas of mononuclear infiltration. Immunoreactivity
analysis was determined from n = 5 wild type mice and n = 5 mdx mice. Scale bar = 100 μm.
Error bars = S.E.
Figure 3. Cont.
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Figure 3. Versikine is localised to regenerating myofibres and mononuclear infiltrate, as well as
within nuclei in mdx TA muscles. Serial cross-sections were stained with versican or versikine and
desmin, phase images were captured to confirm localisation and tissue orientation. (A–D) Versican
was localised to interstitium between myofibres. (E–H) Versikine was highly expressed in regenerating
muscle, as indicated by its association with small desmin positive, centrally nucleated myofibres.
(I,J) In dystrophic muscle cross-sections, nuclear localisation of versikine, but not versican, was also
observed. Scale bars = 100 μm.
2.2. Glucocorticoids Enhance Myoblast Fusion and Myotube Formation
C2C12 myoblasts were used to investigate glucocorticoid mediated effects on transitional matrix
synthesis and remodelling during myogenic differentiation. Similar to skeletal muscle development
in vivo, the myogenic differentiation of C2C12 myoblasts is associated with an upregulation of
transitional matrix genes, such as V1/V0 Vcan, Adamts1, Adamts5, Adamts15, Pcsk6 [9], Has2 and
Hyal2 [8,41]. The two-fold increase in the gene expression of the myogenic differentiation marker
creatine kinase muscle (Ckm) (Figure 4A) and the associated dose dependent increase in total
creatine kinase (CK) enzyme activity (Figure 4B), indicate that low dose glucocorticoid treatment
enhanced myogenic differentiation. Essential to myogenic differentiation is the fusion of myoblasts
into multinucleated myotubes, a multistep process involving migration, alignment, adhesion and
membrane coalescence to form nascent myotubes [50]. Subsequent growth of these nascent myotubes
occurs through the incorporation of additional myoblasts via secondary fusion [51,52]. In accordance
with previously published findings [39,40], the fusion index, which is the proportion of nuclei fused
into multinucleated myotubes compared to total nuclei, was increased in a dose dependent manner
following treatment with 25 nM and 100 nM dexamethasone (Figure 4D). Myotube formation and
maturation is considered to be a two-step process, with distinct signaling pathways contributing
to the formation of nascent myotubes and the growth of mature myotubes [53–55]. Here, nascent
myotubes containing 3–4 myonuclei and growing, mature myotubes undergoing secondary fusion and
containing ≥5 myonuclei, were quantified as previously described [9]. In concordance with the fusion
index data, there was an increase in the number of nascent myotubes (with 3–4 myonuclei) following
treatment with 100 nM dexamethasone (Figure 4E), as well as a dose dependent increase in the number
of mature myotubes with ≥5 myonuclei indicating enhanced secondary myoblast fusion (Figure 4F).
2.3. Glucocorticoids Regulate the Expression of Genes Associated with Transitional Matrix Synthesis and
Processing during Myogenic Differentiation
Glucocorticoids may enhance myogenic differentiation by regulating the expression of genes
associated with transitional matrix synthesis and processing. Specifically, 72 h of treatment with 25 nM
and 100 nM of dexamethasone reduced Tgfb1 mRNA transcript abundance by 50% and 54%, respectively
(Figure 5A). The decrease in Tgfb1 mRNA transcript abundance was associated with a reduction in
versican (V0/V1 Vcan) gene expression by up to 56% (Figure 5B) and Has2 gene expression by up to 58%
(Figure 5C). Has2 is the primary Has gene involved in hyaluronan synthesis in skeletal muscle [26].
Adamts1 mRNA transcripts were increased up to three-fold in dexamethasone treated C2C12 cells
(Figure 5D), whereas Adamts5 or Adamts15 mRNA levels were not affected by glucocorticoid treatment
(Figure 5E,F). ADAMTS proteoglycanases are synthesised as inactive zymogens and become activated
upon proteolytic processing by Furin and/or Pace4 [56]. Treatment with 25 and 100 nM dexamethasone
267
Int. J. Mol. Sci. 2017, 18, 2629
decreased Pcsk6 (Pace4) gene expression by 65% and 68% respectively (Figure 5G), whilst Pcsk3 (Furin)
mRNA levels were not significantly altered (Figure 5H). Lastly, dexamethasone had no effect on Hyal2
mRNA transcript abundance (Figure 5I), the enzyme necessary for hyaluronan degradation [26].
 
Figure 4. Low dose dexamethasone treatment for 72 h increased myogenic differentiation efficacy in
C2C12 myoblasts. (A) The gene expression of myogenic differentiation marker creatine kinase (Ckm)
was increased two-fold in cells treated with 25 nM and 100 nM dexamethasone (Dex) (* p < 0.01);
(B) CK enzyme activity in cell lysates was also increased following treatment with 25 nM (* p = 0.02)
and 100 nM dexamethasone (# p = 0.01); (C) Dexamethasone (Dex) did not significantly increase myosin
heavy chain 1 (Myh1) mRNA transcripts; (D) Fusion index (FI; * p < 0.001) was greater in C2C12 cells
treated with 25 nM and 100 nM dexamethasone compared to untreated control cells, and this increase
was dose dependent (+ p < 0.05); (E) Treatment with 100 nM dexamethasone increased the formation
of nascent myotubes containing 3–4 myonuclei (* p < 0.001); (F) The number of mature myotubes
with ≥5 nuclei was greater in cultures treated with 25 nM or 100 nM versus 0 nM dexamethasone
(* p = 0.017), and this increase was dose dependent (+ p = 0.03); (G) Representative images of C2C12
myotubes. Differentiation C2C12 myoblasts were treated with 0 nM dex (A’,D’), 25nM dex (B’,E’) or
100 nM dex (C’,F’) for 72 h. Myotubes were then stained with phalloidin for F-actin (red) and DAPI
for nuclei (blue). CK enzyme activity was calculated from n = 3 biological replicates performed in
quadruplicate. The fusion index and myotube number were calculated from n = 3 biological replicates
performed in duplicate. Gene expression was determined from n = 3 biological replicates in triplicate.
Scale bar = 200 μm. Error bars = S.E.
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Figure 5. The expression of genes associated with a versican–hyaluronan rich transitional matrix
is modulated by dexamethasone during myoblast differentiation. (A–C) Compared to untreated
control cells, 25 nM or 100 nM dexamethasone treatment decreased Tgfb1 (* p < 0.0001 and * p = 0.0001
respectively), Vcan (* p = 0.005 and * p = 0.0006, respectively) and Has2 mRNA transcripts by
approximately two-fold (* p < 0.0001 and * p = 0.0001, respectively); (D) Adamts1 gene expression was
increased up to three-fold in response to 25 nM and 100 nM dexamethasone treatment (* p = 0.03
and * p < 0.001, respectively); (E,F) Adamts5 and Adamts15 mRNA transcripts were not significantly
increased; (G,H) Pcsk6, but not Pcsk3, mRNA transcripts were decreased approximately two-fold
following treatment with 25 and 100 nM dexamethasone (* p < 0.0001). (I) Hyal2 mRNA levels were not
altered by dexamethasone treatment. Gene expression was determined from n = 3 biological replicates
in triplicate. Error bars = S.E.
The effect of glucocorticoids on versican gene expression was confirmed by western blotting.
Dexamethasone reduced protein levels of full length V0/V1 versican in a dose dependent manner by
up to 50% (Figure 6B). ADAMTS dependent remodelling of versican during myogenic differentiation
appeared not to be altered by glucocorticoids, as indicated by similar protein levels of versikine
following treatment with 25 nM and 100 nM dexamethasone (Figure 6C).
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Figure 6. Versican and versikine protein expression in differentiating C2C12 myoblasts following
dexamethasone treatment. (A) Representative western blots to assess versican and versikine expression
in C2C12 cell lysates, with the respective stain free protein gel image to demonstrate even protein
loading; (B) Decreased versican protein expression following treatment with 25 nM (* p = 0.00002)
and 100 nM dexamethasone (* p = 0.0000001); and this decrease was dose dependent (# p = 0.03);
(C) Versikine protein levels were not altered by dexamethasone treatment. Versican and versikine
protein expression analysis was calculated from n = 3 biological replicates performed in quadruplicate.
Error bars = S.E.
2.4. Glucocorticoids Rescue Myotube Formation in Differentiating Myoblasts Treated with Exogenous Versican
and Versikine
In vitro, versican processing facilitates myoblast fusion and myotube formation, whilst an excess
of versican appears to be detrimental [9]. Therefore, it is possible that reduced versican synthesis may
contribute to the positive effects of glucocorticoids on regenerative myogenesis in dystrophic muscles.
To test this hypothesis, differentiating C2C12 myoblasts were treated with V1 versican, versikine or
empty vector conditioned media supplemented with 0 nM or 100 nM dexamethasone. The addition of
conditioned media made the experimental conditions more challenging, with greater variability in
fusion between biological replicates and a blunted response to dexamethasone. Nonetheless, excess
full length or processed versican decreased myoblast fusion (main effect conditioned media; 2-way
GLM ANOVA; * p < 0.001 for versican treated cells and ** p < 0.02 for versikine treated cells; Figure 7C).
This decrease in fusion was ameliorated with glucocorticoid treatment (main effect dexamethasone;
2-way GLM ANOVA; # p < 0.001 for empty vector or versican treated cells and ## p < 0.001 for empty
vector or versikine treated cells; Figure 7C).
As further evidence that versican impairs myoblast fusion, in cells treated with 0 nM
dexamethasone, the versican conditioned media decreased the number of nascent myotubes compared
to empty vector conditioned media (interaction; 2-way GLM ANOVA; * p < 0.001). Following treatment
with 100 nM dexamethasone, the number of nascent myotubes was similar in cells treated with the
versican or empty vector conditioned media (Figure 7D). Versikine had no effect on the number of
nascent myotubes formed (Figure 7D). Unexpectedly, dexamethasone decreased the number of nascent
myotube in cells treated with versikine or empty vector conditioned media (main effect dexamethasone;
2-way GLM ANOVA; # p < 0.01) (Figure 7D).
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Figure 7. Dexamethasone ameliorated the impairment in myogenic differentiation associated with
excess versican. (A,B) Representative western blots of versican, versikine or empty vector (EV)
conditioned media, with the respective images of stain free protein gels or GAPDH as a loading controls;
(C) The addition of versican and versikine conditioned media compromised myoblast differentiation,
as assessed by fusion index (main effect conditioned media; 2-way GLM ANOVA; * p < 0.001 for
versican conditioned media and ** p < 0.02 for versikine conditioned media relative to cells treated with
the empty vector conditioned media). Whilst, glucocorticoids enhanced myoblast fusion (main effect
dexamethasone; 2-way GLM ANOVA; # p < 0.001 for empty vector or versican treated cells and
## p < 0.001 empty vector or versikine treated cells); (D) In the absence of dexamethasone, excess
versican reduced the formation of nascent myotubes (interaction; 2-way GLM ANOVA; * p < 0.001).
In response to 100 nM dexamethasone, the number of nascent myotubes was similar in cells treated with
versican or empty vector conditioned media. Versikine had no effect on nascent myotube formation,
whilst dexamethasone decreased nascent myotube number in cells treated with versikine or empty
vector conditioned media (main effect dexamethasone; 2-way GLM ANOVA; # p < 0.01); (E) Versican
or versikine reduced the number of mature myotube formed per field of view (FOV) (main effect
conditioned media; 2-way GLM ANOVA; * p < 0.0001 for versican treated cells and ** p < 0.0001
versikine treated cells), and 100 nM dexamethasone ameliorated this decrease in myotube number
(main effect dexamethasone; 2-way GLM ANOVA; # p = 0.0092 for empty vector or versican treated
cells and ## p = 0.0061 empty vector or versikine treated cells); (F) Versican or versikine conditioned
media reduced the migration rate of C2C12 myoblasts compared to empty vector conditioned media
(* p = 0.01 and * p = 0.04 respectively); (G) Myoblast cell number was not different following 24 h and
48 h of treatment with versican or versikine conditioned media compared to empty vector conditioned
media; (H) Representative images of C2C12 myotubes. Differentiating C2C12 myoblasts were treated
with 0 nM dex and EV conditioned media (A’,B’), 100 nM dex and EV conditioned media (C’,D’), 0 nM
dex and versican conditioned media (E’,F’), 100 nM dex and versican conditioned media (G’,H’), 0 nM
dex and versikine conditioned media (I’,J’), or 100 nM dex and versikine conditioned media (K’,L’)
for 72 h. Myotubes were then stained with phalloidin for F-actin (red) and DAPI for nuclei (blue).
Fusion index (FI) and myotube number were calculated from n = 5 biological replicates performed in
duplicate. Migration rate was measured from n = 5 biological replicates performed in duplicate or
triplicate. Myoblast proliferation was assessed from n = 3 biological replicates performed in 8 wells.
Scale bar = 200 μm. Error bars = S.E.
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With regards to the effects of versican, versikine and glucocorticoids on secondary fusion, the
number of mature myotubes was reduced in cells treated with versican or versikine conditioned
media (main effect conditioned media; 2-way GLM ANOVA; * p < 0.0001 for versican treated cells
and ** p < 0.0001 versikine treated cells; Figure 7E). When differentiating myoblasts were treated with
100 nM dexamethasone, the number of mature myotubes increased (main effect dexamethasone; 2-way
GLM ANOVA; # p = 0.0092 for versican treated cells and ## p = 0.0061 versikine treated cells; Figure 7E).
Alignment of myoblasts is essential for fusion, and this depends on carefully regulated
migration [50,57,58]. Versican is known to modulate cell migration and depending on the biological
context the effects can be stimulatory [59,60] or inhibitory [61]. The effects of versikine on cell migration
have not been well characterised. In C2C12 cells treated with versican or versikine conditioned media
for up to 11 h, myoblast migration rate was reduced by 12% and 13%, respectively (Figure 7F).
Thus, excess versican, both the full-length protein and the cleaved bioactive fragment, may also impair
regenerative myogenesis through a reduction in myoblast migration.
Myoblast viability and number can be a confounding factor in determining the efficacy of
myogenic differentiation. Versican has been shown to increase proliferation in various biological
contexts [62,63], including primary turkey myoblasts [27]. In contrast, versikine has been associated
with apoptosis during interdigital web regression [32]. In actively proliferating C2C12 myoblast
cultures, exogenous versican or versikine had no effect on cell number (Figure 6G).
3. Discussion
In dystrophic skeletal muscles, excess synthesis and inappropriate processing of ECM proteins
lead to degeneration, fibrosis and compromised contractile function [17,64]. Similarities in the
mechanisms of ECM expansion in patients with DMD and mdx mice have been observed,
and contribute to the dystrophic pathology of these muscles [12]. The significance of versican in
the generation and remodelling of a transitional matrix during skeletal muscle development and
regeneration is continuing to gain recognition [8,9,27]. We propose that the carefully regulated synthesis
and processing of a versican rich transitional matrix is also an important factor in differentiating
between successful regenerative myogenesis or degeneration and fibrosis. A better understanding
of versican function in muscular dystrophy is needed if progress is to be made in targeting the
dysregulated ECM, which is a hallmark of DMD pathology.
Here, we report that the expression of full-length versican is increased in dystrophic mdx
diaphragm and hindlimb muscles compared to wild type muscles, with the highest level of versican
expression observed in the more severely affected mdx diaphragm muscles. These observations are in
concordance with human data showing increased versican expression in muscle biopsies from patients
with DMD compared to healthy controls, as assessed by immunohistochemistry [65] and microarray
gene expression analysis [66]. Furthermore, deposition of chondroitin sulphate GAG side chains is
upregulated in DMD [15], and V0/V1 versican is a significant source of chondroitin sulphate GAG
chains in skeletal muscle. V0 versican is the most highly glycosylated isoform, followed by the V1
variant [67]. Versican is secreted and synthesised by activated satellite cells and myoblasts [27,68],
newly formed myotubes [28], inflammatory cells [69] and fibroblasts [70].
Versican is transiently upregulated in myoblasts and newly formed myotubes during development
and regeneration [28,71], whilst in healthy, mature skeletal muscle full length versican expression
is quite low. Versican remodelling has been implicated in various developmental processes,
and remodelling by specific ADAMTS proteoglycanases generates versikine [19,32]. Interestingly,
in mdx TA muscles, versikine immunoreactivity was associated with small, recently regenerated
myofibres. Furthermore, in dystrophic muscles, the nuclear localisation of versikine was observed
in both muscle fibres and in mononuclear infiltrate. This is in line with observations by Carthy et al.,
who using the same anti-DPEAAE neo-epitope antibody (ThermoFisher Scientific, PA1-1748A,
Waltham, MA, USA) detected nuclear versikine staining in vascular smooth muscle cells and
proposed a potential role in mitotic spindle organization during cell division [63]. Versikine is further
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degraded by various ECM proteases. This hypothesis is supported by the observation that versikine
immunoreactivity in developing mouse hindlimb muscles at E13.5 days is much higher than in mature
muscles at 3 weeks of age [9]. This further degradation of versikine may account for the lack of
difference in protein levels between diaphragm and TA muscles from mdx and wild type mice, despite
increased V0/V1 versican expression.
In vivo, centrally nucleated fibres are indicative of recent damage and repair, with myoblast
fusion being essential for effective regeneration. In diaphragm muscles from mdx mice, the proportion
of centrally nucleated fibres is much lower, up to 2–3 folds, when compared to dystrophic TA
muscles [48,72]. We hypothesise that excess versican accumulation contributes to the impaired
regenerative capacity of mdx diaphragm muscles. As such, we propose that versican reduction
could be a potential strategy to ameliorate the pathology of dystrophic muscles. In vitro evidence that
processing of versican by ADAMTS5 or -15 facilitates myoblast fusion supports this hypothesis [9].
Furthermore, others have shown that the formation of multinucleated myotubes is associated with
a reduction in chondroitin sulphate GAG sidechains, which also suggests a potential role for versican
processing [73]. It is worth noting that versikine does not contain chondroitin sulphate GAG side
chains [74].
Glucocorticoids improve muscle function in patients with DMD through various cellular
mechanisms [36,75,76]. Of particular interest, are the effects of glucocorticoids on ECM synthesis and
remodelling [77], on TGF-β [78] and TGF-β centred signalling networks, as these are highly relevant
to regenerative myogenesis and fibrosis [12]. Our observation of a concentration dependent increase
in myoblast fusion and myotube formation following low dose, 25 nM and 100 nM, dexamethasone
treatment is in concordance with a number of studies reporting positive effects of glucocorticoids
on myogenesis in vitro [39,40] and muscle regeneration in vivo [12,37]. In contrast to our findings,
Ma et al. [79] reported inhibition of myogenic differentiation of C2C12 and primary mouse myoblasts
following glucocorticoid treatment through the activation of glycogen synthase kinase 3β (GSK-3β).
However, the concentration of dexamethasone used (10 μM) was 100–400 folds higher than our low
dose treatment [79]. Furthermore, with lower concentrations of 10 nM and 100 nM dexamethasone,
no significant decrease in myogenin or myosin heavy chain protein expression was reported, whilst the
fusion index was not assessed [79].
The increase in myotube formation following glucocorticoid treatment was associated with
decreased V0/V1 versican protein and V0/V1 Vcan, Has2 and Tgfb1 mRNA transcript abundance.
This reduction in Tgfb1 gene expression in response to glucocorticoids is in agreement with
in vivo studies in mdx mice [12,78], and in vitro studies using hepatic stellate cells [80] and fetal
lung fibroblasts [81]. In differentiating myoblasts, glucocorticoids appear to have specific effects
on the various Adamts proteoglycanase isoforms and genes involved in ADAMTS activation,
as dexamethasone treatment was also associated with an increase in Adamts1, but not Adamts5 and -15,
gene expression, as well as a decrease in Pcsk6 (but not Pcsk3) mRNA transcript abundance. Altogether,
these data suggest that glucocorticoids may attenuate the synthesis of a transitional, pericellular
matrix, thus facilitating membrane coalescence during fusion in differentiating C2C12 myoblasts [9].
The effects of glucocorticoids on a versican and hyaluronan rich transitional matrix have been described
in other biological contexts. Specifically, glucocorticoid induced skin atrophy is associated with
reduced proteoglycan [82] and hyaluronan synthesis [44,45]. Glucocorticoids have also been reported
to decrease versican expression in cultured rat mesangial cells and airway fibroblasts [43,79].
Myoblast fusion was reduced when differentiating C2C12 myoblasts were treated with versican
conditioned media, supporting our hypothesis that excess versican impairs regenerative myogenesis.
This decrease in myoblast fusion was ameliorated, but not fully reversed, with dexamethasone.
Versikine conditioned media also impaired myoblast fusion, and this impairment was also ameliorated
by glucocorticoid treatment. Hyaluronan can bind to versican, and perhaps also versikine, via the G1
N-terminus link module [25], thus contributing to pericellular matrix expansion. We have previously
shown that expansion and inadequate processing of a versican–hyaluronan rich pericellular matrix
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impairs myoblast fusion and myotube formation [9]. This decrease in fusion was interrogated
further by quantifying the number of nascent and mature myotubes following versican, versikine
and/or dexamethasone treatment. An excess of versican decreased the number of nascent myotubes,
and this decrease was ameliorated by dexamethasone treatment. Whereas, an excess of versikine did
not compromise nascent myotube formation. Myotube hypertrophy and nuclear accretion occurs
via secondary fusion, which involves distinct signalling pathways compared to the formation of
nascent myotubes [51]. Excess versican and versikine reduced the formation of mature myotubes.
Dexamethasone rescued this impairment and increased the number of mature myotubes formed.
Excess versican or versikine may impair myoblast migration, thus potentially contributing to the
observed decrease in myoblast fusion and myotube number. The effects of versican on cell migration
are context dependent, as during development, versican has been suggested to deter muscle cell
migration and thus contribute to the patterning of the limb skeleton and joints [83]. The underlying
mechanism by which versican and versikine regulate cell migration during myogenesis remains to be
determined, but may involve CD44 signalling [57,84,85]. Full length versican, through its chondroitin
sulphate side chains, can bind to the CD44 receptor directly [84]. Through interactions with the link
module on the G1 domain, versican and versikine bind hyaluronan [19], which is also a known ligand
for the CD44 receptor [85]. Altogether, these observations suggest a novel mechanism by which excess
versican could compromise regenerative myogenesis in muscular dystrophy.
We propose that excess accumulation of versican in dystrophin-deficient muscles compromises
regeneration and exacerbates fibrosis. Dadgar et al. [12] have recently confirmed that TGF-β centred
signalling networks are key drivers for fibrosis and failed regeneration in muscular dystrophy.
TGFβ stimulates V0/V1 versican synthesis in various biological contexts [59,86–88]. Furthermore,
the interaction between TGF-β and versican is bidirectional, with versican potentiating TGFβ
signalling [89] and regulating bioavailability [90]. When dystrophic mdx mice were treated with
glucocorticoids, these TGF-β centered networks were suppressed and the dystrophic pathology was
ameliorated [12]. Therefore, our in vitro observations that glucocorticoids reduce V0/V1 versican
(Vcan) and Tgfb1 expression in differentiating myoblasts highlight the relevance of these genes to
regenerative myogenesis, especially in the context of dystrophy.
To fully characterise the role of versican in regenerative myogenesis in dystrophic skeletal muscles
in vivo studies using genetic and/or pharmacological approaches are needed. The advantage of such
in vivo studies is that they will allow the effects of versican on muscle repair and function to be
investigated in the presence of an expanded ECM and increased inflammation. This is important,
given the emerging role of versican [91,92] and versikine [33] in regulating inflammation in various
biological contexts.
4. Materials and Methods
4.1. Mouse Models
All animal studies were approved by the La Trobe University and Deakin University Animal
Ethics Committees, in accordance with the National Health and Medical Research Council (NH&MRC)
guidelines, under the ethics numbers of AEC16-08 for La Trobe University (approved: 1 January 2016),
and G35-2013 and A79/2011 (approved: 1 January 2015 and 1 January 2012, respectively) for Deakin
University. Between 3 and 6 months of age, C57BL/10 (wild type) and mdx mice were deeply
anaesthetised with sodium pentobarbitone (60 mg/kg) and killed by cardiac excision. TA and
diaphragm muscles were collected for immunohistochemical analysis by embedding the blotted
tissues in optimal cutting temperature compound (OCT) and freezing in thawing 2-methylbutane
cooled in liquid nitrogen. TA and diaphragm muscles were also snap frozen in liquid nitrogen for
gene expression analysis.
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4.2. Skeletal Muscle Immunohistochemistry and Histology
Transverse frozen sections were cut from the mid-belly of the TA or diaphragm muscle strips at
a thickness of 8 μm, mounted on slides and stored at −80 ◦C until analysis. Immunohistochemistry
for ADAMTS1 (Origene, TA317919, Rockville, MD, USA), ADAMTS5, ADAMTS15 (Abcam, ab45047,
Cambridge, MA, USA), V0/V1 versican (anti-GAGβ; Merck Millipore, AB1033, Bayswater, VIC,
Australia) or versikine (anti-DPEAAE neo-epitope; Thermo Fisher Scientific, PA1-1748A, Scoresby, VIC,
Australia) were performed as previously described [9,32]. An anti-desmin rabbit polyclonal antibody
(Abcam, ab15200, Cambridge, MA, USA) together with an anti-rabbit Alexa Fluor 488 secondary
antibody (Thermo Fisher Scientific, R37116,) were used to detect myoblasts and newly regenerated
myofibres [93,94]. Representative wild type and mdx TA and diaphragm muscle cross-sections were H
and E stained for muscle architecture, and wheat germ agglutinin to assess fibrosis [95]. For analysis of
V0/V1 versican and versikine immunoreactivity, four non-overlapping representative digital images
were captured with a confocal microscope of each muscle section at 600× magnification (Olympus
Fluoview FV10i) and analysed for area of immunoreactivity using Image-Pro Plus software (Version 7,
Media Cybernetics, Silver Spring, MD, USA).
4.3. Cell Culture and Expression Constructs
HEK293T cells were grown in Dulbecco’s Modified Eagle Medium (DMEM; 25 mM glucose)
containing 10% fetal bovine serum (FBS) in atmospheric O2 and 5% CO2 at 37 ◦C. Cells were transfected
using Lipofectamine 2000 (Thermo Fisher Scientific) with constructs encoding the V1 versican
construct (kindly provided by Dieter Zimmermann), the bioactive G1-DPEAAE versikine fragment was
produced by the insertion of a stop codon in the V1 versican construct after the Glu441-Ala442 peptide
bond cleavage site [32], and empty vector control (pcDNA3.1MycHisA+ (Thermo Fisher Scientific)).
Serum-free conditioned medium was collected for use in the myoblast differentiation experiments,
as previously described [9], and underwent western blotting for confirmation of V1 versican and
versikine protein expression. C2C12 myoblasts, a well characterized in vitro model of myoblast fusion
and regenerative myogenesis [96,97], were maintained in growth medium (25 mM glucose DMEM
plus 10% FBS) in atmospheric O2 and 5% CO2 at 37 ◦C.
4.4. Glucocorticoid Treatment of Differentiating C2C12 Cells
To determine the effects of glucocorticoids on myoblast differentiation, cells were seeded at
25,000 cells/cm2; in duplicate wells for fusion index determination, and in triplicate wells for gene and
protein expression and creatine kinase activity analyses. Following 48 h of proliferation (and at >90%
confluence), myoblasts were treated with differentiation medium (25 mM glucose DMEM plus 2%
horse serum (HS)) supplemented with 0 nM, 25 nM or 100 nM dexamethasone (Prednisolone F,
Sigma-Aldrich, D1756, Castle Hill, NSW, Australia) for 72 h (refreshed every 24 h). The latter is
a low glucocorticoid concentration which has been shown to increase myoblast fusion efficiency
in vitro [39]. Following this, the cells were harvested for biochemical analyses (see below) or fixed
with 4% paraformaldehyde, and stained with Alexa-Fluor 568 phalloidin (1:50; Life Technologies) and
DAPI (1:20; Life Technologies) for 20 min.
Fusion index was used as a proxy readout to assess myoblast differentiation efficacy. Nascent
myotubes with 3–4 myonuclei and mature myotubes with ≥5 myonuclei were quantified, as previously
described [9,50]. For the fusion index, 3 biological replicates (at different passages) in duplicate were
performed. For the control cells treated with 0 nM dexamethasone, the % fusion index for each of the
three biological replicates ranged from 17–20. For each experimental condition and biological replicate,
8897 ± 222 nuclei were counted to assess fusion index and 270 ± 23 myotubes were classified and
counted to assess myotube maturation.
The fusion index data are supported by gene markers of myoblast differentiation and
a commercially available creatine kinase enzyme activity assay kit, as per manufacturer’s instructions
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(ab155901, Abcam) [98]. The cell lysates from the creatine kinase enzyme activity assay were also used
for analysis of versican and versikine protein expression.
4.5. RNA Extraction, Reverse Transcription, and Quantitative RT-PCR
Cells were harvested in triplicate wells, collected in TRIzol (Sigma-Aldrich) and stored at −80 ◦C.
TA and diaphragm muscles were mechanically homogenised in TRIzol. Upon thawing, RNA was
extracted and 1 μg of total RNA was reverse-transcribed using an iScript cDNA synthesis kit
(Bio-Rad, Gladesville, NSW, Australia). Quantitative RT-PCR was performed using iQ SYBR Green
Supermix (Bio-Rad) and oligonucleotide primers for the murine genes of interest (Table 1). Relative
changes in mRNA levels to untreated myotubes were calculated using the ΔCt method. Real time
data was normalised to cDNA content, as determined using a Quant-iT Oligreen ssDNA reagent kit
(Life Technologies).
Table 1. List of primer sequences used for quantitative RT-PCR.
Accession Number Name Forward Sequence (5′-3′) Reverse Sequence (5′-3′)
NM_009621.5 Adamts1 CCTGTGAAGCCAAAGGCATTG TGCACACAGACAGAGGTAGAGT
NM_011782.2 Adamts5 GCTACTGCACAGGGAAGAGG GCCAGGACACCTGCATATTT
NM_001329420.1 Adamts15 GCTCATCTGCCGAGCCAAT CAGCCAGCCTTGATGCACTT
NM_007710.2 Ckm 1 CCGTGTCACCTCTGCTGCTG TCCTTCATATTGCCTCCCTTCTCC
XM_011250822.2 Pcsk3 2 CAGCGAGACCTGAATGTGAA CAGGGTCATAATTGCCTGCT
NM_008216.3 Has2 GGGACCTGGTGAGACAGAAG ATGAGGCAGGGTCAAGCATA
XM_006511645.3 Hyal2 AGCCGCAACTTTGTCAGTTT GAGTCCTCGGGTGTATGTGG
XM_017314318.1 Myh1 3 GCTCAAAGCCCTGTGTTACC CATAGACGGCTTTGGCTAGG
NM_001291184.1 Pcsk6 4 ATTTCCCCAACCTCGTCTCT AGCTGAGTCCTTGCCACCTA
NM_011577.2 Tgfb1 GCCTGAGTGGCTGTCTTTTGA CACAAGAGCAGTGAGCGCTGAA
NM_001081249.1 (V0)
V0/V1 Vcan 5 ACCAAGGAGAAGTTCGAGCA CTTCCCAGGTAGCCAAATCANM_019389.2 (V1)
1 Creatine kinase muscle, 2 Furin, 3 Myosin heavy chain 1 (fast IIx/d isoform), 4 Pace4, 5 Versican (primers detect
the V0 and V1 isoforms).
4.6. Versican or Versikine Treatment and C2C12 Myoblast Differentiation
To assess the effects of glucocorticoids on myotube formation in the presence of excess versican
or versikine, C2C12 cells were seeded at 20,000 cells/cm2 in duplicate wells, 24 h or 48 h later the
differentiation medium was added for 4 or 3 days, respectively. Depending on the experimental
conditions, the differentiation medium was supplemented with 0 nM or 100 nM dexamethasone
and serum-free versican, versikine or empty vector conditioned media (diluted 1:4; refreshed daily).
Fusion index and myotube number were determined and analysed as described above. Five biological
replicates (at different passages) in duplicate were performed, with a total of 3156 ± 96 nuclei and
110 ± 3 myotubes counted per experimental condition for each biological replicate. For the control cells
treated with empty vector conditioned media and 0 nM dexamethasone, the % fusion index for each of
three biological replicates ranged from 19–27%. This greater variability in % fusion compared to the
dexamethasone dose response experiments reflects the more challenging experimental conditions.
4.7. Versican or Versikine Treatment and C2C12 Myoblast Migration and Proliferation
To assess the specific effects of versican and versikine on myoblast migration, a process essential
for effective differentiation [50,57], cells were seeded at 8500 cells/cm2 in triplicate wells and 72 h later
(when 100% confluent) a scratch wound assay was performed [58]. Growth media was supplemented
with serum-free versican, versikine or empty vector conditioned media (diluted 1:4) for up to 11 h.
To determine migration rate, digital images (three per well) were digitally captured at 0 h, 6 h and
11 h post-wounding. The distance between the edges of the scratches was measured using Adobe
Photoshop CS6 (Adobe Systems), with the migration rate calculated in pixels/min.
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To assess the effects of versican and versikine on myoblast proliferation, cells were seeded
at 10,000 cells/cm2 in growth media, supplemented with serum-free versican, versikine or empty
vector conditioned media (diluted 1:4; refreshed daily) for 48 h. Myoblast number was assessed
using the WST-1 cell proliferation reagent (Roche Life Science, Sydney, NSW, Australia), as per the
manufacturer’s directions.
4.8. Western Blot
To improve detection by the anti-V0/V1 versican antibody, the GAG side chains were removed.
Specifically, 1 μL of chondroitinase ABC (Seikagaku, Tokyo, Japan) was added to the versican
conditioned media and to the cell lysates from the creatine kinase enzyme assay for 2 h at 37 ◦C.
The serum free conditioned media containing versikine was subjected to the western blotting as
described by Dancevic et al. [30]. The versican conditioned media and C2C12 cell lysates underwent
SDS-PAGE using pre-cast Mini-PROTEAN TGX Stain-Free Protein Gels (Bio-Rad), which were
transferred onto PVDF membranes. Proteins were visualised by chemiluminescence on a Chemidoc
XRS+ (Bio-Rad) and analysed using ImageLab software (Bio-Rad). Versican and versikine protein levels
were normalised to total optical density of all protein bands on the TGX Stain-Free Protein Gel. Primary
antibodies used were anti-GAGβ (V0/V1 versican) (1:200, Merck Millipore), anti-V0/V1 DPEAAE
neo-epitope (versikine) (1:1000, Thermo Fisher Scientific, PA1-1748A), and anti-GAPDH (1:10,000,
Merck Millipore, AB1033). Secondary antibodies used were peroxidase AffiniPure goat anti-rabbit IgG
(1:5000, Jackson ImmunoResearch Laboratories) and anti-mouse IR680 (1:10,000, Sigma Aldrich).
4.9. Statistical Analyses
For the versican gene expression data, 2-way general linear model (GLM) ANOVA was performed
with the factors being muscle type (diaphragm versus TA) and strain (C57BL/10 versus mdx). For the
quantitation of versican and versikine immunoreactivity in TA and diaphragm muscles from mdx
and wild type mice, independent t-tests were used to assess differences in immunoreactivity between
C57BL/10 and mdx mice for a given muscle type. For the cell culture experiments, independent t-tests,
1-way or 2-way GLM ANOVA were performed as appropriate and followed by Tukey’s post-hoc
analysis where required. All data are presented as mean ± S.E. and were considered statistically
significant when p < 0.05.
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Abbreviations
ADAMTS A disintegrin-like and metalloproteinase domain with thrombospondin-1 repeats
CSPG Chondroitin sulphate proteoglycan
CK Creatine kinase
Ckm Creatine kinase muscle
Dex Dexamethasone
DMEM Dulbecco’s modified eagle medium
DMD Duchenne muscular dystrophy
ECM Extracellular matrix
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EV Empty vector
FI Fusion index
FOV Field of view
GAG Glycosaminoglycan
GLM General linear model




Myh1 Myosin heavy chain 1
OCT Optimum cutting temperature
TA Tibialis anterior
TGF-β Transforming growth factor-β
Vcan Versican
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Abstract: Skeletal muscle tissue engineering (TE) aims to efficiently repair large congenital and
acquired defects. Biological acellular scaffolds are considered a good tool for TE, as decellularization
allows structural preservation of tissue extracellular matrix (ECM) and conservation of its
unique cytokine reservoir and the ability to support angiogenesis, cell viability, and proliferation.
This represents a major advantage compared to synthetic scaffolds, which can acquire these features
only after modification and show limited biocompatibility. In this work, we describe the ability of a
skeletal muscle acellular scaffold to promote vascularization both ex vivo and in vivo. Specifically,
chicken chorioallantoic membrane assay and protein array confirmed the presence of pro-angiogenic
molecules in the decellularized tissue such as HGF, VEGF, and SDF-1α. The acellular muscle
was implanted in BL6/J mice both subcutaneously and ortotopically. In the first condition, the
ECM-derived scaffold appeared vascularized 7 days post-implantation. When the decellularized
diaphragm was ortotopically applied, newly formed blood vessels containing CD31+, αSMA+,
and vWF+ cells were visible inside the scaffold. Systemic injection of Evans Blue proved function
and perfusion of the new vessels, underlying a tissue-regenerative activation. On the contrary,
the implantation of a synthetic matrix made of polytetrafluoroethylene used as control was only
surrounded by vWF+ cells, with no cell migration inside the scaffold and clear foreign body reaction
(giant cells were visible). The molecular profile and the analysis of macrophages confirmed the
tendency of the synthetic scaffold to enhance inflammation instead of regeneration. In conclusion,
we identified the angiogenic potential of a skeletal muscle-derived acellular scaffold and the
pro-regenerative environment activated in vivo, showing clear evidence that the decellularized
diaphragm is a suitable candidate for skeletal muscle tissue engineering and regeneration.
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1. Introduction
In complex organs and tissues the vascular network, besides assuring an appropriate supply of
nutrients and oxygen for regular tissue function, provides a specific interphase to allow the balance of
tissue homeostasis and immune functions [1,2]. The growth of new blood vessels requires interactions
between endothelial cells, soluble growth factors, and a complex network of extracellular matrix
(ECM) components. For all these reasons, to repair a damaged tissue it is of paramount importance to
unravel strategies that keep, and at the same time, stimulate vessels with the final aim of obtaining a
functional regeneration. Thus, for a wide range of clinical applications, the ability to stimulate and
control angiogenesis has a significant impact. Specifically, successful tissue engineering strategies
rely on the efficiency of vascularization and subsequent tissue integration. This aspect is indeed
fundamental to avoid transplant failure and, to date, experimental approaches for organ and tissue
replacement have been focused on different approaches: the functionalization of natural or synthetic
scaffolds with proteins or cells known to be involved in angiogenesis (in situ vascularization) [3,4],
the generation of an efficient vascular network before graft implantation (pre-vascularization) [5,6].
Since angiogenesis in situ relies mainly on the host cells and pre-existing vasculature, limitations
on the use of scaffolds become evident when little porous, non elastic materials and large defects
are considered. Indeed, for skin wounds and small or mid-size ulcers, scaffold implantation
supports spontaneous regeneration [7]. Differently, in cases of transplantation of large portions
of tissue or even whole organs, the prolonged time required for vascularization of the construct
through correct anastomosis with the host could result in the formation of a necrotic core or in the
development of fibrotic tissue, thereby leading to graft failure [8–11]. With the aim of accelerating
angiogenesis, a natural scaffold possessing similar biological and structural features to the native
damaged tissue could be advantageous, since new vessels can be driven from the host tissue toward
the three-dimensional scaffold [12–14]. Moreover, the molecules originally hidden in healthy tissue,
called cryptic molecules, are released from the remodeled ECM and are known to be supportive of
several biological processes [15–17].
As for the other tissues, in skeletal muscle the vascular network also plays a key role during
remodeling and regeneration [12–22]. It is established that the implantation of any foreign device,
from synthetic products or acellular biomaterials to even living tissue constructs, always results in its
interactions with the host immune system, remodeling ECM and influencing neo-angiogenesis [23].
Immune cells, particularly macrophages, play a critical role in regulating wound healing and tissue
remodeling [24]. They can indeed shift the response towards a positive outcome by means of
stimulating new vases formation, matrix remodeling, and immunotolerance [25].
Recently, our group developed an acellular matrix derived from mouse diaphragmatic muscle,
which was able to positively modulate immune response and led to a local proregenerative
environment upon transplantation, both in healthy and diseased mouse models [26].
In this study, we characterized the angiogenic properties of a decellularized diaphragm
(DD) scaffold both ex vivo and in vivo. Specifically, in vivo we have chosen two different
murine models where we applied DD and a synthetic nonfunctionalized material, the expanded
polytetrafluoroethylene (ePTFE) used in clinical practice, as control: the first model expects the implant
under the murine back skin and for the second we used the already established orthotopic implant in
healthy diaphragm [26]. Our findings not only confirm the angiogenic properties of the ECM obtained
by skeletal muscle decellularization, but also underline a highly stable and prolonged angiogenic
stimulus, endorsing the use of this scaffold as an alternative support for skeletal muscle defect repair.
2. Results
2.1. Diaphragm-Derived Decellularized Matrix Retains Angiogenic Potential
Chorion allantoic membrane (CAM) assay was used to evaluate blood vessel chemo-attractive
activity of DD scaffold. Samples along with positive (polyester loaded with VEGF) and negative
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(polyester only) controls were analyzed daily under a stereomicroscope. Seven days after implantation,
neovessels were organized in a network surrounding the tissue samples (Figure 1A). Quantification of
vessel growth (i.e., blood converging towards the matrix) displayed a significant increase in DD with
respect to controls at the same time-point (p < 0.05; Figure 1B).
 
Figure 1. Characterization of diaphragmatic acellular scaffold angiogenic potential. (A) Chorion
allantoic membrane (CAM) assay appearance after 7 days of incubation with negative control,
positive control, and decellularized diaphragm. Scale bar = 1 mm; (B) Number of vessels converging
towards each sample at baseline (0d) and after 7 days; vessels were counted in a blinded fashion;
(C) Immunoblotted membrane array of fresh and decellularized tissue homogenate. 53 angiogenic
factors were detected; (D) Pixel intensity of some of the principal angiogenic factors. Intensity was
calculated using UVITEC Cambridge software (mean ± SD). Quantification of (E) VEGF; (F) SDF-1a;
(G) HGF; and (H) EGF from fresh and decellularized tissue homogenate (mean ± SD). Ctrl− = Negative
Control (inert polyester only); Ctrl+ = Positive Control (polyester with VEGF); DD = Decellularized
Diaphragm; FD = Fresh Diaphragm. * p < 0.01; *** p < 0.0001
To both confirm CAM assay results and verify whether the DD matrix retained pro-angiogenic
factors, an immune array directed against 53 proteins specifically involved in mouse angiogenesis
was performed. Most of the analyzed proteins were detected in the decellularized tissue
(Figure 1C,D), although with lower intensity compared to fresh tissue. In particular, specific angiogenic
cytokines (e.g., VEGF and Angiopoietins), matrikines, and enzymes necessary for endothelialization
(e.g., endothelin or metalloproteases such as MMP9) were detected. Furthermore, for VEGF, SDF-1α,
HGF, and EGF, key factors regulating vasculogenesis and angiogenesis, we have also measured
the amount retained in the decellularized tissue via ELISA test. Despite a significant decrease,
3 out of 4 factors were still present in a detectable amount in the tissue after decellularization
(VEGF: 0.580 ± 0.06 pg/mg in FD, 0.068 ± 0.02 pg/mg in DD; SDF-1α: 2.432 ± 0.204 pg/mg in
FD, 0.642 ± 0.13 pg/mg in DD; HGF: 1.939 ± 0.02 pg/mg in FD, 0.003 ± 0.0001 pg/mg in DD.
Figure 1E–H).
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2.2. Cell-Scaffold Interaction
Once the attraction of new vessels was confirmed, their origin was investigated to identify whether
neovascularization was due to new vessel formation, or if the pre-existing vessels were recellularized
by host cells. To this aim, we performed implantation in GFP+ mice for host cell-tracking (Figure 2A).
 
Figure 2. Scaffold subcutaneous implantation and vessel after DET treatment. (A) Macroscopic
appearance of the implanted DD at day 0 (red circle) and of DD explanted after 7 and 15 days of
implantation; (B) Quantification of hemoglobin over total protein content in control (skin) and DD
after 7 and 15 days of implantation (mean ± SD); (C) Immunofluorescence staining against αSMA
and GFP performed in explanted DD after 7 and 15 days from implantation (upper panel) and CD31
(lower panel); nuclei were counterstained with DAPI; (D) Immunofluorescence staining against αSMA
and Laminin performed in fresh diaphragm (FD) and DD; nuclei were counterstained with DAPI;
(E) Immunofluorescence staining against αSMA and Laminin or CD31 performed in DD after 48 h of
incubation with HUVECs; nuclei were counterstained with DAPI; Scale bar = 100 μm.
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Transplanted patches appeared vascularized at 7 days (Figure 2B), confirming CAM assay results.
The amount of hemoglobin (Hb) quantified on the harvested DD patches, corroborated the previous
data with a tendency of Hb to increment with time, suggesting also a functional angiogenesis with
perfused vessels inside the applied patch (Figure 2C). Immunofluorescence performed on DD excised
7 days post implant revealed the presence of αSMA+ vessels with uneven appearance and morphology
(Figure 2D). Among all, some of them were αSMA+ but did not have any GFP+ cell inside, indicating
the presence of empty vessels (Figure 2D, 7-day right inset). Fifteen days after implant, the majority of
the analyzed vessels had a uniform shape and dimension as pointed out by the presence of GFP+ cells
inside the vessel structure (Figure 2D, 15-day right inset). To confirm the hypothesis that endothelial
cells recolonized leftover vascular structures in the transplanted matrix, HUVEC were seeded in vitro
on top of the DD and 48 h later their migration was analyzed. The vast majority of pre-existing vascular
structures was recognized by HUVEC (CD31+ cells), confirming the influence of old vasculature
structure on patch angiogenic features and host endothelial cell behavior (Figure 2D,E)
2.3. Angiogenic Response to Orthotopic Transplantation of DD vs. ePTFE
Having demonstrated formation of functional vasculature, we evaluated DD angiogenic
properties by orthotopic implantation (Figure 3). Patches were applied on host diaphragm, in order
to challenge the DD with a physiological environment, without any local injury. We compared the
angiogenic effect exerted by our scaffold with that of ePTFE, a prosthetic patch already used in
clinic [27]. From the histological point of view, the H & E staining showed that the biological DD
underwent remodeling coherently to the outcome seen during the previous characterization [26], while
ePTFE was encapsulated by a thick cellular layer, suggesting a beginning of foreign body reaction
(Figure 4A).
Concerning endothelial cell presence, CD31+ cells migrated from the native diaphragm (ND) in
the applied scaffold after 7 and 15 days post implantation (Figure 3A). In both the analyzed time points
endothelial cells increased significantly (p < 0.0001) in DD samples compared to a fresh untreated
diaphragm (Figure 3B). Furthermore, although CD31+ cells could be detected also in the fibrotic
capsule surrounding the implanted ePTFE, their number was not significantly different from a basal
untreated condition (Figure 3B). These results suggest a stronger angiogenic effect of the applied
naturally-derived ECM with respect to prosthetic material.
We co-stained αSMA as a vessels perimetric marker, together with vWF to confirm both vessel
function and luminal size, which allowed the measurement of the vessel size (Figure 3C,D). In the DD
implants, at 7 days postsurgery the distribution was between small and mid-size vessels (from 2.0
to 1.75, and from 1.75 to 1.55, respectively), then after 15 days it resembled a physiological condition
(vessel diameter from 1.55 to lower values) (Figure 3D). On the contrary, at the interface between
ePTFE and ND, vessels had a distribution similar to native condition 7 days postsurgery, whereas
middle-size vessels appeared at the later time point (Figure 3D).
To confirm the presence of functioning and perfused vessels highlighted previously by the
co-expression of αSMA and vWF inside the applied DD, Evans Blue dye was systemically injected.
Red color stain was detected in the lumen of αSMA+ vessels at both time points. Moreover,
the proportion of nonperfused αSMA+ vessels diminished through the time points, indicating an
increase of functional vessels (Figure 4B,C).
288
Int. J. Mol. Sci. 2018, 19, 1319
 
Figure 3. Comparison of angiogenic response after orthotropic implantation of DD vs. ePTFE.
White line marks the normal diaphragm (ND) versus the patch (decellularized diaphragm –DD-
or plastic –ePTFE- or capsule expanded –cePTFE-) (A) Immunofluorescence staining against CD31
and Laminin performed in explanted DD and ePTFE after 7 and 15 days from implantation; nuclei
were counterstained with DAPI; (B) Quantification of CD31+ cells over total cell content in explanted
DD and ePTFE after 7 and 15 days from implantation (mean ± SD); (C) Immunofluorescence staining
against vWF and αSMA performed in explanted DD and ePTFE after 7 and 15 days from implantation;
nuclei were counterstained with DAPI; (D) αSMA+/vWF+ vessels dimension distribution calculated
in fresh tissue, DD and ePTFE after 7 and 15 days from implantation. Symbol legend. Black dots:
vessel dimension of the fresh diaphragm (control); black and white squares: vessel dimension 7 days
post implant; black and white triangles: vessel dimension 15 days post implant. Scale bar = 100 μm.
* p < 0.01; ** p < 0.001; *** p < 0.0001.
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Figure 4. Detection of vases in DD vs. ePTFE after orthotropic implantation. White or black line marks
the normal diaphragm (ND) versus the patch (decellularized diaphragm –DD- or plastic –ePTFE- or
capsule expanded –cePTFE-); (A) Histological appearance of DD and ePTFE-implanted diaphragm.
Haematoxylin&Eosin staining performed in DD and ePTFE after 7 and 15 days from implantation.
No vessels inside the ePTFE; ePTFE 7 days inlet displays a foreign body giant cell. Scale bar = 100 μm;
(B) Functional vessels after 15 days of DD implantation. Immunofluorescence staining against
Laminin performed on DD-implanted diaphragm after 15 days of implantation; Evans Blue dye
is autofluorescent in the red spectrum; nuclei were counterstained with DAPI; (C) Quantification of
αSMA+/EB+ and αSMA+/EB− vessels content in DD after 7 and 15 days from implantation (mean
%); (D) Immunofluorescent staining against CD31+ cells performed n DD- and ePTFE-implanted
diaphragms 7 and 15 days post implantation. Scale bar = 100 μm.
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2.4. Molecular Profiling of Host-Scaffold Interaction
The general pattern of the array data displayed by ePTFE vs. DD implants reflected the difference
between the two materials in terms of properties and exerted tissue response. To aid data interpretation,
proteins of interest were plotted under different categories according to the function or involvement
in angiogenesis. Seven days after surgery, protein quantification in ePTFE implants displayed an
abrupt increase compared to DD, supporting the rapid vessel constitution seen by immunofluorescence
(Figure 4D). Specifically, of the three proteins commonly associated with neoangiogenesis, VEGF, FGF2,
and PDGF-BB, only FGF2 had a different behavior when comparing the two implanted materials
(Figure 5A), increasing in the ePTFE-treated diaphragms after 15 days. Regarding proteins associated
with vessel turnover, Angiopoietin-1 (Angpt-1) raised in both cases, CD105 decreased in DD-implanted
muscles while increasing in ePTFE implants, and Dll4 decreased towards the baseline, returning to
fresh diaphragm (FD) values particularly after 15 days of DD implantation (Figure 5B). The difference
among the stimuli driving angiogenesis in the two implants was confirmed by the mRNA expression
of Flt1 (VEGFR1), which appears to be progressively down- or upregulated after DD or ePTFE
implantation, respectively.
In both treated samples, inflammation-associated proteins seem to indicate the persistence of an
inflammatory state (Figure 5D), since Il-1a and Il-1b lingered overexpressed. Interestingly, the mRNA
levels of TNFα remained considerably high after 15 days in the ePTFE-implanted diaphragms
(Figure 5C). On the contrary, proteins associated with a profibrotic and proangiogenic response (Il-10,
MMP-9, OPN) or with an antifibrotic and antiangiogenic effect (CXC4, MMP-8, PEDF) were expressed
differently upon stimulation of the two materials at both time points. Specifically, in the ePTFE-treated
samples Il-10, MMP-9, and OPN were upregulated also at 15 days, whereas antifibrotic proteins
such as MMP-8 and PEDF were downregulated at the same time point, suggesting a continuous
stimulation through a foreign body reaction. On the contrary, in DD-treated diaphragm MMP-9 and
OPN decreased during the time points, and at the same time, MMP-8 and CXCL4 were more expressed,
with PEDF highly present at the early time point (Figure 5I). In addition, CD26, a protein with a
demonstrated pathogenic role in development of fibrosis of various organs, is differently regulated in
DD and ePTFE with an important overexpression in the latter after 15 days (Figure 5C).
Lastly, although tissue regeneration is generally associated with M2 type macrophages, it is known
that a balance response among M1 and M2 phenotype is essential for a constructive remodelling,
while excess M2 can result in fibrosis. Gene expression of Nos2 (commonly associated with M1), Arg1,
and Klf4 (both associated with the shift toward M2) confirmed our previous results with DD being able
to stimulate a balanced shift from M1 to M2. ePTFE-implanted muscles expressed the three markers
simultaneously, suggesting a copresence of the two different polarization states (Figure 5E,F,H).
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Figure 5. Molecular response and immunoreaction elicited by DD vs. ePTFE. White or black dot
line marks the normal diaphragm (ND) versus the patch (decellularized diaphragm –DD- or plastic
–ePTFE-) (A,B) Quantification of angiogenic factors from DD and ePTFE-implanted diaphragms after
7 and 15 days compared to native tissue (set at 1), grouped by the processes involved (mean ± SD);
(C) Quantification of Il-6 and TNFα mRNA extracted from DD and ePTFE after 7 and 15 days from
implantation, compared to native tissue (set at 1) (mean ± SD); (D) Quantification of factors involved
in both angiogenic and immunomodulatory processes from DD and ePTFE-implanted diaphragms
after 7 and 15 days, compared to native tissue (set at 1) (mean ± SD); (E) Quantification of Nos2, ArgI,
CCl2 and Klf4 mRNA extracted from DD and ePTFE after 7 and 15 days from implantation, compared
to native tissue (set at 1) (mean ± SD); (F) Immunofluorescence staining against pan-macrophages
CD68 antigen performed in DD and ePTFE implanted diaphragms after 15 days; (G) Quantification of
factors involved in both angiogenic and fibrosis processes from DD and ePTFE-implanted diaphragms
after 7 and 15 days, compared to native tissue (set at 1) (mean ± SD); (H) Immunofluorescence staining
against M2 macrophages Arginase I antigen performed in DD and ePTFE-implanted diaphragms after
15 days; (I) Quantification of factors involved in both angiogenic and reconstructive processes from DD
and ePTFE-implanted diaphragms after 7 and 15 days, compared to native tissue (set at 1) (mean ± SD);
Scale bar = 100 μm.
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3. Discussion
Angiogenesis remodels and extends the pre-existing vascular tree forming new capillaries [28]
and this process in the context of tissue regeneration is crucial to modulate the response towards a
proregenerative environment [29,30].
This work was specifically focused on defining the angiogenic properties of DD following
previous studies on the murine model that already demonstrated several proregenerative effects
after in vivo transplantation [26]. At first, we started by characterizing the angiogenic profile of our
DD scaffold. Since it is established that the ECM provides both a mechanical support and a molecular
reservoir able to influence cell behavior [31,32], it was hypothesized that the presence of molecules
regulating vessel formation could be the trigger accounting for CAM result. This hypothesis was
supported by several studies which demonstrated the preservation of the ECM components after
decellularization [33,34], also by the means of bioactive molecules [35–37]. Using a specific panel
against 53 molecules involved in mouse angiogenesis, we more deeply characterized the reservoir
quality of our scaffold. Almost all the spots in the prepatterned mouse angiogenesis array developed
a signal, indicating that most of the essayed angiogenesis-involved molecules were still present and
detectable after decellularization. Focusing on the quantification of four specific cytokines, we were
able to detect VEGF, known to be the master regulatory factor for angiogenesis [38], HGF, involved in
both angiogenesis and skeletal muscle growth/repair [39], and SDF-1a, linked not only to angiogenesis
but also to other proregenerative processes (e.g., chemotaxis of immune cells) [40]. Considering
these data, it was clear that the angiogenic potential persists and is effective despite reduction in
the ECM reservoir. The presence of almost all of the array proteins can be advantageous not only
because the scaffold does not necessarily require preconditioning [41], but also because a desired effect
(angiogenesis, for example) could be further enhanced if a chosen factor is additionally loaded. In this
respect, quantification of the cytokines retained by the DD could be the initial step for a tunable control
of this process.
Next, subcutaneous implant [42] was used as common method to evaluate angiogenic potential
of the biological scaffold. In an allogeneic setting, GFP+ mouse was chosen as recipient to mark and
recognize the host cells and vessels. At both analyzed time points, GFP+/αSMA+ vessels indicated a
complete integration with the host vasculature. Hemoglobin quantification in the explanted tissue
highlighted the functionality of these vessels and blood flow activity. Interestingly, decellularization
preserved the innermost (as intima was depleted) connective layer, but also the hollow structure of the
media, since αSMA+ vessels could be found in the DD. We decided to use endothelial-like cells such
as HUVEC [43] as a tool to investigate whether the vessels preserved after decellularization could be
recognized as vascular mold. We demonstrated that HUVEC migrated towards the vessel structures
considered as their natural location. This result might be a clue of what happens in vivo when cells get
in touch with ECM; however, to really understand the process further, studies are required.
Although the use of synthetic materials is common practice in other areas of medicine, several
products, from both xeno and allogeneic origin, have been already commercialized [30], while others,
both unseeded or seeded with cells, are currently in clinical use (bladder, urethra, and trachea [44–46].
Organs with a high modular complexity, such as the heart, lung, and liver [47–49], are still undergoing
preclinical studies, as well as skeletal muscle [50,51]. With the orthotropic scaffold implantation,
our group already proved the ability of the muscle-derived ECM to exert a proregenerative effect.
Here, in line with the findings on decellularized tissue advantages over synthetic materials [52],
we showed that the regeneration ability was due to the solid angiogenic properties of DD underlying
strong differences between the inert ePTFE, one of the gold standard materials in clinical settings [53].
After histological analyses, DD implants attracted vessels from the host while modulating its response
towards a constructive environment. On the contrary, the ePTFE seemed to have elicited an abrupt
response, which after 15 days appeared to have stabilized. Recipient CD31+ cells could be detected
in the ECM of the decellularized scaffold, as well as functional and pre-existing vessels. Presence
of functional αSMA+/vWf+ vases, as well as retention of the Evans Blue dye [54], indicated the
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constitution of both epithelium and blood flow. ePTFE implants on one hand exerted an effect in
which CD31+ cells were present only inside functional vessels, while on the other hand the rapidly
elicited angiogenesis appeared to be simultaneously regressing, as part of a chronic turnover process.
Indeed, while distribution among the size of the vessels found in DD-implanted animals ultimately
resembled the natural environment with dis-homogeneous vessel dimensions (from small to big), the
synthetic material stabilized on middle size vase dimensions. It is known that the prolonged contact of
any device, either synthetic or biological, results in activation of angiogenesis during the cascade of
events involved in the foreign body reaction [24]. Nevertheless, differences through the analyzed time
points highlighted the properties of the biological scaffold in modulating the host response towards
a functional remodeling. The response to the ePTFE indeed confirmed the behavior seen in a classic
foreign body reaction [55], in which the host enhances angiogenesis to efficiently deliver immune
cells [56] and increases the local angiogenesis (high level of FGF2 and PDGF-BB after 7 days) aiming
only at restoring physiological conditions rather than constituting a proregenerative environment
(Figure 4, ePTFE bars). Instead, implanted DD was recognized as tissue to be remodeled and
reabsorbed, stimulating a regenerative functional angiogenesis, as demonstrated by the comparable
expression of FGF2 and PDGF-BB (Figure 4, DD bars) [57]. The increased downregulation of VEGFr1
upon DD implantation, which conversely seems to be trending towards restoration in ePTFE-implanted
muscles, could be a further indication of the difference between the angiogenic stimuli. A decrease in
VEGFr1 could suggest either an increase in vascular sprouting or a decrease in vessel regression [58].
The two different responses achieved by DD and ePTFE patches could be appreciated also by
the gene expression results. In general, the protein pattern displayed by ePTFE implants showed an
intense increase after 7 days compared to DD, but in both cases for many proteins it trended similarly
towards normal levels (healthy diaphragm line), suggesting that, although different, some extent of
overlap had occurred in the responses. The overall mRNA and protein level (i.e., Il-6, TNFα and Il-1β,
Il-10, Ccl2) were coherent to results previously seen with these two types of materials [59].
Considering the immunomodulation of the innate immune system [60], it is now established
that constructive remodeling requires a fine-tuned balance in immune system cell intervention, not
only to avoid rejection of the graft, but also to avoid the establishment of a chronic response [61,62].
In particular, macrophages were found to be of paramount significance, being a heterogeneous
population influencing inflammation, angiogenesis, and fibrosis, both directly and indirectly [63,64].
In this respect, DD implants displayed a balanced presence of cytokines and chemokines (e.g., FGF2,
CXCL4, Il-10, MMP-3, MMP-8, MMP-9, PEDF) known to be up- or downregulated by cells of the
immune system to keep the physiological equilibrium as already shown [26] and involved in the
remodeling of ECM, which can in turn be supportive of angiogenesis [65,66]. In this context, Real Time
PCR confirmed previous results of a specific time course in macrophage polarization, from M1 to M2,
in DD-transplanted animals, while ePTFE triggered an abrupt increase in the mRNA expression of Il-6,
TNFα, Nos2, and Ccl2, commonly associated with inflammatory cells. The overall profile suggested
that differently polarized macrophages were present simultaneously, probably due to the management
of the fibrotic capsule surrounding the foreign material [67–72].
With the synthetic material, the lack of a balanced progression ultimately resulted in a
nonconstructive response where angiogenesis was not consistent.
Understanding construct–host interactions is essential to avoid any adverse effect by both
modulating foreign body reaction (i.e., graft vs. host) and enhancing regeneration (i.e., functional
integration). Decellularized scaffolds represent a promising tool for tissue engineering. However,
improvement in the development of complex organ decellularization protocols is needed to address
issues that are still unanswered, such as complete xenogeneic antigen depletion, sterilization strategies
to avoid pathogen transmission, and costs and availability for scale-up and large-scale production.
Nevertheless, DD proved to be a promising material, with both pro-angiogenic potential and
immunomodulatory properties. Precisely, the ability to direct the immune system was reflected
in the foreign body reaction, which was driven towards (1) a constructive remodeling, (2) the induction
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of the myogenic program, (3) the formation of stable vessels, and (4) the ultimate reabsorption of the
scaffold into a restoration of normal condition.
4. Materials and Methods
4.1. Animals
All surgical procedures and animal husbandry were carried out in accordance with the University
of Padua’s Animal care and Use Committee (CEASA, protocol number 67/2011 approved on
21 September 2011). Eight 12-week-old male and female C57BL/6J mice (B6) were used as both donors
(diaphragms for scaffolds generation) and recipients (orthotropic implantation). Twelve-week-old
male and female B6 UBC-GFP mice (GFP+) were used as recipients for subcutaneous implantation.
For the experiments carried out in the UK, all surgical procedures and animal husbandry were carried
out in accordance with UK Home Office guidelines under the Animals (Scientific Procedures) Act 1986
and the Local Ethics Committee.
4.2. Diaphragm Decellularization
Twenty four diaphragms, harvested with the whole rib cage, were washed in sterile phosphate
buffered saline (PBS) and either used as fresh diaphragm (FD) controls, or immediately treated with
three cycles of a detergent-enzymatic treatment protocol as previously described [26]. Each cycle was
composed of deionized water at 4 ◦C for 24 h, 4% sodium deoxycholate (Sigma, Milan, Italy) at room
temperature (RT) for 4 h and 2000 kU DNase-I (Sigma, Milan, Italy) in 1 M NaCl (Sigma, Milan, Italy)
at RT for 3 h. At the end of the third cycle, samples (DD) were left in milliQ water for a final washing
step of 72 h, after which they were immediately used or preserved at 4 ◦C in PBS supplemented with
1% Penicillin/Streptomycin (PBS-P/S).
4.3. Chicken Chorioallantoic Membrane Assay
CAM assay was performed as previously described [73]. Fertilized chicken eggs (Henry Stewart
and Co. 6 for negative control and 13 for the experimental conditions) were incubated at 37 ◦C and
constant humidity. At 3 days of incubation, an oval window of approximately 3 cm in diameter was
cut into the shell with small dissecting scissors to reveal the embryo and CAM vessels. The window
was sealed with tape and the eggs were returned to the incubator for a further 5 days. At day 8 of
incubation, 1 mm diameter acellular matrices were placed on the CAM between branches of the blood
vessels. Polyester sections (ePTFE) soaked overnight either in PBS or in 200 ng/mL VEGF in PBS were
used as negative and positive controls, respectively. Eggs with patches (acellular biological matrices
and ePTFE) were examined daily until 7 days after placement wherein they were photographed in ovo
with a stereomicroscope equipped with a Camera System (Leica, Italy) to quantify the blood vessels
surrounding the matrices. The number of blood vessels converging towards the placed tissues was
counted blindly by assessors, with the mean of the counts being considered.
4.4. Proteome Profiler Angiogenesis Array
Samples designated for protein array (5 for each group) were snap frozen and stored at
−80 ◦C until the beginning of the assay. Before start, tissue was thawed and lysed by mechanical
homogenization, and the resulting protein solution was collected in PBS with protease inhibitors
(10 μg/mL Aprotinin, 10 μg/mL Leupeptin, and 10 μg/mL Pepstatin, all Sigma-Aldrich (Milan,
Italy). Nonoperated B6 diaphragms served as control (FD). Three tissue homogenates for each sample
(FD, DD, implanted diaphragms after 7 and 15 days with DD or ePTFE) were pooled for analysis
and concentration of each pool was determined with BCA protein assay kit (Pierce, Thermo Fisher
Scientific, Waltham, MA, USA, performed according to manufacturers’ instructions). Proteome profiler
mouse angiogenesis array ARY015 (R&D Systems, Milan, Italy) was used according to manufacturers’
instructions. Luminescence acquisition and quantification of the pixel density of each spot was
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determined with Alliance (UVITEC, Cambridge, UK). For data analysis, average background signal
(negative control spots) was subtracted from protein spots signal, which was subsequently normalized
to positive control spots and related to signals detected from FD pool (Fold change/FD).
4.5. ELISA Test
Samples designated for ELISA test (5 for each group) were snap frozen and stored at −80 ◦C
until the beginning of the assay. Before start, tissue was thawed, lysed by mechanical homogenization,
and immediately assayed. Nonoperated B6 diaphragms served as control. Three decellularized
diaphragm quarters (from different samples) were pooled and used for each ELISA. Quantikine for
mouse VEGF, HGF, EGF, and SDF-1a (R&D systems) were carried out according to manufacturers’
instructions. Luminescence acquisition and sample quantification was performed using SpectraMax
Plus 384 (Molecular devices, San Jose, CA, USA).
4.6. Subcutaneous Implantation
Mice were gently handled in general anesthesia with O2 and 1.5–2.0% isoflurane (Forane, Merial,
Padova, Italy) inhalation. While in procumbent position, a medial incision was performed on the back
of the mouse allowing the skin to be gently detached from the underlying fascia. For each animal, up to
three portions (0.7 × 0.7 cm each) of acellular scaffold (5 pieces from different animals and for each
time point) were positioned and fixed to the skin side with a Prolene 7/0 suture. Skin was then closed
with a Prolene 6/0 suture and animal left to recover under a heating lamp. Mice were euthanized by
cervical dislocation at 7 and 15 days post-implantation.
4.7. Hemoglobin Quantification
For hemoglobin quantification, DD only were carefully dissected from the host skin to prevent
host tissue contamination. Drabkin’s reagent lyses red blood cells and oxidizes all forms of hemoglobin
(Hb), [74]. Samples were homogenized and diluted 1⁄1000 with Drabkin’s reagent (Sigma) so that the
final HiCN concentration fell within the range of the calibration curve (0–0Æ8 g/L HiCN) produced
using purchased hemoglobin (Sigma). After mixing, samples and standards were incubated at RT for
30 min, protected from light. Absorbance was read at 550 nm with SpectraMax Plus 384 and the Hb
concentration of each sample was calculated from the linear equation of the calibration curve.
4.8. Evans Blue Injection
Evans Blue (Sigma) was diluted to 0.5% in 0.9% NaCl solution. Two hundred μL of the prepared
solution was injected via the tail vein and left diffusing in the bloodstream for 30 min, before animal
euthanasia. To avoid loss of the dye, diaphragm muscles were fixed right after harvesting with 0.25%
Glutaraldehyde (Sigma) in PBS. The procedure was performed only in DD-implanted animals and a
total of 5 for each time point were essayed.
4.9. Human Umbilical Vein Endothelial Cells Culture and Seeding
Human umbilical vein endothelial cells (HUVEC, PromoCell) were expanded in endothelial
medium (PromoCell) and used after passage 2 or 3. For the in vitro experiment of seeding HUVEC
on the top of the decellularized ECM, cells were detached from the culture plate using 0.025%
Trypsin-EDTA (Invitrogen, Carlsbad, CA, USA) and counted, aiming to obtain a concentration of
5 × 105 cells/15 μL, which was the amount distributed on each scaffold (empty of other cells). Samples
were finally left in culture for 48 h and were subsequently fixed and analyzed (5 samples).
4.10. Orthotopic Implantation
Surgical procedure was carried out as previously described [26]. Briefly, while placed in supine
position with its caudal part towards the operator, a medial incision was performed in the abdomen
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of the mouse. To visualize the diaphragm, liver and stomach were then gently moved on the right
downward part of the abdomen with the help of a sterile gauze soaked in warm saline solution. DD or
ePTFE patches (0.7 × 0.7 cm each) were fixed on the left side of the native diaphragm with 4 Prolene
8/0 stitches. The abdominal wall was closed in two layers with 5/0 running suture and the animals
were left to wake up under a heating lamp. Mice were euthanized by cervical dislocation at 7 and
15 days post-implantation (8 mice for each time point).
4.11. Histological Stain and Immunofluorescence
Frozen sections (thickness of 6–8 μm) were stained with HE kit for rapid frozen section (Bio-Optica,
Milano, Italy) under the manufacturer’s instruction. For immunofluorescence analyses, sections were
permeabilized with 0.5% Triton X-100 (10 min), blocked with 5% Horse serum/5% Goat serum
(30 min) and incubated with primary antibodies overnight at 4 ◦C. Slides were then incubated with
secondary antibodies Alexa Fluor-conjugated. Antibodies used are listed in Table S1. Nuclei were
counterstained with fluorescent mounting medium plus 100 ng/mL 4′,6-diamidino-2-phenylindole
(DAPI) (Sigma-Aldrich). For each count performed, n = 8 random pictures were collected and analyzed.
4.12. Vessel Size Analysis
Eight images per group (fresh, transplanted after 7 days, and 15 days) were analyzed to examine
the difference in vessel dimension. To this aim, for each image the perimeter and the area of
alpha smooth muscle actin (αSMA) and von Willebrand Factor (Vwf) double positive vessels were
calculated and their proportion was analytically obtained by means of the fractal dimension index
(FRAC, http://www.umass.edu/landeco/research/fragstats/documents/Metrics/Shape%20Metrics/
Metrics/P9%20-%20FRAC.htm). The formula is commonly used to calculate the proportion of area
and perimeter in irregular shape surfaces. Subsequently, the shape data expressed as vessel lumen
were collected and the groups compared.
4.13. Real Time PCR
Total RNA was extracted using RNeasy Plus Mini kit (QIAGEN GmbH, Milan Italy) following the
supplier’s instructions. RNA was quantified with an ND-2000 spectrophotometer and 1 μg total was
reverse transcripted with SuperScript II and related products (all from Life Technologies, Milan, Italy)
in a 20 μL reaction. Real-time PCR reactions were performed using a LightCycler II (Roche, Milan,
Italy). Reactions were carried out in triplicate using 4 μL of FASTSTART SYBR GREEN MASTER
(Roche) and 2 μL of primers mix Forward and Reverse (final concentration, 300/300 nM) in a final
volume of 20 μL. Serial dilutions of a positive control sample were used to create a standard curve
for the relative quantification. The amount of each mRNA was normalized over the expression of
β2-microglobulin. Primer sequences used are listed in Table S2.
4.14. Statistical Analysis
Image-based counts and measurements were performed with Fiji 30 or alternatively with Imago 1
(Mayachitra, Santa Barbara, CA USA). For each analysis, at least five random pictures were used for
data output. All graphs displayed were produced with GraphPad software (GraphPad Software Inc,
CA, USA) 5 or 6. Data are expressed as means ± SEM. Statistical significance was determined using an
equal-variance Student’s t-test for qRT-PCR analyses (t-test was performed between: DD 7d vs. DD
15d, DD 7d vs. ePTFE 7d, DD 15d vs. ePTFE 15d, ePTFE 7d vs. ePTFE 15d). A p value below 0.05 was
considered to be statistically significant. See Table S3.
5. Conclusions
Summarizing, to understand and make reproducible tissue regeneration approaches, it is of
paramount importance to deepen the investigation of the interactions between scaffold and host,
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unveiling the specific players from either the cellular, mechanical, or molecular side. In this study
we used a tailored scaffold closely resembling the tissue of origin, proving that angiogenic and,
consequently, immunomodulatory properties persist after decellularization and may lead to an
efficient regeneration process [75,76]. These characteristics make our DD a promising scaffold to
be implemented for clinical purposes in tissue engineering-based approaches.
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s1.
Author Contributions: M.E.A.F.: Conception and design, collection and assembly of data, data analysis and
interpretation, manuscript writing; M.P.: Conception and design, collection and assembly of data, data analysis
and interpretation, manuscript writing; C.F., L.U.: experiments performance, data analysis and interpretation,
manuscript writing; E.B. and C.T.: experiments performance, data analysis; A.D. and A.S.: surgical procedures;
P.G.: financial support and final approval of the manuscript; A.J.B.: provision of study material and results;
P.D.C.: manuscript writing and final approval of the manuscript; M.P.: project supervision, data interpretation,
manuscript writing and final approval of the manuscript.
Acknowledgments: M.P. and C.F. are supported by Fondazione Città della Speranza, M.P. is funded by University
of Padova, Grant number GRIC15AIPF, Assegno di Ricerca Senior. P.D.C. is funded by GOSH charity. C.F., M.P.,
L.U. and M P. are co-inventors of Italian Patent N. 0001422436 entitled “Matrice acellulare per ricostruzione in vivo
di muscolo scheletrico”.




cePTFE Capsule Expanded polytetrafluoroethylene
ECM Extracellular matrix
CAM Chorion allantoic membrane
ND Native diaphragm
References
1. Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249–257. [CrossRef]
[PubMed]
2. Rajendran, P.; Rengarajan, T.; Thangavel, J.; Nishigaki, Y.; Sakthisekaran, D.; Sethi, G.; Nishigaki, I.
The vascular endothelium and human diseases. Int. J. Biol. Sci. 2013, 9, 1057–1069. [CrossRef] [PubMed]
3. Conconi, M.T.; Bellini, S.; Teoli, D.; de Coppi, P.; Ribatti, D.; Nico, B.; Simonato, E.; Gamba, P.G.;
Nussdorfer, G.G.; Morpurgo, M.; et al. In vitro and in vivo evaluation of acellular diaphragmatic matrices
seeded with muscle precursors cells and coated with VEGF silica gels to repair muscle defect of the
diaphragm. J. Biomed. Mater. Res. Part A 2009, 89A, 304–316. [CrossRef] [PubMed]
4. Lee, T.T.; García, J.R.; Paez, J.I.; Singh, A.; Phelps, E.A.; Weis, S.; Shafiq, Z.; Shekaran, A.; del Campo, A.;
García, A.J. Light-triggered in vivo activation of adhesive peptides regulates cell adhesion, inflammation
and vascularization of biomaterials. Nat. Mater. 2014, 14, 352–360. [CrossRef] [PubMed]
5. Gholobova, D.; Decroix, L.; van Muylder, V.; Desender, L.; Gerard, M.; Carpentier, G.; Vandenburgh, H.;
Thorrez, L. Endothelial Network Formation Within Human Tissue-Engineered Skeletal Muscle. Tissue Eng.
Part A 2015, 21, 150901071945000. [CrossRef] [PubMed]
6. Miller, J.S.; Stevens, K.R.; Yang, M.T.; Baker, B.M.; Nguyen, D.-H.T.; Cohen, D.M.; Toro, E.; Chen, A.A.;
Galie, P.A.; Yu, X.; et al. Rapid casting of patterned vascular networks for perfusable engineered
three-dimensional tissues. Nat. Mater. 2012, 11, 768–774. [CrossRef] [PubMed]
7. Tremblay, P.L.; Hudon, V.; Berthod, F.; Germain, L.; Auger, F.A. Inosculation of tissue-engineered capillaries
with the host’s vasculature in a reconstructed skin transplanted on mice. Am. J. Transplant. 2005, 5, 1002–1010.
[CrossRef] [PubMed]
8. Atala, A.; Kasper, F.K.; Mikos, A.G. Engineering complex tissues. Sci. Transl. Med. 2012, 4, 160rv12.
[CrossRef] [PubMed]
298
Int. J. Mol. Sci. 2018, 19, 1319
9. Baranski, J.D.; Chaturvedi, R.R.; Stevens, K.R.; Eyckmans, J.; Carvalho, B.; Solorzano, R.D.; Yang, M.T.;
Miller, J.S.; Bhatia, S.N.; Chen, C.S. Geometric control of vascular networks to enhance engineered tissue
integration and function. Proc. Natl. Acad. Sci. USA 2013, 110, 7586–7591. [CrossRef] [PubMed]
10. Folkman, J.; Hochberg, M. Self-regulation of growth in three dimensions. J. Exp. Med. 1973, 138, 745–753.
[CrossRef] [PubMed]
11. Laschke, M.W.; Menger, M.D. Prevascularization in tissue engineering: Current concepts and future
directions. Biotechnol. Adv. 2015. [CrossRef] [PubMed]
12. Burns, J.S.; Kristiansen, M.; Kristensen, L.P.; Larsen, K.H.; Nielsen, M.O.; Christiansen, H.; Nehlin, J.;
Andersen, J.S.; Kassem, M. Decellularized Matrix from Tumorigenic Human Mesenchymal Stem Cells
Promotes Neovascularization with Galectin-1 Dependent Endothelial Interaction. PLoS ONE 2011, 6, e21888.
[CrossRef] [PubMed]
13. Moore, M.C.; Pandolfi, V.; McFetridge, P.S. Novel human-derived extracellular matrix induces in vitro and
in vivo vascularization and inhibits fibrosis. Biomaterials 2015, 49, 37–46. [CrossRef] [PubMed]
14. Totonelli, G.; Maghsoudlou, P.; Georgiades, F.; Garriboli, M.; Koshy, K.; Turmaine, M.; Ashworth, M.;
Sebire, N.J.; Pierro, A.; Eaton, S.; et al. Detergent enzymatic treatment for the development of a natural
acellular matrix for oesophageal regeneration. Pediatr. Surg. Int. 2013, 29, 87–95. [CrossRef] [PubMed]
15. Brown, M.D.; Hudlicka, O. Modulation of physiological angiogenesis in skeletal muscle by mechanical
forces: Involvement of VEGF and metalloproteinases. Angiogenesis 2003, 6, 1–14. [CrossRef] [PubMed]
16. Christov, C.; Chretien, F.; Abou-Khalil, R.; Bassez, G.; Vallet, G.; Authier, F.-J.; Bassaglia, Y.; Shinin, V.;
Tajbakhsh, S.; Chazaud, B.; et al. Muscle Satellite Cells and Endothelial Cells: Close Neighbors and Privileged
Partners. Mol. Biol. Cell 2007, 18, 1397–1409. [CrossRef] [PubMed]
17. Fuoco, C.; Rizzi, R.; Biondo, A.; Longa, E.; Mascaro, A.; Shapira-, K.; Kossovar, O.; Benedetti, S.;
Salvatori, M.L.; Santoleri, S.; et al. In vivo generation of a mature and functional artificial skeletal muscle.
EMBO Mol. Med. 2015, 1–13. [CrossRef] [PubMed]
18. Jank, B.J.; Xiong, L.; Moser, P.T.; Guyette, J.P.; Ren, X.; Cetrulo, C.L.; Leonard, D.A.; Fernandez, L.; Fagan, S.P.;
Ott, H.C. Engineered composite tissue as a bioartificial limb graft. Biomaterials 2015, 61, 246–256. [CrossRef]
[PubMed]
19. Juhas, M.; Engelmayr, G.C.; Fontanella, A.N.; Palmer, G.M.; Bursac, N. Biomimetic engineered muscle with
capacity for vascular integration and functional maturation in vivo. Proc. Natl. Acad. Sci. USA 2014, 111,
5508–5513. [CrossRef] [PubMed]
20. Levenberg, S.; Rouwkema, J.; Macdonald, M.; Garfein, E.S.; Kohane, D.S.; Darland, D.C.; Marini, R.;
van Blitterswijk, C.A.; Mulligan, R.C.; D’Amore, P.A.; et al. Engineering vascularized skeletal muscle tissue.
Nat. Biotechnol. 2005, 23, 879–884. [CrossRef] [PubMed]
21. Shimizu-Motohashi, Y.; Asakura, A. Angiogenesis as a novel therapeutic strategy for Duchenne muscular
dystrophy through decreased ischemia and increased satellite cells. Front. Physiol. 2014, 5, 50. [CrossRef]
[PubMed]
22. Uchida, C.; Nwadozi, E.; Hasanee, A.; Olenich, S.; Olfert, I.M.; Haas, T.L. Muscle-derived vascular endothelial
growth factor regulates microvascular remodelling in response to increased shear stress in mice. Acta Physiol.
2015, 214, 349–360. [CrossRef] [PubMed]
23. Van Amerongen, M.J.; Molema, G.; Plantinga, J.; Moorlag, H.; van Luyn, M.J. Neovascularization and
vascular markers in a foreign body reaction to subcutaneously implanted degradable biomaterial in mice.
Angiogenesis 2002, 5, 173–180. [CrossRef] [PubMed]
24. Kwee, B.J.; Mooney, D.J. Manipulating the Intersection of Angiogenesis and Inflammation. Ann. Biomed. Eng.
2015, 43, 628–640. [CrossRef] [PubMed]
25. Anderson, J.M.; Rodriguez, A.; Chang, D.T. Foreign body reaction to biomaterials. Semin. Immunol. 2008, 20,
86–100. [CrossRef] [PubMed]
26. Piccoli, M.; Urbani, L.; Alvarez-Fallas, M.E.; Franzin, C.; Dedja, A.; Bertin, E.; Zuccolotto, G.; Rosato, A.;
Pavan, P.; Elvassore, N.; et al. Improvement of diaphragmatic performance through orthotopic application
of decellularized extracellular matrix patch. Biomaterials 2016, 74, 245–255. [CrossRef] [PubMed]
27. Romao, R.L.P.; Nasr, A.; Chiu, P.P.L.; Langer, J.C. What is the best prosthetic material for patch repair of
congenital diaphragmatic hernia? Comparison and meta-analysis of porcine small intestinal submucosa and
polytetrafluoroethylene. J. Pediatr. Surg. 2012, 47, 1496–1500. [CrossRef] [PubMed]
299
Int. J. Mol. Sci. 2018, 19, 1319
28. Vailhé, B.; Vittet, D.; Feige, J.J. In vitro models of vasculogenesis and angiogenesis. Lab. Investig. 2001, 81,
439–452. [CrossRef] [PubMed]
29. Bland, E.; Dréau, D.; Burg, K.J.L. Overcoming hypoxia to improve tissue-engineering approaches to
regenerative medicine. J. Tissue Eng. Regen. Med. 2013, 7, 505–514. [CrossRef] [PubMed]
30. Brown, B.N.; Londono, R.; Tottey, S.; Zhang, L.; Kukla, K.A.; Wolf, M.T.; Daly, K.A.; Reing, J.E.; Badylak, S.F.
Macrophage phenotype as a predictor of constructive remodeling following the implantation of biologically
derived surgical mesh materials. Acta Biomater. 2012, 8, 978–987. [CrossRef] [PubMed]
31. Kyriakides, T.R.; Bornstein, P. Matricellular proteins as modulators of wound healing and the foreign body
response. Thromb. Haemost. 2003, 89, 986–992. [CrossRef] [PubMed]
32. Ricard-Blum, S.; Salza, R. Matricryptins and matrikines: Biologically active fragments of the extracellular
matrix. Exp. Dermatol. 2014, 23, 457–463. [CrossRef] [PubMed]
33. Hill, R.C.; Calle, E.A.; Dzieciatkowska, M.; Niklason, L.E.; Hansen, K.C. Quantification of Extracellular Matrix
Proteins from a Rat Lung Scaffold to Provide a Molecular Readout for Tissue Engineering. Mol. Cell. Proteom.
2015, 1, 961–973. [CrossRef] [PubMed]
34. Li, Q.; Uygun, B.E.; Geerts, S.; Ozer, S.; Scalf, M.; Gilpin, S.E.; Ott, H.C.; Yarmush, M.L.; Smith, L.M.;
Welham, N.V.; et al. Proteomic analysis of naturally-sourced biological scaffolds. Biomaterials 2016, 75, 37–46.
[CrossRef] [PubMed]
35. Caralt, M.; Uzarski, J.S.; Iacob, S.; Obergfell, K.P.; Berg, N.; Bijonowski, B.M.; Kiefer, K.M.; Ward, H.H.;
Wandinger-Ness, A.; Miller, W.M.; et al. Optimization and critical evaluation of decellularization strategies to
develop renal extracellular matrix scaffolds as biological templates for organ engineering and transplantation.
Am. J. Transplant. 2015, 15, 64–75. [CrossRef] [PubMed]
36. Hoganson, D.M.; O’Doherty, E.M.; Owens, G.E.; Harilal, D.O.; Goldman, S.M.; Bowley, C.M.; Neville, C.M.;
Kronengold, R.T.; Vacanti, J.P. The retention of extracellular matrix proteins and angiogenic and mitogenic
cytokines in a decellularized porcine dermis. Biomaterials 2010, 31, 6730–6737. [CrossRef] [PubMed]
37. Reing, J.E.; Zhang, L.; Myers-Irvin, J.; Cordero, K.E.; Freytes, D.O.; Heber-Katz, E.; Bedelbaeva, K.;
McIntosh, D.; Dewilde, A.; Braunhut, S.J.; et al. Degradation products of extracellular matrix affect cell
migration and proliferation. Tissue Eng. Part A 2009, 15, 605–614. [CrossRef] [PubMed]
38. Moens, S.; Goveia, J.; Stapor, P.C.; Cantelmo, A.R.; Carmeliet, P. The multifaceted activity of VEGF in
angiogenesis—Implications for therapy responses. Cytokine Growth Factor Rev. 2014, 25, 473–482. [CrossRef]
[PubMed]
39. Latroche, C.; Gitiaux, C.; Chrétien, F.; Desguerre, I.; Mounier, R.; Chazaud, B. Skeletal Muscle
Microvasculature: A Highly Dynamic Lifeline. Physiology 2015, 30, 417–427. [CrossRef] [PubMed]
40. Brzoska, E.; Kowalewska, M.; Markowska-Zagrajek, A.; Kowalski, K.; Archacka, K.; Zimowska, M.;
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Abstract: Several acquired or congenital pathological conditions can affect skeletal muscle leading to
volumetric muscle loss (VML), i.e., an irreversible loss of muscle mass and function. Decellularized
tissues are natural scaffolds derived from tissues or organs, in which the cellular and nuclear contents
are eliminated, but the tridimensional (3D) structure and composition of the extracellular matrix
(ECM) are preserved. Such scaffolds retain biological activity, are biocompatible and do not show
immune rejection upon allogeneic or xenogeneic transplantation. An increase number of reports
suggest that decellularized tissues/organs are promising candidates for clinical application in patients
affected by VML. Here we explore the different strategies used to generate decellularized matrix and
their therapeutic outcome when applied to treat VML conditions, both in patients and in animal
models. The wide variety of VML models, source of tissue and methods of decellularization have led
to discrepant results. Our review study evaluates the biological and clinical significance of reported
studies, with the final aim to clarify the main aspects that should be taken into consideration for the
future application of decellularized tissues in the treatment of VML conditions.
Keywords: skeletal muscle engineering; tissue engineering; volumetric muscle loss; decellularized
tissue; decellularized muscle; acellular tissue; acellular muscle; skeletal muscle regeneration
1. Introduction
The crucial role of the ECM environment in the stem cell niche, and in the regulation of stem cell
identity and differentiation, organogenesis and tissue homeostasis has been a topic of extensive and
intriguing study [1,2]. In the field of regenerative medicine this has allowed for the development of
an increasing number of tissue engineering strategies, in which scaffold materials are used to mimic
in vivo the biological microenvironment of the ECM, providing the components needed to drive cells
toward the regeneration of the tissue of interest. Despite the incredible improvements that have been
made in 3D bioprinting technology, the bona-fide reproduction of a scaffold capable to accurately
mimic complex tissues, such as skeletal muscle, remains a matter that cannot be technically solved [2].
The 3D interactions existing among different components of the ECM is far for being a simple overlay
of proteins organized in a layer-by-layer fashion. Indeed, ECM components not only interact with
each other in specific fashions, but each single component, and also defined isoforms of a same
component, are tissue-specific and even site-specific inside a defined tissue [2,3]. Such complexity,
which likely has a biological meaning for cells, can be preserved in scaffolds only by taking advance of
the native tissue themselves, that is achieved by decellularizing tissues or whole organs. Upon the
removal of nuclear content and cellular elements, decellularized or acellular scaffolds still retain
the architecture and complexity of the native tissues, including vasculature and biofactors present
in the ECM. These characteristics make decellularized matrices the ideal bio-scaffold necessary to
guide host or donor cells toward the regeneration of new and functional tissues. Several studies
have already demonstrated the possibility of successfully obtaining acellular scaffolds from many
organs, such as heart, kidney, pancreas, lung, liver, esophagus and intestine. Importantly, some of
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these decellularization protocols have been adopted to decellularize simple hollow organs such as
the trachea, which have then been successfully transplanted in patient after autologous cell seeding,
i.e., trachea [4–6]. Importantly, the trachea transplant has been achieved without immunosuppression,
a great advantage over conventional transplantation because it avoids potential risks for patients,
including frequent infections and cancer. Acellular tissues are biocompatible and the absence of
rejection after allogeneic or xenogeneic transplantation make them the ideal scaffold for translational
medicine applications and organ replacement [7,8].
Even though skeletal muscle has a remarkable capacity to undergo regeneration, several
pathological conditions can lead to extensive and irreversible muscle loss: i.e., congenital defects,
traumatic injuries, surgical ablations, and neuromuscular diseases [2]. Failure of normal regeneration
results in VML, with loss of muscle function, often associated with scar tissue formation and adipose
tissue substitution. Current treatments for such conditions have limited success [7], leading to
considerable social and economic burden. Therefore, there is a great need for new regenerative
medicine strategies aimed at treating VML conditions. Skeletal muscle is a complex tissue in which
myofiber 3D organization and function is intimately linked to other tissue components, such as
motor neurons, vasculature, myogenic stem cells (including satellite cells, SCs), interstitial cells,
and ECM [9–11]. A tubular network of ECM is intimately connected to all the different cellular
components. However, the ECM does not just provide mechanical support for bearing force
transmission, but also a dynamic signaling environment that is crucial for muscle development,
homeostasis, and regeneration [12,13]. SCs are mitotically quiescent muscle stem cells necessary for
muscle regeneration and located between the basal lamina and myofibers [11]. Defined composition
and mechanical properties of the ECM in SC niche is required to allow SC self-renewal and efficient
muscle regeneration in vivo [11,14–18].
2. Acellular Tissues and Biomaterials for VML Treatment: Types and Methods
The ideal biomaterial for VML repair would need to fill the volumetric loss and sustain SC
activity, while guaranteeing access to both vascular and neural cells for a correct revascularization
and reinnervation of the tissue [7,8,19]. Based on the above points, it is not surprising that acellular
scaffolds derived form a range of different tissues have already been tested in animal models [20–34]
and in small cohorts of patients affected by VML [35,36].
Acellular tissues are mainly generated by using physical, enzymatic, and/or chemical
mechanisms [9,37–39]. Based on its simplicity, the most commonly used method to obtain acellular
tissue is immersion and agitation of the sample, in presence of decellularizing agents. However,
this approach does not allow homogeneous decellularization of large samples and thick tissues,
such as skeletal muscle. To overcome such limitation, perfusion methods have been developed. Indeed,
by using the native vascular tree of the tissue/organ, decellularizing reagents can be homogeneously
distributed across the tissue, allowing better access and deep tissue exposure, ultimately improving
the removal of cellular components from large tissues [40–42]. Jank and colleagues reported the
ability to decellularize rat and primate forearms by perfusion of detergents. The preservation of
the composite architecture allowed the repopulation of muscle and vasculature of the construct
with cells of appropriate phenotypes in vitro, and also supported blood perfusion following in vivo
transplantation [43]. Moreover, a recent report by Gerli and colleagues also successfully generated
a large-scale, acellular composite tissue scaffold from a full cadaveric human upper extremity using
a perfusion method of decellularization [44]. This construct retained its morphological architecture and
perfusable vascular conduits with the preservation of the native ECM components. Such biocompatible
constructs could have significant advantages over the currently implanted matrices, in terms of
nutrient distribution, size-scalability, and immunological response [44]. These studies demonstrate the
possibility of developing more complex and reproducible decellularized organs, which hold higher
regenerative potential and translational efficacy for the treatment of VML conditions.
304
Int. J. Mol. Sci. 2018, 19, 2392
Small intestine submucosa matrix (SIS), urinary bladder matrix (UBM), and skeletal muscle
decellularized scaffolds have been the most commonly used materials to repair VML defects. SIS and
UBM scaffolds are prepared with standardized protocols, and are commercially available, clinically
approved, and have also been used in patients [30]. Conversely, skeletal muscle scaffolds have only
been used in animal models, and their preparation has been shown to be a more complex procedure,
mainly due to tissue complexity and thickness. The main protocols applied to generate decellularized
scaffolds from skeletal muscle are essentially of three types: enzymatic-not detergent [9,24,29],
detergent [31–34], and detergent-enzymatic [33,45,46] treatments. In the literature such scaffolds
are defined as decellularized; however, some of them would be better defined as “anucleated” rather
than “acellular” scaffolds. Indeed, together with the elimination of the nuclear content and the
maintenance of the ECM, such treatments can partially preserve cytoplasmic components of the
original tissue, in particular those belonging to myofibers [24,32,33,39,45,46].
As mentioned above, different sources of tissues and methods of decellularization have been
used to generate acellular scaffolds for the treatment of VML, complicating the understanding
of which scaffold is most ideal. The biological properties of the scaffolds depend on the agent,
or combined-agents, used for inducing decellularization, as well as on the method applied
(i.e., immersion vs. perfusion) and on the characteristics of the primary tissue/organ (density,
cellularity, dominant component in tissue, and thickness) [37]. Another important factor to consider
is whether using a tissue-matched decellularized scaffold can have positive effects on regeneration.
SIS and UBM are scaffolds that can fill the volumetric loss of tissue but do not have any muscular
specific components. Based on the complexity of the biological meaning of ECM—discussed above—
it is reasonable to speculate that matched acellular tissues should be better at instructing host and/or
seeded-donor cells toward the regeneration of the tissue of interest.
While this is not the focus of the present work, it is important to recognize that major work in
the field of skeletal muscle tissue engineering has been undertaken using polymers. Polymers have
some advantages over decellularized tissue, e.g., their manufacture is more reliable and consistent,
allowing a precise design of their geometry as well as mechanical and structural properties. As with
natural scaffolds, they can be loaded with bioactive molecules. Scaffolds used for skeletal muscle
regeneration include (i) synthetic polymers such as poly(ethylene glycolic) (PEG), polyglycolic acid
(PGA), poly(lactic-co-glycolic acid) (PLGA), poly(l-lactic acid) (PLLA), their copolymers (PLLA/PLGA),
and polycaprolactone (PCL); (ii) natural polymers such as alginate, collagen, fibrin, or hyaluronic
acid, or (iii) a combination of the two [47–60]. Rat myoblasts seeded onto PGA meshes and implanted
into the omentum of syngeneic animals generated vascularized constructs in which myoblasts were
found to be organized between strands of degrading polymer mesh [48,49]. In comparison to synthetic
materials, natural polymers may have the advantage of closely resembling the original ECM, or ECM
function of a tissue, and will thus facilitate an efficient regeneration. For example, fibrin itself can
efficiently promote regeneration in skeletal muscle. Fibrin microthreads seeded with adult human cells
improved regeneration of a large defect in the tibialis anterior muscle in murine model of VML, with
new muscle tissue formation and presence of Pax7-positive cells [55]. Efficient muscle regeneration
using fibrin was also previously demonstrated using a 3D fibrin matrix seeded with expanded primary
rat syngeneic myoblasts [56]. Another chief component of the ECM, hyaluronan, has been shown
to promote muscle regeneration when seeded with muscle progenitor cells in a murine model of
VML. Notably, SCs embedded in photo-cross-linkable hyaluronan also promoted functional skeletal
muscle recovery, with the formation of both neural and vascular networks and the reconstitution of
a functional SC niche [57]. Growth factors can also be efficiently associated to synthetic or natural
polymers. Mouse or human mesoangioblasts engineered to express placental-derived growth factor
and encapsulated inside PEG-fibrinogen hydrogels were able to efficiently replace an ablated tibialis
anterior [61]. In another study, an injectable, degradable alginate gel loaded with vascular endothelial
growth factor (VEGF) and insulin-like growth factor 1 (IGF1) led to parallel angiogenesis, reinnervation,
and myogenesis upon ischemic damage in skeletal muscle, with SCs activation, proliferation, and
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simultaneous protection from inflammation and apoptosis [51]. VEGF can also be delivered by
genetically engineering grafted cells. Rat myoblasts transfected with a plasmid encoding VEGF and
suspended in collagen type I showed increased generation of tissue mass after subcutaneous injection
into nude mice compared with nonfunctional VEGF-transfected cells [52]. Besides using factors
promoting angiogenesis, factors that induce cell activation and migration, such as hepatocyte growth
factor (HGF) and fibroblast growth factor (FGF), can also promote scaffold grafting and myogenesis [53].
The role of growth factors and natural polymers was further investigated by a recent paper in which
VEGF, IGF-1, FGF, HGF, and other factors were released locally from alginate microbeads. Such
constructs induced differentiation of urine-derived stem cells into a myogenic lineage, enhanced
revascularization and innervation of the implants and stimulated in vivo resident cell growth [54].
3. VML Models for Testing Acellular Tissues
The translational potential of decellularized tissues has mainly been evaluated in vivo using
surgical animal models of VML. Therefore, the use of such models mainly aim to test the ability of
decellularized tissues to promote (i) cell homing; (ii) regeneration of myofibers and motor neuron
axons; and (iii) angiogenesis. These are all essential steps necessary to have a functional skeletal
muscle in the site of transplantation. Moreover, acellular tissues have been used as natural devices
in which host cells can drive muscle regeneration, as well as used as scaffolding material to deliver
donor cells with the aim to improve cell therapy strategies. In order to evaluate the studies that have
been reported so far, here we compare the results obtained among different acellular scaffolds and
strategies— i.e., with or without donor cells, used for the treatment of VML in comparable animal
models (Table 1).
Mice are commonly used for studying muscle regeneration and testing the regenerative potential
of acellular scaffolds in VML. Sicari and colleagues studied the ability of porcine SIS to promote muscle
regeneration after xenotransplantation in a VML model in which the quadriceps muscle was ablated.
Although no details were reported in terms of functional activity of the implant, the authors concluded
that the scaffold within the defect was associated with constructive tissue remodeling, including the
formation of site-appropriate skeletal muscle tissue [26]. The same model was used in another study
to test the regenerative potential of porcine UBM. In this instance, Fisher and colleagues showed that
the scaffolds promoted the formation of functional skeletal muscle cells, with perivascular stem cell
mobilization and their accumulation within the site of injury [35]. Yet another study reported the ability
of sodium dodecil sulfate (SDS)-derived acellular skeletal muscle to promote the formation of islands
of myofibers after implantation in a tibialis anterior VML model [21]. Recently, few studies strongly
supported the idea that decellularized muscles can offer a favorable environment to donor or host cells
that promotes functional muscle regeneration [31,33,34]. We recently demonstrated that decellularized
skeletal muscles derived with three different perfusion methods per se were able to generate functional
artificial muscles in a xenogeneic immune-competent model of VML, in which the EDL muscle was
surgically resected. In particular, decellularized tissues promoted migration and differentiation of the
host myogenic cells, as well as SC homing, the formation of nervous fibers, neuromuscular junction
and vascular networks [33]. Quarta and colleagues showed that decellularized muscle seeded with
adult muscle stem cells and muscular resident cells were able to generate functional muscle tissue
in a VML model. More in detail, SDS-based acellular muscles were used to deliver and promote the
maintenance of human muscular cells in an immunocompromised murine model of VML in which the
tibialis anterior muscle was ablated. Both innervation and in vivo force production were enhanced
when implantation of bioconstructs was followed by an exercise regimen [31]. Another study showed
the ability of decellularized skeletal muscle to support functional muscle regeneration by host cells,
with less fibrosis and more de novo neuromuscular receptors than either autograft or collagen implants
in a rat model of gastrocnemius VML [32].
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The rat represents the most commonly used animal model for assessing muscle regeneration upon
treatment of VML with acellular tissues. More than 10 years ago, we used a full-thickness defect of the
abdominal wall to evaluate the syngeneic regenerative potential of cell-matrix constructs composed
of SC–derived myoblasts seeded on muscle acellular matrices. Acellular muscles were obtained by
a detergent-enzymatic method, and showed the preservation of both FGF and transforming growth
factor-beta. The implanted construct promoted the formation of skeletal muscle and allowed the
survival of donor cells nine months after surgery. Interestingly, a vesicular acetylcholine transporter
was present on the surface of muscle fibers identified in the implant, suggesting the possible integration
of the nervous system [22]. A similar approach was performed later in a xenogeneic model. Fishman
and colleagues used a VML model of tibialis anterior for the implantation of a construct composed
by rat skeletal muscle scaffolds and murine myoblasts. The decellularized muscle was prepared
using an enzymatic protocol performed under agitation. Unfortunately, the aim of the study was
focused on the immunomodulatory activity of the scaffold and muscle regeneration at the site of
implantation was poorly characterized. However, the authors demonstrated that donor cells displayed
better survival when delivered thought the scaffold, adding relevant information regarding the use of
acellular matrix as scaffolding material for cell therapy approaches [24]. More recently, another study
tested the possible application of UBM as scaffolding material for syngeneic cell delivery. Goldman and
colleagues combined UBM with minced muscle grafts, promoting de novo muscle fiber regeneration
and neuromuscular strength recovery in a VML model in which the tibialis anterior muscle was ablated.
However, this functional improvement was associated with a concomitant reduction in graft-mediated
regeneration, with coincident fibrous matrix deposition and interspersed islands of nascent muscle
fibers. This effect was linked to the inability of UBM to create a favorable environment for efficiently
promoting muscle regeneration [25]. Such results indicate that acellular scaffolds can ameliorate the
survival of delivered cells. However, we can speculate that acellular muscles are better than UBM
scaffolds when it comes to support muscle regeneration and donor cell maintenance.
Studies aimed at using acellular scaffolds with no implementation of cellular therapy have also
been reported in rat VML models. Merritt and colleagues derived skeletal muscle decellularized
tissues from rat by using an SDS-based immersion protocol. The scaffolds were implanted in a model
in which a portion of the lateral gastrocnemius had been removed. After 42 days, growth of blood
vessels and myofibers into the ECM was apparent, but no restoration of force occurred [23]. In another
study, the histomorphologic characteristics and the physiologic activity of the implants were evaluated
in an abdominal wall VML model upon implanting either porcine SIS, carbodiimide-cross-linked
porcine SIS, autologous tissue, or polypropylene mesh. The best histomorphologic results were
obtained with SIS scaffold, which showed islands and sheets of skeletal muscle. On the other hand,
functional recovery was similar between SIS- and autologous tissue-implants. Conversely, implants of
carbodiimide-cross-linked SIS and polypropylene mesh were characterized by a chronic inflammatory
response and produced little or no measurable tetanic force [29]. Despite the range of final responses,
these studies also supported the idea that acellular tissues can per se promote muscle regeneration in
VML models.
Muscular or nonmuscular decellularized tissues implanted in the same VML model have been
used to directly compare their ability to promote muscle regeneration. Wolf and colleagues used
a partial thickness abdominal wall defect model in which they xeno-transplanted muscle-derived
scaffold or SIS-derived matrix. In this study, the muscular tissue was derived from dogs and
decellularized muscles were obtained with an agitation method and an enzymatic and chemical
decellularization process. Even though acellular muscles were shown to have preserved growth
factors, glycosaminoglycans, and basement membrane structural proteins, which differed from those
present in SIS, the remodeling outcome was comparable between the two implanted scaffolds [20].
On the other hand, a different study reported that upon xenotransplantation decellularized muscles
allowed better neovascularization, myogenesis, and functional recellularization than that obtained
with porcine SIS implants. Interestingly, the muscular scaffolds used in this particular study, prepared
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from porcine rectus abdominis, were obtained with a perfusion method and retained the intricate
3D microarchitecture and vasculature networks of the native tissue, many of the bioactive ECM
components and the mechanical properties [28]. Altogether these results strongly support the idea
that the protocol used to decellularize skeletal muscle is fundamental in determining if and to what
extent the obtained scaffold is capable to improve the regenerative response of the hosting tissue.
It is important to underline that the large volume of tissue that needs to be regenerated in patients
affected by VML can be a major limiting step for acellular tissue application in clinic. To address this
point, some studies attempted to apply decellularized matrix to larger animal models. Turner and
colleagues have used a canine VML model, in which the distal third of the vastus lateralis and a portion
of the vastus medialis muscles were resected. This defect was replaced with a scaffold composed of
SIS. Even though the initial remodeling process followed a pattern similar to that reported in other
studies, in the long term the implanted scaffolds showed dense collagenous tissue formation and
islands of skeletal muscle with no successful restoration of tissue functionality [27]. In a more recent
study, similar results were obtained in a porcine VML model in which peroneous tertius muscle
was ablated. By comparing the outcome of implanted SIS, UBM, and hyaluronic acid hydrogel,
Greising and colleagues showed that in all three cases ECM implantation could not orchestrate
a skeletal muscle regeneration capable to lead to a physiological improvement. Instead, a significant
deposition of fibrotic tissue was observed within the defect region three months post-injury [30].
Still, SIS and UBM have been shown to allow functional improvement in patients affected by VML.
In particular, Fisher and colleagues showed that functional improvement was observed in three
out of the five patients after implantation of SIS scaffolds [35]. More recently, a 13-patient cohort
study was performed, using commercially available ECMs—BioDesign (SIS), Matristem (UBM), and
Xenatrix (dermis-ECM)—to repair VML defects. The authors reported that in all cases the acellular
scaffold facilitated functional tissue remodeling, thanks to the recruitment of myogenic progenitor
cells and improved innervation [32]. These clinical results are in contrast with those obtained from
studies performed in large animal models [27,30]. More studies will be needed to determine if the
reason for such discrepancies is related to species-specific biologic responses to decellularized scaffold
implantation. Besides, it is also important to emphasis that so far muscular acellular scaffolds have not
been tested in large animal models or patients.
4. Conclusions and Perspectives
Studies performed on murine and rat VML models have conclusively demonstrated the ability
of acellular scaffolds to promote myogenesis both as stand-alone devices and when associated
with cell therapy strategies. Interestingly, by comparing results obtained between this two animal
models one could speculate that acellular scaffolds derived from skeletal muscle are to be the best
candidate to promote skeletal muscle regeneration in vivo, when compared to SIS and UBM scaffolds.
This conclusion seems to be valid not only when scaffolds are used as devices, but also when they
are associated with cell therapy. The possibility of using decellularized scaffolds as devices represent
an important aspect for their translational application, as it eliminates the limiting steps specifically
related to cell therapy. Perfusion methods of decellularization appear to better preserve instructive cues
necessary to promote functional muscle regeneration by host cells. The recently published method of
composite tissue decellularization, strongly suggest the feasibility of applying such muscular scaffolds
in large animals and patients [43,44].
Overall, we can therefore conclude that despite incredible improvements in the design and
development of synthetic or natural materials, decellularized tissues possess the irreplaceable
advantage of preserving the biological signals that mimics the normal ECM of an in vivo tissue.
Hence, we strongly believe that for the next foreseeable future application of decellularized tissues
will represent a valid and powerful strategy to develop new therapeutic approaches for the cure of
VML conditions.
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Abstract: The traditional view of integrins portrays these highly conserved cell surface receptors
as mediators of cellular attachment to the extracellular matrix (ECM), and to a lesser degree,
as coordinators of leukocyte adhesion to the endothelium. These canonical activities are indispensable;
however, there is also a wide variety of integrin functions mediated by non-ECM ligands that
transcend the traditional roles of integrins. Some of these unorthodox roles involve cell-cell
interactions and are engaged to support immune functions such as leukocyte transmigration,
recognition of opsonization factors, and stimulation of neutrophil extracellular traps. Other cell-cell
interactions mediated by integrins include hematopoietic stem cell and tumor cell homing to
target tissues. Integrins also serve as cell-surface receptors for various growth factors, hormones,
and small molecules. Interestingly, integrins have also been exploited by a wide variety of organisms
including viruses and bacteria to support infectious activities such as cellular adhesion and/or
cellular internalization. Additionally, the disruption of integrin function through the use of soluble
integrin ligands is a common strategy adopted by several parasites in order to inhibit blood clotting
during hematophagy, or by venomous snakes to kill prey. In this review, we strive to go beyond
the matrix and summarize non-ECM ligands that interact with integrins in order to highlight these
non-traditional functions of integrins.
Keywords: integrin; extracellular matrix; counterreceptor; disintegrin; immune system; stem cell;
pathogen; virus; bacteria; venom; growth factor; hormone
1. Introduction
The adhesion of cells to extracellular matrices is a fundamental requirement for multicellular
organisms, and animals employ many mechanisms to fulfill this demand. Amongst these mechanisms
of adhesion, integrins are perhaps the most ubiquitous. Integrins are heterodimeric transmembrane
proteins, made up of non-covalently paired α and β subunits, which serve as adhesion and signaling
hubs at the cell surface. In mammals, there are 18 α-integrin subunits and eight β-integrin subunits
that can combine to form as many as 24 unique heterodimeric receptor complexes [1]. Typically,
ligand binding is carried out through integrin receptor recognition of small peptide sequences.
Target sequences for integrins can be as simple as the RGD or LDV tripeptides, or more complex as
in the case of the GFOGER peptide [1]. Many classical extracellular matrix (ECM) proteins contain
these short integrin recognition motifs. RGD sequences are found in both vitronectin and fibronectin,
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an LDV motif is present in fibronectin, GFOGER is found within collagen, and the target sequence
within laminin has not yet been defined [1]. These sequences are not globally recognized by all
integrins; therefore, integrin heterodimers are often grouped by the target sequences they specialize
in recognizing (Figure 1). Once bound to its ligand, an integrin not only provides adhesion, but also
initiates signaling mechanisms which allow cells to respond to the mechanical and chemical properties
of the cellular microenvironment. The primary signaling mediators working downstream of integrins
include focal adhesion kinase (FAK), Src-family protein tyrosine kinases, and integrin-linked kinase
(ILK) [2]. Upon adhesion, cytoskeletal proteins are recruited to the cytoplasmic tails of integrins,
forming a linkage between the ECM and cytoskeleton [2].
 
Figure 1. Integrin heterodimers and their ligands. Integrins are heterodimeric cell surface receptors
that bind extracellular matrix (ECM) molecules. In addition to this role, integrins also bind many
non-ECM ligands. Integrin subunits connected by a ray represent heterodimeric α/β binding partners.
The inner ring depicts integrin heterodimers grouped into families based upon their classical binding
profile. These families include RGD receptors, collagen (GFOGER) receptors, laminin receptors,
or leukocyte-specific receptors. Within the outer ring, the non-ECM ligands of these families are listed.
Non-ECM ligands include growth factors, hormones, venomous compounds, disintegrins, bacterial
proteins, fungal polysaccharides, viruses, polyphenols, and counterreceptors.
As a family of proteins, integrins and many of their downstream signaling intermediates have
a long evolutionary history. Beginning at the root of the metazoan lineage, sponges have been shown
to express α- and β-integrin subunits [3,4] that bind to peptides in a fashion similar to mammalian
integrins [5]. Interestingly, integrin-encoding genes have been found in the single-celled eukaryotic
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relatives of metazoans, thus the origin of integrins predates the emergence of metazoans [6]. Moreover,
components of integrin signaling machinery such as FAK, Src, and ILK, and integrin-interacting
cytoskeletal proteins such as α-actinin, talin, vinculin, and paxillin, have pre-metazoan origins [6].
This suggests that integrins and their aforementioned signaling machinery may have played an
important role in the evolution of multicellularity.
Beyond their traditional role as mediators of ECM attachment, a vast literature has developed that
describes interactions between integrins and ligands that are not located in the classical extracellular
matrix. For example, integrins have been shown to interact with various proteins on the surfaces of
eukaryotic, prokaryotic, and fungal cells, as well as a range of viruses. Within eukaryotes specifically,
integrin-mediated cell-cell adhesion has been shown to coordinate a range of interactions and processes
including leukocyte extravasation, stem cell homing, tumor cell migration, erythrocyte development,
and interactions in the immune system. For infectious prokaryotes, integrins are exploited as cell
surface adhesion receptors that mediate colonization and/or the bypassing of epithelial or endothelial
barriers. Beyond mediating cellular interactions, integrins can also serve as cell surface receptors for
hormones, growth factors, and polyphenols. Finally, integrins are also common targets for a class of
small molecules called disintegrins, which are components of various snake venoms, and are also
employed by hematophagous parasites. Collectively, the range of non-ECM molecules that interact
with integrins is vast, making integrins indispensable mediators of cell biology at large. The goal of
this review is to highlight some of the best understood non-ECM ligands of integrins and discuss the
diverse biological roles for these interactions.
2. Integrin-Mediated Cell-Cell Interactions
The first integrins discovered were isolated based on their ability to bind to fibronectin, which had
itself just recently been identified (reviewed in [7]). However, in the early days of integrin research,
several groups studying cell-cell adhesion in the immune system were also on the forefront of integrin
identification (reviewed in [8,9]). In fact, integrins that mediate cell-cell adhesion in the immune
system were among the first integrins to be characterized [8]. As more integrins were discovered,
it became apparent that the majority of integrins established cell-ECM connections rather than cell-cell
connections. Nonetheless, it is important to understand that integrins are important mediators of
cell-cell adhesion. The term counterreceptor has often been used to describe membrane-bound,
non-matrix integrin ligands which facilitate cell-cell contact and will be used to differentiate them
from the other non-matrix ligands in this review. While there are many types of counterreceptors,
the best-known examples include the immunoglobulin superfamily cell adhesion molecules (IgCAMs)
and junctional adhesion molecules (JAMs). Collectively, interactions between integrins and these
counterreceptors mediate a range of immune cell functions including leukocyte extravasation from
the blood stream, immunological surveillance in the gut, and hematopoietic stem cell homing
and mobilization. Additionally, non-ECM ligands enhance the interaction between pathogens and
phagocytic immune cells, acting as phagocytic primers and inducers of neutrophil extracellular
traps. Beyond the immune system, non-ECM-based integrin interactions are important during the
transmigration and metastasis of tumor cells, and during erythrocyte development. Integrins and the
non-ECM ligands that mediate these cell-cell interactions are listed in Table 1.
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2.1. Integrin-Counterreceptor Interactions in Leukocyte Extravasation
Integrin-counterreceptor interactions play multiple roles during extravasation, a process in which
white blood cells are recruited from the blood stream to a site of inflammation (depicted in Figure 2).
Extravasation begins when glycoproteins on the leukocyte cell surface, such as P-selectin glycoprotein
ligand-1 (PSGL-1), bind endothelial selectins, which allows the leukocyte to slow down as it rolls along
the vessel wall [33]. Next, local chemokines stimulate leukocyte integrins to adopt a high-affinity state,
causing them to bind specific immunoglobulin superfamily cell adhesion molecules (IgCAMs) on
endothelial cells [34]. There are many integrin-IgCAM pairs involved in this process: αLβ2 (LFA-1)
integrin binds to ICAM1, 2, or 3, αMβ2 (Mac-1) integrin binds to ICAM1, and α4β1 (VLA-4) integrin
binds to VCAM1 or MAdCAM1 (reviewed in [10]). Additionally, leukocyte integrins can bind a family
of proteins known as junctional adhesion molecules (JAMs) found on endothelial cells. Similar to
integrin-IgCAM interactions, integrins display specificity for particular JAM proteins: JAM-A binds to
αLβ2, JAM-B binds to α4β1, and JAM-C binds to αMβ2 [11]. All of these integrin-counterreceptor
binding events serve to tightly adhere the leukocyte to the endothelium, enabling the white blood cell
to cross the endothelial layer (a process known as transendothelial migration) in order to reach the
inflamed tissue.
2.2. Non-ECM Integrin Ligands as Primers for Phagocytosis
One of the best-characterized examples of non-ECM integrin-binding ligands in the immune
system involves the interplay of integrins with the complement system. Complement proteins aid in
the immune system’s clearance of pathogens by attaching to invaders and tagging them for destruction.
Integrin β2 is essential for complement recognition by the complement receptors αMβ2 (Mac-1, CR3)
and αXβ2 (CR4) integrins [23]. αMβ2 and αXβ2 ligation with the iC3b component of complement
induces the phagocytosis of complement opsonized pathogens and particles by phagocytic immune
cells (depicted in Figure 2) [24]. Despite high homology between both integrins, they bind the
iC3b fragment of complement via distinctive receptor sites, which may afford a greater diversity of
leukocytes in opsonized target recognition modes [35]. This leads to the intriguing possibility of
cooperativity between two integrins binding the same complement molecule [35].
Phagocytosis mediated by integrins is not strictly complement dependent. Human cathelicidin
peptide LL-37, an antimicrobial peptide that binds to the prokaryotic cell wall, inserts itself into the
membrane, and enhances phagocytosis by interacting with αMβ2 integrin present on neutrophils
and macrophages [26,27]. As an important part of innate defenses, LL-37 is expressed in various
mammalian tissues and released upon contact with bacterial invaders [29]. For example, upon infection
by Helicobacter pylori, gastric epithelial cells express and secrete LL-37, thus tagging the bacterial
invaders for destruction by phagocytic immune cells (depicted in Figure 2) [28]. Interestingly, LL-37
binds αMβ2 with a comparable strength to complement C3d, a ligand with one of the strongest known
affinities for αMβ2 [25].
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Figure 2. Integrins act as “double agents” during Helicobacter pylori infection in the stomach, serving
to potentiate bacterial pathogenicity while also aiding in the immune response. H. pylori bacteria
in the gastric lumen bind integrins on gastric epithelial cells in order to inject the virulence factor
CagA. As shown in the magnified view of this process, docking of α5β1 integrin is achieved through
integrin affinity for the RGD motif of the CagL protein component of the type IV secretion system
(T4SS). Integrin α5β1-mediated stabilization of the T4SS facilitates the translocation of CagA while
activating intracellular kinases. Once in the cytosol, CagA is phosphorylated by Src family kinases
(SFKs) and Abelson (ABL) kinases, which potentiates its virulence. Phospho-CagA activates Src
homology 2 domain-containing phosphatase-2 (SHP-2) and mitogen-activated protein kinase (MAPK)
signaling, triggering cytoskeletal remodeling. CagA disrupts cell-cell junctions, activates the nuclear
factor-κB (NF-κB) pathway, and stimulates cytokine production. Alternatively, CagL docking with
αVβ5 integrin on gastric G cells activates integrin-linked kinase (ILK), which stimulates epidermal
growth factor receptor (EGFR) and MAPK activation, inducing gastrin production. These mechanisms
increase the permeability of the gastric epithelium, which aids H. pylori dissemination into the
underlying lamina propria. This stimulates an inflammatory response causing the release of the
antimicrobial peptide LL-37 from gastric epithelial cells and recruitment of immune cells from the
blood stream. As shown in the magnified view of the recruitment process, leukocytes first stick to
inflamed endothelium through selectin binding, which facilitates integrin-mediated tight adhesion.
This leads to leukocyte extravasation into the lamina propria, where neutrophils and macrophages
phagocytize bacteria. Phagocytosis is mediated through integrin recognition of the opsonization
factors LL-37 and complement. Neutrophil extracellular traps (NETs) are stimulated through integrin
interaction with pathogens.
2.3. Non-ECM Integrin Ligands as Triggers for NETosis
Another example of non-ECM integrin ligation at work in the innate immune system is the
neutrophil extracellular trap (NET). In the process of NETosis, chromatin is ejected from neutrophils
upon interaction with pathogens, thus entangling foreign invaders in a web of DNA and histones
(depicted in Figure 2) [36]. This process is mediated through pathogen recognition by neutrophil
integrins. For example, the pathogen-associated molecular pattern, β-glucan, found on Candida albicans
is recognized by αMβ2 at a unique lectin-like domain, and its binding stimulates NETosis [21].
Once stimulated, anti-microbial peptides are integrated into NETs. These include defensins and the
αMβ2 ligand LL-37 [22]. NETosis is not exclusively used to trap foreign invaders, as it is also involved
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in wound healing and sterile inflammation [37]. For instance, during cell necrosis the chromatin protein
high-mobility group box 1 (HMGB1 aka amphoterin) is released extracellularly and recruits neutrophils
by binding integrin β2 [38]. HMGB1 has been demonstrated to be an inducer of NETosis when
presented on platelets during thrombosis [30]. This evidence suggests that HMGB1 serves as a molecule
that is capable of signaling to white blood cells the presence of tissue damage through leukocyte
integrins. Although αMβ2 plays a starring role in the literature connecting NETosis and integrins,
other integrins may be involved. Bacterial invasin proteins from Yersinia pseudotuberculosis interact
with neutrophil integrin β1, stimulating phagocytosis while also causing the release of NETs [39].
In addition to trapping cells within a tangle of DNA and histones, fibronectin has been identified in
NETs, which ligates to αVβ3 and α5β1 integrins found on neutrophils and cancer cells, thus potentially
enhancing cancer cell-leukocyte interaction [40]. Collectively, this information demonstrates rich
evidence for the importance of integrin engagement during NETosis.
2.4. Non-ECM Integrin Ligands in Immune Surveillance
The intestinal immune system must display tolerance towards commensal microbiota and food
antigens while still maintaining immunogenicity against pathogens. In the gut mucosa, resident
antigen-presenting cells (APCs) have the job of sampling foreign antigens. APCs then transport these
antigens to specialized gut-associated lymphoid tissue where they can interact with naïve T cells to
promote their maturation. Additionally, the APCs imprint intestinal homing properties on the T cells
through inducing the expression of α4β7 integrin and C-C chemokine receptor type 9, a receptor
for the gut-associated C-C motif chemokine 25 (CCL25) [41]. Mature T effector cells then reenter the
circulation and can be recruited back to the gastrointestinal tract during times of inflammation through
gut endothelial expression of CCL25 and the α4β7 counterreceptor, MAdCAM1 [17]. There is also
a role for α4β1-VCAM1 interactions in the gut; this pair mediates the binding of effector T cells to
inflamed gut epithelium [12].
Integrins in the gut also bind to cadherins to modulate the immune response. For instance,
cadherin 26 binding to integrins αE and α4 can lead to a T cell immunosuppression phenotype [42].
Moreover, this study found that a similar phenotype is provoked through the treatment of T cells with
a soluble form of cadherin 26. So, unlike the integrin-mediated IgCAM interactions in the gut, cadherin
binding appears to moderate the immune response. It has been suggested that this interaction may
therefore be involved in resolving inflammation [42]. Cadherin-integrin interactions in the lungs have
been shown to mediate the engagement of cytotoxic T lymphocytes (CTLs) with cancer cells. Here,
CTLs employ αEβ7 integrin to engage E-cadherin on cancer cell surfaces in order to facilitate accurate
targeting and release of cytotoxic granules [20].
2.5. Integrin-Mediated Stem Cell Homing
The homing and mobilization of hematopoietic stem cells (HSCs) to and from the bone marrow
is also regulated by integrins (reviewed in [13]). After the treatment of hematologic malignancies
with large doses of radiation and/or chemotherapy, transplantation of HSCs is commonly performed.
Success of the HSC engraftment within the bone marrow is dependent upon proper HSC homing to
a bone marrow niche where they can regenerate hematopoietic lineages. New evidence is revealing
that integrin engagement of counterreceptors plays a critical role in this homing process. For example,
Murakami et al. determined that a subpopulation of murine HSCs expressing integrin β7 have
enhanced homing capabilities to bone marrow niches compared to their counterparts which do not
express β7 [18]. Mechanistic insight was provided when it was revealed that α4β7 integrins on HSCs
were binding MAdCAM1 present on endothelial cells within the bone marrow niche, and β7 knockout
HSCs showed decreased CXCR4 homing receptor expression [18].
In addition to α4β7-MAdCAM1 interactions, α4β1-VCAM1 binding also mediates HSC retention
in bone marrow niches. The importance of α4 integrin to this interaction is supported by the
phenotypes of multiple α4 knockout mouse models that show elevated numbers of HSCs in the
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bloodstream relative to wild-type littermates (reviewed in [13]). The treatment of mice with Bortezomib,
which inhibits the expression of VCAM1, also increases HSC mobilization [14]. Together, these results
support a role for integrins in holding HSCs within the bone marrow and have raised great clinical
interest in using Bortezomib-induced mobilization for the harvesting of HSCs from the peripheral
blood of healthy individuals for use in transplantation.
Another integrin-targeting small molecule antagonist is the drug Firategrast; it inhibits α4β1
and α4β7 activity and can also be used to mobilize HSCs from the bone marrow to the circulation,
making HSC harvesting much less invasive. There is particular interest in using Firategrast for in
utero hematopoietic cell transplants (IUHCT). These transplants can be especially useful for diseases
where a more mature immune system can thwart the therapeutic benefit of the transplanted cells
(reviewed in [43]). Firategrast was tested in a mouse model of IUHCT and found to increase long-term
engraftment of HSCs; there was 15% engraftment at six months with Firategrast, compared to 3% with
vehicle alone [44]. The current thinking is that the mobilization of endogenous HSCs through the
disruption of integrin adhesion by Firategrast makes room in the bone marrow for transplanted HSCs
to compete with endogenous cells for niche binding. Although still in preclinical studies, Firategrast is
well-tolerated by adults but has not yet been tested in children (reviewed in [43]).
Some interesting new data on mesenchymal stem cell (MSC) homing demonstrates that the
role of integrin αL (CD11a) in MSC transmigration across vessel endothelium differs from that of
leukocyte extravasation [45]. Using zebrafish whose endothelium was labeled with green fluorescent
protein as a model system, mammalian leukocytes, cardiac stem cells, and MSCs were transplanted
to determine their transmigration properties. As expected, leukocyte extravasation proceeded in
an αL-dependent fashion, as αL-blocking antibodies inhibited leukocyte extravasation. However,
the blocking antibodies did not inhibit the transmigration of cardiac stem cells or MSCs, indicating
that these cells were traversing the endothelium in an αL-independent fashion that was found to rely
on the remodeling of the endothelium for vascular expulsion of these types of stem cells. Based on this
evidence and additional phenotypic differences in the transmigration of cardiac stem cells and MSCs,
the authors have named this alternate process angiopellosis [45].
2.6. Integrin-Counterreceptor Interactions in Tumor Cell Migration
Integrin binding to IgCAMs also mediates tumor cell binding to endothelial cells, influencing
metastasis. Many of these interactions involve L1CAM (reviewed in [46]); this protein contains an
RGD motif that binds to αVβ3 integrin [47,48]. The expression of L1CAM by various types of cancer
cells is utilized to engage αVβ3 on endothelial cells. It has been demonstrated that L1CAM expression
in glioma tumor cells serves to promote the motility of both cancer cells [31] and endothelial cells [32],
thus having important implications for both metastasis and angiogenesis, respectively. Other non-ECM
integrin ligands have been implicated in tumor cell migration. For example, when expressed on cancer
cells, VCAM1 has been identified as a driver of metastasis due to its ability to bind α4β1 integrin
expressed on lymph node endothelium (reviewed in [16]). Additionally, metastatic breast cancer cells
express the transmembrane glycoprotein NMB that contains an RGD motif and can bind to α5β1
integrin on adjacent tumor cells. This interaction activates Src and FAK signaling within the tumor
and leads to increased growth and metastasis [19].
2.7. Integrin-Counterreceptor Interactions in Erythrocyte Development
Since integrins can bind to both ECM and other cells, it is perhaps not surprising that
there are modulators that can push integrins towards either a cell-ECM or a cell-cell interaction.
During erythrocyte differentiation in the bone marrow, immature erythroblasts cluster around a central
macrophage, forming what is known as erythroblastic islands. This cell-cell interaction is mediated
by α4β1 on erythroblasts and VCAM1 on macrophages and is an essential part of the maturation
process [15]. The same α4β1 integrin can bind to fibronectin in the ECM, and the modulation of
α4β1 binding to either macrophages or ECM is in part due to the activity of erythrocyte tetraspanin
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proteins CD81, CD82, and CD151 [49]. These tetraspanins are co-expressed with α4β1 on human
proerythroblasts, where they increase the affinity and/or clustering of integrins to favor α4β1-VCAM1
interactions over α4β1-fibronectin interactions [49].
3. Non-ECM Integrin Ligands of Viruses
Although there is debate as to when viruses first emerged in the evolution of life, it is likely that
viruses (in one form or another) have co-existed with cells for nearly as long as cells have existed [50]. It is
also safe to assume that viruses have a long history of exploiting cell surface receptors to facilitate their
infectious cycles. As already discussed, integrins are first present in evolutionary history at the root of
the metazoan lineage, and perhaps predate metazoans [3,4,6]. Therefore, it is not surprising that many
species of viruses have exploited (and continue to exploit) integrins as a major point of cell attachment,
entry, and eventually infection of target cells. A common theme among many of the viruses discussed
here is the display of RGD motifs on viral capsids to bind to integrins that are commonly found on either
epithelial or endothelial surfaces [51,52]. Presumably, the RGD motif serving as a minimal integrin-binding
unit accommodates the viral quest for genomic minimization. Additionally, RGD-recognizing integrins
are common in tissues targeted by invading viruses. However, RGD-based mechanisms are not the
only means of integrin engagement by viruses, as some viruses employ other integrin targeting motifs.
The virus-integrin interactions we have chosen to highlight are in no way an exhaustive list (for a more
comprehensive review of the subject, refer to [53,54]). Integrins that participate in viral interactions that
we discuss are listed in Table 2 and depicted in Figure 3.
Table 2. Selected integrin binding by viruses.
Integrin Virus Name [Key Refs]





α3β1 Kaposi’s sarcoma-associated herpesvirus [61]Adenovirus [62]
α4β1 Infectious bursal disease virus [63]Rotatvirus [60]
α5β1




α9β1 Kaposi’s sarcoma-associated herpesvirus [67]
αMβ2 Adenovirus [68]




Foot-and-mouth disease virus [74]
Japanese encephalitis virus [75]





Sin Nombre virus [81]
αVβ5





Foot-and-mouth disease virus [84,85]
Epstein-Barr virus [83]
Herpes simplex virus [86]
αVβ8 Epstein-Barr virus [83]Herpes simplex virus [86]
αXβ2 Rotavirus [60]
αIIbβ3 Sin Nombre virus [81]
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Figure 3. Viruses hijack integrins for adhesion and infectivity. Virus families use specific integrins
in order to adhere to target cells for the purposes of internalization and infectivity. Members of the
family Adenoviridae are non-enveloped viruses with icosahedral capsids that have penton base structures
which facilitate RGD-dependent docking with αVβ1, αVβ3, αVβ5, and α5β1 integrins as well as the
RGD-independent engagement ofα3β1. Adenoviruses also targetαMβ2 integrin through an undetermined
mechanism. Birnaviridae contains members who employ a fibronectin-mimicking IDA peptide to bind α4β1
integrin. Members of the Flaviviridae family have an RGD-containing E-protein which binds αVβ3 integrin.
Viruses in the family Hantaviridae target the plexin-semaphorin-integrin (PSI) domain of αVβ3 and αIIbβ3
integrins. Herpesviridae has members that employ a few different mechanisms of integrin engagement for
the purposes of viral entry. The envelope protein BMRF-2 contains an RGD sequence that docks α5β1
integrin. The envelope proteins gH and gL dock with αVβ5, αVβ6, and αVβ8. Another envelope protein,
known as gB, contains both an RGD motif and disintegrin-like domain, which affords viral targeting of
αVβ3, αVβ5, α2β1, α3β1, α6β1, and α9β1 integrins. Members of the Picornaviridae family use capsid
proteins to target integrins. The targeting of α2β1 integrin proceeds in an RGD-independent manner,
while αVβ1, αVβ3, αVβ6, and α5β1 integrins are bound in an RGD-dependent fashion. Reoviridae contains
members which employ a DGE sequence within a VP4 capsid protein to engage α2β1. Additionally,
the reovirus VP7 capsid protein has a GPR tripepetide which recognizes αXβ2, an LDV tripeptide that
ligates α4β1, and a novel NEWLCNPDM amino acid sequence that targets αVβ3. Togaviridae has members
which have a collagen-mimicking spike protein that docks α1β1 integrin.
3.1. Non-ECM Integrin Ligands of Picornaviridae
Viruses of the Picornaviridae family cause a variety of human diseases including aseptic (viral)
meningitis, paralysis, hepatitis, and poliomyelitis [87], and there are currently no approved treatments
to minimize picornavirus infection. Picornaviruses are non-enveloped viruses with icosahedral capsids,
with each face of the 20-sided capsid consisting of three capsid proteins (VP1-3) to form a protomer
with 60 subunits. The VP4 protein is contained within the capsid and is thought to help package the
single-stranded RNA genome (reviewed in [88]). Several picornaviruses have been shown to exploit
integrins as cell surface receptors to facilitate cell invasion. In most cases, the non-ECM ligands that
enable picornavirus binding to integrins are located on the VP1-3 capsid proteins.
Members of Picornaviridae include the enteric cytopathic human orphan (echo) viruses.
Echovirus 1 (EV1) utilizes the α2I functional domain of α2β1 integrin as a docking receptor on the
surface of a target cell [56,57]. Although the precise peptide sequence of EV1 that binds to α2β1
integrin has not been discovered, it is known that EV1 binds to the α2I domain of α2β1 integrin
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10 times more tightly than collagen [56,89,90]. The structure of the EV1 capsid provides a pentameric
arrangement of binding sites for α2β1, which induces the clustering of α2β1 integrins, and is thought
to promote the entry of the virus [56]. During infection, EV1 along with α2β1 integrin are taken into
the host cell via caveolar endocytosis and moved to a caveosome, where it is thought that the virus
ejects its genome into the cytosol [91–94]. While EV1 utilizes a non-RGD signal to bind its integrin
receptor, echovirus 9 (EV9) docks to integrin αVβ3 via an RGD domain located on the EV9 VP1 capsid
protein [72]. RGD motifs are also thought to be critical in host cell attachment for echovirus 22 (EV22)
to αVβ1 integrins [69,70]. Another member of the Picornaviridae family, coxsackievirus A9, utilizes the
coxsackievirus and adenovirus receptor (CAR) together with an RGD motif situated in the C-terminal
of its VP1 to bind αVβ3 and αVβ6 integrins and gain cellular entry [73,95]. Yet another member of the
Picornaviridae family, foot-and-mouth disease virus (FMDV), is a major scourge of animal husbandry.
The VP1 protein of FMDV has an exposed flexible loop, termed the GH loop, which contains an RGD
motif and mediates binding to host α5β1, αVβ3, and αVβ6 integrins [64,74,84,85].
3.2. Non-ECM Integrin Ligands of Flaviviridae
Flaviviridae is a family of single-stranded, positive sense RNA viruses that are commonly
transmitted to human hosts from arthropods such as ticks and mosquitos [96]. Japanese encephalitis
virus (JEV), a mosquito-borne member of the genus Flavivirus, is a leading cause of viral encephalitis
in humans and animals [97,98]. JEV has an envelope protein, called E protein, which contains
an RGD motif [99]. Data suggest that JEV utilizes this RGD motif to bind αVβ3 integrin to aid
in cellular infection. Specifically, JEV infectivity is reduced by shRNA knockdown of integrin αV
and β3 subunits, pretreatment of cells with soluble RGD peptides, or αV/β3 blocking antibodies.
Conversely, the expression of β3 integrin promotes infectivity in otherwise resistant cell lines [75].
Finally, the utilization of integrin receptors appears to be a common infection strategy for the Flaviviridae
family, since other members such as West Nile virus [100–102], Murray Valley encephalitis virus [103],
dengue virus [104], and yellow fever virus [105] have all been connected with integrin-mediated
infection or have at least been demonstrated to possess RGD-containing E proteins.
3.3. Non-ECM Integrin Ligands of Herpesviridae
Members of the Herpesviridae family of viruses also use integrins for cellular attachment and
entry. Epstein-Barr virus (EBV) utilizes α5β1 integrin for infectivity in tongue and nasopharyngeal
epithelium by binding host cell integrins with its RGD-containing envelope glycoprotein, BMRF-2 [65].
In addition, the engagement of EBV envelope glycoproteins gH and gL with αVβ5, αVβ6, and αVβ8
integrins induces a conformation in these glycoproteins which facilitates fusion with the target cell
membrane [83]. More mechanistic insight is provided by herpes simplex virus (HSV), which also
uses gH and gL envelope glycoproteins to dock αVβ6 and αVβ8 integrins, and this engagement
routes HSV to acidic endosomes, thus promoting viral entry [86]. Another herpes virus, Kaposi’s
sarcoma-associated herpesvirus (KSHV), uses αVβ3 [76], αVβ5 [82], and α3β1 [61] integrins as
entry receptors. The expression of the envelope protein, known as glycoprotein B (gB), which is
highly conserved across Herpesviridae and contains an RGD sequence near its N-terminus, affords
KSHV its integrin-binding capacity. However, RGD-mediated binding is not the only mechanism of
KSHV-integrin interaction. KSHV glycoprotein B also contains a disintegrin-like domain (DLD) which
is capable of binding integrin β1 in an RGD-independent fashion [58]. Walker et al. discovered that
α9β1 is the integrin target of the glycoprotein B DLD and plays a critical role in KSHV infection [67].
This mechanism is not unusual among Herpesviridae family members, as human cytomegalovirus
(HMCV) also uses gB to bind αVβ3, α2β1, and α6β1 through its disintegrin-like domain [58,106].
3.4. Non-ECM Integrin Ligands of Togaviridae
Ross River fever is a mosquito-borne disease caused by the Ross River virus (RRV), a member of the
Togaviridae family. This disease induces arthritis by the viral infection of macrophages within synovial
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joints [107]. It is believed that the RRV spike protein, known as E2, contains two conserved domains
which fold in a manner that mimics collagen IV [55]. This allows for the infection of mammalian cells by
docking the collagen receptor, α1β1 integrin, in matrix-binding adherent cell types [55].
3.5. Non-ECM Integrin Ligands of Adenoviridae
Human adenoviruses, known for causing respiratory, gastrointestinal, and ocular infections, are
non-enveloped viruses with icosahedral capsids. At each capsid vertex, a penton base supports
a fiber protein [108]. Many adenoviruses require two receptors for efficient infection of cells.
The coxsackievirus and adenovirus receptor (CAR) is required for the initial adhesion of adenoviral
particles to target cells, while subsequent integrin engagement is required for the internalization of
the viral particle [109]. It is the penton base structure that affords adenoviruses a diverse array of
integrin targets. RGD peptide sequences are located atop each monomer of the penton base, forming
an RGD ring around the fiber protein [78]. The RGD peptides mediate docking to αVβ1, αVβ3, αVβ5,
and α5β1 integrins for the purpose of internalization [66,71,110–112]. Mechanistically, it is thought
that the pentameric structure of the base stimulates integrin clustering and downstream integrin
signaling, which further facilitates viral internalization [113–115]. Adenoviruses also interact with the
laminin binding integrin, α3β1, via its penton base, but in a manner that is RGD-independent [62].
Additionally, αMβ2 integrin on myeloid cells can be targeted by adenoviruses, but this interaction is
dictated through an as yet undetermined sequence within the penton base [68].
3.6. Non-ECM Integrin Ligands of Hantaviridae
As a member of the Hantaviridae family, the rodent-targeting Andes virus can spread to humans
through the inhalation of aerosolized excreted virus, targeting human endothelial cells and resulting
in several fatal diseases such as hantavirus hemorrhagic fever with renal syndrome and hantavirus
pulmonary syndrome [116]. The infection of αVβ3 integrin-expressing endothelial cells occurs through
the viral targeting of the PSI domain within the β3 subunit [77]. Interestingly, a human polymorphism
that has a leucine to proline substitution at position 33 of the integrin β3 PSI domain was experimentally
shown to abolish Andes virus infectivity [77]. Sin Nombre virus also utilizes β3-containing integrins,
such as αIIbβ3 and αVβ3, for viral attachment [81]. Using atomic force microscopy (AFM) to study
membrane dynamics upon Sin Nombre virus interaction, more mechanistic insight was provided for
integrin-dependent hantavirus infectivity. Bondu et al. used AFM data to propose a model in which viral
docking to the β3 PSI domain of αIIbβ3, when the integrin is in a low affinity state, enhances integrin cis
interaction with an RGD-containing G-protein coupled receptor known as P2Y2R [117]. This cis interaction
is thought to induce a switchblade-like conformational change within the integrin that ultimately leads
to the endocytosis of the viral bound integrin [117]. Other pathogenic hantaviruses also bind and cause
the dysregulation of β3 integrins, resulting in the blockade of endothelial cell migration [118], and the
enhancement of vascular endothelial growth factor (VEGF)-mediated vascular permeability [119].
3.7. Non-ECM Integrin Ligands of Birnaviridae
Infectious bursal disease virus (IBDV) is an immunosuppressive avian pathogen in the Birnaviridae
family that attacks the bursa of Fabricius (the site of hematopoiesis in birds) of young chickens,
having a major negative impact on the poultry industry. The IBDV capsid is built by 260 trimers of
the VP2 polypeptide arranged in an icosahedral lattice [120]. VP2 is the only component of the virus capsid,
and contains a conserved, fibronectin-mimicking IDA peptide sequence that binds toα4β1 integrins present
on target cell membranes [63]. IBDV binding to α4β1 integrin triggers c-Src tyrosine phosphorylation and
actin rearrangement, which creates membrane protrusions that internalize the virus [121].
3.8. Non-ECM Integrin Ligands of Reoviridae
The family Reoviridae includes the gastrointestinal pathogens, known as the rotaviruses, which are
the leading etiological factor of diarrheal disease in young children worldwide [122]. The outer layer
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of the rotavirus capsid consists of 60 VP4 spike proteins protruding from a VP7 protein shell [123]. It is
these outermost structures which mediate host cell binding and infectivity. The VP4 spike protein
subunit, VP5, contains a DGE tripeptide sequence that serves to recognize α2β1 integrin on target
cells [59,60]. Rotavirus VP7 contains an αXβ2-recognizing GPR tripeptide, as well as an α4β1 ligating
LDV motif, embedded in a disintegrin-like domain of the protein [60]. Additionally, rotaviruses can
target αVβ3 integrin for the purpose of cellular entry; however, this binding does not occur within
the RGD pocket [80]. Rather, it is a novel αVβ3-targeting NEWLCNPDM amino acid sequence within
the VP7 protein that is thought to mediate rotavirus-αVβ3 interaction [79]. It has been proposed
that reoviruses employ a sequential binding mechanism to multiple receptors for the purpose of
internalization. Initial binding to the counterreceptor JAM-A is thought to position the virus for
subsequent binding to β1 containing integrins that facilitate internalization [124].
4. Non-ECM Integrin Ligands in Venoms
Selectively blocking integrins is a major therapeutic goal when combatting a number of
pathologies, and a wide variety of approaches have been initiated. One rich source for anti-integrin
compounds are venoms from various snake species [125,126], and the study of venom-derived integrin
antagonists remains an active area of research. A venom is defined as a secreted toxin, produced by
various types of animals, which is injected into another animal for the purpose of defense or predation.
The Viperidae family of snakes (collectively known as the vipers) produce a venom which causes
local necrosis and blood coagulation within their prey. The discovery of small integrin-targeting
peptides found in the venom of these snakes initiated the study of disintegrins. These small molecular
weight (40–100 amino acids in length), non-enzymatic proteins were originally characterized by
their platelet-disrupting properties through antagonistic targeting of αIIbβ3 integrin [127]. Since the
identification of the first disintegrins, the field has grown with the discovery of many more examples.
As discussed below, major families of venom-derived disintegrins include the RGD, MLD, PIII,
and KTS/RTS disintegrins. On the other hand, C-type lectin-like proteins are an example of
non-disintegrin toxins, which also disrupt integrin activity. Integrin-targeting venomous compounds
are summarized in Table 3.
Table 3. Integrin binding by small molecules, hormones, growth factors, and venoms.
Integrin Non-ECM Ligand Function [Key Refs]
α1β1 KTS/RTS disintegrins Block cell adhesion [128,129]
α2β1 EMS16 CLP Block adhesion to collagen [130,131]
α3β1 VEGFDisintegrin Lebein 1/2
Cell adhesion [132]
Block cell adhesion [133]
α4β1 MLD disintegrins Block cell adhesion [128]
α4β7 MLD disintegrins Block cell adhesion [128]
α5β1 ANGPTL2 Cancer cell migration/proliferation [134]Macrophage pro-inflammatory response [135]
α6β1 Disintegrin Lebein 1/2 Block cell adhesion [133]
α7β1 Disintegrin Lebein 1/2 Block cell adhesion [133]
α9β1 VEGF-A, -C, -DMLD disintegrins
Endothelial adhesion & lymphangiogenesis [136]










Cancer cell proliferation [143,144]
Podocyte motility [145]
Enhanced endothelial junctions [146]
Endothelial cell adhesion [132]
αVβ5 ANGPTL4 Reduce proteinuria [147]
αVβ6 Pro-TGFβ TGFβ activation [148,149]
Abbreviations: lysine-threonine-serine (KTS), arginine-threonine-serine (RTS), C-type lectin-like protein (CLP),
vascular endothelial growth factor (VEGF), methionine-leucine-aspartic acid (MLD), angiopoietin-like protein
(ANGPTL), dihydrotestosterone (DHT), transforming growth factor β (TGFβ)
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The RGD family of disintegrins is the largest family, although RGD amino acid sequences are not
strictly required to be members in this family. Instead, disintegrins containing RGD or similar amino
acid motifs, such as KGD, MGD, VGD, and WGD, are all capable of targeting RGD-binding integrins,
serving to disrupt their physiological functions. Moreover, not all RGD disintegrins target RGD-binding
integrins exclusively. For example, lebein1 and lebein2 are two RGD-containing disintegrins found in
the venom of Macrovipera lebetina, which have the unusual property of targeting the laminin-binding
integrins α3β1, α6β1, and α7β1 in an RGD-independent fashion [133]. They are thought to mimic the
integrin-binding motif of laminin, thus allowing these molecules to disrupt cellular attachment to the
laminin-rich basement membrane [133].
Other disintegrin families include the MLD-, PIII-, and KTS/RTS-containing disintegrins.
Whereas the RGD family of disintegrins possesses an RGD tripeptide (or similar motif) within the
integrin-binding loop of the protein, the MLD motif is found at this same position in MLD-containing
disintegrins [128]. These MLD disintegrins appear in heterodimeric complexes and are highly
dependent on adjacent sequences to target the α4β1, α4β7, and α9β1 leukocyte specific receptor
family of integrins [128]. PIII class disintegrins are large multi-domain toxins (60–100 kDa) which use
an ECD integrin-targeting tripeptide and contain a metalloprotease domain which is a close homolog to
the ADAM (a disintegrin and metalloprotease) family of metalloproteases [150]. The disintegrin known
as alternagin uses an ECD tripeptide motif to target α2β1 integrin and disrupt matrix binding [151].
Once bound, alternagin uses its protease domain to cleave β1, causing integrin shedding and
further disruption of collagen-induced platelet aggregation [152]. Finally, the KTS/RTS group of
disintegrins, found in Viperidae venom, are monomeric proteins which bind the collagen receptor
α1β1 integrin [129]. This high level of specificity is not matched by RGD and MLD disintegrins,
as KTS/RTS disintegrins only target α1β1 integrin [128].
Another class of toxin found in Viperidae venom is the C-type lectin-like proteins (CLPs).
These proteins do not exhibit the sugar-binding capabilities of C-lectin proteins, but instead target
collagen-binding integrins [153]. The viper species Echis carinatus multisquamatus produces EMS16,
a potent and selective inhibitor of α2β1 integrin [130]. X-ray crystallography reveals that EMS16
spatially blocks collagen-integrin ligation through docking with the α2I domain of α2β1 integrin and
stabilizing a low matrix affinity integrin conformation [131]. Several studies have shown that many
viper-derived CLPs target endothelium and block angiogenesis [130,154,155], while applying CLPs to
cancer cells can inhibit cell-collagen binding [153] and metastasis [156]. Integrins that interact with
CLPs are summarized in Table 3.
5. Bacterial Use of Non-ECM Integrin Ligands
For many bacterial cells, successful adhesion to host cell surfaces is a prerequisite for successful
colonization and/or infection. Many bacteria take advantage of the binding capabilities of integrins
on cell membranes for infectious purposes. Some bacteria utilize specific integrin dimers for cellular
binding, while others exploit extracellular fibrous proteins that naturally bind to integrins for the
purpose of translocating virulence factors. For this review, we will highlight three of the most
commonly studied interactions between bacteria and integrins. There are other notable examples of
bacterial cells using integrins as host cell receptors that we will not discuss: the intimin protein
of Escherichia coli that binds to α4β1 and α5β1 integrins [157], the IpaB, C, and D proteins of
Shigella flexneri that bind to α5β1 integrin [158], and the filamentous hemagglutinin protein of
Bordetella pertussis that binds to αMβ2 integrin [159]. Integrins that participate in bacterial interactions
are listed in Table 4.
5.1. Non-ECM Integrin Ligands of Borrelia burgdorferi
The spirochete Borrelia burgdorferi is the causative agent of Lyme disease, a devastating disease
of the nervous system. The natural reservoir for B. burgdorferi includes mice, birds, and lizards [160].
These spirochetes are transmitted to humans via tick vectors of the Ixodes genus [160]. Once injected
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into the blood stream, B. burgdorferi spirochetes adhere to the microvasculature, transmigrate through
the endothelium, and disseminate into various tissues [161]. Characterizing the proteins that enable
this pathological mechanism illustrates several interesting examples of how microbes take advantage
of host integrins.
A variety of screening techniques have identified at least 19 B. burgdorferi proteins that mediate
or enhance adhesion to target cells [162]. The majority of these proteins mediate indirect adhesion
to mammalian cells via interactions with various ECM molecules. Three proteins however, P66,
BBB07, and BB0172, have been shown to interact with integrins on platelets and a variety of cells
such as endothelial cells. Prior to the discovery of the P66 protein, it had been known for some time
that B. burgdorferi cells could adhere to β3 chain-containing integrins [163,164]. The P66 protein was
later identified by phage display and shown to bind αVβ3 and αIIbβ3 integrins [165]. P66 displays
no typical integrin-binding sites [165], although the adhesion of P66 to integrins can be blocked
by soluble RGD peptides, suggesting that P66 may bind into the RGD pocket of β3 integrins [166].
Moreover, a minimal seven-amino acid sequence (QENDKDT) from P66 was found to bind integrins,
and the deletion of the aspartic acid residues from this peptide eliminated P66 integrin binding [167].
Despite the integrin-binding activity of P66, the deletion of P66 does not appear to affect B. burgdorferi
adhesion to microvasculature, a key step proceeding tissue invasion [168]. Instead, the P66 protein
(presumably via its integrin-binding activity) appears to be essential for the endothelial transmigration
and dissemination of B. burgdorferi spirochetes into host tissues [167,168]. Although P66 deletion did
not affect microvascular adhesion, B. burgdorferi binding to various cells can be blocked by soluble
RGD peptides [163], suggesting the presence of other integrin-binding proteins. In support of this,
two additional integrin-binding outer membrane surface proteins, BBB07 and BB0172, have been
detected on B. burgdorferi [169,170]. Although both BBB07 and BB0172 have been shown to interact
with α3β1 integrins, only BBB07 contains an RGD motif [170]. Currently, there is little known about
the function of α3β1 integrins in endothelial biology, although it has been proposed that α3β1 binding
to Laminin 511 in the basal lamina may be linked to endothelial barrier function [171], which could
provide a link to the transendothelial migration of B. burgdorferi during infection.
5.2. Non-ECM Integrin Ligands of Helicobacter pylori
Helicobacter pylori infects roughly half of the world’s human population and shares responsibility
for gastric complications including stomach ulcers and gastric adenocarcinoma through its infection of
gastric epithelial cells [172–174]. H. pylori utilizes a type IV protein secretion system (T4SS) involving
the cytotoxin-associated gene L (CagL) adhesion tip protein to infect target cells with the virulence
factor, cytotoxin-associated gene A (CagA) [175,176]. The efficiency of CagA injection is enhanced
by an RGD domain present on the CagL protein [177]. CagL interacts primarily with α5β1 integrin;
however, αVβ3, αVβ5, and αVβ6 have also been implicated [178–181]. Interestingly, while the CagL RGD
domain is necessary for CagA injection, additional CagL sequences have been identified that enhance
integrin binding. For example, an RGD helper sequence, FEANE, is located in close proximity to the
RGD domain of CagL and reinforces integrin engagement [177]. Additional domains on CagL that
enhance RGD binding include a TSPSA sequence [182], an LXXL sequence that is directly adjacent
to the RGD domain [181], and a TASLI sequence located opposite the RGD domain in the CagL
integrin-binding domain [182]. CagL-α5β1 interaction leads to the activation of the kinases Src and
FAK [179], followed by subsequent tyrosine phosphorylation of the CagA EPIYA amino acid motifs by Src
and ABL kinases [183]. These phosphorylation events potentiate CagA pathogenicity (reviewed in [184]).
Phospho-CagA interacts with Shp-2 while initiating mitogen-activated protein kinase (MAPK) signaling,
and inducing cytoskeletal rearrangements which serve to cause an elongation of epithelial cells and enhance
their mobility. CagA also disrupts cell-cell junctions while triggering an inflammatory response, including
nuclear factor-κB (NF-κB) activation and chemokine production. Additionally, in a negative feedback loop
phospho-CagA downregulates Src activity, ensuring that a reservoir of nonphospho-CagA remain in the
cell, which is necessary for a prolonged infection. As mentioned previously, CagL is capable of interacting
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with other integrins. Interestingly, a novel mechanism of CagL-αVβ5-induced production of gastrin has
been uncovered. It was found that CagL ligation to αVβ5 on gastric epithelial cells activates ILK, which in
turn activates the epidermal growth factor receptor (EGFR) and subsequently MAPK pathways, serving to
induce gastrin expression [178]. This mechanism may explain H. pylori induced hypergastrinemia, which is
a major risk factor for gastric adenocarcinoma. The integrin-dependent mechanisms of H. pylori infection
discussed here are depicted in Figure 2.
5.3. Non-ECM Integrin Ligands of Yersinia
The Gram-negative bacteria Yersinia enterocolitica and Yersinia pseudotuberculosis commonly cause
foodborne illnesses. These Yersinia species express two adhesion proteins that facilitate cellular
attachment and invasion of target cells in the small intestine. The Yersinia adhesion A (YadA) protein
indirectly binds to integrins via interaction with various molecules of the ECM, but is dispensable
for cellular invasion [185,186]. However, the Yersinia invasin protein directly binds to a variety
of β1 subunit-containing integrins (α3, α4, α5, α6, αV) and is crucial for cellular adhesion and
invasion [187,188]. Yersinia species invading through the small intestine target the apical membrane of
Peyer’s patch M-cells, which express integrin β1 [189,190]. Invasins lack the typical RGD domain used
to bind integrins, although RGD peptides prevent invasin binding to β1 integrins [191]. This suggests
that invasin proteins interact with the RGD binding domain of β1-containing integrin heterodimers.
In support of this, the structural analysis of the invasin protein, and comparison to fibronectin, reveals
similar structures with key conserved integrin-binding residues, suggesting the convergent evolution
of invasins to match fibronectin [192].
Table 4. Integrin binding by bacteria and parasitic organisms.
Integrin Species Binding Protein [Key Refs]





























Ipa B, C, D [158]
EhCP5 [201]
Invasin [187]
α6β1 Yersinia Invasin [187,188]
αMβ2 Bordetella pertussisAncylostoma caninum
Filamentous hemagglutinin protein [159]
Neutrophil inhibitor factor (NIF) [202]








αVβ5 Helicobacter pylori CagL [178,180]
αVβ6 Helicobacter pylori CagL [181]
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6. Protists and Multicellular Parasites That Use Non-ECM Integrin Ligands
A broad array of examples of non-ECM ligands for integrins are employed by many
parasitic organisms. Here we discuss just a few examples, including non-ECM ligands
produced by the amoebozoa Entamoeba histolytica and a range of hematophagic (blood-sucking)
organisms. These examples illustrate the importance of non-ECM ligands to parasitic infections.
Although compared to bacteria and viruses, there is far less literature on the subject of non-ECM
ligands as components of pathogenicity in protozoan and multicellular parasites. Non-ECM integrin
ligands derived from parasitic organisms are summarized in Table 4.
6.1. Non-ECM Integrin Ligands of Entamoeba histolytica
Entamoeba histolytica (Eh) causes amoebic dysentery and liver abscess [205] and is responsible for
~100,000 deaths/year [206]. Eh invasion into host tissues involves multiple integrin-mediated steps.
The best-characterized of these integrin-mediated steps involves the Eh cysteine protease 5 (EhCP5)
binding to αVβ3 integrins [203,204]. The binding of EhCP5 to αVβ3 integrins on colonic epithelial
cells via an RGD domain triggers NF-κB-mediated inflammation [203] and mucin exocytosis [204].
The EhCP5 protein has also been shown to interact with α5β1 integrins to mediate local inflammation,
which is crucial to Eh invasion into host tissues [201]. Additional involvement of integrins in Eh
invasion has been linked to β2 integrin activation and release of reactive oxygen species [207,208]
as well as an integrin β1-like receptor present on Eh trophocytes that mediates adhesion to host
fibronectin [209].
6.2. Non-ECM Integrin Ligands of Hookworms
The hookworm platelet inhibitor (HPI) protein illustrates another fascinating example of non-ECM
integrin ligands. Hookworms are blood-feeding intestinal parasites and a leading cause of iron
deficiency in humans. HPI was isolated from the hookworm Ancylostoma caninum based on its ability
to inhibit the function of integrins αIIbβ3 and α2β1 [193,194]. HPI appears to block platelet aggregation
and blood clothing, thus enabling continued feeding. Interestingly, sequence and structural analysis
has failed to identify any integrin-binding domains in the HPI protein [210]. In addition to the HPI
protein, Ancylostoma caninum also expresses the neutrophil inhibitor factor (NIF) that interacts with
αMβ2 integrins present on neutrophils [202,211]. NIF disrupts αMβ2 interaction with ICAM1 [202],
which is necessary for stable neutrophil adhesion to the endothelium and transendothelial migration,
thus suppressing local inflammation. Collectively, the combined actions of HPI and NIF help ensure
that hookworms are able to feed from their host for a prolonged period of time.
6.3. Non-ECM Integrin Ligands of Blood-Sucking Parasites
In addition to Entamobea histolytica and Ancylostoma caninum, several other examples of
integrin inhibition by hematophagic (blood-sucking) animals have been described in the literature
(reviewed in [212]). Many of these strategies involve non-ECM integrin ligands that interfere
with various integrin-mediated steps that are essential for blood coagulation. The majority of
these non-matrix ligands block platelet αIIbβ3 integrin interactions with fibrin, von Willebrand
factor, and vitronectin, which are collectively essential for blood coagulation. Many of these
integrin disrupting molecules are found in the saliva of hematophagic organisms and not
only inhibit platelet aggregation, but also disrupt neutrophil function and angiogenesis [212].
Examples of these integrin disrupting proteins include the decorsin protein from the leech
Macrobdella decora [195], the vasotab TY and tablysin-15 proteins from the horsefly Tabanus yao [196,197],
and the disagregin (Ornithodoros moubata), YY-39 (Ixodes pacificus and Ixodes scapularis), and variabilin
(Dermacentor variabilis) proteins from ticks [198–200]. Many of these proteins contain RGD or similar
integrin-binding amino acid motifs (KGD, VGD, MLD, KTS, RTS, WGD, or RED) which bind to and
interfere with αIIbβ3 integrin function on platelets. Additional RGD or RGD-like integrin antagonists
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have been identified in silico from other blood-sucking arthropods such as mosquitos and sand
flies [212], but have yet to be explored.
7. Hormones, Small Molecules, and Growth Factors That Mimic Integrin Ligands
To this point, we have focused on the non-ECM integrin ligands utilized by various organisms to
mediate adhesion to target cell membranes. However, as it turns out, a wide variety of small molecules
(including hormones and growth factors) can also interact with integrins, thus broadening the role for
integrins in non-ECM interactions. As described in the examples below, integrins binding to small
molecules serve a number of cellular functions ranging from cell surface receptor-signaling roles, as in
the case of thyroid hormone, dihydrotestosterone, angiopoietin-like proteins (ANGPTLs), and VEGF,
to the activation of growth factors, as in the case of TGFβ. Integrins that interact with hormones, small
molecules, or growth factors are summarized in Table 3 and depicted in Figure 4.
 
Figure 4. Integrins serve as cell surface receptors for growth factors, hormones, and small molecules.
Various growth factors use integrins as cell surface receptors. Angiopoietin-like proteins (ANGPTLs)
bind α5β1 and αVβ3 integrins to facilitate a host of cellular effects. Pro-TGFβ is activated by
αVβ3, αVβ5, αVβ6, and αVβ8 through the integrin-dependent dissociation of an RGD-containing
latency-associated peptide (LAP), thus converting it to its active form. Activated TGFβ acts as a master
regulator of fibrosis, among other roles. Vascular endothelial growth factor (VEGF) ligates α3β1, α9β1,
αVβ3, and other αV-containing integrins, resulting in cellular effects that promote angiogenesis and
lymphangiogenesis. The polyphenol trans-resveratrol, which is derived from grapevines, binds the β3
subunit of αVβ3 integrin near the RGD recognition pocket. This binding event induces extracellular
signal-regulated kinase (ERK) activation and p53-dependent apoptosis, while promoting angiostasis.
Like trans-resveratrol, the active form of testosterone (DHT) also binds the β3 subunit of αVβ3 integrin
near the RGD pocket. DHT-αVβ3 interaction inhibits trans-resveratrol-induced effects and stimulates
cellular proliferation. The thyroid hormones, T3 and T4, utilize αVβ3 integrin as a cell surface receptor
to activate a range of signaling molecules which induce angiogenesis. When binding to αVβ3 integrin,
the thyroid hormone analog tetrac blocks T3/T4 integrin-induced effects.
7.1. Small Molecules and Hormones That Bind Integrins (Resveratrol, Thyroid Hormone, DHT)
Trans-resveratrol is a stilbenoid produced in plants such as grapevines that is well-known for its
anti-inflammatory activity [213], anti-angiogenic function [214], and anticancer properties [215–217].
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Resveratrol binds the extracellular portion of the β3 monomer of αVβ3 integrin near the
RGD pocket [137]. This binding inhibits αVβ3 integrin-dependent endothelial cell adhesion to
vitronectin-coated plates, while also exhibiting angiostatic function and inhibiting tumor growth [139].
Resveratrol binding to αVβ3 integrin induces extracellular signal-regulated kinase (ERK1/2) activation,
which leads to p53-induced apoptosis in various cancer cell lines [137,138]. This evidence implicates
resveratrol binding αVβ3 integrin as being at least in part responsible for resveratrol’s ability to
mitigate angiogenesis and tumorigenesis.
Integrin αVβ3 bears a receptor site for the thyroid hormones T3 and T4 as well as thyroid
hormone analogs (reviewed in [140]). Perhaps the first evidence of this interaction was uncovered
when Hoffman et al. [218] used an αVβ3 inhibitor (SB-273005) to block T4-induced bone resorption in
rats. The binding of T3 and T4 to αVβ3 integrin induces cell proliferation and angiogenesis through
MAPK activation, and this effect is negated by a T4 derivative tetraiodothyroacetic acid (tetrac),
RGD peptide, and αVβ3 integrin-blocking antibodies, suggesting that the thyroid hormone receptor
site is at or near the RGD binding pocket [141–143]. Through radioligand binding experiments, it was
shown that purified αVβ3 integrin binds T4 preferentially over T3, and binds T4 with high affinity,
having a dissociation constant (Kd) of 333 pM and an EC50 of 371 pM [142]. Lin et al. proposed a model
for the thyroid hormone receptor activity of αVβ3 integrin that describes two distinct thyroid hormone
binding sites on αVβ3 [219]. The site known as “site 1” appears to bind T3 but not T4, while another
site called “site 2” binds both T3 and T4 [219]. T3 binding at site 1 leads to Src and phosphatidylinositol
3-kinase (PI3K) activation, which induces nuclear translocation of thyroid hormone receptor (TR)
α1, and these effects can be disrupted through the addition of RGD peptide [219]. Meanwhile,
T3/T4 binding at site 2 induces ERK activation, which causes nuclear translocation of TRβ1, and only
T4-induced effects at this site are disrupted by RGD peptides [219]. This suggests that αVβ3-dependent
thyroid hormone signaling acts as a complex, hierarchical system capable of mediating distinct
site-specific activities. Since some of these activities are disrupted through RGD binding, and this leads
to the possibility that cells embedded in an RGD-rich matrix may respond differentially to thyroid
hormone compared to those embedded in an RGD-deficient matrix. Perhaps this is a mechanism by
which a ubiquitous receptor, such as αVβ3, can provide tissue-specific responses to thyroid hormone.
In addition to thyroid hormones, αVβ3 integrin also interacts with the biologically active form of
testosterone, dihydrotestosterone (DHT). Whether or not this interaction is involved in the normal
physiological roles of DHT is unknown; however, DHT binding to αVβ3 has been implicated in
cancer cell growth. For example, DHT binding to αVβ3 stimulates MDA-MB-231 breast cancer
cell proliferation [143]. Additionally, DHT binding to αVβ3 integrin inhibits resveratrol-induced,
p53-dependent apoptosis effects in MDA-MB-231 cells [144], thus highlighting the complexity of
hormone signaling through αVβ3 integrin. Through these examples, it is clear that αVβ3 integrin has
diverse receptor activity which affords hormones additional non-canonical signaling capacity.
7.2. Growth Factors That Bind Integrins (ANGPTLs, TGFβ, VEGF)
Many growth factors are capable of binding integrins. An interesting example is the
angiopoietin-like proteins (ANGPTLs), also known as angiopoietin-related proteins (ARPs),
which consist of a family of proteins that display structural similarity to the growth factor angiopoietin,
although they do not bind classical angiopoietin receptors [220]. Instead, ANGPTLs have been
demonstrated to bind various integrins through a C-terminal fibronectin-like domain containing
a conserved RGD sequence [221]. In human prostate cancer (LNCaP) cells, ANGPTL2 binds
α5β1 integrin, inducing migration and proliferation, and this effect can be negated by use of
integrin-blocking antibodies [134]. Furthermore, ANGPTL2 binding α5β1 integrin on macrophages
mediates pro-inflammatory responses in mice, and ANGPTL2 knockout mice have muted immune
responses, leaving them more susceptible to infections [135]. In the kidney, glomerular podocyte
motility is enhanced through cytoskeletal rearrangement induced by ANGPTL3 binding podocyte
αVβ3 integrin [145]. The deletion of ANGPTL3 can reduce proteinuria in mouse models of
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nephropathy, and ANGPTL3 activation of integrin β3 has been identified in patients with nephrotic
syndrome [222]. The ANGPTL family also affects vascular integrity. In response to decreased
albumin levels during peak proteinuria, podocytes and extrarenal tissues secrete ANGPTL4 into
the blood, which binds glomerular endothelial αVβ5 integrin and serves to reduce proteinuria [147].
This effect may be explained by another study where surface plasmon resonance and proximity
ligation assays were used to discover that ANGPTL4 also binds another endothelial integrin, αVβ3,
which serves to recruit Src kinase and enhance endothelial junction stability, thereby reducing
vascular permeability [146]. Taken collectively, these studies suggest that ANGPTL3 binding podocyte
integrins enhances proteinuria, whereas ANGPTL4 binding glomerular endothelial integrins decreases
proteinuria. The ANGPTLs are a good example of a protein family that mimics a classical extracellular
matrix protein in order to bind integrins and implement their cellular effects.
Integrins also play a critical role in the activation of TGFβ (reviewed in [148]). An inactive form
of TGFβ (pro-TGFβ) is secreted from cells with an RGD containing latency-associated peptide (LAP)
non-covalently bound to TGFβ, which must be removed before TGFβ is biologically active. While the
RGD binding αVβ6 integrin plays a key role in separating LAP from TGFβ, other αV-containing
integrins, including αVβ3, αVβ5, and αVβ8, have been implicated in this process. Mutation of the
LAP integrin-binding site in mice yields normal levels of pro-TGFβ, but results in a lethal phenotype
which appears identical to TGFβ deletion [223]. LAP separation is mediated by a tensile force generated
by a cell’s cytoskeleton that is transmitted via αVβ6 integrin in order to reshape and activate the
pro-TGFβ [149]. The dependence of pro-TGFβ on αVβ6 for activation, and the fact that TGFβ is
a well-known master regulator of fibrosis [224], has led to the suggestion that the inhibition of αVβ6
integrin binding may represent a clinical strategy to treat diseases characterized by fibrosis, such as
scleroderma [225]. This idea is supported by observations showing that αVβ6 knockout mice [226] or
treatment with αVβ6 blocking antibodies [227,228] substantially decrease fibrosis in mouse models of
lung fibrosis.
The vascular endothelial growth factors (VEGFs) comprise a group of cytokines which are
important mediators of angiogenesis and lymphangiogenesis. VEGF signaling functions through
VEGF binding to a group of receptor tyrosine kinases, known as VEGF receptors (VEGFRs). Since this
pathway is an inducer of angiogenesis, it has been the target of many anticancer therapies with the
hope of inhibiting tumor vascularization. One therapeutic strategy involves inhibiting VEGF-VEGR
binding through the targeting of VEGFRs with monoclonal antibodies [229]. However, this approach
has not proven as effective as drug developers and clinicians envisioned [229,230]. One reason for this
failure may be that VEGFRs are not the only membrane-bound receptor of VEGFs, as these growth
factors are also known to bind integrins. Some VEGF isoforms are integrated into the extracellular
matrix, where they bind α3β1, αVβ3, and other αV integrins to promote endothelial cell adhesion [132].
Interestingly, the solubility of VEGF ligands greatly effects the integrin response. Vlahakis et al. found
that when α9β1 integrin binds immobilized VEGF-A, it induces the recruitment of VEGFR2 into
macromolecular structures at the cell membrane [136]. This serves to permit endothelial cell adherence
and migration on VEGF-A functionalized Petri dishes, and stimulates the phosphorylation of the
downstream effectors paxillin and ERK [136]. In contrast, when soluble VEGF binds α9β1 integrin,
paxillin is phosphorylated, but neither the phosphorylation of ERK nor the formation of VEGFR2
macromolecular complexes are induced [136]. Moreover, VEGF-A is not the only VEGF member to
have these functions. VEGF-C and VEGF-D also bind α9β1 integrin, stimulating the phosphorylation
of paxillin and ERK, while contributing to lymphangiogenesis [231]. Taken together, these findings
suggest a VEGF-induced synergy between VEGFR and integrins. Therefore, it may be beneficial to
co-target integrins when employing an anti-VEGF therapeutic strategy during cancer treatment.
8. Conclusions
Throughout this review, we have sought to venture beyond the matrix and highlight biological
examples of integrin ligands that do not fit the classical model of ECM-mediated integrin function.
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Given the strong conservation of integrins across much of the biological world, it is no surprise that
there exists an extremely diverse array of these non-ECM integrin ligands. Consequently, interactions
between integrins and non-ECM ligands are actively being exploited for a number of applications
in the biotechnology realm. RGD peptides are being used to target liposomes and small molecules
to specific tissues for various purposes, including the improvement of chemotherapeutic delivery
to cancer cells [232–234]. Similarly, RGD peptides are also being used to target viral particles to
various tissues. For instance, the new field of “chemical virology” seeks to load viral capsids with
chemotherapeutics that, in some instances, utilize RGD functionalization to deliver these nanoparticles
to specific tissues [235]. In a related example, a plant virus known as the cowpea mosaic virus,
which does not normally target mammalian cells, was functionalized with RGD peptides to successfully
target cancer cell lines [236]. Demonstrating another example of applied integrin biotechnology, various
artificial “extracellular matrices” are now being created and designed with incorporated RGD peptides
to enable cell seeding and growth [237]. Two exciting examples include the development of graphene
that has been functionalized with RGD peptides, which is being used to detect nitric oxide release from
living cells [238], and DNA origami tubes that have been tagged with RGD peptides and shown to bind
neural stem cells and promote their differentiation [239]. These instances and many others provide
fascinating examples of how the unique binding properties of integrins continue to be uncovered
and utilized.
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